Saunders, E.J.
Dadaev, T.
Brook, M.N.
Wakerell, S.
Govindasami, K.
Rageevakumar, R.
Hussain, N.
Osborne, A.
Keating, D.
Lophatananon, A.
Muir, K.R.
UKGPCS Collaborators,
Darst, B.F.
Conti, D.V.
Haiman, C.A.
Antoniou, A.C.
Eeles, R.A.
Kote-Jarai, Z.
(2024). Identification of Genes with Rare Loss of Function Variants Associated with Aggressive Prostate Cancer and Survival. Eur urol oncol,
Vol.7
(2),
pp. 248-257.
show abstract
full text
BACKGROUND: Prostate cancer (PrCa) is a substantial cause of mortality among men globally. Rare germline mutations in BRCA2 have been validated robustly as increasing risk of aggressive forms with a poorer prognosis; however, evidence remains less definitive for other genes. OBJECTIVE: To detect genes associated with PrCa aggressiveness, through a pooled analysis of rare variant sequencing data from six previously reported studies in the UK Genetic Prostate Cancer Study (UKGPCS). DESIGN, SETTING, AND PARTICIPANTS: We accumulated a cohort of 6805 PrCa cases, in which a set of ten candidate genes had been sequenced in all samples. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We examined the association between rare putative loss of function (pLOF) variants in each gene and aggressive classification (defined as any of death from PrCa, metastatic disease, stage T4, or both stage T3 and Gleason score ≥8). Secondary analyses examined staging phenotypes individually. Cox proportional hazards modelling and Kaplan-Meier survival analyses were used to further examine the relationship between mutation status and survival. RESULTS AND LIMITATIONS: We observed associations between PrCa aggressiveness and pLOF mutations in ATM, BRCA2, MSH2, and NBN (odds ratio = 2.67-18.9). These four genes and MLH1 were additionally associated with one or more secondary analysis phenotype. Carriers of germline mutations in these genes experienced shorter PrCa-specific survival (hazard ratio = 2.15, 95% confidence interval 1.79-2.59, p = 4 × 10-16) than noncarriers. CONCLUSIONS: This study provides further support that rare pLOF variants in specific genes are likely to increase aggressive PrCa risk and may help define the panel of informative genes for screening and treatment considerations. PATIENT SUMMARY: By combining data from several previous studies, we have been able to enhance knowledge regarding genes in which inherited mutations would be expected to increase the risk of more aggressive PrCa. This may, in the future, aid in the identification of men at an elevated risk of dying from PrCa..
Woodcock, D.J.
Sahli, A.
Teslo, R.
Bhandari, V.
Gruber, A.J.
Ziubroniewicz, A.
Gundem, G.
Xu, Y.
Butler, A.
Anokian, E.
Pope, B.J.
Jung, C.-.
Tarabichi, M.
Dentro, S.C.
Farmery, J.H.
CRUK ICGC Prostate Group,
Van Loo, P.
Warren, A.Y.
Gnanapragasam, V.
Hamdy, F.C.
Bova, G.S.
Foster, C.S.
Neal, D.E.
Lu, Y.-.
Kote-Jarai, Z.
Fraser, M.
Bristow, R.G.
Boutros, P.C.
Costello, A.J.
Corcoran, N.M.
Hovens, C.M.
Massie, C.E.
Lynch, A.G.
Brewer, D.S.
Eeles, R.A.
Cooper, C.S.
Wedge, D.C.
(2024). Genomic evolution shapes prostate cancer disease type. Cell genom,
Vol.4
(3),
p. 100511.
show abstract
full text
The development of cancer is an evolutionary process involving the sequential acquisition of genetic alterations that disrupt normal biological processes, enabling tumor cells to rapidly proliferate and eventually invade and metastasize to other tissues. We investigated the genomic evolution of prostate cancer through the application of three separate classification methods, each designed to investigate a different aspect of tumor evolution. Integrating the results revealed the existence of two distinct types of prostate cancer that arise from divergent evolutionary trajectories, designated as the Canonical and Alternative evolutionary disease types. We therefore propose the evotype model for prostate cancer evolution wherein Alternative-evotype tumors diverge from those of the Canonical-evotype through the stochastic accumulation of genetic alterations associated with disruptions to androgen receptor DNA binding. Our model unifies many previous molecular observations, providing a powerful new framework to investigate prostate cancer disease progression..
Darst, B.F.
Saunders, E.
Dadaev, T.
Sheng, X.
Wan, P.
Pooler, L.
Xia, L.Y.
Chanock, S.
Berndt, S.I.
Wang, Y.
Patel, A.V.
Albanes, D.
Weinstein, S.J.
Gnanapragasam, V.
Huff, C.
Couch, F.J.
Wolk, A.
Giles, G.G.
Nguyen-Dumont, T.
Milne, R.L.
Pomerantz, M.M.
Schmidt, J.A.
Travis, R.C.
Key, T.J.
Stopsack, K.H.
Mucci, L.A.
Catalona, W.J.
Marosy, B.
Hetrick, K.N.
Doheny, K.F.
MacInnis, R.J.
Southey, M.C.
Eeles, R.A.
Wiklund, F.
Conti, D.V.
Kote-Jarai, Z.
Haiman, C.A.
(2023). Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive Prostate Cancer. Jama oncol,
Vol.9
(11),
pp. 1514-1524.
show abstract
IMPORTANCE: Germline gene panel testing is recommended for men with advanced prostate cancer (PCa) or a family history of cancer. While evidence is limited for some genes currently included in panel testing, gene panels are also likely to be incomplete and missing genes that influence PCa risk and aggressive disease. OBJECTIVE: To identify genes associated with aggressive PCa. DESIGN, SETTING, AND PARTICIPANTS: A 2-stage exome sequencing case-only genetic association study was conducted including men of European ancestry from 18 international studies. Data analysis was performed from January 2021 to March 2023. Participants were 9185 men with aggressive PCa (including 6033 who died of PCa and 2397 with confirmed metastasis) and 8361 men with nonaggressive PCa. EXPOSURE: Sequencing data were evaluated exome-wide and in a focused investigation of 29 DNA repair pathway and cancer susceptibility genes, many of which are included on gene panels. MAIN OUTCOMES AND MEASURES: The primary study outcomes were aggressive (category T4 or both T3 and Gleason score ≥8 tumors, metastatic PCa, or PCa death) vs nonaggressive PCa (category T1 or T2 and Gleason score ≤6 tumors without known recurrence), and metastatic vs nonaggressive PCa. RESULTS: A total of 17 546 men of European ancestry were included in the analyses; mean (SD) age at diagnosis was 65.1 (9.2) years in patients with aggressive PCa and 63.7 (8.0) years in those with nonaggressive disease. The strongest evidence of association with aggressive or metastatic PCa was noted for rare deleterious variants in known PCa risk genes BRCA2 and ATM (P ≤ 1.9 × 10-6), followed by NBN (P = 1.7 × 10-4). This study found nominal evidence (P < .05) of association with rare deleterious variants in MSH2, XRCC2, and MRE11A. Five other genes had evidence of greater risk (OR≥2) but carrier frequency differences between aggressive and nonaggressive PCa were not statistically significant: TP53, RAD51D, BARD1, GEN1, and SLX4. Deleterious variants in these 11 candidate genes were carried by 2.3% of patients with nonaggressive, 5.6% with aggressive, and 7.0% with metastatic PCa. CONCLUSIONS AND RELEVANCE: The findings of this study provide further support for DNA repair and cancer susceptibility genes to better inform disease management in men with PCa and for extending testing to men with nonaggressive disease, as men carrying deleterious alleles in these genes are likely to develop more advanced disease..
Brook, M.N.
Ní Raghallaigh, H.
Govindasami, K.
Dadaev, T.
Rageevakumar, R.
Keating, D.
Hussain, N.
Osborne, A.
Lophatananon, A.
UKGPCS Collaborators,
Muir, K.R.
Kote-Jarai, Z.
Eeles, R.A.
(2023). Family History of Prostate Cancer and Survival Outcomes in the UK Genetic Prostate Cancer Study. Eur urol,
Vol.83
(3),
pp. 257-266.
show abstract
full text
BACKGROUND: A family history (FH) of prostate cancer (PrCa) is associated with an increased likelihood of PrCa diagnosis. Conflicting evidence exists regarding familial PrCa and clinical outcomes among PrCa patients, including all-cause mortality/overall survival (OS), PrCa-specific survival (PCSS), aggressive histology, and stage at diagnosis. OBJECTIVE: To determine how the number, degree, and age of a PrCa patient's affected relatives are associated with OS and PCSS of those already diagnosed with PrCa. DESIGN, SETTING, AND PARTICIPANTS: The UK Genetic Prostate Cancer Study is a longitudinal, multi-institutional, observational study collecting baseline and follow-up clinical data since 1992. We examined OS and PCSS in 16340 men by degree and number of relatives with prostate and genetically related cancers (breast, ovarian, and colorectal). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome was all-cause mortality among PrCa patients. The risk of death with respect to FH was assessed by calculating hazard ratios from Cox proportional hazard regression models, adjusting for relevant factors. RESULTS AND LIMITATIONS: A stronger FH was inversely associated with the risk of all-cause and PrCa-specific mortality. This association was greater in those with an increasing number (p-trend < 0.001) and increasing closeness (p-trend < 0.001) of the diagnosed relatives. Patients with at least one first-degree relative were at a lower risk of all-cause mortality than those with no FH (hazard ratio = 0.82 [95% confidence interval 0.75-0.89]). The population is largely of European ancestry, and this may cause an issue with representation and generalisation. Data are missing on epidemiological risk factors for death such as smoking and on comorbidities. Recall of family members' diagnoses may affect the classification of FH in unconfirmed cases. CONCLUSIONS: Based on the investigation of the type and timing of relatives' cancers, it is likely that reductions in mortality are due almost completely to a greater awareness of the disease. This study provides information for clinicians guiding patients and their relatives based on their familial risk. It shows the importance of screening and awareness programmes, which are likely to improve survival among men with an FH. PATIENT SUMMARY: We were interested in how a family history of prostate cancer affects survival in prostate cancer patients. We studied 16340 patients, categorised them according to the strength of their family history, and found that the stronger their family history, the better they did in terms of overall survival. We looked at the type and timing of patients' diagnoses compared with those of their relatives and found that this effect is likely to be explained by awareness, which indicates the importance of screening and awareness programmes..
Gheybi, K.
Jiang, J.
Mutambirwa, S.B.
Soh, P.X.
Kote-Jarai, Z.
Jaratlerdsiri, W.
Eeles, R.A.
Bornman, M.S.
Hayes, V.M.
(2023). Evaluating Germline Testing Panels in Southern African Males With Advanced Prostate Cancer. J natl compr canc netw,
Vol.21
(3),
pp. 289-296.e3.
show abstract
full text
BACKGROUND: Germline testing for prostate cancer is on the increase, with clinical implications for risk assessment, treatment, and management. Regardless of family history, NCCN recommends germline testing for patients with metastatic, regional, very-high-risk localized, and high-risk localized prostate cancer. Although African ancestry is a significant risk factor for aggressive prostate cancer, due to a lack of available data no testing criteria have been established for ethnic minorities. PATIENTS AND METHODS: Through deep sequencing, we interrogated the 20 most common germline testing panel genes in 113 Black South African males presenting with largely advanced prostate cancer. Bioinformatic tools were then used to identify the pathogenicity of the variants. RESULTS: After we identified 39 predicted deleterious variants (16 genes), further computational annotation classified 17 variants as potentially oncogenic (12 genes; 17.7% of patients). Rare pathogenic variants included CHEK2 Arg95Ter, BRCA2 Trp31Arg, ATM Arg3047Ter (2 patients), and TP53 Arg282Trp. Notable oncogenic variants of unknown pathogenicity included novel BRCA2 Leu3038Ile in a patient with early-onset disease, whereas patients with FANCA Arg504Cys and RAD51C Arg260Gln reported a family history of prostate cancer. Overall, rare pathogenic and early-onset or familial-associated oncogenic variants were identified in 6.9% (5/72) and 9.2% (8/87) of patients presenting with a Gleason score ≥8 or ≥4 + 3 prostate cancer, respectively. CONCLUSIONS: In this first-of-its-kind study of southern African males, we provide support of African inclusion for advanced, early-onset, and familial prostate cancer genetic testing, indicating clinical value for 30% of current gene panels. Recognizing current panel limitations highlights an urgent need to establish testing guidelines for men of African ancestry. We provide a rationale for considering lowering the pathologic diagnostic inclusion criteria and call for further genome-wide interrogation to ensure the best possible African-relevant prostate cancer gene panel..
Dias, A.
Brook, M.N.
Bancroft, E.K.
Page, E.C.
Chamberlain, A.
Saya, S.
Amin, J.
Mikropoulos, C.
Taylor, N.
Myhill, K.
Thomas, S.
Saunders, E.
Dadaev, T.
Leongamornlert, D.
Dyrsø Jensen, T.
Evans, D.G.
Cybulski, C.
Liljegren, A.
Teo, S.H.
Side, L.
IMPACT study collaborators and Steering Committee,
Kote-Jarai, Z.
Eeles, R.A.
(2023). Serum testosterone and prostate cancer in men with germline BRCA1/2 pathogenic variants. Bjui compass,
Vol.4
(3),
pp. 361-373.
show abstract
full text
OBJECTIVES: The relation of serum androgens and the development of prostate cancer (PCa) is subject of debate. Lower total testosterone (TT) levels have been associated with increased PCa detection and worse pathological features after treatment. However, data from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) and Prostate Cancer Prevention (PCPT) trial groups indicate no association. The aim of this study is to investigate the association of serum androgen levels and PCa detection in a prospective screening study of men at higher genetic risk of aggressive PCa due to BRCA1/2 pathogenic variants (PVs), the IMPACT study. METHODS: Men enrolled in the IMPACT study provided serum samples during regular visits. Hormonal levels were calculated using immunoassays. Free testosterone (FT) was calculated from TT and sex hormone binding globulin (SHBG) using the Sodergard mass equation. Age, body mass index (BMI), prostate-specific antigen (PSA) and hormonal concentrations were compared between genetic cohorts. We also explored associations between age and TT, SHBG, FT and PCa, in the whole subset and stratified by BRCA1/2 PVs status. RESULTS: A total of 777 participants in the IMPACT study had TT and SHBG measurements in serum samples at annual visits, giving 3940 prospective androgen levels, from 266 BRCA1 PVs carriers, 313 BRCA2 PVs carriers and 198 non-carriers. The median number of visits per patient was 5. There was no difference in TT, SHBG and FT between carriers and non-carriers. In a univariate analysis, androgen levels were not associated with PCa. In the analysis stratified by carrier status, no significant association was found between hormonal levels and PCa in non-carriers, BRCA1 or BRCA2 PVs carriers. CONCLUSIONS: Male BRCA1/2 PVs carriers have a similar androgen profile to non-carriers. Hormonal levels were not associated with PCa in men with and without BRCA1/2 PVs. Mechanisms related to the particularly aggressive phenotype of PCa in BRCA2 PVs carriers may therefore not be linked with circulating hormonal levels..
Darst, B.F.
Shen, J.
Madduri, R.K.
Rodriguez, A.A.
Xiao, Y.
Sheng, X.
Saunders, E.J.
Dadaev, T.
Brook, M.N.
Hoffmann, T.J.
Muir, K.
Wan, P.
Le Marchand, L.
Wilkens, L.
Wang, Y.
Schleutker, J.
MacInnis, R.J.
Cybulski, C.
Neal, D.E.
Nordestgaard, B.G.
Nielsen, S.F.
Batra, J.
Clements, J.A.
Cancer BioResource, A.P.
Grönberg, H.
Pashayan, N.
Travis, R.C.
Park, J.Y.
Albanes, D.
Weinstein, S.
Mucci, L.A.
Hunter, D.J.
Penney, K.L.
Tangen, C.M.
Hamilton, R.J.
Parent, M.-.
Stanford, J.L.
Koutros, S.
Wolk, A.
Sørensen, K.D.
Blot, W.J.
Yeboah, E.D.
Mensah, J.E.
Lu, Y.-.
Schaid, D.J.
Thibodeau, S.N.
West, C.M.
Maier, C.
Kibel, A.S.
Cancel-Tassin, G.
Menegaux, F.
John, E.M.
Grindedal, E.M.
Khaw, K.-.
Ingles, S.A.
Vega, A.
Rosenstein, B.S.
Teixeira, M.R.
NC-LA PCaP Investigators,
Kogevinas, M.
Cannon-Albright, L.
Huff, C.
Multigner, L.
Kaneva, R.
Leach, R.J.
Brenner, H.
Hsing, A.W.
Kittles, R.A.
Murphy, A.B.
Logothetis, C.J.
Neuhausen, S.L.
Isaacs, W.B.
Nemesure, B.
Hennis, A.J.
Carpten, J.
Pandha, H.
De Ruyck, K.
Xu, J.
Razack, A.
Teo, S.-.
Canary PASS Investigators,
Newcomb, L.F.
Fowke, J.H.
Neslund-Dudas, C.
Rybicki, B.A.
Gamulin, M.
Usmani, N.
Claessens, F.
Gago-Dominguez, M.
Castelao, J.E.
Townsend, P.A.
Crawford, D.C.
Petrovics, G.
Casey, G.
Roobol, M.J.
Hu, J.F.
Berndt, S.I.
Van Den Eeden, S.K.
Easton, D.F.
Chanock, S.J.
Cook, M.B.
Wiklund, F.
Witte, J.S.
Eeles, R.A.
Kote-Jarai, Z.
Watya, S.
Gaziano, J.M.
Justice, A.C.
Conti, D.V.
Haiman, C.A.
(2023). Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry. Am j hum genet,
Vol.110
(7),
pp. 1200-1206.
show abstract
Genome-wide polygenic risk scores (GW-PRSs) have been reported to have better predictive ability than PRSs based on genome-wide significance thresholds across numerous traits. We compared the predictive ability of several GW-PRS approaches to a recently developed PRS of 269 established prostate cancer-risk variants from multi-ancestry GWASs and fine-mapping studies (PRS269). GW-PRS models were trained with a large and diverse prostate cancer GWAS of 107,247 cases and 127,006 controls that we previously used to develop the multi-ancestry PRS269. Resulting models were independently tested in 1,586 cases and 1,047 controls of African ancestry from the California Uganda Study and 8,046 cases and 191,825 controls of European ancestry from the UK Biobank and further validated in 13,643 cases and 210,214 controls of European ancestry and 6,353 cases and 53,362 controls of African ancestry from the Million Veteran Program. In the testing data, the best performing GW-PRS approach had AUCs of 0.656 (95% CI = 0.635-0.677) in African and 0.844 (95% CI = 0.840-0.848) in European ancestry men and corresponding prostate cancer ORs of 1.83 (95% CI = 1.67-2.00) and 2.19 (95% CI = 2.14-2.25), respectively, for each SD unit increase in the GW-PRS. Compared to the GW-PRS, in African and European ancestry men, the PRS269 had larger or similar AUCs (AUC = 0.679, 95% CI = 0.659-0.700 and AUC = 0.845, 95% CI = 0.841-0.849, respectively) and comparable prostate cancer ORs (OR = 2.05, 95% CI = 1.87-2.26 and OR = 2.21, 95% CI = 2.16-2.26, respectively). Findings were similar in the validation studies. This investigation suggests that current GW-PRS approaches may not improve the ability to predict prostate cancer risk compared to the PRS269 developed from multi-ancestry GWASs and fine-mapping..
Hansen, E.B.
Karlsson, Q.
Merson, S.
Wakerell, S.
Rageevakumar, R.
Jensen, J.B.
Borre, M.
Kote-Jarai, Z.
Eeles, R.A.
Sørensen, K.D.
(2023). Impact of germline DNA repair gene variants on prognosis and treatment of men with advanced prostate cancer. Sci rep,
Vol.13
(1),
p. 19135.
show abstract
full text
The clinical importance of germline variants in DNA repair genes (DRGs) is becoming increasingly recognized, but their impact on advanced prostate cancer prognosis remains unclear. A cohort of 221 newly diagnosed metastatic castration-resistant prostate cancer (mCRPC) patients were screened for pathogenic germline variants in 114 DRGs. The primary endpoint was progression-free survival (PFS) on first-line androgen signaling inhibitor (ARSI) treatment for mCRPC. Secondary endpoints were time to mCRPC progression on initial androgen deprivation therapy (ADT) and overall survival (OS). Twenty-seven patients (12.2%) carried a germline DRG variant. DRG carrier status was independently associated with shorter PFS on first-line ARSI [HR 1.72 (1.06-2.81), P = 0.029]. At initiation of ADT, DRG carrier status was independently associated with shorter progression time to mCRPC [HR 1.56, (1.02-2.39), P = 0.04] and shorter OS [HR 1.99, (1.12-3.52), P = 0.02]. Investigating the contributions of individual germline DRG variants on PFS and OS revealed CHEK2 variants to have little effect. Furthermore, prior taxane treatment was associated with worse PFS on first-line ARSI for DRG carriers excluding CHEK2 (P = 0.0001), but not for noncarriers. In conclusion, germline DRG carrier status holds independent prognostic value for predicting advanced prostate cancer patient outcomes and may potentially inform on optimal treatment sequencing already at the hormone-sensitive stage..
Chen, F.
Madduri, R.K.
Rodriguez, A.A.
Darst, B.F.
Chou, A.
Sheng, X.
Wang, A.
Shen, J.
Saunders, E.J.
Rhie, S.K.
Bensen, J.T.
Ingles, S.A.
Kittles, R.A.
Strom, S.S.
Rybicki, B.A.
Nemesure, B.
Isaacs, W.B.
Stanford, J.L.
Zheng, W.
Sanderson, M.
John, E.M.
Park, J.Y.
Xu, J.
Wang, Y.
Berndt, S.I.
Huff, C.D.
Yeboah, E.D.
Tettey, Y.
Lachance, J.
Tang, W.
Rentsch, C.T.
Cho, K.
Mcmahon, B.H.
Biritwum, R.B.
Adjei, A.A.
Tay, E.
Truelove, A.
Niwa, S.
Sellers, T.A.
Yamoah, K.
Murphy, A.B.
Crawford, D.C.
Patel, A.V.
Bush, W.S.
Aldrich, M.C.
Cussenot, O.
Petrovics, G.
Cullen, J.
Neslund-Dudas, C.M.
Stern, M.C.
Kote-Jarai, Z.
Govindasami, K.
Cook, M.B.
Chokkalingam, A.P.
Hsing, A.W.
Goodman, P.J.
Hoffmann, T.J.
Drake, B.F.
Hu, J.J.
Keaton, J.M.
Hellwege, J.N.
Clark, P.E.
Jalloh, M.
Gueye, S.M.
Niang, L.
Ogunbiyi, O.
Idowu, M.O.
Popoola, O.
Adebiyi, A.O.
Aisuodionoe-Shadrach, O.I.
Ajibola, H.O.
Jamda, M.A.
Oluwole, O.P.
Nwegbu, M.
Adusei, B.
Mante, S.
Darkwa-Abrahams, A.
Mensah, J.E.
Diop, H.
Van Den Eeden, S.K.
Blanchet, P.
Fowke, J.H.
Casey, G.
Hennis, A.J.
Lubwama, A.
Thompson, I.M.
Leach, R.
Easton, D.F.
Preuss, M.H.
Loos, R.J.
Gundell, S.M.
Wan, P.
Mohler, J.L.
Fontham, E.T.
Smith, G.J.
Taylor, J.A.
Srivastava, S.
Eeles, R.A.
Carpten, J.D.
Kibel, A.S.
Multigner, L.
Parent, M.-.
Menegaux, F.
Cancel-Tassin, G.
Klein, E.A.
Andrews, C.
Rebbeck, T.R.
Brureau, L.
Ambs, S.
Edwards, T.L.
Watya, S.
Chanock, S.J.
Witte, J.S.
Blot, W.J.
Michael Gaziano, J.
Justice, A.C.
Conti, D.V.
Haiman, C.A.
(2023). Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry. Eur urol,
Vol.84
(1),
pp. 13-21.
show abstract
full text
BACKGROUND: Genetic factors play an important role in prostate cancer (PCa) susceptibility. OBJECTIVE: To discover common genetic variants contributing to the risk of PCa in men of African ancestry. DESIGN, SETTING, AND PARTICIPANTS: We conducted a meta-analysis of ten genome-wide association studies consisting of 19378 cases and 61620 controls of African ancestry. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Common genotyped and imputed variants were tested for their association with PCa risk. Novel susceptibility loci were identified and incorporated into a multiancestry polygenic risk score (PRS). The PRS was evaluated for associations with PCa risk and disease aggressiveness. RESULTS AND LIMITATIONS: Nine novel susceptibility loci for PCa were identified, of which seven were only found or substantially more common in men of African ancestry, including an African-specific stop-gain variant in the prostate-specific gene anoctamin 7 (ANO7). A multiancestry PRS of 278 risk variants conferred strong associations with PCa risk in African ancestry studies (odds ratios [ORs] >3 and >5 for men in the top PRS decile and percentile, respectively). More importantly, compared with men in the 40-60% PRS category, men in the top PRS decile had a significantly higher risk of aggressive PCa (OR = 1.23, 95% confidence interval = 1.10-1.38, p = 4.4 × 10-4). CONCLUSIONS: This study demonstrates the importance of large-scale genetic studies in men of African ancestry for a better understanding of PCa susceptibility in this high-risk population and suggests a potential clinical utility of PRS in differentiating between the risks of developing aggressive and nonaggressive disease in men of African ancestry. PATIENT SUMMARY: In this large genetic study in men of African ancestry, we discovered nine novel prostate cancer (PCa) risk variants. We also showed that a multiancestry polygenic risk score was effective in stratifying PCa risk, and was able to differentiate risk of aggressive and nonaggressive disease..
Yarmolinsky, J.
Bouras, E.
Constantinescu, A.
Burrows, K.
Bull, C.J.
Vincent, E.E.
Martin, R.M.
Dimopoulou, O.
Lewis, S.J.
Moreno, V.
Vujkovic, M.
Chang, K.-.
Voight, B.F.
Tsao, P.S.
Gunter, M.J.
Hampe, J.
Pellatt, A.J.
Pharoah, P.D.
Schoen, R.E.
Gallinger, S.
Jenkins, M.A.
Pai, R.K.
PRACTICAL consortium,
VA Million Veteran Program,
Gill, D.
Tsilidis, K.K.
(2023). Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis. Diabetologia,
Vol.66
(8),
pp. 1481-1500.
show abstract
AIMS/HYPOTHESIS: Epidemiological studies have generated conflicting findings on the relationship between glucose-lowering medication use and cancer risk. Naturally occurring variation in genes encoding glucose-lowering drug targets can be used to investigate the effect of their pharmacological perturbation on cancer risk. METHODS: We developed genetic instruments for three glucose-lowering drug targets (peroxisome proliferator activated receptor γ [PPARG]; sulfonylurea receptor 1 [ATP binding cassette subfamily C member 8 (ABCC8)]; glucagon-like peptide 1 receptor [GLP1R]) using summary genetic association data from a genome-wide association study of type 2 diabetes in 148,726 cases and 965,732 controls in the Million Veteran Program. Genetic instruments were constructed using cis-acting genome-wide significant (p<5×10-8) SNPs permitted to be in weak linkage disequilibrium (r2<0.20). Summary genetic association estimates for these SNPs were obtained from genome-wide association study (GWAS) consortia for the following cancers: breast (122,977 cases, 105,974 controls); colorectal (58,221 cases, 67,694 controls); prostate (79,148 cases, 61,106 controls); and overall (i.e. site-combined) cancer (27,483 cases, 372,016 controls). Inverse-variance weighted random-effects models adjusting for linkage disequilibrium were employed to estimate causal associations between genetically proxied drug target perturbation and cancer risk. Co-localisation analysis was employed to examine robustness of findings to violations of Mendelian randomisation (MR) assumptions. A Bonferroni correction was employed as a heuristic to define associations from MR analyses as 'strong' and 'weak' evidence. RESULTS: In MR analysis, genetically proxied PPARG perturbation was weakly associated with higher risk of prostate cancer (for PPARG perturbation equivalent to a 1 unit decrease in inverse rank normal transformed HbA1c: OR 1.75 [95% CI 1.07, 2.85], p=0.02). In histological subtype-stratified analyses, genetically proxied PPARG perturbation was weakly associated with lower risk of oestrogen receptor-positive breast cancer (OR 0.57 [95% CI 0.38, 0.85], p=6.45×10-3). In co-localisation analysis, however, there was little evidence of shared causal variants for type 2 diabetes liability and cancer endpoints in the PPARG locus, although these analyses were likely underpowered. There was little evidence to support associations between genetically proxied PPARG perturbation and colorectal or overall cancer risk or between genetically proxied ABCC8 or GLP1R perturbation with risk across cancer endpoints. CONCLUSIONS/INTERPRETATION: Our drug target MR analyses did not find consistent evidence to support an association of genetically proxied PPARG, ABCC8 or GLP1R perturbation with breast, colorectal, prostate or overall cancer risk. Further evaluation of these drug targets using alternative molecular epidemiological approaches may help to further corroborate the findings presented in this analysis. DATA AVAILABILITY: Summary genetic association data for select cancer endpoints were obtained from the public domain: breast cancer ( https://bcac.ccge.medschl.cam.ac.uk/bcacdata/ ); and overall prostate cancer ( http://practical.icr.ac.uk/blog/ ). Summary genetic association data for colorectal cancer can be accessed by contacting GECCO (kafdem at fredhutch.org). Summary genetic association data on advanced prostate cancer can be accessed by contacting PRACTICAL (practical at icr.ac.uk). Summary genetic association data on type 2 diabetes from Vujkovic et al (Nat Genet, 2020) can be accessed through dbGAP under accession number phs001672.v3.p1 (pha004945.1 refers to the European-specific summary statistics). UK Biobank data can be accessed by registering with UK Biobank and completing the registration form in the Access Management System (AMS) ( https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access )..
Watts, E.L.
Perez-Cornago, A.
Fensom, G.K.
Smith-Byrne, K.
Noor, U.
Andrews, C.D.
Gunter, M.J.
Holmes, M.V.
Martin, R.M.
Tsilidis, K.K.
Albanes, D.
Barricarte, A.
Bueno-de-Mesquita, H.B.
Cohn, B.A.
Deschasaux-Tanguy, M.
Dimou, N.L.
Ferrucci, L.
Flicker, L.
Freedman, N.D.
Giles, G.G.
Giovannucci, E.L.
Haiman, C.A.
Hankey, G.J.
Holly, J.M.
Huang, J.
Huang, W.-.
Hurwitz, L.M.
Kaaks, R.
Kubo, T.
Le Marchand, L.
MacInnis, R.J.
Männistö, S.
Metter, E.J.
Mikami, K.
Mucci, L.A.
Olsen, A.W.
Ozasa, K.
Palli, D.
Penney, K.L.
Platz, E.A.
Pollak, M.N.
Roobol, M.J.
Schaefer, C.A.
Schenk, J.M.
Stattin, P.
Tamakoshi, A.
Thysell, E.
Tsai, C.J.
Touvier, M.
Van Den Eeden, S.K.
Weiderpass, E.
Weinstein, S.J.
Wilkens, L.R.
Yeap, B.B.
PRACTICAL Consortium, CRUK, BPC3, CAPS, PEGASUS,
Allen, N.E.
Key, T.J.
Travis, R.C.
(2023). Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis. Int j epidemiol,
Vol.52
(1),
pp. 71-86.
show abstract
BACKGROUND: Previous studies had limited power to assess the associations of circulating insulin-like growth factors (IGFs) and IGF-binding proteins (IGFBPs) with clinically relevant prostate cancer as a primary endpoint, and the association of genetically predicted IGF-I with aggressive prostate cancer is not known. We aimed to investigate the associations of IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 concentrations with overall, aggressive and early-onset prostate cancer. METHODS: Prospective analysis of biomarkers using the Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group dataset (up to 20 studies, 17 009 prostate cancer cases, including 2332 aggressive cases). Odds ratios (OR) and 95% confidence intervals (CI) for prostate cancer were estimated using conditional logistic regression. For IGF-I, two-sample Mendelian randomization (MR) analysis was undertaken using instruments identified using UK Biobank (158 444 men) and outcome data from PRACTICAL (up to 85 554 cases, including 15 167 aggressive cases). Additionally, we used colocalization to rule out confounding by linkage disequilibrium. RESULTS: In observational analyses, IGF-I was positively associated with risks of overall (OR per 1 SD = 1.09: 95% CI 1.07, 1.11), aggressive (1.09: 1.03, 1.16) and possibly early-onset disease (1.11: 1.00, 1.24); associations were similar in MR analyses (OR per 1 SD = 1.07: 1.00, 1.15; 1.10: 1.01, 1.20; and 1.13; 0.98, 1.30, respectively). Colocalization also indicated a shared signal for IGF-I and prostate cancer (PP4: 99%). Men with higher IGF-II (1.06: 1.02, 1.11) and IGFBP-3 (1.08: 1.04, 1.11) had higher risks of overall prostate cancer, whereas higher IGFBP-1 was associated with a lower risk (0.95: 0.91, 0.99); these associations were attenuated following adjustment for IGF-I. CONCLUSIONS: These findings support the role of IGF-I in the development of prostate cancer, including for aggressive disease..
Haiman, C.A.
Kote-Jarai, Z.
Darst, B.F.
Conti, D.V.
(2023). RE: Polygenic risk of any, metastatic, and fatal prostate cancer in the Million Veteran Program. J natl cancer inst,
Vol.115
(3),
pp. 341-342.
Nyberg, T.
Brook, M.N.
Ficorella, L.
Lee, A.
Dennis, J.
Yang, X.
Wilcox, N.
Dadaev, T.
Govindasami, K.
Lush, M.
Leslie, G.
Lophatananon, A.
Muir, K.
Bancroft, E.
Easton, D.F.
Tischkowitz, M.
Kote-Jarai, Z.
Eeles, R.
Antoniou, A.C.
(2023). CanRisk-Prostate: A Comprehensive, Externally Validated Risk Model for the Prediction of Future Prostate Cancer. J clin oncol,
Vol.41
(5),
pp. 1092-1104.
show abstract
full text
PURPOSE: Prostate cancer (PCa) is highly heritable. No validated PCa risk model currently exists. We therefore sought to develop a genetic risk model that can provide personalized predicted PCa risks on the basis of known moderate- to high-risk pathogenic variants, low-risk common genetic variants, and explicit cancer family history, and to externally validate the model in an independent prospective cohort. MATERIALS AND METHODS: We developed a risk model using a kin-cohort comprising individuals from 16,633 PCa families ascertained in the United Kingdom from 1993 to 2017 from the UK Genetic Prostate Cancer Study, and complex segregation analysis adjusting for ascertainment. The model was externally validated in 170,850 unaffected men (7,624 incident PCas) recruited from 2006 to 2010 to the independent UK Biobank prospective cohort study. RESULTS: The most parsimonious model included the effects of pathogenic variants in BRCA2, HOXB13, and BRCA1, and a polygenic score on the basis of 268 common low-risk variants. Residual familial risk was modeled by a hypothetical recessively inherited variant and a polygenic component whose standard deviation decreased log-linearly with age. The model predicted familial risks that were consistent with those reported in previous observational studies. In the validation cohort, the model discriminated well between unaffected men and men with incident PCas within 5 years (C-index, 0.790; 95% CI, 0.783 to 0.797) and 10 years (C-index, 0.772; 95% CI, 0.768 to 0.777). The 50% of men with highest predicted risks captured 86.3% of PCa cases within 10 years. CONCLUSION: To our knowledge, this is the first validated risk model offering personalized PCa risks. The model will assist in counseling men concerned about their risk and can facilitate future risk-stratified population screening approaches..
Wang, A.
Xu, Y.
Yu, Y.
Nead, K.T.
Kim, T.
Xu, K.
Dadaev, T.
Saunders, E.
Sheng, X.
Wan, P.
Pooler, L.
Xia, L.Y.
Chanock, S.
Berndt, S.I.
Gapstur, S.M.
Stevens, V.
Albanes, D.
Weinstein, S.J.
Gnanapragasam, V.
Giles, G.G.
Nguyen-Dumont, T.
Milne, R.L.
Pomerantz, M.M.
Schmidt, J.A.
Stopsack, K.H.
Mucci, L.A.
Catalona, W.J.
Hetrick, K.N.
Doheny, K.F.
MacInnis, R.J.
Southey, M.C.
Eeles, R.A.
Wiklund, F.
Kote-Jarai, Z.
de Smith, A.J.
Conti, D.V.
Huff, C.
Haiman, C.A.
Darst, B.F.
(2023). Clonal hematopoiesis and risk of prostate cancer in large samples of European ancestry men. Hum mol genet,
Vol.32
(3),
pp. 489-495.
show abstract
full text
Little is known regarding the potential relationship between clonal hematopoiesis (CH) of indeterminate potential (CHIP), which is the expansion of hematopoietic stem cells with somatic mutations, and risk of prostate cancer, the fifth leading cause of cancer death of men worldwide. We evaluated the association of age-related CHIP with overall and aggressive prostate cancer risk in two large whole-exome sequencing studies of 75 047 European ancestry men, including 7663 prostate cancer cases, 2770 of which had aggressive disease, and 3266 men carrying CHIP variants. We found that CHIP, defined by over 50 CHIP genes individually and in aggregate, was not significantly associated with overall (aggregate HR = 0.93, 95% CI = 0.76-1.13, P = 0.46) or aggressive (aggregate OR = 1.14, 95% CI = 0.92-1.41, P = 0.22) prostate cancer risk. CHIP was weakly associated with genetic risk of overall prostate cancer, measured using a polygenic risk score (OR = 1.05 per unit increase, 95% CI = 1.01-1.10, P = 0.01). CHIP was not significantly associated with carrying pathogenic/likely pathogenic/deleterious variants in DNA repair genes, which have previously been found to be associated with aggressive prostate cancer. While findings from this study suggest that CHIP is likely not a risk factor for prostate cancer, it will be important to investigate other types of CH in association with prostate cancer risk..
Ito, S.
Liu, X.
Ishikawa, Y.
Conti, D.D.
Otomo, N.
Kote-Jarai, Z.
Suetsugu, H.
Eeles, R.A.
Koike, Y.
Hikino, K.
Yoshino, S.
Tomizuka, K.
Horikoshi, M.
Ito, K.
Uchio, Y.
Momozawa, Y.
Kubo, M.
BioBank Japan Project,
Kamatani, Y.
Matsuda, K.
Haiman, C.A.
Ikegawa, S.
Nakagawa, H.
Terao, C.
(2023). Androgen receptor binding sites enabling genetic prediction of mortality due to prostate cancer in cancer-free subjects. Nat commun,
Vol.14
(1),
p. 4863.
show abstract
full text
Prostate cancer (PrCa) is the second most common cancer worldwide in males. While strongly warranted, the prediction of mortality risk due to PrCa, especially before its development, is challenging. Here, we address this issue by maximizing the statistical power of genetic data with multi-ancestry meta-analysis and focusing on binding sites of the androgen receptor (AR), which has a critical role in PrCa. Taking advantage of large Japanese samples ever, a multi-ancestry meta-analysis comprising more than 300,000 subjects in total identifies 9 unreported loci including ZFHX3, a tumor suppressor gene, and successfully narrows down the statistically finemapped variants compared to European-only studies, and these variants strongly enrich in AR binding sites. A polygenic risk scores (PRS) analysis restricting to statistically finemapped variants in AR binding sites shows among cancer-free subjects, individuals with a PRS in the top 10% have a strongly higher risk of the future death of PrCa (HR: 5.57, P = 4.2 × 10-10). Our findings demonstrate the potential utility of leveraging large-scale genetic data and advanced analytical methods in predicting the mortality of PrCa..
Karunamuni, R.A.
Huynh-Le, M.-.
Fan, C.C.
Thompson, W.
Lui, A.
Martinez, M.E.
Rose, B.S.
Mahal, B.
Eeles, R.A.
Kote-Jarai, Z.
Muir, K.
Lophatananon, A.
UKGPCS Collaborators,
Tangen, C.M.
Goodman, P.J.
Thompson, I.M.
Blot, W.J.
Zheng, W.
Kibel, A.S.
Drake, B.F.
Cussenot, O.
Cancel-Tassin, G.
Menegaux, F.
Truong, T.
Park, J.Y.
Lin, H.-.
Taylor, J.A.
Bensen, J.T.
Mohler, J.L.
Fontham, E.T.
Multigner, L.
Blanchet, P.
Brureau, L.
Romana, M.
Leach, R.J.
John, E.M.
Fowke, J.H.
Bush, W.S.
Aldrich, M.C.
Crawford, D.C.
Cullen, J.
Petrovics, G.
Parent, M.-.
Hu, J.J.
Sanderson, M.
PRACTICAL Consortium,
Mills, I.G.
Andreassen, O.A.
Dale, A.M.
Seibert, T.M.
(2022). Performance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24. Prostate cancer prostatic dis,
Vol.25
(2),
pp. 229-237.
show abstract
full text
BACKGROUND: We previously developed an African-ancestry-specific polygenic hazard score (PHS46+African) that substantially improved prostate cancer risk stratification in men with African ancestry. The model consists of 46 SNPs identified in Europeans and 3 SNPs from 8q24 shown to improve model performance in Africans. Herein, we used principal component (PC) analysis to uncover subpopulations of men with African ancestry for whom the utility of PHS46+African may differ. MATERIALS AND METHODS: Genotypic data were obtained from the PRACTICAL consortium for 6253 men with African genetic ancestry. Genetic variation in a window spanning 3 African-specific 8q24 SNPs was estimated using 93 PCs. A Cox proportional hazards framework was used to identify the pair of PCs most strongly associated with the performance of PHS46+African. A calibration factor (CF) was formulated using Cox coefficients to quantify the extent to which the performance of PHS46+African varies with PC. RESULTS: CF of PHS46+African was strongly associated with the first and twentieth PCs. Predicted CF ranged from 0.41 to 2.94, suggesting that PHS46+African may be up to 7 times more beneficial to some African men than others. The explained relative risk for PHS46+African varied from 3.6% to 9.9% for individuals with low and high CF values, respectively. By cross-referencing our data set with 1000 Genomes, we identified significant associations between continental and calibration groupings. CONCLUSION: We identified PCs within 8q24 that were strongly associated with the performance of PHS46+African. Further research to improve the clinical utility of polygenic risk scores (or models) is needed to improve health outcomes for men of African ancestry..
Benafif, S.
Ni Raghallaigh, H.
McGrowder, E.
Saunders, E.J.
Brook, M.N.
Saya, S.
Rageevakumar, R.
Wakerell, S.
James, D.
Chamberlain, A.
Taylor, N.
Hogben, M.
Benton, B.
D'Mello, L.
Myhill, K.
Mikropoulos, C.
Bowen-Perkins, H.
Rafi, I.
Ferris, M.
Beattie, A.
Kuganolipava, S.
Sevenoaks, T.
Bower, J.
Kumar, P.
Hazell, S.
deSouza, N.M.
Antoniou, A.
Bancroft, E.
Kote-Jarai, Z.
Eeles, R.
(2022). The BARCODE1 Pilot: a feasibility study of using germline single nucleotide polymorphisms to target prostate cancer screening. Bju int,
Vol.129
(3),
pp. 325-336.
show abstract
full text
OBJECTIVES: To assess the feasibility and uptake of a community-based prostate cancer (PCa) screening programme selecting men according to their genetic risk of PCa. To assess the uptake of PCa screening investigations by men invited for screening. The uptake of the pilot study would guide the opening of the larger BARCODE1 study recruiting 5000 men. SUBJECTS AND METHODS: Healthy males aged 55-69 years were invited to participate via their general practitioners (GPs). Saliva samples were collected via mailed collection kits. After DNA extraction, genotyping was conducted using a study specific assay. Genetic risk was based on genotyping 130 germline PCa risk single nucleotide polymorphisms (SNPs). A polygenic risk score (PRS) was calculated for each participant using the sum of weighted alleles for 130 SNPs. Study participants with a PRS lying above the 90th centile value were invited for PCa screening by prostate magnetic resonance imaging (MRI) and biopsy. RESULTS: Invitation letters were sent to 1434 men. The overall study uptake was 26% (375/1436) and 87% of responders were eligible for study entry. DNA genotyping data were available for 297 men and 25 were invited for screening. After exclusions due to medical comorbidity/invitations declined, 18 of 25 men (72%) underwent MRI and biopsy of the prostate. There were seven diagnoses of PCa (38.9%). All cancers were low-risk and were managed with active surveillance. CONCLUSION: The BARCODE1 Pilot has shown this community study in the UK to be feasible, with an overall uptake of 26%. The main BARCODE1 study is now open and will recruit 5000 men. The results of BARCODE1 will be important in defining the role of genetic profiling in targeted PCa population screening. Patient Summary What is the paper about? Very few prostate cancer screening programmes currently exist anywhere in the world. Our pilot study investigated if men in the UK would find it acceptable to have a genetic test based on a saliva sample to examine their risk of prostate cancer development. This test would guide whether men are offered prostate cancer screening tests. What does it mean for patients? We found that the study design was acceptable: 26% of men invited to take part agreed to have the test. The majority of men who were found to have an increased genetic risk of prostate cancer underwent further tests offered (prostate MRI scan and biopsy). We have now expanded the study to enrol 5000 men. The BARCODE1 study will be important in examining whether this approach could be used for large-scale population prostate cancer screening..
Huynh-Le, M.-.
Karunamuni, R.
Fan, C.C.
Asona, L.
Thompson, W.K.
Martinez, M.E.
Eeles, R.A.
Kote-Jarai, Z.
Muir, K.R.
Lophatananon, A.
Schleutker, J.
Pashayan, N.
Batra, J.
Grönberg, H.
Neal, D.E.
Nordestgaard, B.G.
Tangen, C.M.
MacInnis, R.J.
Wolk, A.
Albanes, D.
Haiman, C.A.
Travis, R.C.
Blot, W.J.
Stanford, J.L.
Mucci, L.A.
West, C.M.
Nielsen, S.F.
Kibel, A.S.
Cussenot, O.
Berndt, S.I.
Koutros, S.
Sørensen, K.D.
Cybulski, C.
Grindedal, E.M.
Menegaux, F.
Park, J.Y.
Ingles, S.A.
Maier, C.
Hamilton, R.J.
Rosenstein, B.S.
Lu, Y.-.
Watya, S.
Vega, A.
Kogevinas, M.
Wiklund, F.
Penney, K.L.
Huff, C.D.
Teixeira, M.R.
Multigner, L.
Leach, R.J.
Brenner, H.
John, E.M.
Kaneva, R.
Logothetis, C.J.
Neuhausen, S.L.
De Ruyck, K.
Ost, P.
Razack, A.
Newcomb, L.F.
Fowke, J.H.
Gamulin, M.
Abraham, A.
Claessens, F.
Castelao, J.E.
Townsend, P.A.
Crawford, D.C.
Petrovics, G.
van Schaik, R.H.
Parent, M.-.
Hu, J.J.
Zheng, W.
UKGPCS collaborators,
APCB (Australian Prostate Cancer BioResource),
NC-LA PCaP Investigators,
IMPACT Study Steering Committee and Collaborators,
Canary PASS Investigators,
Profile Study Steering Committee,
PRACTICAL Consortium,
Mills, I.G.
Andreassen, O.A.
Dale, A.M.
Seibert, T.M.
(2022). Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. Prostate cancer prostatic dis,
Vol.25
(4),
pp. 755-761.
show abstract
full text
BACKGROUND: Prostate cancer risk stratification using single-nucleotide polymorphisms (SNPs) demonstrates considerable promise in men of European, Asian, and African genetic ancestries, but there is still need for increased accuracy. We evaluated whether including additional SNPs in a prostate cancer polygenic hazard score (PHS) would improve associations with clinically significant prostate cancer in multi-ancestry datasets. METHODS: In total, 299 SNPs previously associated with prostate cancer were evaluated for inclusion in a new PHS, using a LASSO-regularized Cox proportional hazards model in a training dataset of 72,181 men from the PRACTICAL Consortium. The PHS model was evaluated in four testing datasets: African ancestry, Asian ancestry, and two of European Ancestry-the Cohort of Swedish Men (COSM) and the ProtecT study. Hazard ratios (HRs) were estimated to compare men with high versus low PHS for association with clinically significant, with any, and with fatal prostate cancer. The impact of genetic risk stratification on the positive predictive value (PPV) of PSA testing for clinically significant prostate cancer was also measured. RESULTS: The final model (PHS290) had 290 SNPs with non-zero coefficients. Comparing, for example, the highest and lowest quintiles of PHS290, the hazard ratios (HRs) for clinically significant prostate cancer were 13.73 [95% CI: 12.43-15.16] in ProtecT, 7.07 [6.58-7.60] in African ancestry, 10.31 [9.58-11.11] in Asian ancestry, and 11.18 [10.34-12.09] in COSM. Similar results were seen for association with any and fatal prostate cancer. Without PHS stratification, the PPV of PSA testing for clinically significant prostate cancer in ProtecT was 0.12 (0.11-0.14). For the top 20% and top 5% of PHS290, the PPV of PSA testing was 0.19 (0.15-0.22) and 0.26 (0.19-0.33), respectively. CONCLUSIONS: We demonstrate better genetic risk stratification for clinically significant prostate cancer than prior versions of PHS in multi-ancestry datasets. This is promising for implementing precision-medicine approaches to prostate cancer screening decisions in diverse populations..
Lesueur, F.
Easton, D.F.
Renault, A.-.
Tavtigian, S.V.
Bernstein, J.L.
Kote-Jarai, Z.
Eeles, R.A.
Plaseska-Karanfia, D.
Feliubadaló, L.
Spanish ATM working group,
Arun, B.
Herold, N.
Versmold, B.
Schmutzler, R.K.
GC-HBOC,
Nguyen-Dumont, T.
Southey, M.C.
Dorling, L.
Dunning, A.M.
Ghiorzo, P.
Dalmasso, B.S.
Cavaciuti, E.
Le Gal, D.
Roberts, N.J.
Dominguez-Valentin, M.
Rookus, M.
Taylor, A.M.
Goldstein, A.M.
Goldgar, D.E.
CARRIERS and Ambry Groups,
Stoppa-Lyonnet, D.
Andrieu, N.
(2022). First international workshop of the ATM and cancer risk group (4-5 December 2019). Fam cancer,
Vol.21
(2),
pp. 211-227.
show abstract
full text
The first International Workshop of the ATM and Cancer Risk group focusing on the role of Ataxia-Telangiectasia Mutated (ATM) gene in cancer was held on December 4 and 5, 2019 at Institut Curie in Paris, France. It was motivated by the fact that germline ATM pathogenic variants have been found to be associated with different cancer types. However, due to the lack of precise age-, sex-, and site-specific risk estimates, no consensus on management guidelines for variant carriers exists, and the clinical utility of ATM variant testing is uncertain. The meeting brought together epidemiologists, geneticists, biologists and clinicians to review current knowledge and on-going challenges related to ATM and cancer risk. This report summarizes the meeting sessions content that covered the latest results in family-based and population-based studies, the importance of accurate variant classification, the effect of radiation exposures for ATM variant carriers, and the characteristics of ATM-deficient tumors. The report concludes that ATM variant carriers outside of the context of Ataxia-Telangiectasia may benefit from effective cancer risk management and therapeutic strategies and that efforts to set up large-scale studies in the international framework to achieve this goal are necessary..
Darst, B.F.
Hughley, R.
Pfennig, A.
Hazra, U.
Fan, C.
Wan, P.
Sheng, X.
Xia, L.
Andrews, C.
Chen, F.
Berndt, S.I.
Kote-Jarai, Z.
Govindasami, K.
Bensen, J.T.
Ingles, S.A.
Rybicki, B.A.
Nemesure, B.
John, E.M.
Fowke, J.H.
Huff, C.D.
Strom, S.S.
Isaacs, W.B.
Park, J.Y.
Zheng, W.
Ostrander, E.A.
Walsh, P.C.
Carpten, J.
Sellers, T.A.
Yamoah, K.
Murphy, A.B.
Sanderson, M.
Crawford, D.C.
Gapstur, S.M.
Bush, W.S.
Aldrich, M.C.
Cussenot, O.
Petrovics, G.
Cullen, J.
Neslund-Dudas, C.
Kittles, R.A.
Xu, J.
Stern, M.C.
Chokkalingam, A.P.
Multigner, L.
Parent, M.-.
Menegaux, F.
Cancel-Tassin, G.
Kibel, A.S.
Klein, E.A.
Goodman, P.J.
Stanford, J.L.
Drake, B.F.
Hu, J.J.
Clark, P.E.
Blanchet, P.
Casey, G.
Hennis, A.J.
Lubwama, A.
Thompson, I.M.
Leach, R.J.
Gundell, S.M.
Pooler, L.
Mohler, J.L.
Fontham, E.T.
Smith, G.J.
Taylor, J.A.
Brureau, L.
Blot, W.J.
Biritwum, R.
Tay, E.
Truelove, A.
Niwa, S.
Tettey, Y.
Varma, R.
McKean-Cowdin, R.
Torres, M.
Jalloh, M.
Magueye Gueye, S.
Niang, L.
Ogunbiyi, O.
Oladimeji Idowu, M.
Popoola, O.
Adebiyi, A.O.
Aisuodionoe-Shadrach, O.I.
Nwegbu, M.
Adusei, B.
Mante, S.
Darkwa-Abrahams, A.
Yeboah, E.D.
Mensah, J.E.
Anthony Adjei, A.
Diop, H.
Cook, M.B.
Chanock, S.J.
Watya, S.
Eeles, R.A.
Chiang, C.W.
Lachance, J.
Rebbeck, T.R.
Conti, D.V.
Haiman, C.A.
(2022). A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry. Eur urol,
Vol.81
(5),
pp. 458-462.
show abstract
full text
A rare African ancestry-specific germline deletion variant in HOXB13 (X285K, rs77179853) was recently reported in Martinican men with early-onset prostate cancer. Given the role of HOXB13 germline variation in prostate cancer, we investigated the association between HOXB13 X285K and prostate cancer risk in a large sample of 22 361 African ancestry men, including 11 688 prostate cancer cases. The risk allele was present only in men of West African ancestry, with an allele frequency in men that ranged from 0.40% in Ghana and 0.31% in Nigeria to 0% in Uganda and South Africa, with a range of frequencies in men with admixed African ancestry from North America and Europe (0-0.26%). HOXB13 X285K was associated with 2.4-fold increased odds of prostate cancer (95% confidence interval [CI] = 1.5-3.9, p = 2 × 10-4), with greater risk observed for more aggressive and advanced disease (Gleason ≥8: odds ratio [OR] = 4.7, 95% CI = 2.3-9.5, p = 2 × 10-5; stage T3/T4: OR = 4.5, 95% CI = 2.0-10.0, p = 2 × 10-4; metastatic disease: OR = 5.1, 95% CI = 1.9-13.7, p = 0.001). We estimated that the allele arose in West Africa 1500-4600 yr ago. Further analysis is needed to understand how the HOXB13 X285K variant impacts the HOXB13 protein and function in the prostate. Understanding who carries this mutation may inform prostate cancer screening in men of West African ancestry. PATIENT SUMMARY: A rare African ancestry-specific germline deletion in HOXB13, found only in men of West African ancestry, was reported to be associated with an increased risk of overall and advanced prostate cancer. Understanding who carries this mutation may help inform screening for prostate cancer in men of West African ancestry..
McHugh, J.
Saunders, E.J.
Dadaev, T.
McGrowder, E.
Bancroft, E.
Kote-Jarai, Z.
Eeles, R.
(2022). Prostate cancer risk in men of differing genetic ancestry and approaches to disease screening and management in these groups. Br j cancer,
Vol.126
(10),
pp. 1366-1373.
show abstract
full text
Prostate cancer is the second most common solid tumour in men worldwide and it is also the most common cancer affecting men of African descent. Prostate cancer incidence and mortality vary across regions and populations. Some of this is explained by a large heritable component of this disease. It has been established that men of African and African Caribbean ethnicity are predisposed to prostate cancer (PrCa) that can have an earlier onset and a more aggressive course, thereby leading to poorer outcomes for patients in this group. Literature searches were carried out using the PubMed, EMBASE and Cochrane Library databases to identify studies associated with PrCa risk and its association with ancestry, screening and management of PrCa. In order to be included, studies were required to be published in English in full-text form. An attractive approach is to identify high-risk groups and develop a targeted screening programme for them as the benefits of population-wide screening in PrCa using prostate-specific antigen (PSA) testing in general population screening have shown evidence of benefit; however, the harms are considered to weigh heavier because screening using PSA testing can lead to over-diagnosis and over-treatment. The aim of targeted screening of higher-risk groups identified by genetic risk stratification is to reduce over-diagnosis and treat those who are most likely to benefit..
Burns, D.
Anokian, E.
Saunders, E.J.
Bristow, R.G.
Fraser, M.
Reimand, J.
Schlomm, T.
Sauter, G.
Brors, B.
Korbel, J.
Weischenfeldt, J.
Waszak, S.M.
Corcoran, N.M.
Jung, C.-.
Pope, B.J.
Hovens, C.M.
Cancel-Tassin, G.
Cussenot, O.
Loda, M.
Sander, C.
Hayes, V.M.
Dalsgaard Sorensen, K.
Lu, Y.-.
Hamdy, F.C.
Foster, C.S.
Gnanapragasam, V.
Butler, A.
Lynch, A.G.
Massie, C.E.
CR-UK/Prostate Cancer UK, ICGC, The PPCG,
Woodcock, D.J.
Cooper, C.S.
Wedge, D.C.
Brewer, D.S.
Kote-Jarai, Z.
Eeles, R.A.
(2022). Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical Prostate Cancer Treatment: A Pan Prostate Cancer Group Study. Eur urol,
Vol.82
(2),
pp. 201-211.
show abstract
full text
BACKGROUND: Germline variants explain more than a third of prostate cancer (PrCa) risk, but very few associations have been identified between heritable factors and clinical progression. OBJECTIVE: To find rare germline variants that predict time to biochemical recurrence (BCR) after radical treatment in men with PrCa and understand the genetic factors associated with such progression. DESIGN, SETTING, AND PARTICIPANTS: Whole-genome sequencing data from blood DNA were analysed for 850 PrCa patients with radical treatment from the Pan Prostate Cancer Group (PPCG) consortium from the UK, Canada, Germany, Australia, and France. Findings were validated using 383 patients from The Cancer Genome Atlas (TCGA) dataset. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: A total of 15,822 rare (MAF <1%) predicted-deleterious coding germline mutations were identified. Optimal multifactor and univariate Cox regression models were built to predict time to BCR after radical treatment, using germline variants grouped by functionally annotated gene sets. Models were tested for robustness using bootstrap resampling. RESULTS AND LIMITATIONS: Optimal Cox regression multifactor models showed that rare predicted-deleterious germline variants in "Hallmark" gene sets were consistently associated with altered time to BCR. Three gene sets had a statistically significant association with risk-elevated outcome when modelling all samples: PI3K/AKT/mTOR, Inflammatory response, and KRAS signalling (up). PI3K/AKT/mTOR and KRAS signalling (up) were also associated among patients with higher-grade cancer, as were Pancreas-beta cells, TNFA signalling via NKFB, and Hypoxia, the latter of which was validated in the independent TCGA dataset. CONCLUSIONS: We demonstrate for the first time that rare deleterious coding germline variants robustly associate with time to BCR after radical treatment, including cohort-independent validation. Our findings suggest that germline testing at diagnosis could aid clinical decisions by stratifying patients for differential clinical management. PATIENT SUMMARY: Prostate cancer patients with particular genetic mutations have a higher chance of relapsing after initial radical treatment, potentially providing opportunities to identify patients who might need additional treatments earlier..
Boonen, R.A.
Wiegant, W.W.
Celosse, N.
Vroling, B.
Heijl, S.
Kote-Jarai, Z.
Mijuskovic, M.
Cristea, S.
Solleveld-Westerink, N.
van Wezel, T.
Beerenwinkel, N.
Eeles, R.
Devilee, P.
Vreeswijk, M.P.
Marra, G.
van Attikum, H.
(2022). Functional Analysis Identifies Damaging CHEK2 Missense Variants Associated with Increased Cancer Risk. Cancer res,
Vol.82
(4),
pp. 615-631.
show abstract
full text
UNLABELLED: Heterozygous carriers of germline loss-of-function variants in the tumor suppressor gene checkpoint kinase 2 (CHEK2) are at an increased risk for developing breast and other cancers. While truncating variants in CHEK2 are known to be pathogenic, the interpretation of missense variants of uncertain significance (VUS) is challenging. Consequently, many VUS remain unclassified both functionally and clinically. Here we describe a mouse embryonic stem (mES) cell-based system to quantitatively determine the functional impact of 50 missense VUS in human CHEK2. By assessing the activity of human CHK2 to phosphorylate one of its main targets, Kap1, in Chek2 knockout mES cells, 31 missense VUS in CHEK2 were found to impair protein function to a similar extent as truncating variants, while 9 CHEK2 missense VUS resulted in intermediate functional defects. Mechanistically, most VUS impaired CHK2 kinase function by causing protein instability or by impairing activation through (auto)phosphorylation. Quantitative results showed that the degree of CHK2 kinase dysfunction correlates with an increased risk for breast cancer. Both damaging CHEK2 variants as a group [OR 2.23; 95% confidence interval (CI), 1.62-3.07; P < 0.0001] and intermediate variants (OR 1.63; 95% CI, 1.21-2.20; P = 0.0014) were associated with an increased breast cancer risk, while functional variants did not show this association (OR 1.13; 95% CI, 0.87-1.46; P = 0.378). Finally, a damaging VUS in CHEK2, c.486A>G/p.D162G, was also identified, which cosegregated with familial prostate cancer. Altogether, these functional assays efficiently and reliably identified VUS in CHEK2 that associate with cancer. SIGNIFICANCE: Quantitative assessment of the functional consequences of CHEK2 variants of uncertain significance identifies damaging variants associated with increased cancer risk, which may aid in the clinical management of patients and carriers..
Morales Berstein, F.
McCartney, D.L.
Lu, A.T.
Tsilidis, K.K.
Bouras, E.
Haycock, P.
Burrows, K.
Phipps, A.I.
Buchanan, D.D.
Cheng, I.
PRACTICAL consortium,
Martin, R.M.
Davey Smith, G.
Relton, C.L.
Horvath, S.
Marioni, R.E.
Richardson, T.G.
Richmond, R.C.
(2022). Assessing the causal role of epigenetic clocks in the development of multiple cancers: a Mendelian randomization study. Elife,
Vol.11.
show abstract
full text
BACKGROUND: Epigenetic clocks have been associated with cancer risk in several observational studies. Nevertheless, it is unclear whether they play a causal role in cancer risk or if they act as a non-causal biomarker. METHODS: We conducted a two-sample Mendelian randomization (MR) study to examine the genetically predicted effects of epigenetic age acceleration as measured by HannumAge (nine single-nucleotide polymorphisms (SNPs)), Horvath Intrinsic Age (24 SNPs), PhenoAge (11 SNPs), and GrimAge (4 SNPs) on multiple cancers (i.e. breast, prostate, colorectal, ovarian and lung cancer). We obtained genome-wide association data for biological ageing from a meta-analysis (N = 34,710), and for cancer from the UK Biobank (N cases = 2671-13,879; N controls = 173,493-372,016), FinnGen (N cases = 719-8401; N controls = 74,685-174,006) and several international cancer genetic consortia (N cases = 11,348-122,977; N controls = 15,861-105,974). Main analyses were performed using multiplicative random effects inverse variance weighted (IVW) MR. Individual study estimates were pooled using fixed effect meta-analysis. Sensitivity analyses included MR-Egger, weighted median, weighted mode and Causal Analysis using Summary Effect Estimates (CAUSE) methods, which are robust to some of the assumptions of the IVW approach. RESULTS: Meta-analysed IVW MR findings suggested that higher GrimAge acceleration increased the risk of colorectal cancer (OR = 1.12 per year increase in GrimAge acceleration, 95% CI 1.04-1.20, p = 0.002). The direction of the genetically predicted effects was consistent across main and sensitivity MR analyses. Among subtypes, the genetically predicted effect of GrimAge acceleration was greater for colon cancer (IVW OR = 1.15, 95% CI 1.09-1.21, p = 0.006), than rectal cancer (IVW OR = 1.05, 95% CI 0.97-1.13, p = 0.24). Results were less consistent for associations between other epigenetic clocks and cancers. CONCLUSIONS: GrimAge acceleration may increase the risk of colorectal cancer. Findings for other clocks and cancers were inconsistent. Further work is required to investigate the potential mechanisms underlying the results. FUNDING: FMB was supported by a Wellcome Trust PhD studentship in Molecular, Genetic and Lifecourse Epidemiology (224982/Z/22/Z which is part of grant 218495/Z/19/Z). KKT was supported by a Cancer Research UK (C18281/A29019) programme grant (the Integrative Cancer Epidemiology Programme) and by the Hellenic Republic's Operational Programme 'Competitiveness, Entrepreneurship & Innovation' (OΠΣ 5047228). PH was supported by Cancer Research UK (C18281/A29019). RMM was supported by the NIHR Biomedical Research Centre at University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol and by a Cancer Research UK (C18281/A29019) programme grant (the Integrative Cancer Epidemiology Programme). RMM is a National Institute for Health Research Senior Investigator (NIHR202411). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. GDS and CLR were supported by the Medical Research Council (MC_UU_00011/1 and MC_UU_00011/5, respectively) and by a Cancer Research UK (C18281/A29019) programme grant (the Integrative Cancer Epidemiology Programme). REM was supported by an Alzheimer's Society project grant (AS-PG-19b-010) and NIH grant (U01 AG-18-018, PI: Steve Horvath). RCR is a de Pass Vice Chancellor's Research Fellow at the University of Bristol..
Karunamuni, R.A.
Huynh-Le, M.-.
Fan, C.C.
Thompson, W.
Eeles, R.A.
Kote-Jarai, Z.
Muir, K.
UKGPCS Collaborators,
Lophatananon, A.
Tangen, C.M.
Goodman, P.J.
Thompson, I.M.
Blot, W.J.
Zheng, W.
Kibel, A.S.
Drake, B.F.
Cussenot, O.
Cancel-Tassin, G.
Menegaux, F.
Truong, T.
Park, J.Y.
Lin, H.-.
Bensen, J.T.
Fontham, E.T.
Mohler, J.L.
Taylor, J.A.
Multigner, L.
Blanchet, P.
Brureau, L.
Romana, M.
Leach, R.J.
John, E.M.
Fowke, J.
Bush, W.S.
Aldrich, M.
Crawford, D.C.
Srivastava, S.
Cullen, J.C.
Petrovics, G.
Parent, M.-.
Hu, J.J.
Sanderson, M.
Mills, I.G.
Andreassen, O.A.
Dale, A.M.
Seibert, T.M.
PRACTICAL Consortium,
(2021). African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer. Int j cancer,
Vol.148
(1),
pp. 99-105.
show abstract
Polygenic hazard score (PHS) models are associated with age at diagnosis of prostate cancer. Our model developed in Europeans (PHS46) showed reduced performance in men with African genetic ancestry. We used a cross-validated search to identify single nucleotide polymorphisms (SNPs) that might improve performance in this population. Anonymized genotypic data were obtained from the PRACTICAL consortium for 6253 men with African genetic ancestry. Ten iterations of a 10-fold cross-validation search were conducted to select SNPs that would be included in the final PHS46+African model. The coefficients of PHS46+African were estimated in a Cox proportional hazards framework using age at diagnosis as the dependent variable and PHS46, and selected SNPs as predictors. The performance of PHS46 and PHS46+African was compared using the same cross-validated approach. Three SNPs (rs76229939, rs74421890 and rs5013678) were selected for inclusion in PHS46+African. All three SNPs are located on chromosome 8q24. PHS46+African showed substantial improvements in all performance metrics measured, including a 75% increase in the relative hazard of those in the upper 20% compared to the bottom 20% (2.47-4.34) and a 20% reduction in the relative hazard of those in the bottom 20% compared to the middle 40% (0.65-0.53). In conclusion, we identified three SNPs that substantially improved the association of PHS46 with age at diagnosis of prostate cancer in men with African genetic ancestry to levels comparable to Europeans..
Haldrup, J.
Strand, S.H.
Cieza-Borrella, C.
Jakobsson, M.E.
Riedel, M.
Norgaard, M.
Hedensted, S.
Dagnaes-Hansen, F.
Ulhoi, B.P.
Eeles, R.
Borre, M.
Olsen, J.V.
Thomsen, M.
Kote-Jarai, Z.
Sorensen, K.D.
(2021). FRMD6 has tumor suppressor functions in prostate cancer. Oncogene,
Vol.40
(4),
pp. 763-776.
show abstract
full text
Available tools for prostate cancer (PC) prognosis are suboptimal but may be improved by better knowledge about genes driving tumor aggressiveness. Here, we identified FRMD6 (FERM domain-containing protein 6) as an aberrantly hypermethylated and significantly downregulated gene in PC. Low FRMD6 expression was associated with postoperative biochemical recurrence in two large PC patient cohorts. In overexpression and CRISPR/Cas9 knockout experiments in PC cell lines, FRMD6 inhibited viability, proliferation, cell cycle progression, colony formation, 3D spheroid growth, and tumor xenograft growth in mice. Transcriptomic, proteomic, and phospho-proteomic profiling revealed enrichment of Hippo/YAP and c-MYC signaling upon FRMD6 knockout. Connectivity Map analysis and drug repurposing experiments identified pyroxamide as a new potential therapy for FRMD6 deficient PC cells. Finally, we established orthotropic Frmd6 and Pten, or Pten only (control) knockout in the ROSA26 mouse prostate. After 12 weeks, Frmd6/Pten double knockouts presented high-grade prostatic intraepithelial neoplasia (HG-PIN) and hyperproliferation, while Pten single-knockouts developed only regular PIN lesions and displayed lower proliferation. In conclusion, FRMD6 was identified as a novel tumor suppressor gene and prognostic biomarker candidate in PC..
Conti, D.V.
Darst, B.F.
Moss, L.C.
Saunders, E.J.
Sheng, X.
Chou, A.
Schumacher, F.R.
Olama, A.A.
Benlloch, S.
Dadaev, T.
Brook, M.N.
Sahimi, A.
Hoffmann, T.J.
Takahashi, A.
Matsuda, K.
Momozawa, Y.
Fujita, M.
Muir, K.
Lophatananon, A.
Wan, P.
Le Marchand, L.
Wilkens, L.R.
Stevens, V.L.
Gapstur, S.M.
Carter, B.D.
Schleutker, J.
Tammela, T.L.
Sipeky, C.
Auvinen, A.
Giles, G.G.
Southey, M.C.
MacInnis, R.J.
Cybulski, C.
Wokołorczyk, D.
Lubiński, J.
Neal, D.E.
Donovan, J.L.
Hamdy, F.C.
Martin, R.M.
Nordestgaard, B.G.
Nielsen, S.F.
Weischer, M.
Bojesen, S.E.
Røder, M.A.
Iversen, P.
Batra, J.
Chambers, S.
Moya, L.
Horvath, L.
Clements, J.A.
Tilley, W.
Risbridger, G.P.
Gronberg, H.
Aly, M.
Szulkin, R.
Eklund, M.
Nordström, T.
Pashayan, N.
Dunning, A.M.
Ghoussaini, M.
Travis, R.C.
Key, T.J.
Riboli, E.
Park, J.Y.
Sellers, T.A.
Lin, H.-.
Albanes, D.
Weinstein, S.J.
Mucci, L.A.
Giovannucci, E.
Lindstrom, S.
Kraft, P.
Hunter, D.J.
Penney, K.L.
Turman, C.
Tangen, C.M.
Goodman, P.J.
Thompson, I.M.
Hamilton, R.J.
Fleshner, N.E.
Finelli, A.
Parent, M.-.
Stanford, J.L.
Ostrander, E.A.
Geybels, M.S.
Koutros, S.
Freeman, L.E.
Stampfer, M.
Wolk, A.
Håkansson, N.
Andriole, G.L.
Hoover, R.N.
Machiela, M.J.
Sørensen, K.D.
Borre, M.
Blot, W.J.
Zheng, W.
Yeboah, E.D.
Mensah, J.E.
Lu, Y.-.
Zhang, H.-.
Feng, N.
Mao, X.
Wu, Y.
Zhao, S.-.
Sun, Z.
Thibodeau, S.N.
McDonnell, S.K.
Schaid, D.J.
West, C.M.
Burnet, N.
Barnett, G.
Maier, C.
Schnoeller, T.
Luedeke, M.
Kibel, A.S.
Drake, B.F.
Cussenot, O.
Cancel-Tassin, G.
Menegaux, F.
Truong, T.
Koudou, Y.A.
John, E.M.
Grindedal, E.M.
Maehle, L.
Khaw, K.-.
Ingles, S.A.
Stern, M.C.
Vega, A.
Gómez-Caamaño, A.
Fachal, L.
Rosenstein, B.S.
Kerns, S.L.
Ostrer, H.
Teixeira, M.R.
Paulo, P.
Brandão, A.
Watya, S.
Lubwama, A.
Bensen, J.T.
Fontham, E.T.
Mohler, J.
Taylor, J.A.
Kogevinas, M.
Llorca, J.
Castaño-Vinyals, G.
Cannon-Albright, L.
Teerlink, C.C.
Huff, C.D.
Strom, S.S.
Multigner, L.
Blanchet, P.
Brureau, L.
Kaneva, R.
Slavov, C.
Mitev, V.
Leach, R.J.
Weaver, B.
Brenner, H.
Cuk, K.
Holleczek, B.
Saum, K.-.
Klein, E.A.
Hsing, A.W.
Kittles, R.A.
Murphy, A.B.
Logothetis, C.J.
Kim, J.
Neuhausen, S.L.
Steele, L.
Ding, Y.C.
Isaacs, W.B.
Nemesure, B.
Hennis, A.J.
Carpten, J.
Pandha, H.
Michael, A.
De Ruyck, K.
De Meerleer, G.
Ost, P.
Xu, J.
Razack, A.
Lim, J.
Teo, S.-.
Newcomb, L.F.
Lin, D.W.
Fowke, J.H.
Neslund-Dudas, C.
Rybicki, B.A.
Gamulin, M.
Lessel, D.
Kulis, T.
Usmani, N.
Singhal, S.
Parliament, M.
Claessens, F.
Joniau, S.
Van den Broeck, T.
Gago-Dominguez, M.
Castelao, J.E.
Martinez, M.E.
Larkin, S.
Townsend, P.A.
Aukim-Hastie, C.
Bush, W.S.
Aldrich, M.C.
Crawford, D.C.
Srivastava, S.
Cullen, J.C.
Petrovics, G.
Casey, G.
Roobol, M.J.
Jenster, G.
van Schaik, R.H.
Hu, J.J.
Sanderson, M.
Varma, R.
McKean-Cowdin, R.
Torres, M.
Mancuso, N.
Berndt, S.I.
Van Den Eeden, S.K.
Easton, D.F.
Chanock, S.J.
Cook, M.B.
Wiklund, F.
Nakagawa, H.
Witte, J.S.
Eeles, R.A.
Kote-Jarai, Z.
Haiman, C.A.
(2021). Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nat genet,
Vol.53
(1),
pp. 65-75.
show abstract
full text
Prostate cancer is a highly heritable disease with large disparities in incidence rates across ancestry populations. We conducted a multiancestry meta-analysis of prostate cancer genome-wide association studies (107,247 cases and 127,006 controls) and identified 86 new genetic risk variants independently associated with prostate cancer risk, bringing the total to 269 known risk variants. The top genetic risk score (GRS) decile was associated with odds ratios that ranged from 5.06 (95% confidence interval (CI), 4.84-5.29) for men of European ancestry to 3.74 (95% CI, 3.36-4.17) for men of African ancestry. Men of African ancestry were estimated to have a mean GRS that was 2.18-times higher (95% CI, 2.14-2.22), and men of East Asian ancestry 0.73-times lower (95% CI, 0.71-0.76), than men of European ancestry. These findings support the role of germline variation contributing to population differences in prostate cancer risk, with the GRS offering an approach for personalized risk prediction..
Schaid, D.J.
McDonnell, S.K.
FitzGerald, L.M.
DeRycke, L.
Fogarty, Z.
Giles, G.G.
MacInnis, R.J.
Southey, M.C.
Nguyen-Dumont, T.
Cancel-Tassin, G.
Cussenot, O.
Whittemore, A.S.
Sieh, W.
Ioannidis, N.M.
Hsieh, C.-.
Stanford, J.L.
Schleutker, J.
Cropp, C.D.
Carpten, J.
Hoegel, J.
Eeles, R.
Kote-Jarai, Z.
Ackerman, M.J.
Klein, C.J.
Mandal, D.
Cooney, K.A.
Bailey-Wilson, J.E.
Helfand, B.
Catalona, W.J.
Wiklund, F.
Riska, S.
Bahetti, S.
Larson, M.C.
Cannon Albright, L.
Teerlink, C.
Xu, J.
Isaacs, W.
Ostrander, E.A.
Thibodeau, S.N.
(2021). Two-stage Study of Familial Prostate Cancer by Whole-exome Sequencing and Custom Capture Identifies 10 Novel Genes Associated with the Risk of Prostate Cancer. Eur urol,
Vol.79
(3),
pp. 353-361.
show abstract
full text
BACKGROUND: Family history of prostate cancer (PCa) is a well-known risk factor, and both common and rare genetic variants are associated with the disease. OBJECTIVE: To detect new genetic variants associated with PCa, capitalizing on the role of family history and more aggressive PCa. DESIGN, SETTING, AND PARTICIPANTS: A two-stage design was used. In stage one, whole-exome sequencing was used to identify potential risk alleles among affected men with a strong family history of disease or with more aggressive disease (491 cases and 429 controls). Aggressive disease was based on a sum of scores for Gleason score, node status, metastasis, tumor stage, prostate-specific antigen at diagnosis, systemic recurrence, and time to PCa death. Genes identified in stage one were screened in stage two using a custom-capture design in an independent set of 2917 cases and 1899 controls. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Frequencies of genetic variants (singly or jointly in a gene) were compared between cases and controls. RESULTS AND LIMITATIONS: Eleven genes previously reported to be associated with PCa were detected (ATM, BRCA2, HOXB13, FAM111A, EMSY, HNF1B, KLK3, MSMB, PCAT1, PRSS3, and TERT), as well as an additional 10 novel genes (PABPC1, QK1, FAM114A1, MUC6, MYCBP2, RAPGEF4, RNASEH2B, ULK4, XPO7, and THAP3). Of these 10 novel genes, all but PABPC1 and ULK4 were primarily associated with the risk of aggressive PCa. CONCLUSIONS: Our approach demonstrates the advantage of gene sequencing in the search for genetic variants associated with PCa and the benefits of sampling patients with a strong family history of disease or an aggressive form of disease. PATIENT SUMMARY: Multiple genes are associated with prostate cancer (PCa) among men with a strong family history of this disease or among men with an aggressive form of PCa..
Darst, B.F.
Dadaev, T.
Saunders, E.
Sheng, X.
Wan, P.
Pooler, L.
Xia, L.Y.
Chanock, S.
Berndt, S.I.
Gapstur, S.M.
Stevens, V.
Albanes, D.
Weinstein, S.J.
Gnanapragasam, V.
Giles, G.G.
Nguyen-Dumont, T.
Milne, R.L.
Pomerantz, M.
Schmidt, J.A.
Mucci, L.
Catalona, W.J.
Hetrick, K.N.
Doheny, K.F.
MacInnis, R.J.
Southey, M.C.
Eeles, R.A.
Wiklund, F.
Kote-Jarai, Z.
Conti, D.V.
Haiman, C.A.
(2021). Germline Sequencing DNA Repair Genes in 5545 Men With Aggressive and Nonaggressive Prostate Cancer. J natl cancer inst,
Vol.113
(5),
pp. 616-625.
show abstract
full text
BACKGROUND: There is an urgent need to identify factors specifically associated with aggressive prostate cancer (PCa) risk. We investigated whether rare pathogenic, likely pathogenic, or deleterious (P/LP/D) germline variants in DNA repair genes are associated with aggressive PCa risk in a case-case study of aggressive vs nonaggressive disease. METHODS: Participants were 5545 European-ancestry men, including 2775 nonaggressive and 2770 aggressive PCa cases, which included 467 metastatic cases (16.9%). Samples were assembled from 12 international studies and germline sequenced together. Rare (minor allele frequency < 0.01) P/LP/D variants were analyzed for 155 DNA repair genes. We compared single variant, gene-based, and DNA repair pathway-based burdens by disease aggressiveness. All statistical tests are 2-sided. RESULTS: BRCA2 and PALB2 had the most statistically significant gene-based associations, with 2.5% of aggressive and 0.8% of nonaggressive cases carrying P/LP/D BRCA2 alleles (odds ratio [OR] = 3.19, 95% confidence interval [CI] = 1.94 to 5.25, P = 8.58 × 10-7) and 0.65% of aggressive and 0.11% of nonaggressive cases carrying P/LP/D PALB2 alleles (OR = 6.31, 95% CI = 1.83 to 21.68, P = 4.79 × 10-4). ATM had a nominal association, with 1.6% of aggressive and 0.8% of nonaggressive cases carrying P/LP/D ATM alleles (OR = 1.88, 95% CI = 1.10 to 3.22, P = .02). In aggregate, P/LP/D alleles within 24 literature-curated candidate PCa DNA repair genes were more common in aggressive than nonaggressive cases (carrier frequencies = 14.2% vs 10.6%, respectively; P = 5.56 × 10-5). However, this difference was non-statistically significant (P = .18) on excluding BRCA2, PALB2, and ATM. Among these 24 genes, P/LP/D carriers had a 1.06-year younger diagnosis age (95% CI = -1.65 to 0.48, P = 3.71 × 10-4). CONCLUSIONS: Risk conveyed by DNA repair genes is largely driven by rare P/LP/D alleles within BRCA2, PALB2, and ATM. These findings support the importance of these genes in both screening and disease management considerations..
Karunamuni, R.A.
Huynh-Le, M.-.
Fan, C.C.
Thompson, W.
Eeles, R.A.
Kote-Jarai, Z.
Muir, K.
Lophatananon, A.
UKGPCS collaborators,
Schleutker, J.
Pashayan, N.
Batra, J.
APCB BioResource (Australian Prostate Cancer BioResource),
Grönberg, H.
Walsh, E.I.
Turner, E.L.
Lane, A.
Martin, R.M.
Neal, D.E.
Donovan, J.L.
Hamdy, F.C.
Nordestgaard, B.G.
Tangen, C.M.
MacInnis, R.J.
Wolk, A.
Albanes, D.
Haiman, C.A.
Travis, R.C.
Stanford, J.L.
Mucci, L.A.
West, C.M.
Nielsen, S.F.
Kibel, A.S.
Wiklund, F.
Cussenot, O.
Berndt, S.I.
Koutros, S.
Sørensen, K.D.
Cybulski, C.
Grindedal, E.M.
Park, J.Y.
Ingles, S.A.
Maier, C.
Hamilton, R.J.
Rosenstein, B.S.
Vega, A.
IMPACT Study Steering Committee and Collaborators,
Kogevinas, M.
Penney, K.L.
Teixeira, M.R.
Brenner, H.
John, E.M.
Kaneva, R.
Logothetis, C.J.
Neuhausen, S.L.
Razack, A.
Newcomb, L.F.
Canary PASS Investigators,
Gamulin, M.
Usmani, N.
Claessens, F.
Gago-Dominguez, M.
Townsend, P.A.
Roobol, M.J.
Zheng, W.
Profile Study Steering Committee,
Mills, I.G.
Andreassen, O.A.
Dale, A.M.
Seibert, T.M.
PRACTICAL Consortium,
(2021). Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. Prostate cancer prostatic dis,
Vol.24
(2),
pp. 532-541.
show abstract
full text
BACKGROUND: Polygenic hazard scores (PHS) can identify individuals with increased risk of prostate cancer. We estimated the benefit of additional SNPs on performance of a previously validated PHS (PHS46). MATERIALS AND METHOD: 180 SNPs, shown to be previously associated with prostate cancer, were used to develop a PHS model in men with European ancestry. A machine-learning approach, LASSO-regularized Cox regression, was used to select SNPs and to estimate their coefficients in the training set (75,596 men). Performance of the resulting model was evaluated in the testing/validation set (6,411 men) with two metrics: (1) hazard ratios (HRs) and (2) positive predictive value (PPV) of prostate-specific antigen (PSA) testing. HRs were estimated between individuals with PHS in the top 5% to those in the middle 40% (HR95/50), top 20% to bottom 20% (HR80/20), and bottom 20% to middle 40% (HR20/50). PPV was calculated for the top 20% (PPV80) and top 5% (PPV95) of PHS as the fraction of individuals with elevated PSA that were diagnosed with clinically significant prostate cancer on biopsy. RESULTS: 166 SNPs had non-zero coefficients in the Cox model (PHS166). All HR metrics showed significant improvements for PHS166 compared to PHS46: HR95/50 increased from 3.72 to 5.09, HR80/20 increased from 6.12 to 9.45, and HR20/50 decreased from 0.41 to 0.34. By contrast, no significant differences were observed in PPV of PSA testing for clinically significant prostate cancer. CONCLUSIONS: Incorporating 120 additional SNPs (PHS166 vs PHS46) significantly improved HRs for prostate cancer, while PPV of PSA testing remained the same..
Karlsson, Q.
Brook, M.N.
Dadaev, T.
Wakerell, S.
Saunders, E.J.
Muir, K.
Neal, D.E.
Giles, G.G.
MacInnis, R.J.
Thibodeau, S.N.
McDonnell, S.K.
Cannon-Albright, L.
Teixeira, M.R.
Paulo, P.
Cardoso, M.
Huff, C.
Li, D.
Yao, Y.
Scheet, P.
Permuth, J.B.
Stanford, J.L.
Dai, J.Y.
Ostrander, E.A.
Cussenot, O.
Cancel-Tassin, G.
Hoegel, J.
Herkommer, K.
Schleutker, J.
Tammela, T.L.
Rathinakannan, V.
Sipeky, C.
Wiklund, F.
Grönberg, H.
Aly, M.
Isaacs, W.B.
Dickinson, J.L.
FitzGerald, L.M.
Chua, M.L.
Nguyen-Dumont, T.
PRACTICAL Consortium,
Schaid, D.J.
Southey, M.C.
Eeles, R.A.
Kote-Jarai, Z.
(2021). Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study. Eur urol oncol,
Vol.4
(4),
pp. 570-579.
show abstract
full text
BACKGROUND: Germline ATM mutations are suggested to contribute to predisposition to prostate cancer (PrCa). Previous studies have had inadequate power to estimate variant effect sizes. OBJECTIVE: To precisely estimate the contribution of germline ATM mutations to PrCa risk. DESIGN, SETTING, AND PARTICIPANTS: We analysed next-generation sequencing data from 13 PRACTICAL study groups comprising 5560 cases and 3353 controls of European ancestry. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Variant Call Format files were harmonised, annotated for rare ATM variants, and classified as tier 1 (likely pathogenic) or tier 2 (potentially deleterious). Associations with overall PrCa risk and clinical subtypes were estimated. RESULTS AND LIMITATIONS: PrCa risk was higher in carriers of a tier 1 germline ATM variant, with an overall odds ratio (OR) of 4.4 (95% confidence interval [CI]: 2.0-9.5). There was also evidence that PrCa cases with younger age at diagnosis (<65 yr) had elevated tier 1 variant frequencies (pdifference = 0.04). Tier 2 variants were also associated with PrCa risk, with an OR of 1.4 (95% CI: 1.1-1.7). CONCLUSIONS: Carriers of pathogenic ATM variants have an elevated risk of developing PrCa and are at an increased risk for earlier-onset disease presentation. These results provide information for counselling of men and their families. PATIENT SUMMARY: In this study, we estimated that men who inherit a likely pathogenic mutation in the ATM gene had an approximately a fourfold risk of developing prostate cancer. In addition, they are likely to develop the disease earlier..
Chen, H.
Majumdar, A.
Wang, L.
Kar, S.
Brown, K.M.
Feng, H.
Turman, C.
Dennis, J.
Easton, D.
Michailidou, K.
Simard, J.
Breast Cancer Association Consortium (BCAC),
Bishop, T.
Cheng, I.C.
Huyghe, J.R.
Schmit, S.L.
Colorectal Transdisciplinary Study (CORECT),
Colon Cancer Family Registry Study (CCFR),
Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO),
O'Mara, T.A.
Spurdle, A.B.
Endometrial Cancer Association Consortium (ECAC),
Gharahkhani, P.
Schumacher, J.
Jankowski, J.
Gockel, I.
Esophageal Cancer GWAS Consortium,
Bondy, M.L.
Houlston, R.S.
Jenkins, R.B.
Melin, B.
Glioma International Case Control Consortium (GICC),
Lesseur, C.
Ness, A.R.
Diergaarde, B.
Olshan, A.F.
Head-Neck Cancer GWAS Consortium,
Amos, C.I.
Christiani, D.C.
Landi, M.T.
McKay, J.D.
International Lung Cancer Consortium (ILCCO),
Brossard, M.
Iles, M.M.
Law, M.H.
MacGregor, S.
Melanoma GWAS Consortium,
Beesley, J.
Jones, M.R.
Tyrer, J.
Winham, S.J.
Ovarian Cancer Association Consortium (OCAC),
Klein, A.P.
Petersen, G.
Li, D.
Wolpin, B.M.
Pancreatic Cancer Case-Control Consortium (PANC4),
Pancreatic Cancer Cohort Consortium (PanScan),
Eeles, R.A.
Haiman, C.A.
Kote-Jarai, Z.
Schumacher, F.R.
PRACTICAL consortium,
CRUK,
BPC3,
CAPS,
PEGASUS,
Brennan, P.
Chanock, S.J.
Gaborieau, V.
Purdue, M.P.
Renal Cancer GWAS Consortium,
Pharoah, P.
Hung, R.J.
Amundadottir, L.T.
Kraft, P.
Pasaniuc, B.
Lindström, S.
(2021). Large-scale cross-cancer fine-mapping of the 5p15 33 region reveals multiple independent signals. Hgg adv,
Vol.2
(3),
p. 100041.
show abstract
full text
Genome-wide association studies (GWASs) have identified thousands of cancer risk loci revealing many risk regions shared across multiple cancers. Characterizing the cross-cancer shared genetic basis can increase our understanding of global mechanisms of cancer development. In this study, we collected GWAS summary statistics based on up to 375,468 cancer cases and 530,521 controls for fourteen types of cancer, including breast (overall, estrogen receptor [ER]-positive, and ER-negative), colorectal, endometrial, esophageal, glioma, head/neck, lung, melanoma, ovarian, pancreatic, prostate, and renal cancer, to characterize the shared genetic basis of cancer risk. We identified thirteen pairs of cancers with statistically significant local genetic correlations across eight distinct genomic regions. Specifically, the 5p15.33 region, harboring the TERT and CLPTM1L genes, showed statistically significant local genetic correlations for multiple cancer pairs. We conducted a cross-cancer fine-mapping of the 5p15.33 region based on eight cancers that showed genome-wide significant associations in this region (ER-negative breast, colorectal, glioma, lung, melanoma, ovarian, pancreatic, and prostate cancer). We used an iterative analysis pipeline implementing a subset-based meta-analysis approach based on cancer-specific conditional analyses and identified ten independent cross-cancer associations within this region. For each signal, we conducted cross-cancer fine-mapping to prioritize the most plausible causal variants. Our findings provide a more in-depth understanding of the shared inherited basis across human cancers and expand our knowledge of the 5p15.33 region in carcinogenesis..
Salmon, C.
Song, L.
Muir, K.
UKGPCS Collaborators,
Pashayan, N.
Dunning, A.M.
Batra, J.
APCB BioResource (Australian Prostate Cancer BioResource),
Chambers, S.
Stanford, J.L.
Ostrander, E.A.
Park, J.Y.
Lin, H.-.
Cussenot, O.
Cancel-Tassin, G.
Menegaux, F.
Cordina-Duverger, E.
Kogevinas, M.
Llorca, J.
Kaneva, R.
Slavov, C.
Razack, A.
Lim, J.
Gago-Dominguez, M.
Castelao, J.E.
Kote-Jarai, Z.
Eeles, R.A.
on behalf of the PRACTICAL Consortium,
Parent, M.-.
(2021). Marital status and prostate cancer incidence: a pooled analysis of 12 case-control studies from the PRACTICAL consortium. Eur j epidemiol,
Vol.36
(9),
pp. 913-925.
show abstract
full text
While being in a committed relationship is associated with a better prostate cancer prognosis, little is known about how marital status relates to its incidence. Social support provided by marriage/relationship could promote a healthy lifestyle and an increased healthcare seeking behavior. We investigated the association between marital status and prostate cancer risk using data from the PRACTICAL Consortium. Pooled analyses were conducted combining 12 case-control studies based on histologically-confirmed incident prostate cancers and controls with information on marital status prior to diagnosis/interview. Marital status was categorized as married/partner, separated/divorced, single, or widowed. Tumours with Gleason scores ≥ 8 defined high-grade cancers, and low-grade otherwise. NCI-SEER's summary stages (local, regional, distant) indicated the extent of the cancer. Logistic regression was used to derive odds ratios (ORs) and 95% confidence intervals (CI) for the association between marital status and prostate cancer risk, adjusting for potential confounders. Overall, 14,760 cases and 12,019 controls contributed to analyses. Compared to men who were married/with a partner, widowed men had an OR of 1.19 (95% CI 1.03-1.35) of prostate cancer, with little difference between low- and high-grade tumours. Risk estimates among widowers were 1.14 (95% CI 0.97-1.34) for local, 1.53 (95% CI 1.22-1.92) for regional, and 1.56 (95% CI 1.05-2.32) for distant stage tumours. Single men had elevated risks of high-grade cancers. Our findings highlight elevated risks of incident prostate cancer among widowers, more often characterized by tumours that had spread beyond the prostate at the time of diagnosis. Social support interventions and closer medical follow-up in this sub-population are warranted..
Bancroft, E.K.
Page, E.C.
Brook, M.N.
Thomas, S.
Taylor, N.
Pope, J.
McHugh, J.
Jones, A.-.
Karlsson, Q.
Merson, S.
Ong, K.R.
Hoffman, J.
Huber, C.
Maehle, L.
Grindedal, E.M.
Stormorken, A.
Evans, D.G.
Rothwell, J.
Lalloo, F.
Brady, A.F.
Bartlett, M.
Snape, K.
Hanson, H.
James, P.
McKinley, J.
Mascarenhas, L.
Syngal, S.
Ukaegbu, C.
Side, L.
Thomas, T.
Barwell, J.
Teixeira, M.R.
Izatt, L.
Suri, M.
Macrae, F.A.
Poplawski, N.
Chen-Shtoyerman, R.
Ahmed, M.
Musgrave, H.
Nicolai, N.
Greenhalgh, L.
Brewer, C.
Pachter, N.
Spigelman, A.D.
Azzabi, A.
Helfand, B.T.
Halliday, D.
Buys, S.
Ramon Y Cajal, T.
Donaldson, A.
Cooney, K.A.
Harris, M.
McGrath, J.
Davidson, R.
Taylor, A.
Cooke, P.
Myhill, K.
Hogben, M.
Aaronson, N.K.
Ardern-Jones, A.
Bangma, C.H.
Castro, E.
Dearnaley, D.
Dias, A.
Dudderidge, T.
Eccles, D.M.
Green, K.
Eyfjord, J.
Falconer, A.
Foster, C.S.
Gronberg, H.
Hamdy, F.C.
Johannsson, O.
Khoo, V.
Lilja, H.
Lindeman, G.J.
Lubinski, J.
Axcrona, K.
Mikropoulos, C.
Mitra, A.V.
Moynihan, C.
Ni Raghallaigh, H.
Rennert, G.
Collier, R.
IMPACT Study Collaborators,
Offman, J.
Kote-Jarai, Z.
Eeles, R.A.
(2021). A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. Lancet oncol,
Vol.22
(11),
pp. 1618-1631.
show abstract
full text
BACKGROUND: Lynch syndrome is a rare familial cancer syndrome caused by pathogenic variants in the mismatch repair genes MLH1, MSH2, MSH6, or PMS2, that cause predisposition to various cancers, predominantly colorectal and endometrial cancer. Data are emerging that pathogenic variants in mismatch repair genes increase the risk of early-onset aggressive prostate cancer. The IMPACT study is prospectively assessing prostate-specific antigen (PSA) screening in men with germline mismatch repair pathogenic variants. Here, we report the usefulness of PSA screening, prostate cancer incidence, and tumour characteristics after the first screening round in men with and without these germline pathogenic variants. METHODS: The IMPACT study is an international, prospective study. Men aged 40-69 years without a previous prostate cancer diagnosis and with a known germline pathogenic variant in the MLH1, MSH2, or MSH6 gene, and age-matched male controls who tested negative for a familial pathogenic variant in these genes were recruited from 34 genetic and urology clinics in eight countries, and underwent a baseline PSA screening. Men who had a PSA level higher than 3·0 ng/mL were offered a transrectal, ultrasound-guided, prostate biopsy and a histopathological analysis was done. All participants are undergoing a minimum of 5 years' annual screening. The primary endpoint was to determine the incidence, stage, and pathology of screening-detected prostate cancer in carriers of pathogenic variants compared with non-carrier controls. We used Fisher's exact test to compare the number of cases, cancer incidence, and positive predictive values of the PSA cutoff and biopsy between carriers and non-carriers and the differences between disease types (ie, cancer vs no cancer, clinically significant cancer vs no cancer). We assessed screening outcomes and tumour characteristics by pathogenic variant status. Here we present results from the first round of PSA screening in the IMPACT study. This study is registered with ClinicalTrials.gov, NCT00261456, and is now closed to accrual. FINDINGS: Between Sept 28, 2012, and March 1, 2020, 828 men were recruited (644 carriers of mismatch repair pathogenic variants [204 carriers of MLH1, 305 carriers of MSH2, and 135 carriers of MSH6] and 184 non-carrier controls [65 non-carriers of MLH1, 76 non-carriers of MSH2, and 43 non-carriers of MSH6]), and in order to boost the sample size for the non-carrier control groups, we randomly selected 134 non-carriers from the BRCA1 and BRCA2 cohort of the IMPACT study, who were included in all three non-carrier cohorts. Men were predominantly of European ancestry (899 [93%] of 953 with available data), with a mean age of 52·8 years (SD 8·3). Within the first screening round, 56 (6%) men had a PSA concentration of more than 3·0 ng/mL and 35 (4%) biopsies were done. The overall incidence of prostate cancer was 1·9% (18 of 962; 95% CI 1·1-2·9). The incidence among MSH2 carriers was 4·3% (13 of 305; 95% CI 2·3-7·2), MSH2 non-carrier controls was 0·5% (one of 210; 0·0-2·6), MSH6 carriers was 3·0% (four of 135; 0·8-7·4), and none were detected among the MLH1 carriers, MLH1 non-carrier controls, and MSH6 non-carrier controls. Prostate cancer incidence, using a PSA threshold of higher than 3·0 ng/mL, was higher in MSH2 carriers than in MSH2 non-carrier controls (4·3% vs 0·5%; p=0·011) and MSH6 carriers than MSH6 non-carrier controls (3·0% vs 0%; p=0·034). The overall positive predictive value of biopsy using a PSA threshold of 3·0 ng/mL was 51·4% (95% CI 34·0-68·6), and the overall positive predictive value of a PSA threshold of 3·0 ng/mL was 32·1% (20·3-46·0). INTERPRETATION: After the first screening round, carriers of MSH2 and MSH6 pathogenic variants had a higher incidence of prostate cancer compared with age-matched non-carrier controls. These findings support the use of targeted PSA screening in these men to identify those with clinically significant prostate cancer. Further annual screening rounds will need to confirm these findings. FUNDING: Cancer Research UK, The Ronald and Rita McAulay Foundation, the National Institute for Health Research support to Biomedical Research Centres (The Institute of Cancer Research and Royal Marsden NHS Foundation Trust; Oxford; Manchester and the Cambridge Clinical Research Centre), Mr and Mrs Jack Baker, the Cancer Council of Tasmania, Cancer Australia, Prostate Cancer Foundation of Australia, Cancer Council of Victoria, Cancer Council of South Australia, the Victorian Cancer Agency, Cancer Australia, Prostate Cancer Foundation of Australia, Asociación Española Contra el Cáncer (AECC), the Instituto de Salud Carlos III, Fondo Europeo de Desarrollo Regional (FEDER), the Institut Català de la Salut, Autonomous Government of Catalonia, Fundação para a Ciência e a Tecnologia, National Institutes of Health National Cancer Institute, Swedish Cancer Society, General Hospital in Malmö Foundation for Combating Cancer..
Saunders, E.J.
Kote-Jarai, Z.
Eeles, R.A.
(2021). Identification of Germline Genetic Variants that Increase Prostate Cancer Risk and Influence Development of Aggressive Disease. Cancers (basel),
Vol.13
(4).
show abstract
full text
Prostate cancer (PrCa) is a heterogeneous disease, which presents in individual patients across a diverse phenotypic spectrum ranging from indolent to fatal forms. No robust biomarkers are currently available to enable routine screening for PrCa or to distinguish clinically significant forms, therefore late stage identification of advanced disease and overdiagnosis plus overtreatment of insignificant disease both remain areas of concern in healthcare provision. PrCa has a substantial heritable component, and technological advances since the completion of the Human Genome Project have facilitated improved identification of inherited genetic factors influencing susceptibility to development of the disease within families and populations. These genetic markers hold promise to enable improved understanding of the biological mechanisms underpinning PrCa development, facilitate genetically informed PrCa screening programmes and guide appropriate treatment provision. However, insight remains largely lacking regarding many aspects of their manifestation; especially in relation to genes associated with aggressive phenotypes, risk factors in non-European populations and appropriate approaches to enable accurate stratification of higher and lower risk individuals. This review discusses the methodology used in the elucidation of genetic loci, genes and individual causal variants responsible for modulating PrCa susceptibility; the current state of understanding of the allelic spectrum contributing to PrCa risk; and prospective future translational applications of these discoveries in the developing eras of genomics and personalised medicine..
Huynh-Le, M.-.
Fan, C.C.
Karunamuni, R.
Thompson, W.K.
Martinez, M.E.
Eeles, R.A.
Kote-Jarai, Z.
Muir, K.
Schleutker, J.
Pashayan, N.
Batra, J.
Grönberg, H.
Neal, D.E.
Donovan, J.L.
Hamdy, F.C.
Martin, R.M.
Nielsen, S.F.
Nordestgaard, B.G.
Wiklund, F.
Tangen, C.M.
Giles, G.G.
Wolk, A.
Albanes, D.
Travis, R.C.
Blot, W.J.
Zheng, W.
Sanderson, M.
Stanford, J.L.
Mucci, L.A.
West, C.M.
Kibel, A.S.
Cussenot, O.
Berndt, S.I.
Koutros, S.
Sørensen, K.D.
Cybulski, C.
Grindedal, E.M.
Menegaux, F.
Khaw, K.-.
Park, J.Y.
Ingles, S.A.
Maier, C.
Hamilton, R.J.
Thibodeau, S.N.
Rosenstein, B.S.
Lu, Y.-.
Watya, S.
Vega, A.
Kogevinas, M.
Penney, K.L.
Huff, C.
Teixeira, M.R.
Multigner, L.
Leach, R.J.
Cannon-Albright, L.
Brenner, H.
John, E.M.
Kaneva, R.
Logothetis, C.J.
Neuhausen, S.L.
De Ruyck, K.
Pandha, H.
Razack, A.
Newcomb, L.F.
Fowke, J.H.
Gamulin, M.
Usmani, N.
Claessens, F.
Gago-Dominguez, M.
Townsend, P.A.
Bush, W.S.
Roobol, M.J.
Parent, M.-.
Hu, J.J.
Mills, I.G.
Andreassen, O.A.
Dale, A.M.
Seibert, T.M.
UKGPCS collaborators,
APCB (Australian Prostate Cancer BioResource),
NC-LA PCaP Investigators,
IMPACT Study Steering Committee and Collaborators,
Canary PASS Investigators,
Profile Study Steering Committee,
PRACTICAL Consortium,
(2021). Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. Nat commun,
Vol.12
(1),
p. 1236.
show abstract
full text
Genetic models for cancer have been evaluated using almost exclusively European data, which could exacerbate health disparities. A polygenic hazard score (PHS1) is associated with age at prostate cancer diagnosis and improves screening accuracy in Europeans. Here, we evaluate performance of PHS2 (PHS1, adapted for OncoArray) in a multi-ethnic dataset of 80,491 men (49,916 cases, 30,575 controls). PHS2 is associated with age at diagnosis of any and aggressive (Gleason score ≥ 7, stage T3-T4, PSA ≥ 10 ng/mL, or nodal/distant metastasis) cancer and prostate-cancer-specific death. Associations with cancer are significant within European (n = 71,856), Asian (n = 2,382), and African (n = 6,253) genetic ancestries (p < 10-180). Comparing the 80th/20th PHS2 percentiles, hazard ratios for prostate cancer, aggressive cancer, and prostate-cancer-specific death are 5.32, 5.88, and 5.68, respectively. Within European, Asian, and African ancestries, hazard ratios for prostate cancer are: 5.54, 4.49, and 2.54, respectively. PHS2 risk-stratifies men for any, aggressive, and fatal prostate cancer in a multi-ethnic dataset..
Lin, H.-.
Huang, P.-.
Cheng, C.-.
Tung, H.-.
Fang, Z.
Berglund, A.E.
Chen, A.
French-Kwawu, J.
Harris, D.
Pow-Sang, J.
Yamoah, K.
Cleveland, J.L.
Awasthi, S.
Rounbehler, R.J.
Gerke, T.
Dhillon, J.
Eeles, R.
Kote-Jarai, Z.
Muir, K.
UKGPCS collaborators,
Schleutker, J.
Pashayan, N.
APCB (Australian Prostate Cancer BioResource),
Neal, D.E.
Nielsen, S.F.
Nordestgaard, B.G.
Gronberg, H.
Wiklund, F.
Giles, G.G.
Haiman, C.A.
Travis, R.C.
Stanford, J.L.
Kibel, A.S.
Cybulski, C.
Khaw, K.-.
Maier, C.
Thibodeau, S.N.
Teixeira, M.R.
Cannon-Albright, L.
Brenner, H.
Kaneva, R.
Pandha, H.
PRACTICAL consortium,
Srinivasan, S.
Clements, J.
Batra, J.
Park, J.Y.
(2021). KLK3 SNP-SNP interactions for prediction of prostate cancer aggressiveness. Sci rep,
Vol.11
(1),
p. 9264.
show abstract
Risk classification for prostate cancer (PCa) aggressiveness and underlying mechanisms remain inadequate. Interactions between single nucleotide polymorphisms (SNPs) may provide a solution to fill these gaps. To identify SNP-SNP interactions in the four pathways (the angiogenesis-, mitochondria-, miRNA-, and androgen metabolism-related pathways) associated with PCa aggressiveness, we tested 8587 SNPs for 20,729 cases from the PCa consortium. We identified 3 KLK3 SNPs, and 1083 (P < 3.5 × 10-9) and 3145 (P < 1 × 10-5) SNP-SNP interaction pairs significantly associated with PCa aggressiveness. These SNP pairs associated with PCa aggressiveness were more significant than each of their constituent SNP individual effects. The majority (98.6%) of the 3145 pairs involved KLK3. The 3 most common gene-gene interactions were KLK3-COL4A1:COL4A2, KLK3-CDH13, and KLK3-TGFBR3. Predictions from the SNP interaction-based polygenic risk score based on 24 SNP pairs are promising. The prevalence of PCa aggressiveness was 49.8%, 21.9%, and 7.0% for the PCa cases from our cohort with the top 1%, middle 50%, and bottom 1% risk profiles. Potential biological functions of the identified KLK3 SNP-SNP interactions were supported by gene expression and protein-protein interaction results. Our findings suggest KLK3 SNP interactions may play an important role in PCa aggressiveness..
ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium,
(2020). Pan-cancer analysis of whole genomes. Nature,
Vol.578
(7793),
pp. 82-93.
show abstract
full text
Cancer is driven by genetic change, and the advent of massively parallel sequencing has enabled systematic documentation of this variation at the whole-genome scale1-3. Here we report the integrative analysis of 2,658 whole-cancer genomes and their matching normal tissues across 38 tumour types from the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA). We describe the generation of the PCAWG resource, facilitated by international data sharing using compute clouds. On average, cancer genomes contained 4-5 driver mutations when combining coding and non-coding genomic elements; however, in around 5% of cases no drivers were identified, suggesting that cancer driver discovery is not yet complete. Chromothripsis, in which many clustered structural variants arise in a single catastrophic event, is frequently an early event in tumour evolution; in acral melanoma, for example, these events precede most somatic point mutations and affect several cancer-associated genes simultaneously. Cancers with abnormal telomere maintenance often originate from tissues with low replicative activity and show several mechanisms of preventing telomere attrition to critical levels. Common and rare germline variants affect patterns of somatic mutation, including point mutations, structural variants and somatic retrotransposition. A collection of papers from the PCAWG Consortium describes non-coding mutations that drive cancer beyond those in the TERT promoter4; identifies new signatures of mutational processes that cause base substitutions, small insertions and deletions and structural variation5,6; analyses timings and patterns of tumour evolution7; describes the diverse transcriptional consequences of somatic mutation on splicing, expression levels, fusion genes and promoter activity8,9; and evaluates a range of more-specialized features of cancer genomes8,10-18..
Rheinbay, E.
Nielsen, M.M.
Abascal, F.
Wala, J.A.
Shapira, O.
Tiao, G.
Hornshøj, H.
Hess, J.M.
Juul, R.I.
Lin, Z.
Feuerbach, L.
Sabarinathan, R.
Madsen, T.
Kim, J.
Mularoni, L.
Shuai, S.
Lanzós, A.
Herrmann, C.
Maruvka, Y.E.
Shen, C.
Amin, S.B.
Bandopadhayay, P.
Bertl, J.
Boroevich, K.A.
Busanovich, J.
Carlevaro-Fita, J.
Chakravarty, D.
Chan, C.W.
Craft, D.
Dhingra, P.
Diamanti, K.
Fonseca, N.A.
Gonzalez-Perez, A.
Guo, Q.
Hamilton, M.P.
Haradhvala, N.J.
Hong, C.
Isaev, K.
Johnson, T.A.
Juul, M.
Kahles, A.
Kahraman, A.
Kim, Y.
Komorowski, J.
Kumar, K.
Kumar, S.
Lee, D.
Lehmann, K.-.
Li, Y.
Liu, E.M.
Lochovsky, L.
Park, K.
Pich, O.
Roberts, N.D.
Saksena, G.
Schumacher, S.E.
Sidiropoulos, N.
Sieverling, L.
Sinnott-Armstrong, N.
Stewart, C.
Tamborero, D.
Tubio, J.M.
Umer, H.M.
Uusküla-Reimand, L.
Wadelius, C.
Wadi, L.
Yao, X.
Zhang, C.-.
Zhang, J.
Haber, J.E.
Hobolth, A.
Imielinski, M.
Kellis, M.
Lawrence, M.S.
von Mering, C.
Nakagawa, H.
Raphael, B.J.
Rubin, M.A.
Sander, C.
Stein, L.D.
Stuart, J.M.
Tsunoda, T.
Wheeler, D.A.
Johnson, R.
Reimand, J.
Gerstein, M.
Khurana, E.
Campbell, P.J.
López-Bigas, N.
PCAWG Drivers and Functional Interpretation Working Group,
PCAWG Structural Variation Working Group,
Weischenfeldt, J.
Beroukhim, R.
Martincorena, I.
Pedersen, J.S.
Getz, G.
PCAWG Consortium,
(2020). Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. Nature,
Vol.578
(7793),
pp. 102-111.
show abstract
The discovery of drivers of cancer has traditionally focused on protein-coding genes1-4. Here we present analyses of driver point mutations and structural variants in non-coding regions across 2,658 genomes from the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium5 of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA). For point mutations, we developed a statistically rigorous strategy for combining significance levels from multiple methods of driver discovery that overcomes the limitations of individual methods. For structural variants, we present two methods of driver discovery, and identify regions that are significantly affected by recurrent breakpoints and recurrent somatic juxtapositions. Our analyses confirm previously reported drivers6,7, raise doubts about others and identify novel candidates, including point mutations in the 5' region of TP53, in the 3' untranslated regions of NFKBIZ and TOB1, focal deletions in BRD4 and rearrangements in the loci of AKR1C genes. We show that although point mutations and structural variants that drive cancer are less frequent in non-coding genes and regulatory sequences than in protein-coding genes, additional examples of these drivers will be found as more cancer genomes become available..
PCAWG Transcriptome Core Group,
Calabrese, C.
Davidson, N.R.
Demircioğlu, D.
Fonseca, N.A.
He, Y.
Kahles, A.
Lehmann, K.-.
Liu, F.
Shiraishi, Y.
Soulette, C.M.
Urban, L.
Greger, L.
Li, S.
Liu, D.
Perry, M.D.
Xiang, Q.
Zhang, F.
Zhang, J.
Bailey, P.
Erkek, S.
Hoadley, K.A.
Hou, Y.
Huska, M.R.
Kilpinen, H.
Korbel, J.O.
Marin, M.G.
Markowski, J.
Nandi, T.
Pan-Hammarström, Q.
Pedamallu, C.S.
Siebert, R.
Stark, S.G.
Su, H.
Tan, P.
Waszak, S.M.
Yung, C.
Zhu, S.
Awadalla, P.
Creighton, C.J.
Meyerson, M.
Ouellette, B.F.
Wu, K.
Yang, H.
PCAWG Transcriptome Working Group,
Brazma, A.
Brooks, A.N.
Göke, J.
Rätsch, G.
Schwarz, R.F.
Stegle, O.
Zhang, Z.
PCAWG Consortium,
(2020). Genomic basis for RNA alterations in cancer. Nature,
Vol.578
(7793),
pp. 129-136.
show abstract
Transcript alterations often result from somatic changes in cancer genomes1. Various forms of RNA alterations have been described in cancer, including overexpression2, altered splicing3 and gene fusions4; however, it is difficult to attribute these to underlying genomic changes owing to heterogeneity among patients and tumour types, and the relatively small cohorts of patients for whom samples have been analysed by both transcriptome and whole-genome sequencing. Here we present, to our knowledge, the most comprehensive catalogue of cancer-associated gene alterations to date, obtained by characterizing tumour transcriptomes from 1,188 donors of the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA)5. Using matched whole-genome sequencing data, we associated several categories of RNA alterations with germline and somatic DNA alterations, and identified probable genetic mechanisms. Somatic copy-number alterations were the major drivers of variations in total gene and allele-specific expression. We identified 649 associations of somatic single-nucleotide variants with gene expression in cis, of which 68.4% involved associations with flanking non-coding regions of the gene. We found 1,900 splicing alterations associated with somatic mutations, including the formation of exons within introns in proximity to Alu elements. In addition, 82% of gene fusions were associated with structural variants, including 75 of a new class, termed 'bridged' fusions, in which a third genomic location bridges two genes. We observed transcriptomic alteration signatures that differ between cancer types and have associations with variations in DNA mutational signatures. This compendium of RNA alterations in the genomic context provides a rich resource for identifying genes and mechanisms that are functionally implicated in cancer..
Gerstung, M.
Jolly, C.
Leshchiner, I.
Dentro, S.C.
Gonzalez, S.
Rosebrock, D.
Mitchell, T.J.
Rubanova, Y.
Anur, P.
Yu, K.
Tarabichi, M.
Deshwar, A.
Wintersinger, J.
Kleinheinz, K.
Vázquez-García, I.
Haase, K.
Jerman, L.
Sengupta, S.
Macintyre, G.
Malikic, S.
Donmez, N.
Livitz, D.G.
Cmero, M.
Demeulemeester, J.
Schumacher, S.
Fan, Y.
Yao, X.
Lee, J.
Schlesner, M.
Boutros, P.C.
Bowtell, D.D.
Zhu, H.
Getz, G.
Imielinski, M.
Beroukhim, R.
Sahinalp, S.C.
Ji, Y.
Peifer, M.
Markowetz, F.
Mustonen, V.
Yuan, K.
Wang, W.
Morris, Q.D.
PCAWG Evolution & Heterogeneity Working Group,
Spellman, P.T.
Wedge, D.C.
Van Loo, P.
PCAWG Consortium,
(2020). The evolutionary history of 2,658 cancers. Nature,
Vol.578
(7793),
pp. 122-128.
show abstract
Cancer develops through a process of somatic evolution1,2. Sequencing data from a single biopsy represent a snapshot of this process that can reveal the timing of specific genomic aberrations and the changing influence of mutational processes3. Here, by whole-genome sequencing analysis of 2,658 cancers as part of the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA)4, we reconstruct the life history and evolution of mutational processes and driver mutation sequences of 38 types of cancer. Early oncogenesis is characterized by mutations in a constrained set of driver genes, and specific copy number gains, such as trisomy 7 in glioblastoma and isochromosome 17q in medulloblastoma. The mutational spectrum changes significantly throughout tumour evolution in 40% of samples. A nearly fourfold diversification of driver genes and increased genomic instability are features of later stages. Copy number alterations often occur in mitotic crises, and lead to simultaneous gains of chromosomal segments. Timing analyses suggest that driver mutations often precede diagnosis by many years, if not decades. Together, these results determine the evolutionary trajectories of cancer, and highlight opportunities for early cancer detection..
Zhang, Y.D.
Hurson, A.N.
Zhang, H.
Choudhury, P.P.
Easton, D.F.
Milne, R.L.
Simard, J.
Hall, P.
Michailidou, K.
Dennis, J.
Schmidt, M.K.
Chang-Claude, J.
Gharahkhani, P.
Whiteman, D.
Campbell, P.T.
Hoffmeister, M.
Jenkins, M.
Peters, U.
Hsu, L.
Gruber, S.B.
Casey, G.
Schmit, S.L.
O'Mara, T.A.
Spurdle, A.B.
Thompson, D.J.
Tomlinson, I.
De Vivo, I.
Landi, M.T.
Law, M.H.
Iles, M.M.
Demenais, F.
Kumar, R.
MacGregor, S.
Bishop, D.T.
Ward, S.V.
Bondy, M.L.
Houlston, R.
Wiencke, J.K.
Melin, B.
Barnholtz-Sloan, J.
Kinnersley, B.
Wrensch, M.R.
Amos, C.I.
Hung, R.J.
Brennan, P.
McKay, J.
Caporaso, N.E.
Berndt, S.I.
Birmann, B.M.
Camp, N.J.
Kraft, P.
Rothman, N.
Slager, S.L.
Berchuck, A.
Pharoah, P.D.
Sellers, T.A.
Gayther, S.A.
Pearce, C.L.
Goode, E.L.
Schildkraut, J.M.
Moysich, K.B.
Amundadottir, L.T.
Jacobs, E.J.
Klein, A.P.
Petersen, G.M.
Risch, H.A.
Stolzenberg-Solomon, R.Z.
Wolpin, B.M.
Li, D.
Eeles, R.A.
Haiman, C.A.
Kote-Jarai, Z.
Schumacher, F.R.
Al Olama, A.A.
Purdue, M.P.
Scelo, G.
Dalgaard, M.D.
Greene, M.H.
Grotmol, T.
Kanetsky, P.A.
McGlynn, K.A.
Nathanson, K.L.
Turnbull, C.
Wiklund, F.
Breast Cancer Association Consortium (BCAC),
Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON),
Colon Cancer Family Registry (CCFR),
Transdisciplinary Studies of Genetic Variation in Colorectal Cancer (CORECT),
Endometrial Cancer Association Consortium (ECAC),
Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO),
Melanoma Genetics Consortium (GenoMEL),
Glioma International Case-Control Study (GICC),
International Lung Cancer Consortium (ILCCO),
Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Consortium,
International Consortium of Investigators Working on Non-Hodgkin’s Lymphoma Epidemiologic Studies (InterLymph),
Ovarian Cancer Association Consortium (OCAC),
Oral Cancer GWAS,
Pancreatic Cancer Case-Control Consortium (PanC4),
Pancreatic Cancer Cohort Consortium (PanScan),
Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL),
Renal Cancer GWAS,
Testicular Cancer Consortium (TECAC),
Chanock, S.J.
Chatterjee, N.
Garcia-Closas, M.
(2020). Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers. Nat commun,
Vol.11
(1),
p. 3353.
show abstract
full text
Genome-wide association studies (GWAS) have led to the identification of hundreds of susceptibility loci across cancers, but the impact of further studies remains uncertain. Here we analyse summary-level data from GWAS of European ancestry across fourteen cancer sites to estimate the number of common susceptibility variants (polygenicity) and underlying effect-size distribution. All cancers show a high degree of polygenicity, involving at a minimum of thousands of loci. We project that sample sizes required to explain 80% of GWAS heritability vary from 60,000 cases for testicular to over 1,000,000 cases for lung cancer. The maximum relative risk achievable for subjects at the 99th risk percentile of underlying polygenic risk scores (PRS), compared to average risk, ranges from 12 for testicular to 2.5 for ovarian cancer. We show that PRS have potential for risk stratification for cancers of breast, colon and prostate, but less so for others because of modest heritability and lower incidence..
Brandão, A.
Paulo, P.
Maia, S.
Pinheiro, M.
Peixoto, A.
Cardoso, M.
Silva, M.P.
Santos, C.
Eeles, R.A.
Kote-Jarai, Z.
Muir, K.
Ukgpcs Collaborators,
Schleutker, J.
Wang, Y.
Pashayan, N.
Batra, J.
Apcb BioResource,
Grönberg, H.
Neal, D.E.
Nordestgaard, B.G.
Tangen, C.M.
Southey, M.C.
Wolk, A.
Albanes, D.
Haiman, C.A.
Travis, R.C.
Stanford, J.L.
Mucci, L.A.
West, C.M.
Nielsen, S.F.
Kibel, A.S.
Cussenot, O.
Berndt, S.I.
Koutros, S.
Sørensen, K.D.
Cybulski, C.
Grindedal, E.M.
Park, J.Y.
Ingles, S.A.
Maier, C.
Hamilton, R.J.
Rosenstein, B.S.
Vega, A.
The Impact Study Steering Committee And Collaborators,
Kogevinas, M.
Wiklund, F.
Penney, K.L.
Brenner, H.
John, E.M.
Kaneva, R.
Logothetis, C.J.
Neuhausen, S.L.
Ruyck, K.D.
Razack, A.
Newcomb, L.F.
Canary Pass Investigators,
Lessel, D.
Usmani, N.
Claessens, F.
Gago-Dominguez, M.
Townsend, P.A.
Roobol, M.J.
The Profile Study Steering Committee,
The Practical Consortium,
Teixeira, M.R.
(2020). The CHEK2 Variant C 349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor. Cancers (basel),
Vol.12
(11).
show abstract
full text
The identification of recurrent founder variants in cancer predisposing genes may have important implications for implementing cost-effective targeted genetic screening strategies. In this study, we evaluated the prevalence and relative risk of the CHEK2 recurrent variant c.349A>G in a series of 462 Portuguese patients with early-onset and/or familial/hereditary prostate cancer (PrCa), as well as in the large multicentre PRACTICAL case-control study comprising 55,162 prostate cancer cases and 36,147 controls. Additionally, we investigated the potential shared ancestry of the carriers by performing identity-by-descent, haplotype and age estimation analyses using high-density SNP data from 70 variant carriers belonging to 11 different populations included in the PRACTICAL consortium. The CHEK2 missense variant c.349A>G was found significantly associated with an increased risk for PrCa (OR 1.9; 95% CI: 1.1-3.2). A shared haplotype flanking the variant in all carriers was identified, strongly suggesting a common founder of European origin. Additionally, using two independent statistical algorithms, implemented by DMLE+2.3 and ESTIAGE, we were able to estimate the age of the variant between 2300 and 3125 years. By extending the haplotype analysis to 14 additional carrier families, a shared core haplotype was revealed among all carriers matching the conserved region previously identified in the high-density SNP analysis. These findings are consistent with CHEK2 c.349A>G being a founder variant associated with increased PrCa risk, suggesting its potential usefulness for cost-effective targeted genetic screening in PrCa families..
Reyna, M.A.
Haan, D.
Paczkowska, M.
Verbeke, L.P.
Vazquez, M.
Kahraman, A.
Pulido-Tamayo, S.
Barenboim, J.
Wadi, L.
Dhingra, P.
Shrestha, R.
Getz, G.
Lawrence, M.S.
Pedersen, J.S.
Rubin, M.A.
Wheeler, D.A.
Brunak, S.
Izarzugaza, J.M.
Khurana, E.
Marchal, K.
von Mering, C.
Sahinalp, S.C.
Valencia, A.
PCAWG Drivers and Functional Interpretation Working Group,
Reimand, J.
Stuart, J.M.
Raphael, B.J.
PCAWG Consortium,
(2020). Pathway and network analysis of more than 2500 whole cancer genomes. Nat commun,
Vol.11
(1),
p. 729.
show abstract
The catalog of cancer driver mutations in protein-coding genes has greatly expanded in the past decade. However, non-coding cancer driver mutations are less well-characterized and only a handful of recurrent non-coding mutations, most notably TERT promoter mutations, have been reported. Here, as part of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium, which aggregated whole genome sequencing data from 2658 cancer across 38 tumor types, we perform multi-faceted pathway and network analyses of non-coding mutations across 2583 whole cancer genomes from 27 tumor types compiled by the ICGC/TCGA PCAWG project that was motivated by the success of pathway and network analyses in prioritizing rare mutations in protein-coding genes. While few non-coding genomic elements are recurrently mutated in this cohort, we identify 93 genes harboring non-coding mutations that cluster into several modules of interacting proteins. Among these are promoter mutations associated with reduced mRNA expression in TP53, TLE4, and TCF4. We find that biological processes had variable proportions of coding and non-coding mutations, with chromatin remodeling and proliferation pathways altered primarily by coding mutations, while developmental pathways, including Wnt and Notch, altered by both coding and non-coding mutations. RNA splicing is primarily altered by non-coding mutations in this cohort, and samples containing non-coding mutations in well-known RNA splicing factors exhibit similar gene expression signatures as samples with coding mutations in these genes. These analyses contribute a new repertoire of possible cancer genes and mechanisms that are altered by non-coding mutations and offer insights into additional cancer vulnerabilities that can be investigated for potential therapeutic treatments..
Ahmed, M.
Goh, C.
Saunders, E.
Cieza-Borrella, C.
PRACTICAL consortium,
Kote-Jarai, Z.
Schumacher, F.R.
Eeles, R.
(2020). Germline genetic variation in prostate susceptibility does not predict outcomes in the chemoprevention trials PCPT and SELECT. Prostate cancer prostatic dis,
Vol.23
(2),
pp. 333-342.
show abstract
full text
BACKGROUND: The development of prostate cancer can be influenced by genetic and environmental factors. Numerous germline SNPs influence prostate cancer susceptibility. The functional pathways in which these SNPs increase prostate cancer susceptibility are unknown. Finasteride is currently not being used routinely as a chemoprevention agent but the long term outcomes of the PCPT trial are awaited. The outcomes of the SELECT trial have not recommended the use of chemoprevention in preventing prostate cancer. This study investigated whether germline risk SNPs could be used to predict outcomes in the PCPT and SELECT trial. METHODS: Genotyping was performed in European men entered into the PCPT trial (n = 2434) and SELECT (n = 4885). Next generation genotyping was performed using Affymetrix® Eureka™ Genotyping protocols. Logistic regression models were used to test the association of risk scores and the outcomes in the PCPT and SELECT trials. RESULTS: Of the 100 SNPs, 98 designed successfully and genotyping was validated for samples genotyped on other platforms. A number of SNPs predicted for aggressive disease in both trials. Men with a higher polygenic score are more likely to develop prostate cancer in both trials, but the score did not predict for other outcomes in the trial. CONCLUSION: Men with a higher polygenic risk score are more likely to develop prostate cancer. There were no interactions of these germline risk SNPs and the chemoprevention agents in the SELECT and PCPT trials..
Wu, L.
Yang, Y.
Guo, X.
Shu, X.-.
Cai, Q.
Shu, X.
Li, B.
Tao, R.
Wu, C.
Nikas, J.B.
Sun, Y.
Zhu, J.
Roobol, M.J.
Giles, G.G.
Brenner, H.
John, E.M.
Clements, J.
Grindedal, E.M.
Park, J.Y.
Stanford, J.L.
Kote-Jarai, Z.
Haiman, C.A.
Eeles, R.A.
Zheng, W.
Long, J.
PRACTICAL consortium,
CRUK Consortium,
BPC3 Consortium,
CAPS Consortium,
PEGASUS Consortium,
(2020). An integrative multi-omics analysis to identify candidate DNA methylation biomarkers related to prostate cancer risk. Nat commun,
Vol.11
(1),
p. 3905.
show abstract
full text
It remains elusive whether some of the associations identified in genome-wide association studies of prostate cancer (PrCa) may be due to regulatory effects of genetic variants on CpG sites, which may further influence expression of PrCa target genes. To search for CpG sites associated with PrCa risk, here we establish genetic models to predict methylation (N = 1,595) and conduct association analyses with PrCa risk (79,194 cases and 61,112 controls). We identify 759 CpG sites showing an association, including 15 located at novel loci. Among those 759 CpG sites, methylation of 42 is associated with expression of 28 adjacent genes. Among 22 genes, 18 show an association with PrCa risk. Overall, 25 CpG sites show consistent association directions for the methylation-gene expression-PrCa pathway. We identify DNA methylation biomarkers associated with PrCa, and our findings suggest that specific CpG sites may influence PrCa via regulating expression of candidate PrCa target genes..
Huynh-Le, M.-.
Fan, C.C.
Karunamuni, R.
Walsh, E.I.
Turner, E.L.
Lane, J.A.
Martin, R.M.
Neal, D.E.
Donovan, J.L.
Hamdy, F.C.
Parsons, J.K.
Eeles, R.A.
Easton, D.F.
Kote-Jarai, Z.
Amin Al Olama, A.
Benlloch Garcia, S.
Muir, K.
Grönberg, H.
Wiklund, F.
Aly, M.
Schleutker, J.
Sipeky, C.
Tammela, T.L.
Nordestgaard, B.G.
Key, T.J.
Travis, R.C.
Pharoah, P.D.
Pashayan, N.
Khaw, K.-.
Thibodeau, S.N.
McDonnell, S.K.
Schaid, D.J.
Maier, C.
Vogel, W.
Luedeke, M.
Herkommer, K.
Kibel, A.S.
Cybulski, C.
Wokolorczyk, D.
Kluzniak, W.
Cannon-Albright, L.A.
Brenner, H.
Schöttker, B.
Holleczek, B.
Park, J.Y.
Sellers, T.A.
Lin, H.-.
Slavov, C.K.
Kaneva, R.P.
Mitev, V.I.
Batra, J.
Clements, J.A.
Spurdle, A.B.
Teixeira, M.R.
Paulo, P.
Maia, S.
Pandha, H.
Michael, A.
Mills, I.G.
Andreassen, O.A.
Dale, A.M.
Seibert, T.M.
Australian Prostate Cancer BioResource (APCB),
PRACTICAL Consortium,
(2020). A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data. Cancer epidemiol biomarkers prev,
Vol.29
(9),
pp. 1731-1738.
show abstract
full text
BACKGROUND: A polygenic hazard score (PHS), the weighted sum of 54 SNP genotypes, was previously validated for association with clinically significant prostate cancer and for improved prostate cancer screening accuracy. Here, we assess the potential impact of PHS-informed screening. METHODS: United Kingdom population incidence data (Cancer Research United Kingdom) and data from the Cluster Randomized Trial of PSA Testing for Prostate Cancer were combined to estimate age-specific clinically significant prostate cancer incidence (Gleason score ≥7, stage T3-T4, PSA ≥10, or nodal/distant metastases). Using HRs estimated from the ProtecT prostate cancer trial, age-specific incidence rates were calculated for various PHS risk percentiles. Risk-equivalent age, when someone with a given PHS percentile has prostate cancer risk equivalent to an average 50-year-old man (50-year-standard risk), was derived from PHS and incidence data. Positive predictive value (PPV) of PSA testing for clinically significant prostate cancer was calculated using PHS-adjusted age groups. RESULTS: The expected age at diagnosis of clinically significant prostate cancer differs by 19 years between the 1st and 99th PHS percentiles: men with PHS in the 1st and 99th percentiles reach the 50-year-standard risk level at ages 60 and 41, respectively. PPV of PSA was higher for men with higher PHS-adjusted age. CONCLUSIONS: PHS provides individualized estimates of risk-equivalent age for clinically significant prostate cancer. Screening initiation could be adjusted by a man's PHS. IMPACT: Personalized genetic risk assessments could inform prostate cancer screening decisions..
Karunamuni, R.A.
Huynh-Le, M.-.
Fan, C.C.
Eeles, R.A.
Easton, D.F.
Kote-Jarai, Z.
Amin Al Olama, A.
Benlloch Garcia, S.
Muir, K.
Gronberg, H.
Wiklund, F.
Aly, M.
Schleutker, J.
Sipeky, C.
Tammela, T.L.
Nordestgaard, B.G.
Key, T.J.
Travis, R.C.
Neal, D.E.
Donovan, J.L.
Hamdy, F.C.
Pharoah, P.
Pashayan, N.
Khaw, K.-.
Thibodeau, S.N.
McDonnell, S.K.
Schaid, D.J.
Maier, C.
Vogel, W.
Luedeke, M.
Herkommer, K.
Kibel, A.S.
Cybulski, C.
Wokolorczyk, D.
Kluzniak, W.
Cannon-Albright, L.
Brenner, H.
Schöttker, B.
Holleczek, B.
Park, J.Y.
Sellers, T.A.
Lin, H.-.
Slavov, C.
Kaneva, R.
Mitev, V.
Batra, J.
Clements, J.A.
Spurdle, A.
Australian Prostate Cancer BioResource (APCB),
Teixeira, M.R.
Paulo, P.
Maia, S.
Pandha, H.
Michael, A.
Mills, I.G.
Andreassen, O.A.
Dale, A.M.
Seibert, T.M.
PRACTICAL Consortium,
(2020). The effect of sample size on polygenic hazard models for prostate cancer. Eur j hum genet,
Vol.28
(10),
pp. 1467-1475.
show abstract
full text
We determined the effect of sample size on performance of polygenic hazard score (PHS) models in prostate cancer. Age and genotypes were obtained for 40,861 men from the PRACTICAL consortium. The dataset included 201,590 SNPs per subject, and was split into training and testing sets. Established-SNP models considered 65 SNPs that had been previously associated with prostate cancer. Discovery-SNP models used stepwise selection to identify new SNPs. The performance of each PHS model was calculated for random sizes of the training set. The performance of a representative Established-SNP model was estimated for random sizes of the testing set. Mean HR98/50 (hazard ratio of top 2% to average in test set) of the Established-SNP model increased from 1.73 [95% CI: 1.69-1.77] to 2.41 [2.40-2.43] when the number of training samples was increased from 1 thousand to 30 thousand. Corresponding HR98/50 of the Discovery-SNP model increased from 1.05 [0.93-1.18] to 2.19 [2.16-2.23]. HR98/50 of a representative Established-SNP model using testing set sample sizes of 0.6 thousand and 6 thousand observations were 1.78 [1.70-1.85] and 1.73 [1.71-1.76], respectively. We estimate that a study population of 20 thousand men is required to develop Discovery-SNP PHS models while 10 thousand men should be sufficient for Established-SNP models..
Gilson, C.
Ingleby, F.
Gilbert, D.C.
Parry, M.A.
Atako, N.B.
Ali, A.
Hoyle, A.
Clarke, N.W.
Gannon, M.
Wanstall, C.
Brawley, C.
Mason, M.D.
Malik, Z.
Simmons, A.
Loehr, A.
Parry-Jones, A.
Eeles, R.
Kote-Jarai, Z.
James, N.D.
Amos, C.
Parmar, M.K.
Langley, R.E.
Sydes, M.R.
Attard, G.
Chowdhury, S.
STAMPEDE Investigators,
(2020). Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial. Jco precis oncol,
Vol.4,
pp. 882-897.
show abstract
PURPOSE: The STAMPEDE trial recruits men with newly diagnosed, high-risk, hormone-sensitive prostate cancer. To ascertain the feasibility of targeted next-generation sequencing (tNGS) and the prevalence of baseline genomic aberrations, we sequenced tumor and germline DNA from patients with metastatic prostate cancer (mPCa) starting long-term androgen-deprivation therapy (ADT). METHODS: In a 2-stage approach, archival, formalin-fixed, paraffin-embedded (FFPE) prostate tumor core biopsy samples were retrospectively subjected to 2 tNGS assays. Prospective enrollment enabled validation using tNGS in tumor and germline DNA. RESULTS: In stage 1, tNGS data were obtained from 185 tumors from 287 patients (65%); 98% had de novo mPCa. We observed PI3K pathway aberrations in 43%, due to PTEN copy-number loss (34%) and/or activating mutations in PIK3 genes or AKT (18%) and TP53 mutation or loss in 33%. No androgen receptor (AR) aberrations were detected; RB1 loss was observed in < 1%. In stage 2, 93 (92%) of 101 FFPE tumors (biopsy obtained within 8 months) were successfully sequenced prospectively. The prevalence of DNA damage repair (DDR) deficiency was 14% (somatic) and 5% (germline). BRCA2 mutations and mismatch repair gene mutations were exclusive to high-volume disease. Aberrant DDR (22% v 15%), Wnt pathway (16% v 4%), and chromatin remodeling (16% v 8%) were all more common in high-volume compared with low-volume disease, but the small numbers limited statistical comparisons. CONCLUSION: Prospective genomic characterization is feasible using residual diagnostic tumor samples and reveals that the genomic landscapes of de novo high-volume mPCa and advanced metastatic prostate cancer have notable similarities (PI3K pathway, DDR, Wnt, chromatin remodeling) and differences (AR, RB1). These results will inform the design and conduct of biomarker-directed trials in men with metastatic hormone-sensitive prostate cancer..
Hollis, B.
Day, F.R.
Busch, A.S.
Thompson, D.J.
Soares, A.L.
Timmers, P.R.
Kwong, A.
Easton, D.F.
Joshi, P.K.
Timpson, N.J.
PRACTICAL Consortium,
23andMe Research Team,
Ong, K.K.
Perry, J.R.
(2020). Genomic analysis of male puberty timing highlights shared genetic basis with hair colour and lifespan. Nat commun,
Vol.11
(1),
p. 1536.
show abstract
The timing of puberty is highly variable and is associated with long-term health outcomes. To date, understanding of the genetic control of puberty timing is based largely on studies in women. Here, we report a multi-trait genome-wide association study for male puberty timing with an effective sample size of 205,354 men. We find moderately strong genomic correlation in puberty timing between sexes (rg = 0.68) and identify 76 independent signals for male puberty timing. Implicated mechanisms include an unexpected link between puberty timing and natural hair colour, possibly reflecting common effects of pituitary hormones on puberty and pigmentation. Earlier male puberty timing is genetically correlated with several adverse health outcomes and Mendelian randomization analyses show a genetic association between male puberty timing and shorter lifespan. These findings highlight the relationships between puberty timing and health outcomes, and demonstrate the value of genetic studies of puberty timing in both sexes..
Aladwani, M.
Lophatananon, A.
Robinson, F.
Rahman, A.
Ollier, W.
Kote-Jarai, Z.
Dearnaley, D.
Koveela, G.
Hussain, N.
Rageevakumar, R.
Keating, D.
Osborne, A.
Dadaev, T.
Brook, M.
British Association of Urological Surgeons’ Section of Oncology,
Eeles, R.
Muir, K.R.
(2020). Relationship of self-reported body size and shape with risk for prostate cancer: A UK case-control study. Plos one,
Vol.15
(9),
p. e0238928.
show abstract
full text
INTRODUCTION: Previous evidence has suggested a relationship between male self-reported body size and the risk of developing prostate cancer. In this UK-wide case-control study, we have explored the possible association of prostate cancer risk with male self-reported body size. We also investigated body shape as a surrogate marker for fat deposition around the body. As obesity and excessive adiposity have been linked with increased risk for developing a number of different cancers, further investigation of self-reported body size and shape and their potential relationship with prostate cancer was considered to be appropriate. OBJECTIVE: The study objective was to investigate whether underlying associations exist between prostate cancer risk and male self-reported body size and shape. METHODS: Data were collected from a large case-control study of men (1928 cases and 2043 controls) using self-administered questionnaires. Data from self-reported pictograms of perceived body size relating to three decades of life (20's, 30's and 40's) were recorded and analysed, including the pattern of change. The associations of self-identified body shape with prostate cancer risk were also explored. RESULTS: Self-reported body size for men in their 20's, 30's and 40's did not appear to be associated with prostate cancer risk. More than half of the subjects reported an increase in self-reported body size throughout these three decades of life. Furthermore, no association was observed between self-reported body size changes and prostate cancer risk. Using 'symmetrical' body shape as a reference group, subjects with an 'apple' shape showed a significant 27% reduction in risk (Odds ratio = 0.73, 95% C.I. 0.57-0.92). CONCLUSIONS: Change in self-reported body size throughout early to mid-adulthood in males is not a significant risk factor for the development of prostate cancer. Body shape indicative of body fat distribution suggested that an 'apple' body shape was protective and inversely associated with prostate cancer risk when compared with 'symmetrical' shape. Further studies which investigate prostate cancer risk and possible relationships with genetic factors known to influence body shape may shed further light on any underlying associations..
Adams, C.D.
Richmond, R.
Ferreira, D.L.
Spiller, W.
Tan, V.
Zheng, J.
Würtz, P.
Donovan, J.
Hamdy, F.
Neal, D.
Lane, J.A.
Smith, G.D.
Relton, C.
Eeles, R.A.
Haiman, C.A.
Kote-Jarai, Z.
Schumacher, F.R.
Olama, A.A.
Benlloch, S.
Muir, K.
Berndt, S.I.
Conti, D.V.
Wiklund, F.
Chanock, S.J.
Gapstur, S.
Stevens, V.L.
Tangen, C.M.
Batra, J.
Clements, J.A.
Gronberg, H.
Pashayan, N.
Schleutker, J.
Albanes, D.
Wolk, A.
West, C.M.
Mucci, L.A.
Cancel-Tassin, G.
Koutros, S.
Sorensen, K.D.
Maehle, L.
Travis, R.C.
Hamilton, R.J.
Ingles, S.A.
Rosenstein, B.S.
Lu, Y.-.
Giles, G.G.
Kibel, A.S.
Vega, A.
Kogevinas, M.
Penney, K.L.
Park, J.Y.
Stanford, J.L.
Cybulski, C.
Nordestgaard, B.G.
Brenner, H.
Maier, C.
Kim, J.
John, E.M.
Teixeira, M.R.
Neuhausen, S.L.
De Ruyck, K.
Razack, A.
Newcomb, L.F.
Lessel, D.
Kaneva, R.P.
Usmani, N.
Claessens, F.
Townsend, P.A.
Dominguez, M.G.
Roobol, M.J.
Menegaux, F.
Khaw, K.-.
Cannon-Albright, L.A.
Pandha, H.
Thibodeau, S.N.
Martin, R.M.
PRACTICAL consortium,
(2019). Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study. Cancer epidemiol biomarkers prev,
Vol.28
(1),
pp. 208-216.
show abstract
full text
BACKGROUND: Whether associations between circulating metabolites and prostate cancer are causal is unknown. We report on the largest study of metabolites and prostate cancer (2,291 cases and 2,661 controls) and appraise causality for a subset of the prostate cancer-metabolite associations using two-sample Mendelian randomization (MR). METHODS: The case-control portion of the study was conducted in nine UK centers with men ages 50-69 years who underwent prostate-specific antigen screening for prostate cancer within the Prostate Testing for Cancer and Treatment (ProtecT) trial. Two data sources were used to appraise causality: a genome-wide association study (GWAS) of metabolites in 24,925 participants and a GWAS of prostate cancer in 44,825 cases and 27,904 controls within the Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) consortium. RESULTS: Thirty-five metabolites were strongly associated with prostate cancer (P < 0.0014, multiple-testing threshold). These fell into four classes: (i) lipids and lipoprotein subclass characteristics (total cholesterol and ratios, cholesterol esters and ratios, free cholesterol and ratios, phospholipids and ratios, and triglyceride ratios); (ii) fatty acids and ratios; (iii) amino acids; (iv) and fluid balance. Fourteen top metabolites were proxied by genetic variables, but MR indicated these were not causal. CONCLUSIONS: We identified 35 circulating metabolites associated with prostate cancer presence, but found no evidence of causality for those 14 testable with MR. Thus, the 14 MR-tested metabolites are unlikely to be mechanistically important in prostate cancer risk. IMPACT: The metabolome provides a promising set of biomarkers that may aid prostate cancer classification..
Wu, L.
Wang, J.
Cai, Q.
Cavazos, T.B.
Emami, N.C.
Long, J.
Shu, X.-.
Lu, Y.
Guo, X.
Bauer, J.A.
Pasaniuc, B.
Penney, K.L.
Freedman, M.L.
Kote-Jarai, Z.
Witte, J.S.
Haiman, C.A.
Eeles, R.A.
Zheng, W.
PRACTICAL, CRUK, BPC3, CAPS, PEGASUS Consortia,
(2019). Identification of Novel Susceptibility Loci and Genes for Prostate Cancer Risk: A Transcriptome-Wide Association Study in Over 140,000 European Descendants. Cancer res,
Vol.79
(13),
pp. 3192-3204.
show abstract
full text
Genome-wide association study-identified prostate cancer risk variants explain only a relatively small fraction of its familial relative risk, and the genes responsible for many of these identified associations remain unknown. To discover novel prostate cancer genetic loci and possible causal genes at previously identified risk loci, we performed a transcriptome-wide association study in 79,194 cases and 61,112 controls of European ancestry. Using data from the Genotype-Tissue Expression Project, we established genetic models to predict gene expression across the transcriptome for both prostate models and cross-tissue models and evaluated model performance using two independent datasets. We identified significant associations for 137 genes at P < 2.61 × 10-6, a Bonferroni-corrected threshold, including nine genes that remained significant at P < 2.61 × 10-6 after adjusting for all known prostate cancer risk variants in nearby regions. Of the 128 remaining associated genes, 94 have not yet been reported as potential target genes at known loci. We silenced 14 genes and many showed a consistent effect on viability and colony-forming efficiency in three cell lines. Our study provides substantial new information to advance our understanding of prostate cancer genetics and biology. SIGNIFICANCE: This study identifies novel prostate cancer genetic loci and possible causal genes, advancing our understanding of the molecular mechanisms that drive prostate cancer..
Bancroft, E.K.
Saya, S.
Page, E.C.
Myhill, K.
Thomas, S.
Pope, J.
Chamberlain, A.
Hart, R.
Glover, W.
Cook, J.
Rosario, D.J.
Helfand, B.T.
Hutten Selkirk, C.
Davidson, R.
Longmuir, M.
Eccles, D.M.
Gadea, N.
Brewer, C.
Barwell, J.
Salinas, M.
Greenhalgh, L.
Tischkowitz, M.
Henderson, A.
Evans, D.G.
Buys, S.S.
IMPACT Study Steering Committee,
IMPACT Collaborators,
Eeles, R.A.
Aaronson, N.K.
(2019). Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations. Bju int,
Vol.123
(2),
pp. 284-292.
show abstract
full text
OBJECTIVES: To report the baseline results of a longitudinal psychosocial study that forms part of the IMPACT study, a multi-national investigation of targeted prostate cancer (PCa) screening among men with a known pathogenic germline mutation in the BRCA1 or BRCA2 genes. PARTICPANTS AND METHODS: Men enrolled in the IMPACT study were invited to complete a questionnaire at collaborating sites prior to each annual screening visit. The questionnaire included sociodemographic characteristics and the following measures: the Hospital Anxiety and Depression Scale (HADS), Impact of Event Scale (IES), 36-item short-form health survey (SF-36), Memorial Anxiety Scale for Prostate Cancer, Cancer Worry Scale-Revised, risk perception and knowledge. The results of the baseline questionnaire are presented. RESULTS: A total of 432 men completed questionnaires: 98 and 160 had mutations in BRCA1 and BRCA2 genes, respectively, and 174 were controls (familial mutation negative). Participants' perception of PCa risk was influenced by genetic status. Knowledge levels were high and unrelated to genetic status. Mean scores for the HADS and SF-36 were within reported general population norms and mean IES scores were within normal range. IES mean intrusion and avoidance scores were significantly higher in BRCA1/BRCA2 carriers than in controls and were higher in men with increased PCa risk perception. At the multivariate level, risk perception contributed more significantly to variance in IES scores than genetic status. CONCLUSION: This is the first study to report the psychosocial profile of men with BRCA1/BRCA2 mutations undergoing PCa screening. No clinically concerning levels of general or cancer-specific distress or poor quality of life were detected in the cohort as a whole. A small subset of participants reported higher levels of distress, suggesting the need for healthcare professionals offering PCa screening to identify these risk factors and offer additional information and support to men seeking PCa screening..
Nyberg, T.
Govindasami, K.
Leslie, G.
Dadaev, T.
Bancroft, E.
Ni Raghallaigh, H.
Brook, M.N.
Hussain, N.
Keating, D.
Lee, A.
McMahon, R.
Morgan, A.
Mullen, A.
Osborne, A.
Rageevakumar, R.
UK Genetic Prostate Cancer Study Collaborators,
Kote-Jarai, Z.
Eeles, R.
Antoniou, A.C.
(2019). Homeobox B13 G84E Mutation and Prostate Cancer Risk. Eur urol,
Vol.75
(5),
pp. 834-845.
show abstract
full text
BACKGROUND: The homeobox B13 (HOXB13) G84E mutation has been recommended for use in genetic counselling for prostate cancer (PCa), but the magnitude of PCa risk conferred by this mutation is uncertain. OBJECTIVE: To obtain precise risk estimates for mutation carriers and information on how these vary by family history and other factors. DESIGN, SETTING, AND PARTICIPANTS: Two-fold: a systematic review and meta-analysis of published risk estimates, and a kin-cohort study comprising pedigree data on 11983 PCa patients enrolled during 1993-2014 from 189 UK hospitals and who had been genotyped for HOXB13 G84E. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Relative and absolute PCa risks. Complex segregation analysis with ascertainment adjustment to derive age-specific risks applicable to the population, and to investigate how these vary by family history and birth cohort. RESULTS AND LIMITATIONS: A meta-analysis of case-control studies revealed significant heterogeneity between reported relative risks (RRs; range: 0.95-33.0, p<0.001) and differences by case selection (p=0.007). Based on case-control studies unselected for PCa family history, the pooled RR estimate was 3.43 (95% confidence interval [CI] 2.78-4.23). In the kin-cohort study, PCa risk for mutation carriers varied by family history (p<0.001). There was a suggestion that RRs decrease with age, but this was not significant (p=0.068). We found higher RR estimates for men from more recent birth cohorts (p=0.004): 3.09 (95% CI 2.03-4.71) for men born in 1929 or earlier and 5.96 (95% CI 4.01-8.88) for men born in 1930 or later. The absolute PCa risk by age 85 for a male HOXB13 G84E carrier varied from 60% for those with no PCa family history to 98% for those with two relatives diagnosed at young ages, compared with an average risk of 15% for noncarriers. Limitations include the reliance on self-reported cancer family history. CONCLUSIONS: PCa risks for HOXB13 G84E mutation carriers are heterogeneous. Counselling should not be based on average risk estimates but on age-specific absolute risk estimates tailored to individual mutation carriers' family history and birth cohort. PATIENT SUMMARY: Men who carry a hereditary mutation in the homeobox B13 (HOXB13) gene have a higher than average risk for developing prostate cancer. In our study, we examined a large number of families of men with prostate cancer recruited across UK hospitals, to assess what other factors may contribute to this risk and to assess whether we could create a precise model to help in predicting a man's prostate cancer risk. We found that the risk of developing prostate cancer in men who carry this genetic mutation is also affected by a family history of prostate cancer and their year of birth. This information can be used to assess more personalised prostate cancer risks to men who carry HOXB13 mutations and hence better counsel them on more personalised risk management options, such as tailoring prostate cancer screening frequency..
Loveday, C.
Sud, A.
Litchfield, K.
Levy, M.
Holroyd, A.
Broderick, P.
Kote-Jarai, Z.
Dunning, A.M.
Muir, K.
Peto, J.
Eeles, R.
Easton, D.F.
Dudakia, D.
Orr, N.
Pashayan, N.
UK Testicular Cancer Collaboration,
PRACTICAL Consortium,
Reid, A.
Huddart, R.A.
Houlston, R.S.
Turnbull, C.
(2019). Runs of homozygosity and testicular cancer risk. Andrology,
Vol.7
(4),
pp. 555-564.
show abstract
full text
BACKGROUND: Testicular germ cell tumour (TGCT) is highly heritable but > 50% of the genetic risk remains unexplained. Epidemiological observation of greater relative risk to brothers of men with TGCT compared to sons has long alluded to recessively acting TGCT genetic susceptibility factors, but to date none have been reported. Runs of homozygosity (RoH) are a signature indicating underlying recessively acting alleles and have been associated with increased risk of other cancer types. OBJECTIVE: To examine whether RoH are associated with TGCT risk. METHODS: We performed a genome-wide RoH analysis using GWAS data from 3206 TGCT cases and 7422 controls uniformly genotyped using the OncoArray platform. RESULTS: Global measures of homozygosity were not significantly different between cases and controls, and the frequency of individual consensus RoH was not significantly different between cases and controls, after correction for multiple testing. RoH at three regions, 11p13-11p14.3, 5q14.1-5q22.3 and 13q14.11-13q.14.13, were, however, nominally statistically significant at p < 0.01. Intriguingly, RoH200 at 11p13-11p14.3 encompasses Wilms tumour 1 (WT1), a recognized cancer susceptibility gene with roles in sex determination and developmental transcriptional regulation, processes repeatedly implicated in TGCT aetiology. DISCUSSION AND CONCLUSION: Overall, our data do not support a major role in the risk of TGCT for recessively acting alleles acting through homozygosity, as measured by RoH in outbred populations of cases and controls..
Leongamornlert, D.A.
Saunders, E.J.
Wakerell, S.
Whitmore, I.
Dadaev, T.
Cieza-Borrella, C.
Benafif, S.
Brook, M.N.
Donovan, J.L.
Hamdy, F.C.
Neal, D.E.
Muir, K.
Govindasami, K.
Conti, D.V.
Kote-Jarai, Z.
Eeles, R.A.
(2019). Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel. Eur urol,
Vol.76
(3),
pp. 329-337.
show abstract
full text
BACKGROUND: Rare germline mutations in DNA repair genes are associated with prostate cancer (PCa) predisposition and prognosis. OBJECTIVE: To quantify the frequency of germline DNA repair gene mutations in UK PCa cases and controls, in order to more comprehensively evaluate the contribution of individual genes to overall PCa risk and likelihood of aggressive disease. DESIGN, SETTING, AND PARTICIPANTS: We sequenced 167 DNA repair and eight PCa candidate genes in a UK-based cohort of 1281 young-onset PCa cases (diagnosed at ≤60yr) and 1160 selected controls. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Gene-level SKAT-O and gene-set adaptive combination of p values (ADA) analyses were performed separately for cases versus controls, and aggressive (Gleason score ≥8, n=201) versus nonaggressive (Gleason score ≤7, n=1048) cases. RESULTS AND LIMITATIONS: We identified 233 unique protein truncating variants (PTVs) with minor allele frequency <0.5% in controls in 97 genes. The total proportion of PTV carriers was higher in cases than in controls (15% vs 12%, odds ratio [OR]=1.29, 95% confidence interval [CI] 1.01-1.64, p=0.036). Gene-level analyses selected NBN (pSKAT-O=2.4×10-4) for overall risk and XPC (pSKAT-O=1.6×10-4) for aggressive disease, both at candidate-level significance (p<3.1×10-4 and p<3.4×10-4, respectively). Gene-set analysis identified a subset of 20 genes associated with increased PCa risk (OR=3.2, 95% CI 2.1-4.8, pADA=4.1×10-3) and four genes that increased risk of aggressive disease (OR=11.2, 95% CI 4.6-27.7, pADA=5.6×10-3), three of which overlap the predisposition gene set. CONCLUSIONS: The union of the gene-level and gene-set-level analyses identified 23 unique DNA repair genes associated with PCa predisposition or risk of aggressive disease. These findings will help facilitate the development of a PCa-specific sequencing panel with both predictive and prognostic potential. PATIENT SUMMARY: This large sequencing study assessed the rate of inherited DNA repair gene mutations between prostate cancer patients and disease-free men. A panel of 23 genes was identified, which may improve risk prediction or treatment pathways in future clinical practice..
Callender, T.
Emberton, M.
Morris, S.
Eeles, R.
Kote-Jarai, Z.
Pharoah, P.D.
Pashayan, N.
(2019). Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling study. Plos med,
Vol.16
(12),
p. e1002998.
show abstract
full text
BACKGROUND: The United States Preventive Services Task Force supports individualised decision-making for prostate-specific antigen (PSA)-based screening in men aged 55-69. Knowing how the potential benefits and harms of screening vary by an individual's risk of developing prostate cancer could inform decision-making about screening at both an individual and population level. This modelling study examined the benefit-harm tradeoffs and the cost-effectiveness of a risk-tailored screening programme compared to age-based and no screening. METHODS AND FINDINGS: A life-table model, projecting age-specific prostate cancer incidence and mortality, was developed of a hypothetical cohort of 4.48 million men in England aged 55 to 69 years with follow-up to age 90. Risk thresholds were based on age and polygenic profile. We compared no screening, age-based screening (quadrennial PSA testing from 55 to 69), and risk-tailored screening (men aged 55 to 69 years with a 10-year absolute risk greater than a threshold receive quadrennial PSA testing from the age they reach the risk threshold). The analysis was undertaken from the health service perspective, including direct costs borne by the health system for risk assessment, screening, diagnosis, and treatment. We used probabilistic sensitivity analyses to account for parameter uncertainty and discounted future costs and benefits at 3.5% per year. Our analysis should be considered cautiously in light of limitations related to our model's cohort-based structure and the uncertainty of input parameters in mathematical models. Compared to no screening over 35 years follow-up, age-based screening prevented the most deaths from prostate cancer (39,272, 95% uncertainty interval [UI]: 16,792-59,685) at the expense of 94,831 (95% UI: 84,827-105,630) overdiagnosed cancers. Age-based screening was the least cost-effective strategy studied. The greatest number of quality-adjusted life-years (QALYs) was generated by risk-based screening at a 10-year absolute risk threshold of 4%. At this threshold, risk-based screening led to one-third fewer overdiagnosed cancers (64,384, 95% UI: 57,382-72,050) but averted 6.3% fewer (9,695, 95% UI: 2,853-15,851) deaths from prostate cancer by comparison with age-based screening. Relative to no screening, risk-based screening at a 4% 10-year absolute risk threshold was cost-effective in 48.4% and 57.4% of the simulations at willingness-to-pay thresholds of GBP£20,000 (US$26,000) and £30,000 ($39,386) per QALY, respectively. The cost-effectiveness of risk-tailored screening improved as the threshold rose. CONCLUSIONS: Based on the results of this modelling study, offering screening to men at higher risk could potentially reduce overdiagnosis and improve the benefit-harm tradeoff and the cost-effectiveness of a prostate cancer screening program. The optimal threshold will depend on societal judgements of the appropriate balance of benefits-harms and cost-effectiveness..
Page, E.C.
Bancroft, E.K.
Brook, M.N.
Assel, M.
Hassan Al Battat, M.
Thomas, S.
Taylor, N.
Chamberlain, A.
Pope, J.
Raghallaigh, H.N.
Evans, D.G.
Rothwell, J.
Maehle, L.
Grindedal, E.M.
James, P.
Mascarenhas, L.
McKinley, J.
Side, L.
Thomas, T.
van Asperen, C.
Vasen, H.
Kiemeney, L.A.
Ringelberg, J.
Jensen, T.D.
Osther, P.J.
Helfand, B.T.
Genova, E.
Oldenburg, R.A.
Cybulski, C.
Wokolorczyk, D.
Ong, K.-.
Huber, C.
Lam, J.
Taylor, L.
Salinas, M.
Feliubadaló, L.
Oosterwijk, J.C.
van Zelst-Stams, W.
Cook, J.
Rosario, D.J.
Domchek, S.
Powers, J.
Buys, S.
O'Toole, K.
Ausems, M.G.
Schmutzler, R.K.
Rhiem, K.
Izatt, L.
Tripathi, V.
Teixeira, M.R.
Cardoso, M.
Foulkes, W.D.
Aprikian, A.
van Randeraad, H.
Davidson, R.
Longmuir, M.
Ruijs, M.W.
Helderman van den Enden, A.T.
Adank, M.
Williams, R.
Andrews, L.
Murphy, D.G.
Halliday, D.
Walker, L.
Liljegren, A.
Carlsson, S.
Azzabi, A.
Jobson, I.
Morton, C.
Shackleton, K.
Snape, K.
Hanson, H.
Harris, M.
Tischkowitz, M.
Taylor, A.
Kirk, J.
Susman, R.
Chen-Shtoyerman, R.
Spigelman, A.
Pachter, N.
Ahmed, M.
Ramon Y Cajal, T.
Zgajnar, J.
Brewer, C.
Gadea, N.
Brady, A.F.
van Os, T.
Gallagher, D.
Johannsson, O.
Donaldson, A.
Barwell, J.
Nicolai, N.
Friedman, E.
Obeid, E.
Greenhalgh, L.
Murthy, V.
Copakova, L.
Saya, S.
McGrath, J.
Cooke, P.
Rønlund, K.
Richardson, K.
Henderson, A.
Teo, S.H.
Arun, B.
Kast, K.
Dias, A.
Aaronson, N.K.
Ardern-Jones, A.
Bangma, C.H.
Castro, E.
Dearnaley, D.
Eccles, D.M.
Tricker, K.
Eyfjord, J.
Falconer, A.
Foster, C.
Gronberg, H.
Hamdy, F.C.
Stefansdottir, V.
Khoo, V.
Lindeman, G.J.
Lubinski, J.
Axcrona, K.
Mikropoulos, C.
Mitra, A.
Moynihan, C.
Rennert, G.
Suri, M.
Wilson, P.
Dudderidge, T.
IMPACT Study Collaborators,
Offman, J.
Kote-Jarai, Z.
Vickers, A.
Lilja, H.
Eeles, R.A.
(2019). Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. Eur urol,
Vol.76
(6),
pp. 831-842.
show abstract
full text
BACKGROUND: Mutations in BRCA2 cause a higher risk of early-onset aggressive prostate cancer (PrCa). The IMPACT study is evaluating targeted PrCa screening using prostate-specific-antigen (PSA) in men with germline BRCA1/2 mutations. OBJECTIVE: To report the utility of PSA screening, PrCa incidence, positive predictive value of PSA, biopsy, and tumour characteristics after 3 yr of screening, by BRCA status. DESIGN, SETTING, AND PARTICIPANTS: Men aged 40-69 yr with a germline pathogenic BRCA1/2 mutation and male controls testing negative for a familial BRCA1/2 mutation were recruited. Participants underwent PSA screening for 3 yr, and if PSA > 3.0 ng/ml, men were offered prostate biopsy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: PSA levels, PrCa incidence, and tumour characteristics were evaluated. Statistical analyses included Poisson regression offset by person-year follow-up, chi-square tests for proportion t tests for means, and Kruskal-Wallis for medians. RESULTS AND LIMITATIONS: A total of 3027 patients (2932 unique individuals) were recruited (919 BRCA1 carriers, 709 BRCA1 noncarriers, 902 BRCA2 carriers, and 497 BRCA2 noncarriers). After 3 yr of screening, 527 men had PSA > 3.0 ng/ml, 357 biopsies were performed, and 112 PrCa cases were diagnosed (31 BRCA1 carriers, 19 BRCA1 noncarriers, 47 BRCA2 carriers, and 15 BRCA2 noncarriers). Higher compliance with biopsy was observed in BRCA2 carriers compared with noncarriers (73% vs 60%). Cancer incidence rate per 1000 person years was higher in BRCA2 carriers than in noncarriers (19.4 vs 12.0; p = 0.03); BRCA2 carriers were diagnosed at a younger age (61 vs 64 yr; p = 0.04) and were more likely to have clinically significant disease than BRCA2 noncarriers (77% vs 40%; p = 0.01). No differences in age or tumour characteristics were detected between BRCA1 carriers and BRCA1 noncarriers. The 4 kallikrein marker model discriminated better (area under the curve [AUC] = 0.73) for clinically significant cancer at biopsy than PSA alone (AUC = 0.65). CONCLUSIONS: After 3 yr of screening, compared with noncarriers, BRCA2 mutation carriers were associated with a higher incidence of PrCa, younger age of diagnosis, and clinically significant tumours. Therefore, systematic PSA screening is indicated for men with a BRCA2 mutation. Further follow-up is required to assess the role of screening in BRCA1 mutation carriers. PATIENT SUMMARY: We demonstrate that after 3 yr of prostate-specific antigen (PSA) testing, we detect more serious prostate cancers in men with BRCA2 mutations than in those without these mutations. We recommend that male BRCA2 carriers are offered systematic PSA screening..
Law, P.J.
Timofeeva, M.
Fernandez-Rozadilla, C.
Broderick, P.
Studd, J.
Fernandez-Tajes, J.
Farrington, S.
Svinti, V.
Palles, C.
Orlando, G.
Sud, A.
Holroyd, A.
Penegar, S.
Theodoratou, E.
Vaughan-Shaw, P.
Campbell, H.
Zgaga, L.
Hayward, C.
Campbell, A.
Harris, S.
Deary, I.J.
Starr, J.
Gatcombe, L.
Pinna, M.
Briggs, S.
Martin, L.
Jaeger, E.
Sharma-Oates, A.
East, J.
Leedham, S.
Arnold, R.
Johnstone, E.
Wang, H.
Kerr, D.
Kerr, R.
Maughan, T.
Kaplan, R.
Al-Tassan, N.
Palin, K.
Hänninen, U.A.
Cajuso, T.
Tanskanen, T.
Kondelin, J.
Kaasinen, E.
Sarin, A.-.
Eriksson, J.G.
Rissanen, H.
Knekt, P.
Pukkala, E.
Jousilahti, P.
Salomaa, V.
Ripatti, S.
Palotie, A.
Renkonen-Sinisalo, L.
Lepistö, A.
Böhm, J.
Mecklin, J.-.
Buchanan, D.D.
Win, A.-.
Hopper, J.
Jenkins, M.E.
Lindor, N.M.
Newcomb, P.A.
Gallinger, S.
Duggan, D.
Casey, G.
Hoffmann, P.
Nöthen, M.M.
Jöckel, K.-.
Easton, D.F.
Pharoah, P.D.
Peto, J.
Canzian, F.
Swerdlow, A.
Eeles, R.A.
Kote-Jarai, Z.
Muir, K.
Pashayan, N.
PRACTICAL consortium,
Harkin, A.
Allan, K.
McQueen, J.
Paul, J.
Iveson, T.
Saunders, M.
Butterbach, K.
Chang-Claude, J.
Hoffmeister, M.
Brenner, H.
Kirac, I.
Matošević, P.
Hofer, P.
Brezina, S.
Gsur, A.
Cheadle, J.P.
Aaltonen, L.A.
Tomlinson, I.
Houlston, R.S.
Dunlop, M.G.
(2019). Association analyses identify 31 new risk loci for colorectal cancer susceptibility. Nat commun,
Vol.10
(1),
p. 2154.
show abstract
full text
Colorectal cancer (CRC) is a leading cause of cancer-related death worldwide, and has a strong heritable basis. We report a genome-wide association analysis of 34,627 CRC cases and 71,379 controls of European ancestry that identifies SNPs at 31 new CRC risk loci. We also identify eight independent risk SNPs at the new and previously reported European CRC loci, and a further nine CRC SNPs at loci previously only identified in Asian populations. We use in situ promoter capture Hi-C (CHi-C), gene expression, and in silico annotation methods to identify likely target genes of CRC SNPs. Whilst these new SNP associations implicate target genes that are enriched for known CRC pathways such as Wnt and BMP, they also highlight novel pathways with no prior links to colorectal tumourigenesis. These findings provide further insight into CRC susceptibility and enhance the prospects of applying genetic risk scores to personalised screening and prevention..
Wu, L.
Shu, X.
Bao, J.
Guo, X.
Kote-Jarai, Z.
Haiman, C.A.
Eeles, R.A.
Zheng, W.
PRACTICAL, CRUK, BPC3, CAPS, PEGASUS Consortia,
(2019). Analysis of Over 140,000 European Descendants Identifies Genetically Predicted Blood Protein Biomarkers Associated with Prostate Cancer Risk. Cancer res,
Vol.79
(18),
pp. 4592-4598.
show abstract
full text
Several blood protein biomarkers have been associated with prostate cancer risk. However, most studies assessed only a small number of biomarkers and/or included a small sample size. To identify novel protein biomarkers of prostate cancer risk, we studied 79,194 cases and 61,112 controls of European ancestry, included in the PRACTICAL/ELLIPSE consortia, using genetic instruments of protein quantitative trait loci for 1,478 plasma proteins. A total of 31 proteins were associated with prostate cancer risk including proteins encoded by GSTP1, whose methylation level was shown previously to be associated with prostate cancer risk, and MSMB, SPINT2, IGF2R, and CTSS, which were previously implicated as potential target genes of prostate cancer risk variants identified in genome-wide association studies. A total of 18 proteins inversely correlated and 13 positively correlated with prostate cancer risk. For 28 of the identified proteins, gene somatic changes of short indels, splice site, nonsense, or missense mutations were detected in patients with prostate cancer in The Cancer Genome Atlas. Pathway enrichment analysis showed that relevant genes were significantly enriched in cancer-related pathways. In conclusion, this study identifies 31 candidates of protein biomarkers for prostate cancer risk and provides new insights into the biology and genetics of prostate tumorigenesis. SIGNIFICANCE: Integration of genomics and proteomics data identifies biomarkers associated with prostate cancer risk..
Jiang, X.
Finucane, H.K.
Schumacher, F.R.
Schmit, S.L.
Tyrer, J.P.
Han, Y.
Michailidou, K.
Lesseur, C.
Kuchenbaecker, K.B.
Dennis, J.
Conti, D.V.
Casey, G.
Gaudet, M.M.
Huyghe, J.R.
Albanes, D.
Aldrich, M.C.
Andrew, A.S.
Andrulis, I.L.
Anton-Culver, H.
Antoniou, A.C.
Antonenkova, N.N.
Arnold, S.M.
Aronson, K.J.
Arun, B.K.
Bandera, E.V.
Barkardottir, R.B.
Barnes, D.R.
Batra, J.
Beckmann, M.W.
Benitez, J.
Benlloch, S.
Berchuck, A.
Berndt, S.I.
Bickeböller, H.
Bien, S.A.
Blomqvist, C.
Boccia, S.
Bogdanova, N.V.
Bojesen, S.E.
Bolla, M.K.
Brauch, H.
Brenner, H.
Brenton, J.D.
Brook, M.N.
Brunet, J.
Brunnström, H.
Buchanan, D.D.
Burwinkel, B.
Butzow, R.
Cadoni, G.
Caldés, T.
Caligo, M.A.
Campbell, I.
Campbell, P.T.
Cancel-Tassin, G.
Cannon-Albright, L.
Campa, D.
Caporaso, N.
Carvalho, A.L.
Chan, A.T.
Chang-Claude, J.
Chanock, S.J.
Chen, C.
Christiani, D.C.
Claes, K.B.
Claessens, F.
Clements, J.
Collée, J.M.
Correa, M.C.
Couch, F.J.
Cox, A.
Cunningham, J.M.
Cybulski, C.
Czene, K.
Daly, M.B.
deFazio, A.
Devilee, P.
Diez, O.
Gago-Dominguez, M.
Donovan, J.L.
Dörk, T.
Duell, E.J.
Dunning, A.M.
Dwek, M.
Eccles, D.M.
Edlund, C.K.
Edwards, D.R.
Ellberg, C.
Evans, D.G.
Fasching, P.A.
Ferris, R.L.
Liloglou, T.
Figueiredo, J.C.
Fletcher, O.
Fortner, R.T.
Fostira, F.
Franceschi, S.
Friedman, E.
Gallinger, S.J.
Ganz, P.A.
Garber, J.
García-Sáenz, J.A.
Gayther, S.A.
Giles, G.G.
Godwin, A.K.
Goldberg, M.S.
Goldgar, D.E.
Goode, E.L.
Goodman, M.T.
Goodman, G.
Grankvist, K.
Greene, M.H.
Gronberg, H.
Gronwald, J.
Guénel, P.
Håkansson, N.
Hall, P.
Hamann, U.
Hamdy, F.C.
Hamilton, R.J.
Hampe, J.
Haugen, A.
Heitz, F.
Herrero, R.
Hillemanns, P.
Hoffmeister, M.
Høgdall, E.
Hong, Y.-.
Hopper, J.L.
Houlston, R.
Hulick, P.J.
Hunter, D.J.
Huntsman, D.G.
Idos, G.
Imyanitov, E.N.
Ingles, S.A.
Isaacs, C.
Jakubowska, A.
James, P.
Jenkins, M.A.
Johansson, M.
Johansson, M.
John, E.M.
Joshi, A.D.
Kaneva, R.
Karlan, B.Y.
Kelemen, L.E.
Kühl, T.
Khaw, K.-.
Khusnutdinova, E.
Kibel, A.S.
Kiemeney, L.A.
Kim, J.
Kjaer, S.K.
Knight, J.A.
Kogevinas, M.
Kote-Jarai, Z.
Koutros, S.
Kristensen, V.N.
Kupryjanczyk, J.
Lacko, M.
Lam, S.
Lambrechts, D.
Landi, M.T.
Lazarus, P.
Le, N.D.
Lee, E.
Lejbkowicz, F.
Lenz, H.-.
Leslie, G.
Lessel, D.
Lester, J.
Levine, D.A.
Li, L.
Li, C.I.
Lindblom, A.
Lindor, N.M.
Liu, G.
Loupakis, F.
Lubiński, J.
Maehle, L.
Maier, C.
Mannermaa, A.
Marchand, L.L.
Margolin, S.
May, T.
McGuffog, L.
Meindl, A.
Middha, P.
Miller, A.
Milne, R.L.
MacInnis, R.J.
Modugno, F.
Montagna, M.
Moreno, V.
Moysich, K.B.
Mucci, L.
Muir, K.
Mulligan, A.M.
Nathanson, K.L.
Neal, D.E.
Ness, A.R.
Neuhausen, S.L.
Nevanlinna, H.
Newcomb, P.A.
Newcomb, L.F.
Nielsen, F.C.
Nikitina-Zake, L.
Nordestgaard, B.G.
Nussbaum, R.L.
Offit, K.
Olah, E.
Olama, A.A.
Olopade, O.I.
Olshan, A.F.
Olsson, H.
Osorio, A.
Pandha, H.
Park, J.Y.
Pashayan, N.
Parsons, M.T.
Pejovic, T.
Penney, K.L.
Peters, W.H.
Phelan, C.M.
Phipps, A.I.
Plaseska-Karanfilska, D.
Pring, M.
Prokofyeva, D.
Radice, P.
Stefansson, K.
Ramus, S.J.
Raskin, L.
Rennert, G.
Rennert, H.S.
van Rensburg, E.J.
Riggan, M.J.
Risch, H.A.
Risch, A.
Roobol, M.J.
Rosenstein, B.S.
Rossing, M.A.
De Ruyck, K.
Saloustros, E.
Sandler, D.P.
Sawyer, E.J.
Schabath, M.B.
Schleutker, J.
Schmidt, M.K.
Setiawan, V.W.
Shen, H.
Siegel, E.M.
Sieh, W.
Singer, C.F.
Slattery, M.L.
Sorensen, K.D.
Southey, M.C.
Spurdle, A.B.
Stanford, J.L.
Stevens, V.L.
Stintzing, S.
Stone, J.
Sundfeldt, K.
Sutphen, R.
Swerdlow, A.J.
Tajara, E.H.
Tangen, C.M.
Tardon, A.
Taylor, J.A.
Teare, M.D.
Teixeira, M.R.
Terry, M.B.
Terry, K.L.
Thibodeau, S.N.
Thomassen, M.
Bjørge, L.
Tischkowitz, M.
Toland, A.E.
Torres, D.
Townsend, P.A.
Travis, R.C.
Tung, N.
Tworoger, S.S.
Ulrich, C.M.
Usmani, N.
Vachon, C.M.
Van Nieuwenhuysen, E.
Vega, A.
Aguado-Barrera, M.E.
Wang, Q.
Webb, P.M.
Weinberg, C.R.
Weinstein, S.
Weissler, M.C.
Weitzel, J.N.
West, C.M.
White, E.
Whittemore, A.S.
Wichmann, H.-.
Wiklund, F.
Winqvist, R.
Wolk, A.
Woll, P.
Woods, M.
Wu, A.H.
Wu, X.
Yannoukakos, D.
Zheng, W.
Zienolddiny, S.
Ziogas, A.
Zorn, K.K.
Lane, J.M.
Saxena, R.
Thomas, D.
Hung, R.J.
Diergaarde, B.
McKay, J.
Peters, U.
Hsu, L.
García-Closas, M.
Eeles, R.A.
Chenevix-Trench, G.
Brennan, P.J.
Haiman, C.A.
Simard, J.
Easton, D.F.
Gruber, S.B.
Pharoah, P.D.
Price, A.L.
Pasaniuc, B.
Amos, C.I.
Kraft, P.
Lindström, S.
(2019). Shared heritability and functional enrichment across six solid cancers. Nat commun,
Vol.10
(1),
p. 431.
show abstract
full text
Quantifying the genetic correlation between cancers can provide important insights into the mechanisms driving cancer etiology. Using genome-wide association study summary statistics across six cancer types based on a total of 296,215 cases and 301,319 controls of European ancestry, here we estimate the pair-wise genetic correlations between breast, colorectal, head/neck, lung, ovary and prostate cancer, and between cancers and 38 other diseases. We observed statistically significant genetic correlations between lung and head/neck cancer (rg = 0.57, p = 4.6 × 10-8), breast and ovarian cancer (rg = 0.24, p = 7 × 10-5), breast and lung cancer (rg = 0.18, p =1.5 × 10-6) and breast and colorectal cancer (rg = 0.15, p = 1.1 × 10-4). We also found that multiple cancers are genetically correlated with non-cancer traits including smoking, psychiatric diseases and metabolic characteristics. Functional enrichment analysis revealed a significant excess contribution of conserved and regulatory regions to cancer heritability. Our comprehensive analysis of cross-cancer heritability suggests that solid tumors arising across tissues share in part a common germline genetic basis..
Dias, A.
Kote-Jarai, Z.
Mikropoulos, C.
Eeles, R.
(2018). Prostate Cancer Germline Variations and Implications for Screening and Treatment. Cold spring harb perspect med,
Vol.8
(9).
show abstract
full text
Prostate cancer (PCa) is a highly heritable disease, and rapid evolution of sequencing technologies has enabled marked progression of our understanding of its genetic inheritance. A complex polygenic model that involves common low-penetrance susceptibility alleles causing individually small but cumulatively significant risk and rarer genetic variants causing greater risk represent the current most accepted model. Through genome-wide association studies, more than 100 single-nucleotide polymorphisms (SNPs) associated with PCa risk have been identified. Consistent reports have identified germline mutations in the genes BRCA1, BRCA2, MMR, HOXB13, CHEK2, and NBS1 as conferring moderate risks, with some leading to a more aggressive disease behavior. Considering this knowledge, several research strategies have been developed to determine whether targeted prostate screening using genetic information can overcome the limitations of population-based prostate-specific antigen (PSA) screening. Germline DNA-repair mutations are more frequent in men with metastatic disease than previously thought, and these patients have a more favorable response to therapy with poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors. Genomic information is a practical tool that has the potential to enable the concept of precision medicine to become a reality in all steps of PCa patient care..
Mancuso, N.
Gayther, S.
Gusev, A.
Zheng, W.
Penney, K.L.
Kote-Jarai, Z.
Eeles, R.
Freedman, M.
Haiman, C.
Pasaniuc, B.
PRACTICAL consortium,
(2018). Large-scale transcriptome-wide association study identifies new prostate cancer risk regions. Nat commun,
Vol.9
(1),
p. 4079.
show abstract
full text
Although genome-wide association studies (GWAS) for prostate cancer (PrCa) have identified more than 100 risk regions, most of the risk genes at these regions remain largely unknown. Here we integrate the largest PrCa GWAS (N = 142,392) with gene expression measured in 45 tissues (N = 4458), including normal and tumor prostate, to perform a multi-tissue transcriptome-wide association study (TWAS) for PrCa. We identify 217 genes at 84 independent 1 Mb regions associated with PrCa risk, 9 of which are regions with no genome-wide significant SNP within 2 Mb. 23 genes are significant in TWAS only for alternative splicing models in prostate tumor thus supporting the hypothesis of splicing driving risk for continued oncogenesis. Finally, we use a Bayesian probabilistic approach to estimate credible sets of genes containing the causal gene at a pre-defined level; this reduced the list of 217 associations to 109 genes in the 90% credible set. Overall, our findings highlight the power of integrating expression with PrCa GWAS to identify novel risk loci and prioritize putative causal genes at known risk loci..
Wedge, D.C.
Gundem, G.
Mitchell, T.
Woodcock, D.J.
Martincorena, I.
Ghori, M.
Zamora, J.
Butler, A.
Whitaker, H.
Kote-Jarai, Z.
Alexandrov, L.B.
Van Loo, P.
Massie, C.E.
Dentro, S.
Warren, A.Y.
Verrill, C.
Berney, D.M.
Dennis, N.
Merson, S.
Hawkins, S.
Howat, W.
Lu, Y.-.
Lambert, A.
Kay, J.
Kremeyer, B.
Karaszi, K.
Luxton, H.
Camacho, N.
Marsden, L.
Edwards, S.
Matthews, L.
Bo, V.
Leongamornlert, D.
McLaren, S.
Ng, A.
Yu, Y.
Zhang, H.
Dadaev, T.
Thomas, S.
Easton, D.F.
Ahmed, M.
Bancroft, E.
Fisher, C.
Livni, N.
Nicol, D.
Tavaré, S.
Gill, P.
Greenman, C.
Khoo, V.
Van As, N.
Kumar, P.
Ogden, C.
Cahill, D.
Thompson, A.
Mayer, E.
Rowe, E.
Dudderidge, T.
Gnanapragasam, V.
Shah, N.C.
Raine, K.
Jones, D.
Menzies, A.
Stebbings, L.
Teague, J.
Hazell, S.
Corbishley, C.
CAMCAP Study Group,
de Bono, J.
Attard, G.
Isaacs, W.
Visakorpi, T.
Fraser, M.
Boutros, P.C.
Bristow, R.G.
Workman, P.
Sander, C.
TCGA Consortium,
Hamdy, F.C.
Futreal, A.
McDermott, U.
Al-Lazikani, B.
Lynch, A.G.
Bova, G.S.
Foster, C.S.
Brewer, D.S.
Neal, D.E.
Cooper, C.S.
Eeles, R.A.
(2018). Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nat genet,
Vol.50
(5),
pp. 682-692.
show abstract
full text
Prostate cancer represents a substantial clinical challenge because it is difficult to predict outcome and advanced disease is often fatal. We sequenced the whole genomes of 112 primary and metastatic prostate cancer samples. From joint analysis of these cancers with those from previous studies (930 cancers in total), we found evidence for 22 previously unidentified putative driver genes harboring coding mutations, as well as evidence for NEAT1 and FOXA1 acting as drivers through noncoding mutations. Through the temporal dissection of aberrations, we identified driver mutations specifically associated with steps in the progression of prostate cancer, establishing, for example, loss of CHD1 and BRCA2 as early events in cancer development of ETS fusion-negative cancers. Computational chemogenomic (canSAR) analysis of prostate cancer mutations identified 11 targets of approved drugs, 7 targets of investigational drugs, and 62 targets of compounds that may be active and should be considered candidates for future clinical trials..
Matejcic, M.
Saunders, E.J.
Dadaev, T.
Brook, M.N.
Wang, K.
Sheng, X.
Olama, A.A.
Schumacher, F.R.
Ingles, S.A.
Govindasami, K.
Benlloch, S.
Berndt, S.I.
Albanes, D.
Koutros, S.
Muir, K.
Stevens, V.L.
Gapstur, S.M.
Tangen, C.M.
Batra, J.
Clements, J.
Gronberg, H.
Pashayan, N.
Schleutker, J.
Wolk, A.
West, C.
Mucci, L.
Kraft, P.
Cancel-Tassin, G.
Sorensen, K.D.
Maehle, L.
Grindedal, E.M.
Strom, S.S.
Neal, D.E.
Hamdy, F.C.
Donovan, J.L.
Travis, R.C.
Hamilton, R.J.
Rosenstein, B.
Lu, Y.-.
Giles, G.G.
Kibel, A.S.
Vega, A.
Bensen, J.T.
Kogevinas, M.
Penney, K.L.
Park, J.Y.
Stanford, J.L.
Cybulski, C.
Nordestgaard, B.G.
Brenner, H.
Maier, C.
Kim, J.
Teixeira, M.R.
Neuhausen, S.L.
De Ruyck, K.
Razack, A.
Newcomb, L.F.
Lessel, D.
Kaneva, R.
Usmani, N.
Claessens, F.
Townsend, P.A.
Gago-Dominguez, M.
Roobol, M.J.
Menegaux, F.
Khaw, K.-.
Cannon-Albright, L.A.
Pandha, H.
Thibodeau, S.N.
Schaid, D.J.
PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium,
Wiklund, F.
Chanock, S.J.
Easton, D.F.
Eeles, R.A.
Kote-Jarai, Z.
Conti, D.V.
Haiman, C.A.
(2018). Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nat commun,
Vol.9
(1),
p. 4616.
show abstract
full text
Chromosome 8q24 is a susceptibility locus for multiple cancers, including prostate cancer. Here we combine genetic data across the 8q24 susceptibility region from 71,535 prostate cancer cases and 52,935 controls of European ancestry to define the overall contribution of germline variation at 8q24 to prostate cancer risk. We identify 12 independent risk signals for prostate cancer (p < 4.28 × 10-15), including three risk variants that have yet to be reported. From a polygenic risk score (PRS) model, derived to assess the cumulative effect of risk variants at 8q24, men in the top 1% of the PRS have a 4-fold (95%CI = 3.62-4.40) greater risk compared to the population average. These 12 variants account for ~25% of what can be currently explained of the familial risk of prostate cancer by known genetic risk factors. These findings highlight the overwhelming contribution of germline variation at 8q24 on prostate cancer risk which has implications for population risk stratification..
FitzGerald, L.M.
Zhao, S.
Leonardson, A.
Geybels, M.S.
Kolb, S.
Lin, D.W.
Wright, J.L.
Eeles, R.
Kote-Jarai, Z.
Govindasami, K.
Giles, G.G.
Southey, M.C.
Schleutker, J.
Tammela, T.L.
Sipeky, C.
Penney, K.L.
Stampfer, M.J.
Gronberg, H.
Wiklund, F.
Stattin, P.
Hugosson, J.
Karyadi, D.M.
Ostrander, E.A.
Feng, Z.
Stanford, J.L.
(2018). Germline variants in IL4, MGMT and AKT1 are associated with prostate cancer-specific mortality: An analysis of 12,082 prostate cancer cases. Prostate cancer prostatic dis,
Vol.21
(2),
pp. 228-237.
show abstract
full text
BACKGROUND: Prostate cancer (PCa) is a leading cause of mortality and genetic factors can influence tumour aggressiveness. Several germline variants have been associated with PCa-specific mortality (PCSM), but further replication evidence is needed. METHODS: Twenty-two previously identified PCSM-associated genetic variants were genotyped in seven PCa cohorts (12,082 patients; 1544 PCa deaths). For each cohort, Cox proportional hazards models were used to calculate hazard ratios and 95% confidence intervals for risk of PCSM associated with each variant. Data were then combined using a meta-analysis approach. RESULTS: Fifteen SNPs were associated with PCSM in at least one of the seven cohorts. In the meta-analysis, after adjustment for clinicopathological factors, variants in the MGMT (rs2308327; HR 0.90; p-value = 3.5 × 10-2) and IL4 (rs2070874; HR 1.22; p-value = 1.1 × 10-3) genes were confirmed to be associated with risk of PCSM. In analyses limited to men diagnosed with local or regional stage disease, a variant in AKT1, rs2494750, was also confirmed to be associated with PCSM risk (HR 0.81; p-value = 3.6 × 10-2). CONCLUSIONS: This meta-analysis confirms the association of three genetic variants with risk of PCSM, providing further evidence that genetic background plays a role in PCa-specific survival. While these variants alone are not sufficient as prognostic biomarkers, these results may provide insights into the biological pathways modulating tumour aggressiveness..
Mijuskovic, M.
Saunders, E.J.
Leongamornlert, D.A.
Wakerell, S.
Whitmore, I.
Dadaev, T.
Cieza-Borrella, C.
Govindasami, K.
Brook, M.N.
Haiman, C.A.
Conti, D.V.
Eeles, R.A.
Kote-Jarai, Z.
(2018). Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease. Br j cancer,
Vol.119
(1),
pp. 96-104.
show abstract
full text
BACKGROUND: Prostate cancer (PrCa) demonstrates a heterogeneous clinical presentation ranging from largely indolent to lethal. We sought to identify a signature of rare inherited variants that distinguishes between these two extreme phenotypes. METHODS: We sequenced germline whole exomes from 139 aggressive (metastatic, age of diagnosis < 60) and 141 non-aggressive (low clinical grade, age of diagnosis ≥60) PrCa cases. We conducted rare variant association analyses at gene and gene set levels using SKAT and Bayesian risk index techniques. GO term enrichment analysis was performed for genes with the highest differential burden of rare disruptive variants. RESULTS: Protein truncating variants (PTVs) in specific DNA repair genes were significantly overrepresented among patients with the aggressive phenotype, with BRCA2, ATM and NBN the most frequently mutated genes. Differential burden of rare variants was identified between metastatic and non-aggressive cases for several genes implicated in angiogenesis, conferring both deleterious and protective effects. CONCLUSIONS: Inherited PTVs in several DNA repair genes distinguish aggressive from non-aggressive PrCa cases. Furthermore, inherited variants in genes with roles in angiogenesis may be potential predictors for risk of metastases. If validated in a larger dataset, these findings have potential for future clinical application..
Schumacher, F.R.
Al Olama, A.A.
Berndt, S.I.
Benlloch, S.
Ahmed, M.
Saunders, E.J.
Dadaev, T.
Leongamornlert, D.
Anokian, E.
Cieza-Borrella, C.
Goh, C.
Brook, M.N.
Sheng, X.
Fachal, L.
Dennis, J.
Tyrer, J.
Muir, K.
Lophatananon, A.
Stevens, V.L.
Gapstur, S.M.
Carter, B.D.
Tangen, C.M.
Goodman, P.J.
Thompson, I.M.
Batra, J.
Chambers, S.
Moya, L.
Clements, J.
Horvath, L.
Tilley, W.
Risbridger, G.P.
Gronberg, H.
Aly, M.
Nordström, T.
Pharoah, P.
Pashayan, N.
Schleutker, J.
Tammela, T.L.
Sipeky, C.
Auvinen, A.
Albanes, D.
Weinstein, S.
Wolk, A.
Håkansson, N.
West, C.M.
Dunning, A.M.
Burnet, N.
Mucci, L.A.
Giovannucci, E.
Andriole, G.L.
Cussenot, O.
Cancel-Tassin, G.
Koutros, S.
Beane Freeman, L.E.
Sorensen, K.D.
Orntoft, T.F.
Borre, M.
Maehle, L.
Grindedal, E.M.
Neal, D.E.
Donovan, J.L.
Hamdy, F.C.
Martin, R.M.
Travis, R.C.
Key, T.J.
Hamilton, R.J.
Fleshner, N.E.
Finelli, A.
Ingles, S.A.
Stern, M.C.
Rosenstein, B.S.
Kerns, S.L.
Ostrer, H.
Lu, Y.-.
Zhang, H.-.
Feng, N.
Mao, X.
Guo, X.
Wang, G.
Sun, Z.
Giles, G.G.
Southey, M.C.
MacInnis, R.J.
FitzGerald, L.M.
Kibel, A.S.
Drake, B.F.
Vega, A.
Gómez-Caamaño, A.
Szulkin, R.
Eklund, M.
Kogevinas, M.
Llorca, J.
Castaño-Vinyals, G.
Penney, K.L.
Stampfer, M.
Park, J.Y.
Sellers, T.A.
Lin, H.-.
Stanford, J.L.
Cybulski, C.
Wokolorczyk, D.
Lubinski, J.
Ostrander, E.A.
Geybels, M.S.
Nordestgaard, B.G.
Nielsen, S.F.
Weischer, M.
Bisbjerg, R.
Røder, M.A.
Iversen, P.
Brenner, H.
Cuk, K.
Holleczek, B.
Maier, C.
Luedeke, M.
Schnoeller, T.
Kim, J.
Logothetis, C.J.
John, E.M.
Teixeira, M.R.
Paulo, P.
Cardoso, M.
Neuhausen, S.L.
Steele, L.
Ding, Y.C.
De Ruyck, K.
De Meerleer, G.
Ost, P.
Razack, A.
Lim, J.
Teo, S.-.
Lin, D.W.
Newcomb, L.F.
Lessel, D.
Gamulin, M.
Kulis, T.
Kaneva, R.
Usmani, N.
Singhal, S.
Slavov, C.
Mitev, V.
Parliament, M.
Claessens, F.
Joniau, S.
Van den Broeck, T.
Larkin, S.
Townsend, P.A.
Aukim-Hastie, C.
Gago-Dominguez, M.
Castelao, J.E.
Martinez, M.E.
Roobol, M.J.
Jenster, G.
van Schaik, R.H.
Menegaux, F.
Truong, T.
Koudou, Y.A.
Xu, J.
Khaw, K.-.
Cannon-Albright, L.
Pandha, H.
Michael, A.
Thibodeau, S.N.
McDonnell, S.K.
Schaid, D.J.
Lindstrom, S.
Turman, C.
Ma, J.
Hunter, D.J.
Riboli, E.
Siddiq, A.
Canzian, F.
Kolonel, L.N.
Le Marchand, L.
Hoover, R.N.
Machiela, M.J.
Cui, Z.
Kraft, P.
Amos, C.I.
Conti, D.V.
Easton, D.F.
Wiklund, F.
Chanock, S.J.
Henderson, B.E.
Kote-Jarai, Z.
Haiman, C.A.
Eeles, R.A.
Profile Study,
Australian Prostate Cancer BioResource (APCB),
IMPACT Study,
Canary PASS Investigators,
Breast and Prostate Cancer Cohort Consortium (BPC3),
PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium,
Cancer of the Prostate in Sweden (CAPS),
Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS),
Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium,
(2018). Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat genet,
Vol.50
(7),
pp. 928-936.
show abstract
full text
Genome-wide association studies (GWAS) and fine-mapping efforts to date have identified more than 100 prostate cancer (PrCa)-susceptibility loci. We meta-analyzed genotype data from a custom high-density array of 46,939 PrCa cases and 27,910 controls of European ancestry with previously genotyped data of 32,255 PrCa cases and 33,202 controls of European ancestry. Our analysis identified 62 novel loci associated (P < 5.0 × 10-8) with PrCa and one locus significantly associated with early-onset PrCa (≤55 years). Our findings include missense variants rs1800057 (odds ratio (OR) = 1.16; P = 8.2 × 10-9; G>C, p.Pro1054Arg) in ATM and rs2066827 (OR = 1.06; P = 2.3 × 10-9; T>G, p.Val109Gly) in CDKN1B. The combination of all loci captured 28.4% of the PrCa familial relative risk, and a polygenic risk score conferred an elevated PrCa risk for men in the ninetieth to ninety-ninth percentiles (relative risk = 2.69; 95% confidence interval (CI): 2.55-2.82) and first percentile (relative risk = 5.71; 95% CI: 5.04-6.48) risk stratum compared with the population average. These findings improve risk prediction, enhance fine-mapping, and provide insight into the underlying biology of PrCa1..
Benafif, S.
Kote-Jarai, Z.
Eeles, R.A.
PRACTICAL Consortium,
(2018). A Review of Prostate Cancer Genome-Wide Association Studies (GWAS). Cancer epidemiol biomarkers prev,
Vol.27
(8),
pp. 845-857.
show abstract
full text
Prostate cancer is the most common cancer in men in Europe and the United States. The genetic heritability of prostate cancer is contributed to by both rarely occurring genetic variants with higher penetrance and moderate to commonly occurring variants conferring lower risks. The number of identified variants belonging to the latter category has increased dramatically in the last 10 years with the development of the genome-wide association study (GWAS) and the collaboration of international consortia that have led to the sharing of large-scale genotyping data. Over 40 prostate cancer GWAS have been reported, with approximately 170 common variants now identified. Clinical utility of these variants could include strategies for population-based risk stratification to target prostate cancer screening to men with an increased genetic risk of disease development, while for those who develop prostate cancer, identifying genetic variants could allow treatment to be tailored based on a genetic profile in the early disease setting. Functional studies of identified variants are needed to fully understand underlying mechanisms of disease and identify novel targets for treatment. This review will outline the GWAS carried out in prostate cancer and the common variants identified so far, and how these may be utilized clinically in the screening for and management of prostate cancer. Cancer Epidemiol Biomarkers Prev; 27(8); 845-57. ©2018 AACR..
Sud, A.
Thomsen, H.
Orlando, G.
Försti, A.
Law, P.J.
Broderick, P.
Cooke, R.
Hariri, F.
Pastinen, T.
Easton, D.F.
Pharoah, P.D.
Dunning, A.M.
Peto, J.
Canzian, F.
Eeles, R.
Kote-Jarai, Z.
Muir, K.
Pashayan, N.
Campa, D.
PRACTICAL Consortium,
Hoffmann, P.
Nöthen, M.M.
Jöckel, K.-.
von Strandmann, E.P.
Swerdlow, A.J.
Engert, A.
Orr, N.
Hemminki, K.
Houlston, R.S.
(2018). Genome-wide association study implicates immune dysfunction in the development of Hodgkin lymphoma. Blood,
Vol.132
(19),
pp. 2040-2052.
show abstract
full text
To further our understanding of inherited susceptibility to Hodgkin lymphoma (HL), we performed a meta-analysis of 7 genome-wide association studies totaling 5325 HL cases and 22 423 control patients. We identify 5 new HL risk loci at 6p21.31 (rs649775; P = 2.11 × 10-10), 6q23.3 (rs1002658; P = 2.97 × 10-8), 11q23.1 (rs7111520; P = 1.44 × 10-11), 16p11.2 (rs6565176; P = 4.00 × 10-8), and 20q13.12 (rs2425752; P = 2.01 × 10-8). Integration of gene expression, histone modification, and in situ promoter capture Hi-C data at the 5 new and 13 known risk loci implicates dysfunction of the germinal center reaction, disrupted T-cell differentiation and function, and constitutive NF-κB activation as mechanisms of predisposition. These data provide further insights into the genetic susceptibility and biology of HL..
Vijayakrishnan, J.
Studd, J.
Broderick, P.
Kinnersley, B.
Holroyd, A.
Law, P.J.
Kumar, R.
Allan, J.M.
Harrison, C.J.
Moorman, A.V.
Vora, A.
Roman, E.
Rachakonda, S.
Kinsey, S.E.
Sheridan, E.
Thompson, P.D.
Irving, J.A.
Koehler, R.
Hoffmann, P.
Nöthen, M.M.
Heilmann-Heimbach, S.
Jöckel, K.-.
Easton, D.F.
Pharaoh, P.D.
Dunning, A.M.
Peto, J.
Canzian, F.
Swerdlow, A.
Eeles, R.A.
Kote-Jarai, Z.
Muir, K.
Pashayan, N.
PRACTICAL Consortium,
Greaves, M.
Zimmerman, M.
Bartram, C.R.
Schrappe, M.
Stanulla, M.
Hemminki, K.
Houlston, R.S.
(2018). Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia. Nat commun,
Vol.9
(1),
p. 1340.
show abstract
full text
Genome-wide association studies (GWAS) have advanced our understanding of susceptibility to B-cell precursor acute lymphoblastic leukemia (BCP-ALL); however, much of the heritable risk remains unidentified. Here, we perform a GWAS and conduct a meta-analysis with two existing GWAS, totaling 2442 cases and 14,609 controls. We identify risk loci for BCP-ALL at 8q24.21 (rs28665337, P = 3.86 × 10-9, odds ratio (OR) = 1.34) and for ETV6-RUNX1 fusion-positive BCP-ALL at 2q22.3 (rs17481869, P = 3.20 × 10-8, OR = 2.14). Our findings provide further insights into genetic susceptibility to ALL and its biology..
Loveday, C.
Law, P.
Litchfield, K.
Levy, M.
Holroyd, A.
Broderick, P.
Kote-Jarai, Z.
Dunning, A.M.
Muir, K.
Peto, J.
Eeles, R.
Easton, D.F.
Dudakia, D.
Orr, N.
Pashayan, N.
UK Testicular Cancer Collaboration, The PRACTICAL Consortium,
Reid, A.
Huddart, R.A.
Houlston, R.S.
Turnbull, C.
(2018). Large-scale Analysis Demonstrates Familial Testicular Cancer to have Polygenic Aetiology. Eur urol,
Vol.74
(3),
pp. 248-252.
show abstract
full text
UNLABELLED: Testicular germ cell tumour (TGCT) is the most common cancer in young men. Multiplex TGCT families have been well reported and analyses of population cancer registries have demonstrated a four- to eightfold risk to male relatives of TGCT patients. Early linkage analysis and recent large-scale germline exome analysis in TGCT cases demonstrate absence of major high-penetrance TGCT susceptibility gene(s). Serial genome-wide association study analyses in sporadic TGCT have in total reported 49 independent risk loci. To date, it has not been demonstrated whether familial TGCT arises due to enrichment of the same common variants underpinning susceptibility to sporadic TGCT or is due to shared environmental/lifestyle factors or disparate rare genetic TGCT susceptibility factors. Here we present polygenic risk score analysis of 37 TGCT susceptibility single-nucleotide polymorphisms in 236 familial and 3931 sporadic TGCT cases, and 12 368 controls, which demonstrates clear enrichment for TGCT susceptibility alleles in familial compared to sporadic cases (p=0.0001), with the majority of familial cases (84-100%) being attributable to polygenic enrichment. These analyses reveal TGCT as the first rare malignancy of early adulthood in which familial clustering is driven by the aggregate effects of polygenic variation in the absence of a major high-penetrance susceptibility gene. PATIENT SUMMARY: To date, it has been unclear whether familial clusters of testicular germ cell tumour (TGCT) arise due to genetics or shared environmental or lifestyle factors. We present large-scale genetic analyses comparing 236 familial TGCT cases, 3931 isolated TGCT cases, and 12 368 controls. We show that familial TGCT is caused, at least in part, by presence of a higher dose of the same common genetic variants that cause susceptibility to TGCT in general..
Seibert, T.M.
Fan, C.C.
Wang, Y.
Zuber, V.
Karunamuni, R.
Parsons, J.K.
Eeles, R.A.
Easton, D.F.
Kote-Jarai, Z.
Al Olama, A.A.
Garcia, S.B.
Muir, K.
Grönberg, H.
Wiklund, F.
Aly, M.
Schleutker, J.
Sipeky, C.
Tammela, T.L.
Nordestgaard, B.G.
Nielsen, S.F.
Weischer, M.
Bisbjerg, R.
Røder, M.A.
Iversen, P.
Key, T.J.
Travis, R.C.
Neal, D.E.
Donovan, J.L.
Hamdy, F.C.
Pharoah, P.
Pashayan, N.
Khaw, K.-.
Maier, C.
Vogel, W.
Luedeke, M.
Herkommer, K.
Kibel, A.S.
Cybulski, C.
Wokolorczyk, D.
Kluzniak, W.
Cannon-Albright, L.
Brenner, H.
Cuk, K.
Saum, K.-.
Park, J.Y.
Sellers, T.A.
Slavov, C.
Kaneva, R.
Mitev, V.
Batra, J.
Clements, J.A.
Spurdle, A.
Teixeira, M.R.
Paulo, P.
Maia, S.
Pandha, H.
Michael, A.
Kierzek, A.
Karow, D.S.
Mills, I.G.
Andreassen, O.A.
Dale, A.M.
PRACTICAL Consortium*,
(2018). Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. Bmj,
Vol.360,
p. j5757.
show abstract
full text
OBJECTIVES: To develop and validate a genetic tool to predict age of onset of aggressive prostate cancer (PCa) and to guide decisions of who to screen and at what age. DESIGN: Analysis of genotype, PCa status, and age to select single nucleotide polymorphisms (SNPs) associated with diagnosis. These polymorphisms were incorporated into a survival analysis to estimate their effects on age at diagnosis of aggressive PCa (that is, not eligible for surveillance according to National Comprehensive Cancer Network guidelines; any of Gleason score ≥7, stage T3-T4, PSA (prostate specific antigen) concentration ≥10 ng/L, nodal metastasis, distant metastasis). The resulting polygenic hazard score is an assessment of individual genetic risk. The final model was applied to an independent dataset containing genotype and PSA screening data. The hazard score was calculated for these men to test prediction of survival free from PCa. SETTING: Multiple institutions that were members of international PRACTICAL consortium. PARTICIPANTS: All consortium participants of European ancestry with known age, PCa status, and quality assured custom (iCOGS) array genotype data. The development dataset comprised 31 747 men; the validation dataset comprised 6411 men. MAIN OUTCOME MEASURES: Prediction with hazard score of age of onset of aggressive cancer in validation set. RESULTS: In the independent validation set, the hazard score calculated from 54 single nucleotide polymorphisms was a highly significant predictor of age at diagnosis of aggressive cancer (z=11.2, P<10-16). When men in the validation set with high scores (>98th centile) were compared with those with average scores (30th-70th centile), the hazard ratio for aggressive cancer was 2.9 (95% confidence interval 2.4 to 3.4). Inclusion of family history in a combined model did not improve prediction of onset of aggressive PCa (P=0.59), and polygenic hazard score performance remained high when family history was accounted for. Additionally, the positive predictive value of PSA screening for aggressive PCa was increased with increasing polygenic hazard score. CONCLUSIONS: Polygenic hazard scores can be used for personalised genetic risk estimates that can predict for age at onset of aggressive PCa..
Dadaev, T.
Saunders, E.J.
Newcombe, P.J.
Anokian, E.
Leongamornlert, D.A.
Brook, M.N.
Cieza-Borrella, C.
Mijuskovic, M.
Wakerell, S.
Olama, A.A.
Schumacher, F.R.
Berndt, S.I.
Benlloch, S.
Ahmed, M.
Goh, C.
Sheng, X.
Zhang, Z.
Muir, K.
Govindasami, K.
Lophatananon, A.
Stevens, V.L.
Gapstur, S.M.
Carter, B.D.
Tangen, C.M.
Goodman, P.
Thompson, I.M.
Batra, J.
Chambers, S.
Moya, L.
Clements, J.
Horvath, L.
Tilley, W.
Risbridger, G.
Gronberg, H.
Aly, M.
Nordström, T.
Pharoah, P.
Pashayan, N.
Schleutker, J.
Tammela, T.L.
Sipeky, C.
Auvinen, A.
Albanes, D.
Weinstein, S.
Wolk, A.
Hakansson, N.
West, C.
Dunning, A.M.
Burnet, N.
Mucci, L.
Giovannucci, E.
Andriole, G.
Cussenot, O.
Cancel-Tassin, G.
Koutros, S.
Freeman, L.E.
Sorensen, K.D.
Orntoft, T.F.
Borre, M.
Maehle, L.
Grindedal, E.M.
Neal, D.E.
Donovan, J.L.
Hamdy, F.C.
Martin, R.M.
Travis, R.C.
Key, T.J.
Hamilton, R.J.
Fleshner, N.E.
Finelli, A.
Ingles, S.A.
Stern, M.C.
Rosenstein, B.
Kerns, S.
Ostrer, H.
Lu, Y.-.
Zhang, H.-.
Feng, N.
Mao, X.
Guo, X.
Wang, G.
Sun, Z.
Giles, G.G.
Southey, M.C.
MacInnis, R.J.
FitzGerald, L.M.
Kibel, A.S.
Drake, B.F.
Vega, A.
Gómez-Caamaño, A.
Fachal, L.
Szulkin, R.
Eklund, M.
Kogevinas, M.
Llorca, J.
Castaño-Vinyals, G.
Penney, K.L.
Stampfer, M.
Park, J.Y.
Sellers, T.A.
Lin, H.-.
Stanford, J.L.
Cybulski, C.
Wokolorczyk, D.
Lubinski, J.
Ostrander, E.A.
Geybels, M.S.
Nordestgaard, B.G.
Nielsen, S.F.
Weisher, M.
Bisbjerg, R.
Røder, M.A.
Iversen, P.
Brenner, H.
Cuk, K.
Holleczek, B.
Maier, C.
Luedeke, M.
Schnoeller, T.
Kim, J.
Logothetis, C.J.
John, E.M.
Teixeira, M.R.
Paulo, P.
Cardoso, M.
Neuhausen, S.L.
Steele, L.
Ding, Y.C.
De Ruyck, K.
De Meerleer, G.
Ost, P.
Razack, A.
Lim, J.
Teo, S.-.
Lin, D.W.
Newcomb, L.F.
Lessel, D.
Gamulin, M.
Kulis, T.
Kaneva, R.
Usmani, N.
Slavov, C.
Mitev, V.
Parliament, M.
Singhal, S.
Claessens, F.
Joniau, S.
Van den Broeck, T.
Larkin, S.
Townsend, P.A.
Aukim-Hastie, C.
Gago-Dominguez, M.
Castelao, J.E.
Martinez, M.E.
Roobol, M.J.
Jenster, G.
van Schaik, R.H.
Menegaux, F.
Truong, T.
Koudou, Y.A.
Xu, J.
Khaw, K.-.
Cannon-Albright, L.
Pandha, H.
Michael, A.
Kierzek, A.
Thibodeau, S.N.
McDonnell, S.K.
Schaid, D.J.
Lindstrom, S.
Turman, C.
Ma, J.
Hunter, D.J.
Riboli, E.
Siddiq, A.
Canzian, F.
Kolonel, L.N.
Le Marchand, L.
Hoover, R.N.
Machiela, M.J.
Kraft, P.
PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium,
Freedman, M.
Wiklund, F.
Chanock, S.
Henderson, B.E.
Easton, D.F.
Haiman, C.A.
Eeles, R.A.
Conti, D.V.
Kote-Jarai, Z.
(2018). Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nat commun,
Vol.9
(1),
p. 2256.
show abstract
full text
Prostate cancer is a polygenic disease with a large heritable component. A number of common, low-penetrance prostate cancer risk loci have been identified through GWAS. Here we apply the Bayesian multivariate variable selection algorithm JAM to fine-map 84 prostate cancer susceptibility loci, using summary data from a large European ancestry meta-analysis. We observe evidence for multiple independent signals at 12 regions and 99 risk signals overall. Only 15 original GWAS tag SNPs remain among the catalogue of candidate variants identified; the remainder are replaced by more likely candidates. Biological annotation of our credible set of variants indicates significant enrichment within promoter and enhancer elements, and transcription factor-binding sites, including AR, ERG and FOXA1. In 40 regions at least one variant is colocalised with an eQTL in prostate cancer tissue. The refined set of candidate variants substantially increase the proportion of familial relative risk explained by these known susceptibility regions, which highlights the importance of fine-mapping studies and has implications for clinical risk profiling..
Went, M.
Sud, A.
Försti, A.
Halvarsson, B.-.
Weinhold, N.
Kimber, S.
van Duin, M.
Thorleifsson, G.
Holroyd, A.
Johnson, D.C.
Li, N.
Orlando, G.
Law, P.J.
Ali, M.
Chen, B.
Mitchell, J.S.
Gudbjartsson, D.F.
Kuiper, R.
Stephens, O.W.
Bertsch, U.
Broderick, P.
Campo, C.
Bandapalli, O.R.
Einsele, H.
Gregory, W.A.
Gullberg, U.
Hillengass, J.
Hoffmann, P.
Jackson, G.H.
Jöckel, K.-.
Johnsson, E.
Kristinsson, S.Y.
Mellqvist, U.-.
Nahi, H.
Easton, D.
Pharoah, P.
Dunning, A.
Peto, J.
Canzian, F.
Swerdlow, A.
Eeles, R.A.
Kote-Jarai, Z.
Muir, K.
Pashayan, N.
Nickel, J.
Nöthen, M.M.
Rafnar, T.
Ross, F.M.
da Silva Filho, M.I.
Thomsen, H.
Turesson, I.
Vangsted, A.
Andersen, N.F.
Waage, A.
Walker, B.A.
Wihlborg, A.-.
Broyl, A.
Davies, F.E.
Thorsteinsdottir, U.
Langer, C.
Hansson, M.
Goldschmidt, H.
Kaiser, M.
Sonneveld, P.
Stefansson, K.
Morgan, G.J.
Hemminki, K.
Nilsson, B.
Houlston, R.S.
PRACTICAL consortium,
(2018). Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. Nat commun,
Vol.9
(1),
p. 3707.
show abstract
full text
Genome-wide association studies (GWAS) have transformed our understanding of susceptibility to multiple myeloma (MM), but much of the heritability remains unexplained. We report a new GWAS, a meta-analysis with previous GWAS and a replication series, totalling 9974 MM cases and 247,556 controls of European ancestry. Collectively, these data provide evidence for six new MM risk loci, bringing the total number to 23. Integration of information from gene expression, epigenetic profiling and in situ Hi-C data for the 23 risk loci implicate disruption of developmental transcriptional regulators as a basis of MM susceptibility, compatible with altered B-cell differentiation as a key mechanism. Dysregulation of autophagy/apoptosis and cell cycle signalling feature as recurrently perturbed pathways. Our findings provide further insight into the biological basis of MM..
Lin, H.-.
Huang, P.-.
Chen, D.-.
Tung, H.-.
Sellers, T.A.
Pow-Sang, J.M.
Eeles, R.
Easton, D.
Kote-Jarai, Z.
Amin Al Olama, A.
Benlloch, S.
Muir, K.
Giles, G.G.
Wiklund, F.
Gronberg, H.
Haiman, C.A.
Schleutker, J.
Nordestgaard, B.G.
Travis, R.C.
Hamdy, F.
Neal, D.E.
Pashayan, N.
Khaw, K.-.
Stanford, J.L.
Blot, W.J.
Thibodeau, S.N.
Maier, C.
Kibel, A.S.
Cybulski, C.
Cannon-Albright, L.
Brenner, H.
Kaneva, R.
Batra, J.
Teixeira, M.R.
Pandha, H.
Lu, Y.-.
PRACTICAL Consortium,
Park, J.Y.
(2018). AA9int: SNP interaction pattern search using non-hierarchical additive model set. Bioinformatics,
Vol.34
(24),
pp. 4141-4150.
show abstract
MOTIVATION: The use of single nucleotide polymorphism (SNP) interactions to predict complex diseases is getting more attention during the past decade, but related statistical methods are still immature. We previously proposed the SNP Interaction Pattern Identifier (SIPI) approach to evaluate 45 SNP interaction patterns/patterns. SIPI is statistically powerful but suffers from a large computation burden. For large-scale studies, it is necessary to use a powerful and computation-efficient method. The objective of this study is to develop an evidence-based mini-version of SIPI as the screening tool or solitary use and to evaluate the impact of inheritance mode and model structure on detecting SNP-SNP interactions. RESULTS: We tested two candidate approaches: the 'Five-Full' and 'AA9int' method. The Five-Full approach is composed of the five full interaction models considering three inheritance modes (additive, dominant and recessive). The AA9int approach is composed of nine interaction models by considering non-hierarchical model structure and the additive mode. Our simulation results show that AA9int has similar statistical power compared to SIPI and is superior to the Five-Full approach, and the impact of the non-hierarchical model structure is greater than that of the inheritance mode in detecting SNP-SNP interactions. In summary, it is recommended that AA9int is a powerful tool to be used either alone or as the screening stage of a two-stage approach (AA9int+SIPI) for detecting SNP-SNP interactions in large-scale studies. AVAILABILITY AND IMPLEMENTATION: The 'AA9int' and 'parAA9int' functions (standard and parallel computing version) are added in the SIPI R package, which is freely available at https://linhuiyi.github.io/LinHY_Software/. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online..
Mikropoulos, C.
Hutten Selkirk, C.G.
Saya, S.
Bancroft, E.
Vertosick, E.
Dadaev, T.
Brendler, C.
Page, E.
Dias, A.
Evans, D.G.
Rothwell, J.
Maehle, L.
Axcrona, K.
Richardson, K.
Eccles, D.
Jensen, T.
Osther, P.J.
van Asperen, C.J.
Vasen, H.
Kiemeney, L.A.
Ringelberg, J.
Cybulski, C.
Wokolorczyk, D.
Hart, R.
Glover, W.
Lam, J.
Taylor, L.
Salinas, M.
Feliubadaló, L.
Oldenburg, R.
Cremers, R.
Verhaegh, G.
van Zelst-Stams, W.A.
Oosterwijk, J.C.
Cook, J.
Rosario, D.J.
Buys, S.S.
Conner, T.
Domchek, S.
Powers, J.
Ausems, M.G.
Teixeira, M.R.
Maia, S.
Izatt, L.
Schmutzler, R.
Rhiem, K.
Foulkes, W.D.
Boshari, T.
Davidson, R.
Ruijs, M.
Helderman-van den Enden, A.T.
Andrews, L.
Walker, L.
Snape, K.
Henderson, A.
Jobson, I.
Lindeman, G.J.
Liljegren, A.
Harris, M.
Adank, M.A.
Kirk, J.
Taylor, A.
Susman, R.
Chen-Shtoyerman, R.
Pachter, N.
Spigelman, A.
Side, L.
Zgajnar, J.
Mora, J.
Brewer, C.
Gadea, N.
Brady, A.F.
Gallagher, D.
van Os, T.
Donaldson, A.
Stefansdottir, V.
Barwell, J.
James, P.A.
Murphy, D.
Friedman, E.
Nicolai, N.
Greenhalgh, L.
Obeid, E.
Murthy, V.
Copakova, L.
McGrath, J.
Teo, S.-.
Strom, S.
Kast, K.
Leongamornlert, D.A.
Chamberlain, A.
Pope, J.
Newlin, A.C.
Aaronson, N.
Ardern-Jones, A.
Bangma, C.
Castro, E.
Dearnaley, D.
Eyfjord, J.
Falconer, A.
Foster, C.S.
Gronberg, H.
Hamdy, F.C.
Johannsson, O.
Khoo, V.
Lubinski, J.
Grindedal, E.M.
McKinley, J.
Shackleton, K.
Mitra, A.V.
Moynihan, C.
Rennert, G.
Suri, M.
Tricker, K.
IMPACT study collaborators,
Moss, S.
Kote-Jarai, Z.
Vickers, A.
Lilja, H.
Helfand, B.T.
Eeles, R.A.
(2018). Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. Br j cancer,
Vol.118
(6),
p. e17.
show abstract
full text
This corrects the article DOI: 10.1038/bjc.2017.429..
Loveday, C.
Litchfield, K.
Levy, M.
Holroyd, A.
Broderick, P.
Kote-Jarai, Z.
Dunning, A.M.
Muir, K.
Peto, J.
Eeles, R.
Easton, D.F.
Dudakia, D.
Orr, N.
Pashayan, N.
Reid, A.
Huddart, R.A.
Houlston, R.S.
Turnbull, C.
(2018). Validation of loci at 2q14 2 and 15q21 3 as risk factors for testicular cancer. Oncotarget,
Vol.9
(16),
pp. 12630-12638.
show abstract
full text
Testicular germ cell tumor (TGCT), the most common cancer in men aged 18 to 45 years, has a strong heritable basis. Genome-wide association studies (GWAS) have proposed single nucleotide polymorphisms (SNPs) at a number of loci influencing TGCT risk. To further evaluate the association of recently proposed risk SNPs with TGCT at 2q14.2, 3q26.2, 7q36.3, 10q26.13 and 15q21.3, we analyzed genotype data on 3,206 cases and 7,422 controls. Our analysis provides independent replication of the associations for risk SNPs at 2q14.2 (rs2713206 at P = 3.03 × 10-2; P-meta = 3.92 × 10-8; nearest gene, TFCP2L1) and rs12912292 at 15q21.3 (P = 7.96 × 10-11; P-meta = 1.55 × 10-19; nearest gene PRTG). Case-only analyses did not reveal specific associations with TGCT histology. TFCP2L1 joins the growing list of genes located within TGCT risk loci with biologically plausible roles in developmental transcriptional regulation, further highlighting the importance of this phenomenon in TGCT oncogenesis..
Brunner, C.
Davies, N.M.
Martin, R.M.
Eeles, R.
Easton, D.
Kote-Jarai, Z.
Al Olama, A.A.
Benlloch, S.
Muir, K.
Giles, G.
Wiklund, F.
Gronberg, H.
Haiman, C.A.
Schleutker, J.
Nordestgaard, B.G.
Travis, R.C.
Neal, D.
Donovan, J.
Hamdy, F.C.
Pashayan, N.
Khaw, K.-.
Stanford, J.L.
Blot, W.J.
Thibodeau, S.
Maier, C.
Kibel, A.S.
Cybulski, C.
Cannon-Albright, L.
Brenner, H.
Park, J.
Kaneva, R.
Batra, J.
Teixeira, M.R.
Pandha, H.
PRACTICAL Consortium,,
Zuccolo, L.
(2017). Alcohol consumption and prostate cancer incidence and progression: A Mendelian randomisation study. Int j cancer,
Vol.140
(1),
pp. 75-85.
show abstract
full text
Prostate cancer is the most common cancer in men in developed countries, and is a target for risk reduction strategies. The effects of alcohol consumption on prostate cancer incidence and survival remain unclear, potentially due to methodological limitations of observational studies. In this study, we investigated the associations of genetic variants in alcohol-metabolising genes with prostate cancer incidence and survival. We analysed data from 23,868 men with prostate cancer and 23,051 controls from 25 studies within the international PRACTICAL Consortium. Study-specific associations of 68 single nucleotide polymorphisms (SNPs) in 8 alcohol-metabolising genes (Alcohol Dehydrogenases (ADHs) and Aldehyde Dehydrogenases (ALDHs)) with prostate cancer diagnosis and prostate cancer-specific mortality, by grade, were assessed using logistic and Cox regression models, respectively. The data across the 25 studies were meta-analysed using fixed-effect and random-effects models. We found little evidence that variants in alcohol metabolising genes were associated with prostate cancer diagnosis. Four variants in two genes exceeded the multiple testing threshold for associations with prostate cancer mortality in fixed-effect meta-analyses. SNPs within ALDH1A2 associated with prostate cancer mortality were rs1441817 (fixed effects hazard ratio, HRfixed = 0.78; 95% confidence interval (95%CI):0.66,0.91; p values = 0.002); rs12910509, HRfixed = 0.76; 95%CI:0.64,0.91; p values = 0.003); and rs8041922 (HRfixed = 0.76; 95%CI:0.64,0.91; p values = 0.002). These SNPs were in linkage disequilibrium with each other. In ALDH1B1, rs10973794 (HRfixed = 1.43; 95%CI:1.14,1.79; p values = 0.002) was associated with prostate cancer mortality in men with low-grade prostate cancer. These results suggest that alcohol consumption is unlikely to affect prostate cancer incidence, but it may influence disease progression..
Sud, A.
Thomsen, H.
Law, P.J.
Försti, A.
Filho, M.I.
Holroyd, A.
Broderick, P.
Orlando, G.
Lenive, O.
Wright, L.
Cooke, R.
Easton, D.
Pharoah, P.
Dunning, A.
Peto, J.
Canzian, F.
Eeles, R.
Kote-Jarai, Z.
Muir, K.
Pashayan, N.
PRACTICAL consortium,
Hoffmann, P.
Nöthen, M.M.
Jöckel, K.-.
Strandmann, E.P.
Lightfoot, T.
Kane, E.
Roman, E.
Lake, A.
Montgomery, D.
Jarrett, R.F.
Swerdlow, A.J.
Engert, A.
Orr, N.
Hemminki, K.
Houlston, R.S.
(2017). Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility. Nat commun,
Vol.8
(1),
p. 1892.
show abstract
full text
Several susceptibility loci for classical Hodgkin lymphoma have been reported. However, much of the heritable risk is unknown. Here, we perform a meta-analysis of two existing genome-wide association studies, a new genome-wide association study, and replication totalling 5,314 cases and 16,749 controls. We identify risk loci for all classical Hodgkin lymphoma at 6q22.33 (rs9482849, P = 1.52 × 10-8) and for nodular sclerosis Hodgkin lymphoma at 3q28 (rs4459895, P = 9.43 × 10-17), 6q23.3 (rs6928977, P = 4.62 × 10-11), 10p14 (rs3781093, P = 9.49 × 10-13), 13q34 (rs112998813, P = 4.58 × 10-8) and 16p13.13 (rs34972832, P = 2.12 × 10-8). Additionally, independent loci within the HLA region are observed for nodular sclerosis Hodgkin lymphoma (rs9269081, HLA-DPB1*03:01, Val86 in HLA-DRB1) and mixed cellularity Hodgkin lymphoma (rs1633096, rs13196329, Val86 in HLA-DRB1). The new and established risk loci localise to areas of active chromatin and show an over-representation of transcription factor binding for determinants of B-cell development and immune response..
Amos, C.I.
Dennis, J.
Wang, Z.
Byun, J.
Schumacher, F.R.
Gayther, S.A.
Casey, G.
Hunter, D.J.
Sellers, T.A.
Gruber, S.B.
Dunning, A.M.
Michailidou, K.
Fachal, L.
Doheny, K.
Spurdle, A.B.
Li, Y.
Xiao, X.
Romm, J.
Pugh, E.
Coetzee, G.A.
Hazelett, D.J.
Bojesen, S.E.
Caga-Anan, C.
Haiman, C.A.
Kamal, A.
Luccarini, C.
Tessier, D.
Vincent, D.
Bacot, F.
Van Den Berg, D.J.
Nelson, S.
Demetriades, S.
Goldgar, D.E.
Couch, F.J.
Forman, J.L.
Giles, G.G.
Conti, D.V.
Bickeböller, H.
Risch, A.
Waldenberger, M.
Brüske-Hohlfeld, I.
Hicks, B.D.
Ling, H.
McGuffog, L.
Lee, A.
Kuchenbaecker, K.
Soucy, P.
Manz, J.
Cunningham, J.M.
Butterbach, K.
Kote-Jarai, Z.
Kraft, P.
FitzGerald, L.
Lindström, S.
Adams, M.
McKay, J.D.
Phelan, C.M.
Benlloch, S.
Kelemen, L.E.
Brennan, P.
Riggan, M.
O'Mara, T.A.
Shen, H.
Shi, Y.
Thompson, D.J.
Goodman, M.T.
Nielsen, S.F.
Berchuck, A.
Laboissiere, S.
Schmit, S.L.
Shelford, T.
Edlund, C.K.
Taylor, J.A.
Field, J.K.
Park, S.K.
Offit, K.
Thomassen, M.
Schmutzler, R.
Ottini, L.
Hung, R.J.
Marchini, J.
Amin Al Olama, A.
Peters, U.
Eeles, R.A.
Seldin, M.F.
Gillanders, E.
Seminara, D.
Antoniou, A.C.
Pharoah, P.D.
Chenevix-Trench, G.
Chanock, S.J.
Simard, J.
Easton, D.F.
(2017). The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers. Cancer epidemiol biomarkers prev,
Vol.26
(1),
pp. 126-135.
show abstract
full text
BACKGROUND: Common cancers develop through a multistep process often including inherited susceptibility. Collaboration among multiple institutions, and funding from multiple sources, has allowed the development of an inexpensive genotyping microarray, the OncoArray. The array includes a genome-wide backbone, comprising 230,000 SNPs tagging most common genetic variants, together with dense mapping of known susceptibility regions, rare variants from sequencing experiments, pharmacogenetic markers, and cancer-related traits. METHODS: The OncoArray can be genotyped using a novel technology developed by Illumina to facilitate efficient genotyping. The consortium developed standard approaches for selecting SNPs for study, for quality control of markers, and for ancestry analysis. The array was genotyped at selected sites and with prespecified replicate samples to permit evaluation of genotyping accuracy among centers and by ethnic background. RESULTS: The OncoArray consortium genotyped 447,705 samples. A total of 494,763 SNPs passed quality control steps with a sample success rate of 97% of the samples. Participating sites performed ancestry analysis using a common set of markers and a scoring algorithm based on principal components analysis. CONCLUSIONS: Results from these analyses will enable researchers to identify new susceptibility loci, perform fine-mapping of new or known loci associated with either single or multiple cancers, assess the degree of overlap in cancer causation and pleiotropic effects of loci that have been identified for disease-specific risk, and jointly model genetic, environmental, and lifestyle-related exposures. IMPACT: Ongoing analyses will shed light on etiology and risk assessment for many types of cancer. Cancer Epidemiol Biomarkers Prev; 26(1); 126-35. ©2016 AACR..
Conti, D.V.
Wang, K.
Sheng, X.
Bensen, J.T.
Hazelett, D.J.
Cook, M.B.
Ingles, S.A.
Kittles, R.A.
Strom, S.S.
Rybicki, B.A.
Nemesure, B.
Isaacs, W.B.
Stanford, J.L.
Zheng, W.
Sanderson, M.
John, E.M.
Park, J.Y.
Xu, J.
Stevens, V.L.
Berndt, S.I.
Huff, C.D.
Wang, Z.
Yeboah, E.D.
Tettey, Y.
Biritwum, R.B.
Adjei, A.A.
Tay, E.
Truelove, A.
Niwa, S.
Sellers, T.A.
Yamoah, K.
Murphy, A.B.
Crawford, D.C.
Gapstur, S.M.
Bush, W.S.
Aldrich, M.C.
Cussenot, O.
Petrovics, G.
Cullen, J.
Neslund-Dudas, C.
Stern, M.C.
Jarai, Z.-.
Govindasami, K.
Chokkalingam, A.P.
Hsing, A.W.
Goodman, P.J.
Hoffmann, T.
Drake, B.F.
Hu, J.J.
Clark, P.E.
Van Den Eeden, S.K.
Blanchet, P.
Fowke, J.H.
Casey, G.
Hennis, A.J.
Han, Y.
Lubwama, A.
Thompson, I.M.
Leach, R.
Easton, D.F.
Schumacher, F.
Van den Berg, D.J.
Gundell, S.M.
Stram, A.
Wan, P.
Xia, L.
Pooler, L.C.
Mohler, J.L.
Fontham, E.T.
Smith, G.J.
Taylor, J.A.
Srivastava, S.
Eeles, R.A.
Carpten, J.
Kibel, A.S.
Multigner, L.
Parent, M.-.
Menegaux, F.
Cancel-Tassin, G.
Klein, E.A.
Brureau, L.
Stram, D.O.
Watya, S.
Chanock, S.J.
Witte, J.S.
Blot, W.J.
Henderson, B.E.
Haiman, C.A.
PRACTICAL/ELLIPSE Consortium,
(2017). Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry. J natl cancer inst,
Vol.109
(8).
show abstract
full text
Prostate cancer incidence is 1.6-fold higher in African Americans than in other populations. The risk factors that drive this disparity are unknown and potentially consist of social, environmental, and genetic influences. To investigate the genetic basis of prostate cancer in men of African ancestry, we performed a genome-wide association meta-analysis using two-sided statistical tests in 10 202 case subjects and 10 810 control subjects. We identified novel signals on chromosomes 13q34 and 22q12, with the risk-associated alleles found only in men of African ancestry (13q34: rs75823044, risk allele frequency = 2.2%, odds ratio [OR] = 1.55, 95% confidence interval [CI] = 1.37 to 1.76, P = 6.10 × 10-12; 22q12.1: rs78554043, risk allele frequency = 1.5%, OR = 1.62, 95% CI = 1.39 to 1.89, P = 7.50 × 10-10). At 13q34, the signal is located 5' of the gene IRS2 and 3' of a long noncoding RNA, while at 22q12 the candidate functional allele is a missense variant in the CHEK2 gene. These findings provide further support for the role of ancestry-specific germline variation in contributing to population differences in prostate cancer risk..
Larson, N.B.
McDonnell, S.
Cannon Albright, L.
Teerlink, C.
Stanford, J.
Ostrander, E.A.
Isaacs, W.B.
Xu, J.
Cooney, K.A.
Lange, E.
Schleutker, J.
Carpten, J.D.
Powell, I.
Bailey-Wilson, J.E.
Cussenot, O.
Cancel-Tassin, G.
Giles, G.G.
MacInnis, R.J.
Maier, C.
Whittemore, A.S.
Hsieh, C.-.
Wiklund, F.
Catalona, W.J.
Foulkes, W.
Mandal, D.
Eeles, R.
Kote-Jarai, Z.
Ackerman, M.J.
Olson, T.M.
Klein, C.J.
Thibodeau, S.N.
Schaid, D.J.
(2017). gsSKAT: Rapid gene set analysis and multiple testing correction for rare-variant association studies using weighted linear kernels. Genet epidemiol,
Vol.41
(4),
pp. 297-308.
show abstract
full text
Next-generation sequencing technologies have afforded unprecedented characterization of low-frequency and rare genetic variation. Due to low power for single-variant testing, aggregative methods are commonly used to combine observed rare variation within a single gene. Causal variation may also aggregate across multiple genes within relevant biomolecular pathways. Kernel-machine regression and adaptive testing methods for aggregative rare-variant association testing have been demonstrated to be powerful approaches for pathway-level analysis, although these methods tend to be computationally intensive at high-variant dimensionality and require access to complete data. An additional analytical issue in scans of large pathway definition sets is multiple testing correction. Gene set definitions may exhibit substantial genic overlap, and the impact of the resultant correlation in test statistics on Type I error rate control for large agnostic gene set scans has not been fully explored. Herein, we first outline a statistical strategy for aggregative rare-variant analysis using component gene-level linear kernel score test summary statistics as well as derive simple estimators of the effective number of tests for family-wise error rate control. We then conduct extensive simulation studies to characterize the behavior of our approach relative to direct application of kernel and adaptive methods under a variety of conditions. We also apply our method to two case-control studies, respectively, evaluating rare variation in hereditary prostate cancer and schizophrenia. Finally, we provide open-source R code for public use to facilitate easy application of our methods to existing rare-variant analysis results..
Litchfield, K.
Levy, M.
Orlando, G.
Loveday, C.
Law, P.J.
Migliorini, G.
Holroyd, A.
Broderick, P.
Karlsson, R.
Haugen, T.B.
Kristiansen, W.
Nsengimana, J.
Fenwick, K.
Assiotis, I.
Kote-Jarai, Z.
Dunning, A.M.
Muir, K.
Peto, J.
Eeles, R.
Easton, D.F.
Dudakia, D.
Orr, N.
Pashayan, N.
UK Testicular Cancer Collaboration,
PRACTICAL Consortium,
Bishop, D.T.
Reid, A.
Huddart, R.A.
Shipley, J.
Grotmol, T.
Wiklund, F.
Houlston, R.S.
Turnbull, C.
(2017). Identification of 19 new risk loci and potential regulatory mechanisms influencing susceptibility to testicular germ cell tumor. Nat genet,
Vol.49
(7),
pp. 1133-1140.
show abstract
full text
Genome-wide association studies (GWAS) have transformed understanding of susceptibility to testicular germ cell tumors (TGCTs), but much of the heritability remains unexplained. Here we report a new GWAS, a meta-analysis with previous GWAS and a replication series, totaling 7,319 TGCT cases and 23,082 controls. We identify 19 new TGCT risk loci, roughly doubling the number of known TGCT risk loci to 44. By performing in situ Hi-C in TGCT cells, we provide evidence for a network of physical interactions among all 44 TGCT risk SNPs and candidate causal genes. Our findings implicate widespread disruption of developmental transcriptional regulators as a basis of TGCT susceptibility, consistent with failed primordial germ cell differentiation as an initiating step in oncogenesis. Defective microtubule assembly and dysregulation of KIT-MAPK signaling also feature as recurrently disrupted pathways. Our findings support a polygenic model of risk and provide insight into the biological basis of TGCT..
Camacho, N.
Van Loo, P.
Edwards, S.
Kay, J.D.
Matthews, L.
Haase, K.
Clark, J.
Dennis, N.
Thomas, S.
Kremeyer, B.
Zamora, J.
Butler, A.P.
Gundem, G.
Merson, S.
Luxton, H.
Hawkins, S.
Ghori, M.
Marsden, L.
Lambert, A.
Karaszi, K.
Pelvender, G.
Massie, C.E.
Kote-Jarai, Z.
Raine, K.
Jones, D.
Howat, W.J.
Hazell, S.
Livni, N.
Fisher, C.
Ogden, C.
Kumar, P.
Thompson, A.
Nicol, D.
Mayer, E.
Dudderidge, T.
Yu, Y.
Zhang, H.
Shah, N.C.
Gnanapragasam, V.J.
CRUK-ICGC Prostate Group,
Isaacs, W.
Visakorpi, T.
Hamdy, F.
Berney, D.
Verrill, C.
Warren, A.Y.
Wedge, D.C.
Lynch, A.G.
Foster, C.S.
Lu, Y.J.
Bova, G.S.
Whitaker, H.C.
McDermott, U.
Neal, D.E.
Eeles, R.
Cooper, C.S.
Brewer, D.S.
(2017). Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data. Plos genet,
Vol.13
(9),
p. e1007001.
show abstract
full text
A variety of models have been proposed to explain regions of recurrent somatic copy number alteration (SCNA) in human cancer. Our study employs Whole Genome DNA Sequence (WGS) data from tumor samples (n = 103) to comprehensively assess the role of the Knudson two hit genetic model in SCNA generation in prostate cancer. 64 recurrent regions of loss and gain were detected, of which 28 were novel, including regions of loss with more than 15% frequency at Chr4p15.2-p15.1 (15.53%), Chr6q27 (16.50%) and Chr18q12.3 (17.48%). Comprehensive mutation screens of genes, lincRNA encoding sequences, control regions and conserved domains within SCNAs demonstrated that a two-hit genetic model was supported in only a minor proportion of recurrent SCNA losses examined (15/40). We found that recurrent breakpoints and regions of inversion often occur within Knudson model SCNAs, leading to the identification of ZNF292 as a target gene for the deletion at 6q14.3-q15 and NKX3.1 as a two-hit target at 8p21.3-p21.2. The importance of alterations of lincRNA sequences was illustrated by the identification of a novel mutational hotspot at the KCCAT42, FENDRR, CAT1886 and STCAT2 loci at the 16q23.1-q24.3 loss. Our data confirm that the burden of SCNAs is predictive of biochemical recurrence, define nine individual regions that are associated with relapse, and highlight the possible importance of ion channel and G-protein coupled-receptor (GPCR) pathways in cancer development. We concluded that a two-hit genetic model accounts for about one third of SCNA indicating that mechanisms, such haploinsufficiency and epigenetic inactivation, account for the remaining SCNA losses..
Taylor, A.E.
Martin, R.M.
Geybels, M.S.
Stanford, J.L.
Shui, I.
Eeles, R.
Easton, D.
Kote-Jarai, Z.
Amin Al Olama, A.
Benlloch, S.
Muir, K.
Giles, G.G.
Wiklund, F.
Gronberg, H.
Haiman, C.A.
Schleutker, J.
Nordestgaard, B.G.
Travis, R.C.
Neal, D.
Pashayan, N.
Khaw, K.-.
Blot, W.
Thibodeau, S.
Maier, C.
Kibel, A.S.
Cybulski, C.
Cannon-Albright, L.
Brenner, H.
Park, J.
Kaneva, R.
Batra, J.
Teixeira, M.R.
Pandha, H.
PRACTICAL Consortium,
Donovan, J.
Munafò, M.R.
(2017). Investigating the possible causal role of coffee consumption with prostate cancer risk and progression using Mendelian randomization analysis. Int j cancer,
Vol.140
(2),
pp. 322-328.
show abstract
full text
Coffee consumption has been shown in some studies to be associated with lower risk of prostate cancer. However, it is unclear if this association is causal or due to confounding or reverse causality. We conducted a Mendelian randomisation analysis to investigate the causal effects of coffee consumption on prostate cancer risk and progression. We used two genetic variants robustly associated with caffeine intake (rs4410790 and rs2472297) as proxies for coffee consumption in a sample of 46,687 men of European ancestry from 25 studies in the PRACTICAL consortium. Associations between genetic variants and prostate cancer case status, stage and grade were assessed by logistic regression and with all-cause and prostate cancer-specific mortality using Cox proportional hazards regression. There was no clear evidence that a genetic risk score combining rs4410790 and rs2472297 was associated with prostate cancer risk (OR per additional coffee increasing allele: 1.01, 95% CI: 0.98,1.03) or having high-grade compared to low-grade disease (OR: 1.01, 95% CI: 0.97,1.04). There was some evidence that the genetic risk score was associated with higher odds of having nonlocalised compared to localised stage disease (OR: 1.03, 95% CI: 1.01, 1.06). Amongst men with prostate cancer, there was no clear association between the genetic risk score and all-cause mortality (HR: 1.00, 95% CI: 0.97,1.04) or prostate cancer-specific mortality (HR: 1.03, 95% CI: 0.98,1.08). These results, which should have less bias from confounding than observational estimates, are not consistent with a substantial effect of coffee consumption on reducing prostate cancer incidence or progression..
Lin, H.-.
Chen, D.-.
Huang, P.-.
Liu, Y.-.
Ochoa, A.
Zabaleta, J.
Mercante, D.E.
Fang, Z.
Sellers, T.A.
Pow-Sang, J.M.
Cheng, C.-.
Eeles, R.
Easton, D.
Kote-Jarai, Z.
Amin Al Olama, A.
Benlloch, S.
Muir, K.
Giles, G.G.
Wiklund, F.
Gronberg, H.
Haiman, C.A.
Schleutker, J.
Nordestgaard, B.G.
Travis, R.C.
Hamdy, F.
Pashayan, N.
Khaw, K.-.
Stanford, J.L.
Blot, W.J.
Thibodeau, S.N.
Maier, C.
Kibel, A.S.
Cybulski, C.
Cannon-Albright, L.
Brenner, H.
Kaneva, R.
Batra, J.
Teixeira, M.R.
Pandha, H.
Lu, Y.-.
PRACTICAL Consortium,
Park, J.Y.
(2017). SNP interaction pattern identifier (SIPI): an intensive search for SNP-SNP interaction patterns. Bioinformatics,
Vol.33
(6),
pp. 822-833.
show abstract
full text
MOTIVATION: Testing SNP-SNP interactions is considered as a key for overcoming bottlenecks of genetic association studies. However, related statistical methods for testing SNP-SNP interactions are underdeveloped. RESULTS: We propose the SNP Interaction Pattern Identifier (SIPI), which tests 45 biologically meaningful interaction patterns for a binary outcome. SIPI takes non-hierarchical models, inheritance modes and mode coding direction into consideration. The simulation results show that SIPI has higher power than MDR (Multifactor Dimensionality Reduction), AA_Full, Geno_Full (full interaction model with additive or genotypic mode) and SNPassoc in detecting interactions. Applying SIPI to the prostate cancer PRACTICAL consortium data with approximately 21 000 patients, the four SNP pairs in EGFR-EGFR , EGFR-MMP16 and EGFR-CSF1 were found to be associated with prostate cancer aggressiveness with the exact or similar pattern in the discovery and validation sets. A similar match for external validation of SNP-SNP interaction studies is suggested. We demonstrated that SIPI not only searches for more meaningful interaction patterns but can also overcome the unstable nature of interaction patterns. AVAILABILITY AND IMPLEMENTATION: The SIPI software is freely available at http://publichealth.lsuhsc.edu/LinSoftware/ . CONTACT: [email protected]. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online..
Lophatananon, A.
Stewart-Brown, S.
Kote-Jarai, Z.
Olama, A.A.
Garcia, S.B.
Neal, D.E.
Hamdy, F.C.
Donovan, J.L.
Giles, G.G.
Fitzgerald, L.M.
Southey, M.C.
Pharoah, P.
Pashayan, N.
Gronberg, H.
Wiklund, F.
Aly, M.
Stanford, J.L.
Brenner, H.
Dieffenbach, A.K.
Arndt, V.
Park, J.Y.
Lin, H.-.
Sellers, T.
Slavov, C.
Kaneva, R.
Mitev, V.
Batra, J.
Spurdle, A.
Clements, J.A.
APCB BioResource,
PRACTICAL consortium,
Easton, D.
Eeles, R.A.
Muir, K.
(2017). Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium. Br j cancer,
Vol.117
(5),
pp. 734-743.
show abstract
full text
BACKGROUND: Evidence on height and prostate cancer risk is mixed, however, recent studies with large data sets support a possible role for its association with the risk of aggressive prostate cancer. METHODS: We analysed data from the PRACTICAL consortium consisting of 6207 prostate cancer cases and 6016 controls and a subset of high grade cases (2480 cases). We explored height, polymorphisms in genes related to growth processes as main effects and their possible interactions. RESULTS: The results suggest that height is associated with high-grade prostate cancer risk. Men with height >180 cm are at a 22% increased risk as compared to men with height <173 cm (OR 1.22, 95% CI 1.01-1.48). Genetic variants in the growth pathway gene showed an association with prostate cancer risk. The aggregate scores of the selected variants identified a significantly increased risk of overall prostate cancer and high-grade prostate cancer by 13% and 15%, respectively, in the highest score group as compared to lowest score group. CONCLUSIONS: There was no evidence of gene-environment interaction between height and the selected candidate SNPs.Our findings suggest a role of height in high-grade prostate cancer. The effect of genetic variants in the genes related to growth is seen in all cases and high-grade prostate cancer. There is no interaction between these two exposures..
Mancuso, N.
Rohland, N.
Rand, K.A.
Tandon, A.
Allen, A.
Quinque, D.
Mallick, S.
Li, H.
Stram, A.
Sheng, X.
Kote-Jarai, Z.
Easton, D.F.
Eeles, R.A.
PRACTICAL consortium,
Le Marchand, L.
Lubwama, A.
Stram, D.
Watya, S.
Conti, D.V.
Henderson, B.
Haiman, C.A.
Pasaniuc, B.
Reich, D.
(2016). The contribution of rare variation to prostate cancer heritability. Nat genet,
Vol.48
(1),
pp. 30-35.
show abstract
full text
We report targeted sequencing of 63 known prostate cancer risk regions in a multi-ancestry study of 9,237 men and use the data to explore the contribution of low-frequency variation to disease risk. We show that SNPs with minor allele frequencies (MAFs) of 0.1-1% explain a substantial fraction of prostate cancer risk in men of African ancestry. We estimate that these SNPs account for 0.12 (standard error (s.e.) = 0.05) of variance in risk (∼42% of the variance contributed by SNPs with MAF of 0.1-50%). This contribution is much larger than the fraction of neutral variation due to SNPs in this class, implying that natural selection has driven down the frequency of many prostate cancer risk alleles; we estimate the coupling between selection and allelic effects at 0.48 (95% confidence interval [0.19, 0.78]) under the Eyre-Walker model. Our results indicate that rare variants make a disproportionate contribution to genetic risk for prostate cancer and suggest the possibility that rare variants may also have an outsize effect on other common traits..
Scarbrough, P.M.
Weber, R.P.
Iversen, E.S.
Brhane, Y.
Amos, C.I.
Kraft, P.
Hung, R.J.
Sellers, T.A.
Witte, J.S.
Pharoah, P.
Henderson, B.E.
Gruber, S.B.
Hunter, D.J.
Garber, J.E.
Joshi, A.D.
McDonnell, K.
Easton, D.F.
Eeles, R.
Kote-Jarai, Z.
Muir, K.
Doherty, J.A.
Schildkraut, J.M.
(2016). A Cross-Cancer Genetic Association Analysis of the DNA Repair and DNA Damage Signaling Pathways for Lung, Ovary, Prostate, Breast, and Colorectal Cancer. Cancer epidemiol biomarkers prev,
Vol.25
(1),
pp. 193-200.
show abstract
full text
BACKGROUND: DNA damage is an established mediator of carcinogenesis, although genome-wide association studies (GWAS) have identified few significant loci. This cross-cancer site, pooled analysis was performed to increase the power to detect common variants of DNA repair genes associated with cancer susceptibility. METHODS: We conducted a cross-cancer analysis of 60,297 single nucleotide polymorphisms, at 229 DNA repair gene regions, using data from the NCI Genetic Associations and Mechanisms in Oncology (GAME-ON) Network. Our analysis included data from 32 GWAS and 48,734 controls and 51,537 cases across five cancer sites (breast, colon, lung, ovary, and prostate). Because of the unavailability of individual data, data were analyzed at the aggregate level. Meta-analysis was performed using the Association analysis for SubSETs (ASSET) software. To test for genetic associations that might escape individual variant testing due to small effect sizes, pathway analysis of eight DNA repair pathways was performed using hierarchical modeling. RESULTS: We identified three susceptibility DNA repair genes, RAD51B (P < 5.09 × 10(-6)), MSH5 (P < 5.09 × 10(-6)), and BRCA2 (P = 5.70 × 10(-6)). Hierarchical modeling identified several pleiotropic associations with cancer risk in the base excision repair, nucleotide excision repair, mismatch repair, and homologous recombination pathways. CONCLUSIONS: Only three susceptibility loci were identified, which had all been previously reported. In contrast, hierarchical modeling identified several pleiotropic cancer risk associations in key DNA repair pathways. IMPACT: Results suggest that many common variants in DNA repair genes are likely associated with cancer susceptibility through small effect sizes that do not meet stringent significance testing criteria..
Amin Al Olama, A.
Eeles, R.A.
Kote-Jarai, Z.
Easton, D.F.
(2016). Risk Analysis of Prostate Cancer in PRACTICAL Consortium--Response. Cancer epidemiol biomarkers prev,
Vol.25
(1),
p. 223.
Bonilla, C.
Lewis, S.J.
Rowlands, M.-.
Gaunt, T.R.
Davey Smith, G.
Gunnell, D.
Palmer, T.
Donovan, J.L.
Hamdy, F.C.
Neal, D.E.
Eeles, R.
Easton, D.
Kote-Jarai, Z.
Al Olama, A.A.
Benlloch, S.
Muir, K.
Giles, G.G.
Wiklund, F.
Grönberg, H.
Haiman, C.A.
Schleutker, J.
Nordestgaard, B.G.
Travis, R.C.
Pashayan, N.
Khaw, K.-.
Stanford, J.L.
Blot, W.J.
Thibodeau, S.
Maier, C.
Kibel, A.S.
Cybulski, C.
Cannon-Albright, L.
Brenner, H.
Park, J.
Kaneva, R.
Batra, J.
Teixeira, M.R.
Pandha, H.
PRACTICAL consortium,
Lathrop, M.
Martin, R.M.
Holly, J.M.
(2016). Assessing the role of insulin-like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating levels. Int j cancer,
Vol.139
(7),
pp. 1520-1533.
show abstract
full text
Circulating insulin-like growth factors (IGFs) and their binding proteins (IGFBPs) are associated with prostate cancer. Using genetic variants as instruments for IGF peptides, we investigated whether these associations are likely to be causal. We identified from the literature 56 single nucleotide polymorphisms (SNPs) in the IGF axis previously associated with biomarker levels (8 from a genome-wide association study [GWAS] and 48 in reported candidate genes). In ∼700 men without prostate cancer and two replication cohorts (N ∼ 900 and ∼9,000), we examined the properties of these SNPS as instrumental variables (IVs) for IGF-I, IGF-II, IGFBP-2 and IGFBP-3. Those confirmed as strong IVs were tested for association with prostate cancer risk, low (< 7) vs. high (≥ 7) Gleason grade, localised vs. advanced stage, and mortality, in 22,936 controls and 22,992 cases. IV analysis was used in an attempt to estimate the causal effect of circulating IGF peptides on prostate cancer. Published SNPs in the IGFBP1/IGFBP3 gene region, particularly rs11977526, were strong instruments for IGF-II and IGFBP-3, less so for IGF-I. Rs11977526 was associated with high (vs. low) Gleason grade (OR per IGF-II/IGFBP-3 level-raising allele 1.05; 95% CI: 1.00, 1.10). Using rs11977526 as an IV we estimated the causal effect of a one SD increase in IGF-II (∼265 ng/mL) on risk of high vs. low grade disease as 1.14 (95% CI: 1.00, 1.31). Because of the potential for pleiotropy of the genetic instruments, these findings can only causally implicate the IGF pathway in general, not any one specific biomarker..
Scott, R.A.
Freitag, D.F.
Li, L.
Chu, A.Y.
Surendran, P.
Young, R.
Grarup, N.
Stancáková, A.
Chen, Y.
Varga, T.V.
Yaghootkar, H.
Luan, J.
Zhao, J.H.
Willems, S.M.
Wessel, J.
Wang, S.
Maruthur, N.
Michailidou, K.
Pirie, A.
van der Lee, S.J.
Gillson, C.
Al Olama, A.A.
Amouyel, P.
Arriola, L.
Arveiler, D.
Aviles-Olmos, I.
Balkau, B.
Barricarte, A.
Barroso, I.
Garcia, S.B.
Bis, J.C.
Blankenberg, S.
Boehnke, M.
Boeing, H.
Boerwinkle, E.
Borecki, I.B.
Bork-Jensen, J.
Bowden, S.
Caldas, C.
Caslake, M.
CVD50 consortium,
Cupples, L.A.
Cruchaga, C.
Czajkowski, J.
den Hoed, M.
Dunn, J.A.
Earl, H.M.
Ehret, G.B.
Ferrannini, E.
Ferrieres, J.
Foltynie, T.
Ford, I.
Forouhi, N.G.
Gianfagna, F.
Gonzalez, C.
Grioni, S.
Hiller, L.
Jansson, J.-.
Jørgensen, M.E.
Jukema, J.W.
Kaaks, R.
Kee, F.
Kerrison, N.D.
Key, T.J.
Kontto, J.
Kote-Jarai, Z.
Kraja, A.T.
Kuulasmaa, K.
Kuusisto, J.
Linneberg, A.
Liu, C.
Marenne, G.
Mohlke, K.L.
Morris, A.P.
Muir, K.
Müller-Nurasyid, M.
Munroe, P.B.
Navarro, C.
Nielsen, S.F.
Nilsson, P.M.
Nordestgaard, B.G.
Packard, C.J.
Palli, D.
Panico, S.
Peloso, G.M.
Perola, M.
Peters, A.
Poole, C.J.
Quirós, J.R.
Rolandsson, O.
Sacerdote, C.
Salomaa, V.
Sánchez, M.-.
Sattar, N.
Sharp, S.J.
Sims, R.
Slimani, N.
Smith, J.A.
Thompson, D.J.
Trompet, S.
Tumino, R.
van der A, D.L.
van der Schouw, Y.T.
Virtamo, J.
Walker, M.
Walter, K.
GERAD_EC Consortium,
Neurology Working Group of the Cohorts for Heart,
Aging Research in Genomic Epidemiology (CHARGE),
Alzheimer’s Disease Genetics Consortium,
Pancreatic Cancer Cohort Consortium,
European Prospective Investigation into Cancer and Nutrition–Cardiovascular Disease (EPIC-CVD),
EPIC-InterAct,
Abraham, J.E.
Amundadottir, L.T.
Aponte, J.L.
Butterworth, A.S.
Dupuis, J.
Easton, D.F.
Eeles, R.A.
Erdmann, J.
Franks, P.W.
Frayling, T.M.
Hansen, T.
Howson, J.M.
Jørgensen, T.
Kooner, J.
Laakso, M.
Langenberg, C.
McCarthy, M.I.
Pankow, J.S.
Pedersen, O.
Riboli, E.
Rotter, J.I.
Saleheen, D.
Samani, N.J.
Schunkert, H.
Vollenweider, P.
O'Rahilly, S.
CHARGE consortium,
CHD Exome+ Consortium,
CARDIOGRAM Exome Consortium,
Deloukas, P.
Danesh, J.
Goodarzi, M.O.
Kathiresan, S.
Meigs, J.B.
Ehm, M.G.
Wareham, N.J.
Waterworth, D.M.
(2016). A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. Sci transl med,
Vol.8
(341),
p. 341ra76.
show abstract
full text
Regulatory authorities have indicated that new drugs to treat type 2 diabetes (T2D) should not be associated with an unacceptable increase in cardiovascular risk. Human genetics may be able to guide development of antidiabetic therapies by predicting cardiovascular and other health endpoints. We therefore investigated the association of variants in six genes that encode drug targets for obesity or T2D with a range of metabolic traits in up to 11,806 individuals by targeted exome sequencing and follow-up in 39,979 individuals by targeted genotyping, with additional in silico follow-up in consortia. We used these data to first compare associations of variants in genes encoding drug targets with the effects of pharmacological manipulation of those targets in clinical trials. We then tested the association of those variants with disease outcomes, including coronary heart disease, to predict cardiovascular safety of these agents. A low-frequency missense variant (Ala316Thr; rs10305492) in the gene encoding glucagon-like peptide-1 receptor (GLP1R), the target of GLP1R agonists, was associated with lower fasting glucose and T2D risk, consistent with GLP1R agonist therapies. The minor allele was also associated with protection against heart disease, thus providing evidence that GLP1R agonists are not likely to be associated with an unacceptable increase in cardiovascular risk. Our results provide an encouraging signal that these agents may be associated with benefit, a question currently being addressed in randomized controlled trials. Genetic variants associated with metabolic traits and multiple disease outcomes can be used to validate therapeutic targets at an early stage in the drug development process..
Fehringer, G.
Kraft, P.
Pharoah, P.D.
Eeles, R.A.
Chatterjee, N.
Schumacher, F.R.
Schildkraut, J.M.
Lindström, S.
Brennan, P.
Bickeböller, H.
Houlston, R.S.
Landi, M.T.
Caporaso, N.
Risch, A.
Amin Al Olama, A.
Berndt, S.I.
Giovannucci, E.L.
Grönberg, H.
Kote-Jarai, Z.
Ma, J.
Muir, K.
Stampfer, M.J.
Stevens, V.L.
Wiklund, F.
Willett, W.C.
Goode, E.L.
Permuth, J.B.
Risch, H.A.
Reid, B.M.
Bezieau, S.
Brenner, H.
Chan, A.T.
Chang-Claude, J.
Hudson, T.J.
Kocarnik, J.K.
Newcomb, P.A.
Schoen, R.E.
Slattery, M.L.
White, E.
Adank, M.A.
Ahsan, H.
Aittomäki, K.
Baglietto, L.
Blomquist, C.
Canzian, F.
Czene, K.
Dos-Santos-Silva, I.
Eliassen, A.H.
Figueroa, J.D.
Flesch-Janys, D.
Fletcher, O.
Garcia-Closas, M.
Gaudet, M.M.
Johnson, N.
Hall, P.
Hazra, A.
Hein, R.
Hofman, A.
Hopper, J.L.
Irwanto, A.
Johansson, M.
Kaaks, R.
Kibriya, M.G.
Lichtner, P.
Liu, J.
Lund, E.
Makalic, E.
Meindl, A.
Müller-Myhsok, B.
Muranen, T.A.
Nevanlinna, H.
Peeters, P.H.
Peto, J.
Prentice, R.L.
Rahman, N.
Sanchez, M.J.
Schmidt, D.F.
Schmutzler, R.K.
Southey, M.C.
Tamimi, R.
Travis, R.C.
Turnbull, C.
Uitterlinden, A.G.
Wang, Z.
Whittemore, A.S.
Yang, X.R.
Zheng, W.
Buchanan, D.D.
Casey, G.
Conti, D.V.
Edlund, C.K.
Gallinger, S.
Haile, R.W.
Jenkins, M.
Le Marchand, L.
Li, L.
Lindor, N.M.
Schmit, S.L.
Thibodeau, S.N.
Woods, M.O.
Rafnar, T.
Gudmundsson, J.
Stacey, S.N.
Stefansson, K.
Sulem, P.
Chen, Y.A.
Tyrer, J.P.
Christiani, D.C.
Wei, Y.
Shen, H.
Hu, Z.
Shu, X.-.
Shiraishi, K.
Takahashi, A.
Bossé, Y.
Obeidat, M.
Nickle, D.
Timens, W.
Freedman, M.L.
Li, Q.
Seminara, D.
Chanock, S.J.
Gong, J.
Peters, U.
Gruber, S.B.
Amos, C.I.
Sellers, T.A.
Easton, D.F.
Hunter, D.J.
Haiman, C.A.
Henderson, B.E.
Hung, R.J.
Ovarian Cancer Association Consortium (OCAC),
PRACTICAL Consortium,
Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON),
Colorectal Transdisciplinary (CORECT) Study,
African American Breast Cancer Consortium (AABC) and African Ancestry Prostate Cancer Consortium (AAPC),
(2016). Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations. Cancer res,
Vol.76
(17),
pp. 5103-5114.
show abstract
full text
Identifying genetic variants with pleiotropic associations can uncover common pathways influencing multiple cancers. We took a two-stage approach to conduct genome-wide association studies for lung, ovary, breast, prostate, and colorectal cancer from the GAME-ON/GECCO Network (61,851 cases, 61,820 controls) to identify pleiotropic loci. Findings were replicated in independent association studies (55,789 cases, 330,490 controls). We identified a novel pleiotropic association at 1q22 involving breast and lung squamous cell carcinoma, with eQTL analysis showing an association with ADAM15/THBS3 gene expression in lung. We also identified a known breast cancer locus CASP8/ALS2CR12 associated with prostate cancer, a known cancer locus at CDKN2B-AS1 with different variants associated with lung adenocarcinoma and prostate cancer, and confirmed the associations of a breast BRCA2 locus with lung and serous ovarian cancer. This is the largest study to date examining pleiotropy across multiple cancer-associated loci, identifying common mechanisms of cancer development and progression. Cancer Res; 76(17); 5103-14. ©2016 AACR..
Bonilla, C.
Lewis, S.J.
Martin, R.M.
Donovan, J.L.
Hamdy, F.C.
Neal, D.E.
Eeles, R.
Easton, D.
Kote-Jarai, Z.
Al Olama, A.A.
Benlloch, S.
Muir, K.
Giles, G.G.
Wiklund, F.
Gronberg, H.
Haiman, C.A.
Schleutker, J.
Nordestgaard, B.G.
Travis, R.C.
Pashayan, N.
Khaw, K.-.
Stanford, J.L.
Blot, W.J.
Thibodeau, S.
Maier, C.
Kibel, A.S.
Cybulski, C.
Cannon-Albright, L.
Brenner, H.
Park, J.
Kaneva, R.
Batra, J.
Teixeira, M.R.
Pandha, H.
Lathrop, M.
Davey Smith, G.
PRACTICAL consortium,
(2016). Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort. Bmc med,
Vol.14,
p. 66.
show abstract
full text
BACKGROUND: Epidemiological studies have observed a positive association between an earlier age at sexual development and prostate cancer, but markers of sexual maturation in boys are imprecise and observational estimates are likely to suffer from a degree of uncontrolled confounding. To obtain causal estimates, we examined the role of pubertal development in prostate cancer using genetic polymorphisms associated with Tanner stage in adolescent boys in a Mendelian randomization (MR) approach. METHODS: We derived a weighted genetic risk score for pubertal development, combining 13 SNPs associated with male Tanner stage. A higher score indicated a later puberty onset. We examined the association of this score with prostate cancer risk, stage and grade in the UK-based ProtecT case-control study (n = 2,927), and used the PRACTICAL consortium (n = 43,737) as a replication sample. RESULTS: In ProtecT, the puberty genetic score was inversely associated with prostate cancer grade (odds ratio (OR) of high- vs. low-grade cancer, per tertile of the score: 0.76; 95 % CI, 0.64-0.89). In an instrumental variable estimation of the causal OR, later physical development in adolescence (equivalent to a difference of one Tanner stage between pubertal boys of the same age) was associated with a 77 % (95 % CI, 43-91 %) reduced odds of high Gleason prostate cancer. In PRACTICAL, the puberty genetic score was associated with prostate cancer stage (OR of advanced vs. localized cancer, per tertile: 0.95; 95 % CI, 0.91-1.00) and prostate cancer-specific mortality (hazard ratio amongst cases, per tertile: 0.94; 95 % CI, 0.90-0.98), but not with disease grade. CONCLUSIONS: Older age at sexual maturation is causally linked to a reduced risk of later prostate cancer, especially aggressive disease..
Bull, C.J.
Bonilla, C.
Holly, J.M.
Perks, C.M.
Davies, N.
Haycock, P.
Yu, O.H.
Richards, J.B.
Eeles, R.
Easton, D.
Kote-Jarai, Z.
Amin Al Olama, A.
Benlloch, S.
Muir, K.
Giles, G.G.
MacInnis, R.J.
Wiklund, F.
Gronberg, H.
Haiman, C.A.
Schleutker, J.
Nordestgaard, B.G.
Travis, R.C.
Neal, D.
Pashayan, N.
Khaw, K.-.
Stanford, J.L.
Blot, W.J.
Thibodeau, S.
Maier, C.
Kibel, A.S.
Cybulski, C.
Cannon-Albright, L.
Brenner, H.
Park, J.
Kaneva, R.
Batra, J.
Teixeira, M.R.
Micheal, A.
Pandha, H.
Smith, G.D.
Lewis, S.J.
Martin, R.M.
PRACTICAL consortium,
(2016). Blood lipids and prostate cancer: a Mendelian randomization analysis. Cancer med,
Vol.5
(6),
pp. 1125-1136.
show abstract
full text
Genetic risk scores were used as unconfounded instruments for specific lipid traits (Mendelian randomization) to assess whether circulating lipids causally influence prostate cancer risk. Data from 22,249 prostate cancer cases and 22,133 controls from 22 studies within the international PRACTICAL consortium were analyzed. Allele scores based on single nucleotide polymorphisms (SNPs) previously reported to be uniquely associated with each of low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglyceride (TG) levels, were first validated in an independent dataset, and then entered into logistic regression models to estimate the presence (and direction) of any causal effect of each lipid trait on prostate cancer risk. There was weak evidence for an association between the LDL genetic score and cancer grade: the odds ratio (OR) per genetically instrumented standard deviation (SD) in LDL, comparing high- (≥7 Gleason score) versus low-grade (<7 Gleason score) cancers was 1.50 (95% CI: 0.92, 2.46; P = 0.11). A genetically instrumented SD increase in TGs was weakly associated with stage: the OR for advanced versus localized cancer per unit increase in genetic risk score was 1.68 (95% CI: 0.95, 3.00; P = 0.08). The rs12916-T variant in 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) was inversely associated with prostate cancer (OR: 0.97; 95% CI: 0.94, 1.00; P = 0.03). In conclusion, circulating lipids, instrumented by our genetic risk scores, did not appear to alter prostate cancer risk. We found weak evidence that higher LDL and TG levels increase aggressive prostate cancer risk, and that a variant in HMGCR (that mimics the LDL lowering effect of statin drugs) reduces risk. However, inferences are limited by sample size and evidence of pleiotropy..
Castro, E.
Mikropoulos, C.
Bancroft, E.K.
Dadaev, T.
Goh, C.
Taylor, N.
Saunders, E.
Borley, N.
Keating, D.
Page, E.C.
Saya, S.
Hazell, S.
Livni, N.
deSouza, N.
Neal, D.
Hamdy, F.C.
Kumar, P.
Antoniou, A.C.
Kote-Jarai, Z.
PROFILE Study Steering Committee,
Eeles, R.A.
(2016). The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer. Oncologist,
Vol.21
(6),
pp. 716-722.
show abstract
full text
BACKGROUND: A better assessment of individualized prostate cancer (PrCa) risk is needed to improve screening. The use of the prostate-specific antigen (PSA) level for screening in the general population has limitations and is not currently advocated. Approximately 100 common single nucleotide polymorphisms (SNPs) have been identified that are associated with the risk of developing PrCa. The PROFILE pilot study explored the feasibility of using SNP profiling in men with a family history (FH) of PrCa to investigate the probability of detecting PrCa at prostate biopsy (PB). The primary aim of this pilot study was to determine the safety and feasibility of PrCa screening using transrectal ultrasound-guided PB with or without diffusion-weighted magnetic resonance imaging (DW-MRI) in men with a FH. A secondary aim was to evaluate the potential use of SNP profiling as a screening tool in this population. PATIENTS AND METHODS: A total of 100 men aged 40-69 years with a FH of PrCa underwent PB, regardless of their baseline PSA level. Polygenic risk scores (PRSs) were calculated for each participant using 71 common PrCa susceptibility alleles. We treated the disease outcome at PB as the outcome variable and evaluated its associations with the PRS, PSA level, and DW-MRI findings using univariate logistic regression. RESULTS: Of the 100 men, 25 were diagnosed with PrCa, of whom 12 (48%) had clinically significant disease. Four adverse events occurred and no deaths. The PSA level and age at study entry were associated with PrCa at PB (p = .00037 and p = .00004, respectively). CONCLUSION: The results of the present pilot study have demonstrated that PB is a feasible and safe method of PrCa screening in men with a FH, with a high proportion of PrCa identified requiring radical treatment. It is feasible to collect data on PrCa-risk SNPs to evaluate their combined effect as a potential screening tool. A larger prospective study powered to detect statistical associations is in progress. IMPLICATIONS FOR PRACTICE: Prostate biopsy is a feasible and safe approach to prostate cancer screening in men with a family history and detects a high proportion of prostate cancer that needs radical treatment. Calculating a polygenic risk score using prostate cancer risk single nucleotide polymorphisms could be a potential future screening tool for prostate cancer..
Ioannidis, N.M.
Rothstein, J.H.
Pejaver, V.
Middha, S.
McDonnell, S.K.
Baheti, S.
Musolf, A.
Li, Q.
Holzinger, E.
Karyadi, D.
Cannon-Albright, L.A.
Teerlink, C.C.
Stanford, J.L.
Isaacs, W.B.
Xu, J.
Cooney, K.A.
Lange, E.M.
Schleutker, J.
Carpten, J.D.
Powell, I.J.
Cussenot, O.
Cancel-Tassin, G.
Giles, G.G.
MacInnis, R.J.
Maier, C.
Hsieh, C.-.
Wiklund, F.
Catalona, W.J.
Foulkes, W.D.
Mandal, D.
Eeles, R.A.
Kote-Jarai, Z.
Bustamante, C.D.
Schaid, D.J.
Hastie, T.
Ostrander, E.A.
Bailey-Wilson, J.E.
Radivojac, P.
Thibodeau, S.N.
Whittemore, A.S.
Sieh, W.
(2016). REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. Am j hum genet,
Vol.99
(4),
pp. 877-885.
show abstract
full text
The vast majority of coding variants are rare, and assessment of the contribution of rare variants to complex traits is hampered by low statistical power and limited functional data. Improved methods for predicting the pathogenicity of rare coding variants are needed to facilitate the discovery of disease variants from exome sequencing studies. We developed REVEL (rare exome variant ensemble learner), an ensemble method for predicting the pathogenicity of missense variants on the basis of individual tools: MutPred, FATHMM, VEST, PolyPhen, SIFT, PROVEAN, MutationAssessor, MutationTaster, LRT, GERP, SiPhy, phyloP, and phastCons. REVEL was trained with recently discovered pathogenic and rare neutral missense variants, excluding those previously used to train its constituent tools. When applied to two independent test sets, REVEL had the best overall performance (p < 10-12) as compared to any individual tool and seven ensemble methods: MetaSVM, MetaLR, KGGSeq, Condel, CADD, DANN, and Eigen. Importantly, REVEL also had the best performance for distinguishing pathogenic from rare neutral variants with allele frequencies <0.5%. The area under the receiver operating characteristic curve (AUC) for REVEL was 0.046-0.182 higher in an independent test set of 935 recent SwissVar disease variants and 123,935 putatively neutral exome sequencing variants and 0.027-0.143 higher in an independent test set of 1,953 pathogenic and 2,406 benign variants recently reported in ClinVar than the AUCs for other ensemble methods. We provide pre-computed REVEL scores for all possible human missense variants to facilitate the identification of pathogenic variants in the sea of rare variants discovered as sequencing studies expand in scale..
Gusev, A.
Shi, H.
Kichaev, G.
Pomerantz, M.
Li, F.
Long, H.W.
Ingles, S.A.
Kittles, R.A.
Strom, S.S.
Rybicki, B.A.
Nemesure, B.
Isaacs, W.B.
Zheng, W.
Pettaway, C.A.
Yeboah, E.D.
Tettey, Y.
Biritwum, R.B.
Adjei, A.A.
Tay, E.
Truelove, A.
Niwa, S.
Chokkalingam, A.P.
John, E.M.
Murphy, A.B.
Signorello, L.B.
Carpten, J.
Leske, M.C.
Wu, S.-.
Hennis, A.J.
Neslund-Dudas, C.
Hsing, A.W.
Chu, L.
Goodman, P.J.
Klein, E.A.
Witte, J.S.
Casey, G.
Kaggwa, S.
Cook, M.B.
Stram, D.O.
Blot, W.J.
Eeles, R.A.
Easton, D.
Kote-Jarai, Z.
Al Olama, A.A.
Benlloch, S.
Muir, K.
Giles, G.G.
Southey, M.C.
Fitzgerald, L.M.
Gronberg, H.
Wiklund, F.
Aly, M.
Henderson, B.E.
Schleutker, J.
Wahlfors, T.
Tammela, T.L.
Nordestgaard, B.G.
Key, T.J.
Travis, R.C.
Neal, D.E.
Donovan, J.L.
Hamdy, F.C.
Pharoah, P.
Pashayan, N.
Khaw, K.-.
Stanford, J.L.
Thibodeau, S.N.
McDonnell, S.K.
Schaid, D.J.
Maier, C.
Vogel, W.
Luedeke, M.
Herkommer, K.
Kibel, A.S.
Cybulski, C.
Wokolorczyk, D.
Kluzniak, W.
Cannon-Albright, L.
Teerlink, C.
Brenner, H.
Dieffenbach, A.K.
Arndt, V.
Park, J.Y.
Sellers, T.A.
Lin, H.-.
Slavov, C.
Kaneva, R.
Mitev, V.
Batra, J.
Spurdle, A.
Clements, J.A.
Teixeira, M.R.
Pandha, H.
Michael, A.
Paulo, P.
Maia, S.
Kierzek, A.
PRACTICAL consortium,
Conti, D.V.
Albanes, D.
Berg, C.
Berndt, S.I.
Campa, D.
Crawford, E.D.
Diver, W.R.
Gapstur, S.M.
Gaziano, J.M.
Giovannucci, E.
Hoover, R.
Hunter, D.J.
Johansson, M.
Kraft, P.
Le Marchand, L.
Lindström, S.
Navarro, C.
Overvad, K.
Riboli, E.
Siddiq, A.
Stevens, V.L.
Trichopoulos, D.
Vineis, P.
Yeager, M.
Trynka, G.
Raychaudhuri, S.
Schumacher, F.R.
Price, A.L.
Freedman, M.L.
Haiman, C.A.
Pasaniuc, B.
(2016). Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. Nat commun,
Vol.7,
p. 10979.
show abstract
full text
Although genome-wide association studies have identified over 100 risk loci that explain ∼33% of familial risk for prostate cancer (PrCa), their functional effects on risk remain largely unknown. Here we use genotype data from 59,089 men of European and African American ancestries combined with cell-type-specific epigenetic data to build a genomic atlas of single-nucleotide polymorphism (SNP) heritability in PrCa. We find significant differences in heritability between variants in prostate-relevant epigenetic marks defined in normal versus tumour tissue as well as between tissue and cell lines. The majority of SNP heritability lies in regions marked by H3k27 acetylation in prostate adenoc7arcinoma cell line (LNCaP) or by DNaseI hypersensitive sites in cancer cell lines. We find a high degree of similarity between European and African American ancestries suggesting a similar genetic architecture from common variation underlying PrCa risk. Our findings showcase the power of integrating functional annotation with genetic data to understand the genetic basis of PrCa..
Teerlink, C.C.
Leongamornlert, D.
Dadaev, T.
Thomas, A.
Farnham, J.
Stephenson, R.A.
Riska, S.
McDonnell, S.K.
Schaid, D.J.
Catalona, W.J.
Zheng, S.L.
Cooney, K.A.
Ray, A.M.
Zuhlke, K.A.
Lange, E.M.
Giles, G.G.
Southey, M.C.
Fitzgerald, L.M.
Rinckleb, A.
Luedeke, M.
Maier, C.
Stanford, J.L.
Ostrander, E.A.
Kaikkonen, E.M.
Sipeky, C.
Tammela, T.
Schleutker, J.
Wiley, K.E.
Isaacs, S.D.
Walsh, P.C.
Isaacs, W.B.
Xu, J.
Cancel-Tassin, G.
Cussenot, O.
Mandal, D.
Laurie, C.
Laurie, C.
PRACTICAL consortium,
International Consortium for Prostate Cancer Genetics,
Thibodeau, S.N.
Eeles, R.A.
Kote-Jarai, Z.
Cannon-Albright, L.
(2016). Genome-wide association of familial prostate cancer cases identifies evidence for a rare segregating haplotype at 8q24 21. Hum genet,
Vol.135
(8),
pp. 923-938.
show abstract
full text
Previous genome-wide association studies (GWAS) of prostate cancer risk focused on cases unselected for family history and have reported over 100 significant associations. The International Consortium for Prostate Cancer Genetics (ICPCG) has now performed a GWAS of 2511 (unrelated) familial prostate cancer cases and 1382 unaffected controls from 12 member sites. All samples were genotyped on the Illumina 5M+exome single nucleotide polymorphism (SNP) platform. The GWAS identified a significant evidence for association for SNPs in six regions previously associated with prostate cancer in population-based cohorts, including 3q26.2, 6q25.3, 8q24.21, 10q11.23, 11q13.3, and 17q12. Of note, SNP rs138042437 (p = 1.7e(-8)) at 8q24.21 achieved a large estimated effect size in this cohort (odds ratio = 13.3). 116 previously sampled affected relatives of 62 risk-allele carriers from the GWAS cohort were genotyped for this SNP, identifying 78 additional affected carriers in 62 pedigrees. A test for an excess number of affected carriers among relatives exhibited strong evidence for co-segregation of the variant with disease (p = 8.5e(-11)). The majority (92 %) of risk-allele carriers at rs138042437 had a consistent estimated haplotype spanning approximately 100 kb of 8q24.21 that contained the minor alleles of three rare SNPs (dosage minor allele frequencies <1.7 %), rs183373024 (PRNCR1), previously associated SNP rs188140481, and rs138042437 (CASC19). Strong evidence for co-segregation of a SNP on the haplotype further characterizes the haplotype as a prostate cancer predisposition locus..
Larson, N.B.
McDonnell, S.
Albright, L.C.
Teerlink, C.
Stanford, J.
Ostrander, E.A.
Isaacs, W.B.
Xu, J.
Cooney, K.A.
Lange, E.
Schleutker, J.
Carpten, J.D.
Powell, I.
Bailey-Wilson, J.
Cussenot, O.
Cancel-Tassin, G.
Giles, G.
MacInnis, R.
Maier, C.
Whittemore, A.S.
Hsieh, C.-.
Wiklund, F.
Catalona, W.J.
Foulkes, W.
Mandal, D.
Eeles, R.
Kote-Jarai, Z.
Ackerman, M.J.
Olson, T.M.
Klein, C.J.
Thibodeau, S.N.
Schaid, D.J.
(2016). Post hoc Analysis for Detecting Individual Rare Variant Risk Associations Using Probit Regression Bayesian Variable Selection Methods in Case-Control Sequencing Studies. Genet epidemiol,
Vol.40
(6),
pp. 461-469.
show abstract
full text
Rare variants (RVs) have been shown to be significant contributors to complex disease risk. By definition, these variants have very low minor allele frequencies and traditional single-marker methods for statistical analysis are underpowered for typical sequencing study sample sizes. Multimarker burden-type approaches attempt to identify aggregation of RVs across case-control status by analyzing relatively small partitions of the genome, such as genes. However, it is generally the case that the aggregative measure would be a mixture of causal and neutral variants, and these omnibus tests do not directly provide any indication of which RVs may be driving a given association. Recently, Bayesian variable selection approaches have been proposed to identify RV associations from a large set of RVs under consideration. Although these approaches have been shown to be powerful at detecting associations at the RV level, there are often computational limitations on the total quantity of RVs under consideration and compromises are necessary for large-scale application. Here, we propose a computationally efficient alternative formulation of this method using a probit regression approach specifically capable of simultaneously analyzing hundreds to thousands of RVs. We evaluate our approach to detect causal variation on simulated data and examine sensitivity and specificity in instances of high RV dimensionality as well as apply it to pathway-level RV analysis results from a prostate cancer (PC) risk case-control sequencing study. Finally, we discuss potential extensions and future directions of this work..
Kar, S.P.
Beesley, J.
Amin Al Olama, A.
Michailidou, K.
Tyrer, J.
Kote-Jarai, Z.
Lawrenson, K.
Lindstrom, S.
Ramus, S.J.
Thompson, D.J.
ABCTB Investigators,
Kibel, A.S.
Dansonka-Mieszkowska, A.
Michael, A.
Dieffenbach, A.K.
Gentry-Maharaj, A.
Whittemore, A.S.
Wolk, A.
Monteiro, A.
Peixoto, A.
Kierzek, A.
Cox, A.
Rudolph, A.
Gonzalez-Neira, A.
Wu, A.H.
Lindblom, A.
Swerdlow, A.
AOCS Study Group & Australian Cancer Study (Ovarian Cancer),
APCB BioResource,
Ziogas, A.
Ekici, A.B.
Burwinkel, B.
Karlan, B.Y.
Nordestgaard, B.G.
Blomqvist, C.
Phelan, C.
McLean, C.
Pearce, C.L.
Vachon, C.
Cybulski, C.
Slavov, C.
Stegmaier, C.
Maier, C.
Ambrosone, C.B.
Høgdall, C.K.
Teerlink, C.C.
Kang, D.
Tessier, D.C.
Schaid, D.J.
Stram, D.O.
Cramer, D.W.
Neal, D.E.
Eccles, D.
Flesch-Janys, D.
Edwards, D.R.
Wokozorczyk, D.
Levine, D.A.
Yannoukakos, D.
Sawyer, E.J.
Bandera, E.V.
Poole, E.M.
Goode, E.L.
Khusnutdinova, E.
Høgdall, E.
Song, F.
Bruinsma, F.
Heitz, F.
Modugno, F.
Hamdy, F.C.
Wiklund, F.
Giles, G.G.
Olsson, H.
Wildiers, H.
Ulmer, H.-.
Pandha, H.
Risch, H.A.
Darabi, H.
Salvesen, H.B.
Nevanlinna, H.
Gronberg, H.
Brenner, H.
Brauch, H.
Anton-Culver, H.
Song, H.
Lim, H.-.
McNeish, I.
Campbell, I.
Vergote, I.
Gronwald, J.
Lubiński, J.
Stanford, J.L.
Benítez, J.
Doherty, J.A.
Permuth, J.B.
Chang-Claude, J.
Donovan, J.L.
Dennis, J.
Schildkraut, J.M.
Schleutker, J.
Hopper, J.L.
Kupryjanczyk, J.
Park, J.Y.
Figueroa, J.
Clements, J.A.
Knight, J.A.
Peto, J.
Cunningham, J.M.
Pow-Sang, J.
Batra, J.
Czene, K.
Lu, K.H.
Herkommer, K.
Khaw, K.-.
kConFab Investigators,
Matsuo, K.
Muir, K.
Offitt, K.
Chen, K.
Moysich, K.B.
Aittomäki, K.
Odunsi, K.
Kiemeney, L.A.
Massuger, L.F.
Fitzgerald, L.M.
Cook, L.S.
Cannon-Albright, L.
Hooning, M.J.
Pike, M.C.
Bolla, M.K.
Luedeke, M.
Teixeira, M.R.
Goodman, M.T.
Schmidt, M.K.
Riggan, M.
Aly, M.
Rossing, M.A.
Beckmann, M.W.
Moisse, M.
Sanderson, M.
Southey, M.C.
Jones, M.
Lush, M.
Hildebrandt, M.A.
Hou, M.-.
Schoemaker, M.J.
Garcia-Closas, M.
Bogdanova, N.
Rahman, N.
NBCS Investigators,
Le, N.D.
Orr, N.
Wentzensen, N.
Pashayan, N.
Peterlongo, P.
Guénel, P.
Brennan, P.
Paulo, P.
Webb, P.M.
Broberg, P.
Fasching, P.A.
Devilee, P.
Wang, Q.
Cai, Q.
Li, Q.
Kaneva, R.
Butzow, R.
Kopperud, R.K.
Schmutzler, R.K.
Stephenson, R.A.
MacInnis, R.J.
Hoover, R.N.
Winqvist, R.
Ness, R.
Milne, R.L.
Travis, R.C.
Benlloch, S.
Olson, S.H.
McDonnell, S.K.
Tworoger, S.S.
Maia, S.
Berndt, S.
Lee, S.C.
Teo, S.-.
Thibodeau, S.N.
Bojesen, S.E.
Gapstur, S.M.
Kjær, S.K.
Pejovic, T.
Tammela, T.L.
GENICA Network,
PRACTICAL consortium,
Dörk, T.
Brüning, T.
Wahlfors, T.
Key, T.J.
Edwards, T.L.
Menon, U.
Hamann, U.
Mitev, V.
Kosma, V.-.
Setiawan, V.W.
Kristensen, V.
Arndt, V.
Vogel, W.
Zheng, W.
Sieh, W.
Blot, W.J.
Kluzniak, W.
Shu, X.-.
Gao, Y.-.
Schumacher, F.
Freedman, M.L.
Berchuck, A.
Dunning, A.M.
Simard, J.
Haiman, C.A.
Spurdle, A.
Sellers, T.A.
Hunter, D.J.
Henderson, B.E.
Kraft, P.
Chanock, S.J.
Couch, F.J.
Hall, P.
Gayther, S.A.
Easton, D.F.
Chenevix-Trench, G.
Eeles, R.
Pharoah, P.D.
Lambrechts, D.
(2016). Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer discov,
Vol.6
(9),
pp. 1052-1067.
show abstract
full text
UNLABELLED: Breast, ovarian, and prostate cancers are hormone-related and may have a shared genetic basis, but this has not been investigated systematically by genome-wide association (GWA) studies. Meta-analyses combining the largest GWA meta-analysis data sets for these cancers totaling 112,349 cases and 116,421 controls of European ancestry, all together and in pairs, identified at P < 10(-8) seven new cross-cancer loci: three associated with susceptibility to all three cancers (rs17041869/2q13/BCL2L11; rs7937840/11q12/INCENP; rs1469713/19p13/GATAD2A), two breast and ovarian cancer risk loci (rs200182588/9q31/SMC2; rs8037137/15q26/RCCD1), and two breast and prostate cancer risk loci (rs5013329/1p34/NSUN4; rs9375701/6q23/L3MBTL3). Index variants in five additional regions previously associated with only one cancer also showed clear association with a second cancer type. Cell-type-specific expression quantitative trait locus and enhancer-gene interaction annotations suggested target genes with potential cross-cancer roles at the new loci. Pathway analysis revealed significant enrichment of death receptor signaling genes near loci with P < 10(-5) in the three-cancer meta-analysis. SIGNIFICANCE: We demonstrate that combining large-scale GWA meta-analysis findings across cancer types can identify completely new risk loci common to breast, ovarian, and prostate cancers. We show that the identification of such cross-cancer risk loci has the potential to shed new light on the shared biology underlying these hormone-related cancers. Cancer Discov; 6(9); 1052-67. ©2016 AACR.This article is highlighted in the In This Issue feature, p. 932..
Saunders, E.J.
Dadaev, T.
Leongamornlert, D.A.
Al Olama, A.A.
Benlloch, S.
Giles, G.G.
Wiklund, F.
Gronberg, H.
Haiman, C.A.
Schleutker, J.
Nordestgaard, B.G.
Travis, R.C.
Neal, D.
Pasayan, N.
Khaw, K.-.
Stanford, J.L.
Blot, W.J.
Thibodeau, S.N.
Maier, C.
Kibel, A.S.
Cybulski, C.
Cannon-Albright, L.
Brenner, H.
Park, J.Y.
Kaneva, R.
Batra, J.
Teixeira, M.R.
Pandha, H.
Govindasami, K.
Muir, K.
UK Genetic Prostate Cancer Study Collaborators,
UK ProtecT Study Collaborators,
PRACTICAL Consortium,
Easton, D.F.
Eeles, R.A.
Kote-Jarai, Z.
(2016). Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array. Br j cancer,
Vol.114
(8),
pp. 945-952.
show abstract
full text
BACKGROUND: Germline mutations within DNA-repair genes are implicated in susceptibility to multiple forms of cancer. For prostate cancer (PrCa), rare mutations in BRCA2 and BRCA1 give rise to moderately elevated risk, whereas two of B100 common, low-penetrance PrCa susceptibility variants identified so far by genome-wide association studies implicate RAD51B and RAD23B. METHODS: Genotype data from the iCOGS array were imputed to the 1000 genomes phase 3 reference panel for 21 780 PrCa cases and 21 727 controls from the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) consortium. We subsequently performed single variant, gene and pathway-level analyses using 81 303 SNPs within 20 Kb of a panel of 179 DNA-repair genes. RESULTS: Single SNP analyses identified only the previously reported association with RAD51B. Gene-level analyses using the SKAT-C test from the SNP-set (Sequence) Kernel Association Test (SKAT) identified a significant association with PrCa for MSH5. Pathway-level analyses suggested a possible role for the translesion synthesis pathway in PrCa risk and Homologous recombination/Fanconi Anaemia pathway for PrCa aggressiveness, even though after adjustment for multiple testing these did not remain significant. CONCLUSIONS: MSH5 is a novel candidate gene warranting additional follow-up as a prospective PrCa-risk locus. MSH5 has previously been reported as a pleiotropic susceptibility locus for lung, colorectal and serous ovarian cancers..
Southey, M.C.
Goldgar, D.E.
Winqvist, R.
Pylkäs, K.
Couch, F.
Tischkowitz, M.
Foulkes, W.D.
Dennis, J.
Michailidou, K.
van Rensburg, E.J.
Heikkinen, T.
Nevanlinna, H.
Hopper, J.L.
Dörk, T.
Claes, K.B.
Reis-Filho, J.
Teo, Z.L.
Radice, P.
Catucci, I.
Peterlongo, P.
Tsimiklis, H.
Odefrey, F.A.
Dowty, J.G.
Schmidt, M.K.
Broeks, A.
Hogervorst, F.B.
Verhoef, S.
Carpenter, J.
Clarke, C.
Scott, R.J.
Fasching, P.A.
Haeberle, L.
Ekici, A.B.
Beckmann, M.W.
Peto, J.
Dos-Santos-Silva, I.
Fletcher, O.
Johnson, N.
Bolla, M.K.
Sawyer, E.J.
Tomlinson, I.
Kerin, M.J.
Miller, N.
Marme, F.
Burwinkel, B.
Yang, R.
Guénel, P.
Truong, T.
Menegaux, F.
Sanchez, M.
Bojesen, S.
Nielsen, S.F.
Flyger, H.
Benitez, J.
Zamora, M.P.
Perez, J.I.
Menéndez, P.
Anton-Culver, H.
Neuhausen, S.
Ziogas, A.
Clarke, C.A.
Brenner, H.
Arndt, V.
Stegmaier, C.
Brauch, H.
Brüning, T.
Ko, Y.-.
Muranen, T.A.
Aittomäki, K.
Blomqvist, C.
Bogdanova, N.V.
Antonenkova, N.N.
Lindblom, A.
Margolin, S.
Mannermaa, A.
Kataja, V.
Kosma, V.-.
Hartikainen, J.M.
Spurdle, A.B.
Investigators, K.
Australian Ovarian Cancer Study Group,
Wauters, E.
Smeets, D.
Beuselinck, B.
Floris, G.
Chang-Claude, J.
Rudolph, A.
Seibold, P.
Flesch-Janys, D.
Olson, J.E.
Vachon, C.
Pankratz, V.S.
McLean, C.
Haiman, C.A.
Henderson, B.E.
Schumacher, F.
Le Marchand, L.
Kristensen, V.
Alnæs, G.G.
Zheng, W.
Hunter, D.J.
Lindstrom, S.
Hankinson, S.E.
Kraft, P.
Andrulis, I.
Knight, J.A.
Glendon, G.
Mulligan, A.M.
Jukkola-Vuorinen, A.
Grip, M.
Kauppila, S.
Devilee, P.
Tollenaar, R.A.
Seynaeve, C.
Hollestelle, A.
Garcia-Closas, M.
Figueroa, J.
Chanock, S.J.
Lissowska, J.
Czene, K.
Darabi, H.
Eriksson, M.
Eccles, D.M.
Rafiq, S.
Tapper, W.J.
Gerty, S.M.
Hooning, M.J.
Martens, J.W.
Collée, J.M.
Tilanus-Linthorst, M.
Hall, P.
Li, J.
Brand, J.S.
Humphreys, K.
Cox, A.
Reed, M.W.
Luccarini, C.
Baynes, C.
Dunning, A.M.
Hamann, U.
Torres, D.
Ulmer, H.U.
Rüdiger, T.
Jakubowska, A.
Lubinski, J.
Jaworska, K.
Durda, K.
Slager, S.
Toland, A.E.
Ambrosone, C.B.
Yannoukakos, D.
Swerdlow, A.
Ashworth, A.
Orr, N.
Jones, M.
González-Neira, A.
Pita, G.
Alonso, M.R.
Álvarez, N.
Herrero, D.
Tessier, D.C.
Vincent, D.
Bacot, F.
Simard, J.
Dumont, M.
Soucy, P.
Eeles, R.
Muir, K.
Wiklund, F.
Gronberg, H.
Schleutker, J.
Nordestgaard, B.G.
Weischer, M.
Travis, R.C.
Neal, D.
Donovan, J.L.
Hamdy, F.C.
Khaw, K.-.
Stanford, J.L.
Blot, W.J.
Thibodeau, S.
Schaid, D.J.
Kelley, J.L.
Maier, C.
Kibel, A.S.
Cybulski, C.
Cannon-Albright, L.
Butterbach, K.
Park, J.
Kaneva, R.
Batra, J.
Teixeira, M.R.
Kote-Jarai, Z.
Olama, A.A.
Benlloch, S.
Renner, S.P.
Hartmann, A.
Hein, A.
Ruebner, M.
Lambrechts, D.
Van Nieuwenhuysen, E.
Vergote, I.
Lambretchs, S.
Doherty, J.A.
Rossing, M.A.
Nickels, S.
Eilber, U.
Wang-Gohrke, S.
Odunsi, K.
Sucheston-Campbell, L.E.
Friel, G.
Lurie, G.
Killeen, J.L.
Wilkens, L.R.
Goodman, M.T.
Runnebaum, I.
Hillemanns, P.A.
Pelttari, L.M.
Butzow, R.
Modugno, F.
Edwards, R.P.
Ness, R.B.
Moysich, K.B.
du Bois, A.
Heitz, F.
Harter, P.
Kommoss, S.
Karlan, B.Y.
Walsh, C.
Lester, J.
Jensen, A.
Kjaer, S.K.
Høgdall, E.
Peissel, B.
Bonanni, B.
Bernard, L.
Goode, E.L.
Fridley, B.L.
Vierkant, R.A.
Cunningham, J.M.
Larson, M.C.
Fogarty, Z.C.
Kalli, K.R.
Liang, D.
Lu, K.H.
Hildebrandt, M.A.
Wu, X.
Levine, D.A.
Dao, F.
Bisogna, M.
Berchuck, A.
Iversen, E.S.
Marks, J.R.
Akushevich, L.
Cramer, D.W.
Schildkraut, J.
Terry, K.L.
Poole, E.M.
Stampfer, M.
Tworoger, S.S.
Bandera, E.V.
Orlow, I.
Olson, S.H.
Bjorge, L.
Salvesen, H.B.
van Altena, A.M.
Aben, K.K.
Kiemeney, L.A.
Massuger, L.F.
Pejovic, T.
Bean, Y.
Brooks-Wilson, A.
Kelemen, L.E.
Cook, L.S.
Le, N.D.
Górski, B.
Gronwald, J.
Menkiszak, J.
Høgdall, C.K.
Lundvall, L.
Nedergaard, L.
Engelholm, S.A.
Dicks, E.
Tyrer, J.
Campbell, I.
McNeish, I.
Paul, J.
Siddiqui, N.
Glasspool, R.
Whittemore, A.S.
Rothstein, J.H.
McGuire, V.
Sieh, W.
Cai, H.
Shu, X.-.
Teten, R.T.
Sutphen, R.
McLaughlin, J.R.
Narod, S.A.
Phelan, C.M.
Monteiro, A.N.
Fenstermacher, D.
Lin, H.-.
Permuth, J.B.
Sellers, T.A.
Chen, Y.A.
Tsai, Y.-.
Chen, Z.
Gentry-Maharaj, A.
Gayther, S.A.
Ramus, S.J.
Menon, U.
Wu, A.H.
Pearce, C.L.
Van Den Berg, D.
Pike, M.C.
Dansonka-Mieszkowska, A.
Plisiecka-Halasa, J.
Moes-Sosnowska, J.
Kupryjanczyk, J.
Pharoah, P.D.
Song, H.
Winship, I.
Chenevix-Trench, G.
Giles, G.G.
Tavtigian, S.V.
Easton, D.F.
Milne, R.L.
(2016). PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. J med genet,
Vol.53
(12),
pp. 800-811.
show abstract
full text
BACKGROUND: The rarity of mutations in PALB2, CHEK2 and ATM make it difficult to estimate precisely associated cancer risks. Population-based family studies have provided evidence that at least some of these mutations are associated with breast cancer risk as high as those associated with rare BRCA2 mutations. We aimed to estimate the relative risks associated with specific rare variants in PALB2, CHEK2 and ATM via a multicentre case-control study. METHODS: We genotyped 10 rare mutations using the custom iCOGS array: PALB2 c.1592delT, c.2816T>G and c.3113G>A, CHEK2 c.349A>G, c.538C>T, c.715G>A, c.1036C>T, c.1312G>T, and c.1343T>G and ATM c.7271T>G. We assessed associations with breast cancer risk (42 671 cases and 42 164 controls), as well as prostate (22 301 cases and 22 320 controls) and ovarian (14 542 cases and 23 491 controls) cancer risk, for each variant. RESULTS: For European women, strong evidence of association with breast cancer risk was observed for PALB2 c.1592delT OR 3.44 (95% CI 1.39 to 8.52, p=7.1×10-5), PALB2 c.3113G>A OR 4.21 (95% CI 1.84 to 9.60, p=6.9×10-8) and ATM c.7271T>G OR 11.0 (95% CI 1.42 to 85.7, p=0.0012). We also found evidence of association with breast cancer risk for three variants in CHEK2, c.349A>G OR 2.26 (95% CI 1.29 to 3.95), c.1036C>T OR 5.06 (95% CI 1.09 to 23.5) and c.538C>T OR 1.33 (95% CI 1.05 to 1.67) (p≤0.017). Evidence for prostate cancer risk was observed for CHEK2 c.1343T>G OR 3.03 (95% CI 1.53 to 6.03, p=0.0006) for African men and CHEK2 c.1312G>T OR 2.21 (95% CI 1.06 to 4.63, p=0.030) for European men. No evidence of association with ovarian cancer was found for any of these variants. CONCLUSIONS: This report adds to accumulating evidence that at least some variants in these genes are associated with an increased risk of breast cancer that is clinically important..
MacInnis, R.J.
Schmidt, D.F.
Makalic, E.
Severi, G.
FitzGerald, L.M.
Reumann, M.
Kapuscinski, M.K.
Kowalczyk, A.
Zhou, Z.
Goudey, B.
Qian, G.
Bui, Q.M.
Park, D.J.
Freeman, A.
Southey, M.C.
Al Olama, A.A.
Kote-Jarai, Z.
Eeles, R.A.
Hopper, J.L.
Giles, G.G.
UK Genetic Prostate Cancer Study Collaborators,
(2016). Use of a Novel Nonparametric Version of DEPTH to Identify Genomic Regions Associated with Prostate Cancer Risk. Cancer epidemiol biomarkers prev,
Vol.25
(12),
pp. 1619-1624.
show abstract
full text
BACKGROUND: We have developed a genome-wide association study analysis method called DEPTH (DEPendency of association on the number of Top Hits) to identify genomic regions potentially associated with disease by considering overlapping groups of contiguous markers (e.g., SNPs) across the genome. DEPTH is a machine learning algorithm for feature ranking of ultra-high dimensional datasets, built from well-established statistical tools such as bootstrapping, penalized regression, and decision trees. Unlike marginal regression, which considers each SNP individually, the key idea behind DEPTH is to rank groups of SNPs in terms of their joint strength of association with the outcome. Our aim was to compare the performance of DEPTH with that of standard logistic regression analysis. METHODS: We selected 1,854 prostate cancer cases and 1,894 controls from the UK for whom 541,129 SNPs were measured using the Illumina Infinium HumanHap550 array. Confirmation was sought using 4,152 cases and 2,874 controls, ascertained from the UK and Australia, for whom 211,155 SNPs were measured using the iCOGS Illumina Infinium array. RESULTS: From the DEPTH analysis, we identified 14 regions associated with prostate cancer risk that had been reported previously, five of which would not have been identified by conventional logistic regression. We also identified 112 novel putative susceptibility regions. CONCLUSIONS: DEPTH can reveal new risk-associated regions that would not have been identified using a conventional logistic regression analysis of individual SNPs. IMPACT: This study demonstrates that the DEPTH algorithm could identify additional genetic susceptibility regions that merit further investigation. Cancer Epidemiol Biomarkers Prev; 25(12); 1619-24. ©2016 AACR..
Behjati, S.
Gundem, G.
Wedge, D.C.
Roberts, N.D.
Tarpey, P.S.
Cooke, S.L.
Van Loo, P.
Alexandrov, L.B.
Ramakrishna, M.
Davies, H.
Nik-Zainal, S.
Hardy, C.
Latimer, C.
Raine, K.M.
Stebbings, L.
Menzies, A.
Jones, D.
Shepherd, R.
Butler, A.P.
Teague, J.W.
Jorgensen, M.
Khatri, B.
Pillay, N.
Shlien, A.
Futreal, P.A.
Badie, C.
ICGC Prostate Group,
McDermott, U.
Bova, G.S.
Richardson, A.L.
Flanagan, A.M.
Stratton, M.R.
Campbell, P.J.
(2016). Mutational signatures of ionizing radiation in second malignancies. Nat commun,
Vol.7,
p. 12605.
show abstract
full text
Ionizing radiation is a potent carcinogen, inducing cancer through DNA damage. The signatures of mutations arising in human tissues following in vivo exposure to ionizing radiation have not been documented. Here, we searched for signatures of ionizing radiation in 12 radiation-associated second malignancies of different tumour types. Two signatures of somatic mutation characterize ionizing radiation exposure irrespective of tumour type. Compared with 319 radiation-naive tumours, radiation-associated tumours carry a median extra 201 deletions genome-wide, sized 1-100 base pairs often with microhomology at the junction. Unlike deletions of radiation-naive tumours, these show no variation in density across the genome or correlation with sequence context, replication timing or chromatin structure. Furthermore, we observe a significant increase in balanced inversions in radiation-associated tumours. Both small deletions and inversions generate driver mutations. Thus, ionizing radiation generates distinctive mutational signatures that explain its carcinogenic potential..
Dadaev, T.
Leongamornlert, D.A.
Saunders, E.J.
Eeles, R.
Kote-Jarai, Z.
(2016). LocusExplorer: a user-friendly tool for integrated visualization of human genetic association data and biological annotations. Bioinformatics,
Vol.32
(6),
pp. 949-951.
show abstract
full text
UNLABELLED: : In this article, we present LocusExplorer, a data visualization and exploration tool for genetic association data. LocusExplorer is written in R using the Shiny library, providing access to powerful R-based functions through a simple user interface. LocusExplorer allows users to simultaneously display genetic, statistical and biological data for humans in a single image and allows dynamic zooming and customization of the plot features. Publication quality plots may then be produced in a variety of file formats. AVAILABILITY AND IMPLEMENTATION: LocusExplorer is open source and runs through R and a web browser. It is available at www.oncogenetics.icr.ac.uk/LocusExplorer/ or can be installed locally and the source code accessed from https://github.com/oncogenetics/LocusExplorer CONTACT: [email protected]..
Karami, S.
Han, Y.
Pande, M.
Cheng, I.
Rudd, J.
Pierce, B.L.
Nutter, E.L.
Schumacher, F.R.
Kote-Jarai, Z.
Lindstrom, S.
Witte, J.S.
Fang, S.
Han, J.
Kraft, P.
Hunter, D.J.
Song, F.
Hung, R.J.
McKay, J.
Gruber, S.B.
Chanock, S.J.
Risch, A.
Shen, H.
Haiman, C.A.
Boardman, L.
Ulrich, C.M.
Casey, G.
Peters, U.
Amin Al Olama, A.
Berchuck, A.
Berndt, S.I.
Bezieau, S.
Brennan, P.
Brenner, H.
Brinton, L.
Caporaso, N.
Chan, A.T.
Chang-Claude, J.
Christiani, D.C.
Cunningham, J.M.
Easton, D.
Eeles, R.A.
Eisen, T.
Gala, M.
Gallinger, S.J.
Gayther, S.A.
Goode, E.L.
Grönberg, H.
Henderson, B.E.
Houlston, R.
Joshi, A.D.
Küry, S.
Landi, M.T.
Le Marchand, L.
Muir, K.
Newcomb, P.A.
Permuth-Wey, J.
Pharoah, P.
Phelan, C.
Potter, J.D.
Ramus, S.J.
Risch, H.
Schildkraut, J.
Slattery, M.L.
Song, H.
Wentzensen, N.
White, E.
Wiklund, F.
Zanke, B.W.
Sellers, T.A.
Zheng, W.
Chatterjee, N.
Amos, C.I.
Doherty, J.A.
GECCO and the GAME-ON Network: CORECT, DRIVE, ELLIPSE, FOCI, and TRICL,
(2016). Telomere structure and maintenance gene variants and risk of five cancer types. Int j cancer,
Vol.139
(12),
pp. 2655-2670.
show abstract
full text
Telomeres cap chromosome ends, protecting them from degradation, double-strand breaks, and end-to-end fusions. Telomeres are maintained by telomerase, a reverse transcriptase encoded by TERT, and an RNA template encoded by TERC. Loci in the TERT and adjoining CLPTM1L region are associated with risk of multiple cancers. We therefore investigated associations between variants in 22 telomere structure and maintenance gene regions and colorectal, breast, prostate, ovarian, and lung cancer risk. We performed subset-based meta-analyses of 204,993 directly-measured and imputed SNPs among 61,851 cancer cases and 74,457 controls of European descent. Independent associations for SNP minor alleles were identified using sequential conditional analysis (with gene-level p value cutoffs ≤3.08 × 10-5 ). Of the thirteen independent SNPs observed to be associated with cancer risk, novel findings were observed for seven loci. Across the DCLRE1B region, rs974494 and rs12144215 were inversely associated with prostate and lung cancers, and colorectal, breast, and prostate cancers, respectively. Across the TERC region, rs75316749 was positively associated with colorectal, breast, ovarian, and lung cancers. Across the DCLRE1B region, rs974404 and rs12144215 were inversely associated with prostate and lung cancers, and colorectal, breast, and prostate cancers, respectively. Near POT1, rs116895242 was inversely associated with colorectal, ovarian, and lung cancers, and RTEL1 rs34978822 was inversely associated with prostate and lung cancers. The complex association patterns in telomere-related genes across cancer types may provide insight into mechanisms through which telomere dysfunction in different tissues influences cancer risk..
Luedeke, M.
Rinckleb, A.E.
FitzGerald, L.M.
Geybels, M.S.
Schleutker, J.
Eeles, R.A.
Teixeira, M.R.
Cannon-Albright, L.
Ostrander, E.A.
Weikert, S.
Herkommer, K.
Wahlfors, T.
Visakorpi, T.
Leinonen, K.A.
Tammela, T.L.
Cooper, C.S.
Kote-Jarai, Z.
Edwards, S.
Goh, C.L.
McCarthy, F.
Parker, C.
Flohr, P.
Paulo, P.
Jerónimo, C.
Henrique, R.
Krause, H.
Wach, S.
Lieb, V.
Rau, T.T.
Vogel, W.
Kuefer, R.
Hofer, M.D.
Perner, S.
Rubin, M.A.
Agarwal, A.M.
Easton, D.F.
Al Olama, A.A.
Benlloch, S.
PRACTICAL consortium,
Hoegel, J.
Stanford, J.L.
Maier, C.
(2016). Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic TMPRSS2:ERG fusion status. Hum mol genet,
Vol.25
(24),
pp. 5490-5499.
show abstract
full text
Molecular and epidemiological differences have been described between TMPRSS2:ERG fusion-positive and fusion-negative prostate cancer (PrCa). Assuming two molecularly distinct subtypes, we have examined 27 common PrCa risk variants, previously identified in genome-wide association studies, for subtype specific associations in a total of 1221 TMPRSS2:ERG phenotyped PrCa cases. In meta-analyses of a discovery set of 552 cases with TMPRSS2:ERG data and 7650 unaffected men from five centers we have found support for the hypothesis that several common risk variants are associated with one particular subtype rather than with PrCa in general. Risk variants were analyzed in case-case comparisons (296 TMPRSS2:ERG fusion-positive versus 256 fusion-negative cases) and an independent set of 669 cases with TMPRSS2:ERG data was established to replicate the top five candidates. Significant differences (P < 0.00185) between the two subtypes were observed for rs16901979 (8q24) and rs1859962 (17q24), which were enriched in TMPRSS2:ERG fusion-negative (OR = 0.53, P = 0.0007) and TMPRSS2:ERG fusion-positive PrCa (OR = 1.30, P = 0.0016), respectively. Expression quantitative trait locus analysis was performed to investigate mechanistic links between risk variants, fusion status and target gene mRNA levels. For rs1859962 at 17q24, genotype dependent expression was observed for the candidate target gene SOX9 in TMPRSS2:ERG fusion-positive PrCa, which was not evident in TMPRSS2:ERG negative tumors. The present study established evidence for the first two common PrCa risk variants differentially associated with TMPRSS2:ERG fusion status. TMPRSS2:ERG phenotyping of larger studies is required to determine comprehensive sets of variants with subtype-specific roles in PrCa..
Marzec, J.
Mao, X.
Li, M.
Wang, M.
Feng, N.
Gou, X.
Wang, G.
Sun, Z.
Xu, J.
Xu, H.
Zhang, X.
Zhao, S.-.
Ren, G.
Yu, Y.
Wu, Y.
Wu, J.
Xue, Y.
Zhou, B.
Zhang, Y.
Xu, X.
Li, J.
He, W.
Benlloch, S.
Ross-Adams, H.
Chen, L.
Li, J.
Hong, Y.
Kote-Jarai, Z.
Cui, X.
Hou, J.
Guo, J.
Xu, L.
Yin, C.
Zhou, Y.
Neal, D.E.
Oliver, T.
Cao, G.
Zhang, Z.
Easton, D.F.
Chelala, C.
PRACTICAL Consortium,
CHIPGECS Group,
Al Olama, A.A.
Eeles, R.A.
Zhang, H.
Lu, Y.-.
(2016). A genetic study and meta-analysis of the genetic predisposition of prostate cancer in a Chinese population. Oncotarget,
Vol.7
(16),
pp. 21393-21403.
show abstract
full text
Prostate cancer predisposition has been extensively investigated in European populations, but there have been few studies of other ethnic groups. To investigate prostate cancer susceptibility in the under-investigated Chinese population, we performed single-nucleotide polymorphism (SNP) array analysis on a cohort of Chinese cases and controls and then meta-analysis with data from the existing Chinese prostate cancer genome-wide association study (GWAS). Genotyping 211,155 SNPs in 495 cases and 640 controls of Chinese ancestry identified several new suggestive Chinese prostate cancer predisposition loci. However, none of them reached genome-wide significance level either by meta-analysis or replication study. The meta-analysis with the Chinese GWAS data revealed that four 8q24 loci are the main contributors to Chinese prostate cancer risk and the risk alleles from three of them exist at much higher frequencies in Chinese than European populations. We also found that several predisposition loci reported in Western populations have different effect on Chinese men. Therefore, this first extensive single-nucleotide polymorphism study of Chinese prostate cancer in comparison with European population indicates that four loci on 8q24 contribute to a great risk of prostate cancer in a considerable large proportion of Chinese men. Based on those four loci, the top 10% of the population have six- or two-fold prostate cancer risk compared with men of the bottom 10% or median risk respectively, which may facilitate the design of prostate cancer genetic risk screening and prevention in Chinese men. These findings also provide additional insights into the etiology and pathogenesis of prostate cancer..
Khankari, N.K.
Murff, H.J.
Zeng, C.
Wen, W.
Eeles, R.A.
Easton, D.F.
Kote-Jarai, Z.
Al Olama, A.A.
Benlloch, S.
Muir, K.
Giles, G.G.
Wiklund, F.
Gronberg, H.
Haiman, C.A.
Schleutker, J.
Nordestgaard, B.G.
Travis, R.C.
Donovan, J.L.
Pashayan, N.
Khaw, K.-.
Stanford, J.L.
Blot, W.J.
Thibodeau, S.N.
Maier, C.
Kibel, A.S.
Cybulski, C.
Cannon-Albright, L.
Brenner, H.
Park, J.
Kaneva, R.
Batra, J.
Teixeira, M.R.
Pandha, H.
Zheng, W.
PRACTICAL consortium,
(2016). Polyunsaturated fatty acids and prostate cancer risk: a Mendelian randomisation analysis from the PRACTICAL consortium. Br j cancer,
Vol.115
(5),
pp. 624-631.
show abstract
full text
BACKGROUND: Prostate cancer is a common cancer worldwide with no established modifiable lifestyle factors to guide prevention. The associations between polyunsaturated fatty acids (PUFAs) and prostate cancer risk have been inconsistent. Using Mendelian randomisation, we evaluated associations between PUFAs and prostate cancer risk. METHODS: We used individual-level data from a consortium of 22 721 cases and 23 034 controls of European ancestry. Externally-weighted PUFA-specific polygenic risk scores (wPRSs), with explanatory variation ranging from 0.65 to 33.07%, were constructed and used to evaluate associations with prostate cancer risk per one standard deviation (s.d.) increase in genetically-predicted plasma PUFA levels using multivariable-adjusted unconditional logistic regression. RESULTS: No overall association was observed between the genetically-predicted PUFAs evaluated in this study and prostate cancer risk. However, risk reductions were observed for short-chain PUFAs, linoleic (ORLA=0.95, 95%CI=0.92, 0.98) and α-linolenic acids (ORALA=0.96, 95%CI=0.93, 0.98), among men <62 years; whereas increased risk was found among men ⩾62 years for LA (ORLA=1.04, 95%CI=1.01, 1.07). For long-chain PUFAs (i.e., arachidonic, eicosapentaenoic, and docosapentaenoic acids), increased risks were observed among men <62 years (ORAA=1.05, 95%CI=1.02, 1.08; OREPA=1.04, 95%CI=1.01, 1.06; ORDPA=1.05, 95%CI=1.02, 1.08). CONCLUSION: Results from this study suggest that circulating ω-3 and ω-6 PUFAs may have a different role in the aetiology of early- and late-onset prostate cancer..
Amin Al Olama, A.
Dadaev, T.
Hazelett, D.J.
Li, Q.
Leongamornlert, D.
Saunders, E.J.
Stephens, S.
Cieza-Borrella, C.
Whitmore, I.
Benlloch Garcia, S.
Giles, G.G.
Southey, M.C.
Fitzgerald, L.
Gronberg, H.
Wiklund, F.
Aly, M.
Henderson, B.E.
Schumacher, F.
Haiman, C.A.
Schleutker, J.
Wahlfors, T.
Tammela, T.L.
Nordestgaard, B.G.
Key, T.J.
Travis, R.C.
Neal, D.E.
Donovan, J.L.
Hamdy, F.C.
Pharoah, P.
Pashayan, N.
Khaw, K.-.
Stanford, J.L.
Thibodeau, S.N.
Mcdonnell, S.K.
Schaid, D.J.
Maier, C.
Vogel, W.
Luedeke, M.
Herkommer, K.
Kibel, A.S.
Cybulski, C.
Wokołorczyk, D.
Kluzniak, W.
Cannon-Albright, L.
Brenner, H.
Butterbach, K.
Arndt, V.
Park, J.Y.
Sellers, T.
Lin, H.-.
Slavov, C.
Kaneva, R.
Mitev, V.
Batra, J.
Clements, J.A.
Spurdle, A.
Teixeira, M.R.
Paulo, P.
Maia, S.
Pandha, H.
Michael, A.
Kierzek, A.
Govindasami, K.
Guy, M.
Lophatonanon, A.
Muir, K.
Viñuela, A.
Brown, A.A.
PRACTICAL Consortium,
COGS-CRUK GWAS-ELLIPSE (Part of GAME-ON) Initiative,
Australian Prostate Cancer BioResource,
UK Genetic Prostate Cancer Study Collaborators,
UK ProtecT Study Collaborators,
Freedman, M.
Conti, D.V.
Easton, D.
Coetzee, G.A.
Eeles, R.A.
Kote-Jarai, Z.
(2015). Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. Hum mol genet,
Vol.24
(19),
pp. 5589-5602.
show abstract
Genome-wide association studies (GWAS) have identified numerous common prostate cancer (PrCa) susceptibility loci. We have fine-mapped 64 GWAS regions known at the conclusion of the iCOGS study using large-scale genotyping and imputation in 25 723 PrCa cases and 26 274 controls of European ancestry. We detected evidence for multiple independent signals at 16 regions, 12 of which contained additional newly identified significant associations. A single signal comprising a spectrum of correlated variation was observed at 39 regions; 35 of which are now described by a novel more significantly associated lead SNP, while the originally reported variant remained as the lead SNP only in 4 regions. We also confirmed two association signals in Europeans that had been previously reported only in East-Asian GWAS. Based on statistical evidence and linkage disequilibrium (LD) structure, we have curated and narrowed down the list of the most likely candidate causal variants for each region. Functional annotation using data from ENCODE filtered for PrCa cell lines and eQTL analysis demonstrated significant enrichment for overlap with bio-features within this set. By incorporating the novel risk variants identified here alongside the refined data for existing association signals, we estimate that these loci now explain ∼38.9% of the familial relative risk of PrCa, an 8.9% improvement over the previously reported GWAS tag SNPs. This suggests that a significant fraction of the heritability of PrCa may have been hidden during the discovery phase of GWAS, in particular due to the presence of multiple independent signals within the same region..
Han, Y.
Hazelett, D.J.
Wiklund, F.
Schumacher, F.R.
Stram, D.O.
Berndt, S.I.
Wang, Z.
Rand, K.A.
Hoover, R.N.
Machiela, M.J.
Yeager, M.
Burdette, L.
Chung, C.C.
Hutchinson, A.
Yu, K.
Xu, J.
Travis, R.C.
Key, T.J.
Siddiq, A.
Canzian, F.
Takahashi, A.
Kubo, M.
Stanford, J.L.
Kolb, S.
Gapstur, S.M.
Diver, W.R.
Stevens, V.L.
Strom, S.S.
Pettaway, C.A.
Al Olama, A.A.
Kote-Jarai, Z.
Eeles, R.A.
Yeboah, E.D.
Tettey, Y.
Biritwum, R.B.
Adjei, A.A.
Tay, E.
Truelove, A.
Niwa, S.
Chokkalingam, A.P.
Isaacs, W.B.
Chen, C.
Lindstrom, S.
Le Marchand, L.
Giovannucci, E.L.
Pomerantz, M.
Long, H.
Li, F.
Ma, J.
Stampfer, M.
John, E.M.
Ingles, S.A.
Kittles, R.A.
Murphy, A.B.
Blot, W.J.
Signorello, L.B.
Zheng, W.
Albanes, D.
Virtamo, J.
Weinstein, S.
Nemesure, B.
Carpten, J.
Leske, M.C.
Wu, S.-.
Hennis, A.J.
Rybicki, B.A.
Neslund-Dudas, C.
Hsing, A.W.
Chu, L.
Goodman, P.J.
Klein, E.A.
Zheng, S.L.
Witte, J.S.
Casey, G.
Riboli, E.
Li, Q.
Freedman, M.L.
Hunter, D.J.
Gronberg, H.
Cook, M.B.
Nakagawa, H.
Kraft, P.
Chanock, S.J.
Easton, D.F.
Henderson, B.E.
Coetzee, G.A.
Conti, D.V.
Haiman, C.A.
(2015). Integration of multiethnic fine-mapping and genomic annotation to prioritize candidate functional SNPs at prostate cancer susceptibility regions. Hum mol genet,
Vol.24
(19),
pp. 5603-5618.
show abstract
Interpretation of biological mechanisms underlying genetic risk associations for prostate cancer is complicated by the relatively large number of risk variants (n = 100) and the thousands of surrogate SNPs in linkage disequilibrium. Here, we combined three distinct approaches: multiethnic fine-mapping, putative functional annotation (based upon epigenetic data and genome-encoded features), and expression quantitative trait loci (eQTL) analyses, in an attempt to reduce this complexity. We examined 67 risk regions using genotyping and imputation-based fine-mapping in populations of European (cases/controls: 8600/6946), African (cases/controls: 5327/5136), Japanese (cases/controls: 2563/4391) and Latino (cases/controls: 1034/1046) ancestry. Markers at 55 regions passed a region-specific significance threshold (P-value cutoff range: 3.9 × 10(-4)-5.6 × 10(-3)) and in 30 regions we identified markers that were more significantly associated with risk than the previously reported variants in the multiethnic sample. Novel secondary signals (P < 5.0 × 10(-6)) were also detected in two regions (rs13062436/3q21 and rs17181170/3p12). Among 666 variants in the 55 regions with P-values within one order of magnitude of the most-associated marker, 193 variants (29%) in 48 regions overlapped with epigenetic or other putative functional marks. In 11 of the 55 regions, cis-eQTLs were detected with nearby genes. For 12 of the 55 regions (22%), the most significant region-specific, prostate-cancer associated variant represented the strongest candidate functional variant based on our annotations; the number of regions increased to 20 (36%) and 27 (49%) when examining the 2 and 3 most significantly associated variants in each region, respectively. These results have prioritized subsets of candidate variants for downstream functional evaluation..
Kote-Jarai, Z.
Mikropoulos, C.
Leongamornlert, D.A.
Dadaev, T.
Tymrakiewicz, M.
Saunders, E.J.
Jones, M.
Jugurnauth-Little, S.
Govindasami, K.
Guy, M.
Hamdy, F.C.
Donovan, J.L.
Neal, D.E.
Lane, J.A.
Dearnaley, D.
Wilkinson, R.A.
Sawyer, E.J.
Morgan, A.
Antoniou, A.C.
Eeles, R.A.
UK Genetic Prostate Cancer Study Collaborators, and the ProtecT Study Group,
(2015). Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes. Ann oncol,
Vol.26
(4),
pp. 756-761.
show abstract
BACKGROUND: A rare recurrent missense variant in HOXB13 (rs138213197/G84E) was recently reported to be associated with hereditary prostate cancer. Population-based studies have established that, since the frequency of this single-nucleotide polymorphism (SNP) varies between geographic regions, the associated proportion of prostate cancer (PrCa) risk contribution is also highly variable by country. PATIENTS AND METHODS: This is the largest comprehensive case-control study assessing the prevalence of the HOXB13 G84E variant to date and is the first in the UK population. We genotyped 8652 men diagnosed with PrCa within the UK Genetic Prostate Cancer Study (UKGPCS) and 5252 healthy men from the UK ProtecT study. RESULTS: HOXB13 G84E was identified in 0.5% of the healthy controls and 1.5% of the PrCa cases, and it was associated with a 2.93-fold increased risk of PrCa [95% confidence interval (CI) 1.94-4.59; P = 6.27 × 10(-8)]. The risk was even higher among men with family history of PrCa [odds ratio (OR) = 4.53, 95% CI 2.86-7.34; P = 3.1 × 10(-8)] and in young-onset PrCa (diagnosed up to the age of 55 years; OR = 3.11, 95% CI 1.98-5.00; P = 6.1 × 10(-7)). There was no significant association between Gleason Score, presenting prostate specific antigen, tumour-node-metastasis (TNM) stage or NCCN risk group and carrier status. HOXB13 G84E was not associated with overall or cancer-specific survival. We found that the polygenic PrCa risk score (PR score), calculated using the 71 known single-nucleotide polymorphisms (SNPs) associated with PrCa and the HOXB13 G84E variant act multiplicatively on PrCa risk. Based on the estimated prevalence and risk, this rare variant explains ∼1% of the familial risk of PrCa in the UK population. CONCLUSIONS: The clinical importance of HOXB13 G84E in PrCa management has not been established. This variant was found to have no effect on prognostic implications but could be used for stratifying screening, by identifying men at high risk. CLINICAL TRIALS NUMBERS: Prostate Testing for Cancer and Treatment (ProtecT): NCT02044172. UK GENETIC PROSTATE CANCER STUDY: Epidemiology and Molecular Genetics Studies (UKGPCS): NCT01737242..
Cooper, C.S.
Eeles, R.
Wedge, D.C.
Van Loo, P.
Gundem, G.
Alexandrov, L.B.
Kremeyer, B.
Butler, A.
Lynch, A.G.
Camacho, N.
Massie, C.E.
Kay, J.
Luxton, H.J.
Edwards, S.
Kote-Jarai, Z.
Dennis, N.
Merson, S.
Leongamornlert, D.
Zamora, J.
Corbishley, C.
Thomas, S.
Nik-Zainal, S.
O'Meara, S.
Matthews, L.
Clark, J.
Hurst, R.
Mithen, R.
Bristow, R.G.
Boutros, P.C.
Fraser, M.
Cooke, S.
Raine, K.
Jones, D.
Menzies, A.
Stebbings, L.
Hinton, J.
Teague, J.
McLaren, S.
Mudie, L.
Hardy, C.
Anderson, E.
Joseph, O.
Goody, V.
Robinson, B.
Maddison, M.
Gamble, S.
Greenman, C.
Berney, D.
Hazell, S.
Livni, N.
ICGC Prostate Group,
Fisher, C.
Ogden, C.
Kumar, P.
Thompson, A.
Woodhouse, C.
Nicol, D.
Mayer, E.
Dudderidge, T.
Shah, N.C.
Gnanapragasam, V.
Voet, T.
Campbell, P.
Futreal, A.
Easton, D.
Warren, A.Y.
Foster, C.S.
Stratton, M.R.
Whitaker, H.C.
McDermott, U.
Brewer, D.S.
Neal, D.E.
(2015). Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nat genet,
Vol.47
(4),
pp. 367-372.
show abstract
full text
Genome-wide DNA sequencing was used to decrypt the phylogeny of multiple samples from distinct areas of cancer and morphologically normal tissue taken from the prostates of three men. Mutations were present at high levels in morphologically normal tissue distant from the cancer, reflecting clonal expansions, and the underlying mutational processes at work in morphologically normal tissue were also at work in cancer. Our observations demonstrate the existence of ongoing abnormal mutational processes, consistent with field effects, underlying carcinogenesis. This mechanism gives rise to extensive branching evolution and cancer clone mixing, as exemplified by the coexistence of multiple cancer lineages harboring distinct ERG fusions within a single cancer nodule. Subsets of mutations were shared either by morphologically normal and malignant tissues or between different ERG lineages, indicating earlier or separate clonal cell expansions. Our observations inform on the origin of multifocal disease and have implications for prostate cancer therapy in individual cases..
Stegeman, S.
Amankwah, E.
Klein, K.
O'Mara, T.A.
Kim, D.
Lin, H.-.
Permuth-Wey, J.
Sellers, T.A.
Srinivasan, S.
Eeles, R.
Easton, D.
Kote-Jarai, Z.
Amin Al Olama, A.
Benlloch, S.
Muir, K.
Giles, G.G.
Wiklund, F.
Gronberg, H.
Haiman, C.A.
Schleutker, J.
Nordestgaard, B.G.
Travis, R.C.
Neal, D.
Pharoah, P.
Khaw, K.-.
Stanford, J.L.
Blot, W.J.
Thibodeau, S.
Maier, C.
Kibel, A.S.
Cybulski, C.
Cannon-Albright, L.
Brenner, H.
Kaneva, R.
Teixeira, M.R.
PRACTICAL Consortium,
Australian Prostate Cancer BioResource,
Spurdle, A.B.
Clements, J.A.
Park, J.Y.
Batra, J.
(2015). A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer. Cancer discov,
Vol.5
(4),
pp. 368-379.
show abstract
UNLABELLED: Prostate cancer is the second most common malignancy among men worldwide. Genome-wide association studies have identified 100 risk variants for prostate cancer, which can explain approximately 33% of the familial risk of the disease. We hypothesized that a comprehensive analysis of genetic variations found within the 3' untranslated region of genes predicted to affect miRNA binding (miRSNP) can identify additional prostate cancer risk variants. We investigated the association between 2,169 miRSNPs and prostate cancer risk in a large-scale analysis of 22,301 cases and 22,320 controls of European ancestry from 23 participating studies. Twenty-two miRSNPs were associated (P<2.3×10(-5)) with risk of prostate cancer, 10 of which were within 7 genes previously not mapped by GWAS studies. Further, using miRNA mimics and reporter gene assays, we showed that miR-3162-5p has specific affinity for the KLK3 rs1058205 miRSNP T-allele, whereas miR-370 has greater affinity for the VAMP8 rs1010 miRSNP A-allele, validating their functional role. SIGNIFICANCE: Findings from this large association study suggest that a focus on miRSNPs, including functional evaluation, can identify candidate risk loci below currently accepted statistical levels of genome-wide significance. Studies of miRNAs and their interactions with SNPs could provide further insights into the mechanisms of prostate cancer risk..
Amin Al Olama, A.
Benlloch, S.
Antoniou, A.C.
Giles, G.G.
Severi, G.
Neal, D.E.
Hamdy, F.C.
Donovan, J.L.
Muir, K.
Schleutker, J.
Henderson, B.E.
Haiman, C.A.
Schumacher, F.R.
Pashayan, N.
Pharoah, P.D.
Ostrander, E.A.
Stanford, J.L.
Batra, J.
Clements, J.A.
Chambers, S.K.
Weischer, M.
Nordestgaard, B.G.
Ingles, S.A.
Sorensen, K.D.
Orntoft, T.F.
Park, J.Y.
Cybulski, C.
Maier, C.
Doerk, T.
Dickinson, J.L.
Cannon-Albright, L.
Brenner, H.
Rebbeck, T.R.
Zeigler-Johnson, C.
Habuchi, T.
Thibodeau, S.N.
Cooney, K.A.
Chappuis, P.O.
Hutter, P.
Kaneva, R.P.
Foulkes, W.D.
Zeegers, M.P.
Lu, Y.-.
Zhang, H.-.
Stephenson, R.
Cox, A.
Southey, M.C.
Spurdle, A.B.
FitzGerald, L.
Leongamornlert, D.
Saunders, E.
Tymrakiewicz, M.
Guy, M.
Dadaev, T.
Little, S.J.
Govindasami, K.
Sawyer, E.
Wilkinson, R.
Herkommer, K.
Hopper, J.L.
Lophatonanon, A.
Rinckleb, A.E.
Kote-Jarai, Z.
Eeles, R.A.
Easton, D.F.
UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology,
UK ProtecT Study Collaborators,
PRACTICAL Consortium,
(2015). Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. Cancer epidemiol biomarkers prev,
Vol.24
(7),
pp. 1121-1129.
show abstract
BACKGROUND: Genome-wide association studies have identified multiple genetic variants associated with prostate cancer risk which explain a substantial proportion of familial relative risk. These variants can be used to stratify individuals by their risk of prostate cancer. METHODS: We genotyped 25 prostate cancer susceptibility loci in 40,414 individuals and derived a polygenic risk score (PRS). We estimated empirical odds ratios (OR) for prostate cancer associated with different risk strata defined by PRS and derived age-specific absolute risks of developing prostate cancer by PRS stratum and family history. RESULTS: The prostate cancer risk for men in the top 1% of the PRS distribution was 30.6 (95% CI, 16.4-57.3) fold compared with men in the bottom 1%, and 4.2 (95% CI, 3.2-5.5) fold compared with the median risk. The absolute risk of prostate cancer by age of 85 years was 65.8% for a man with family history in the top 1% of the PRS distribution, compared with 3.7% for a man in the bottom 1%. The PRS was only weakly correlated with serum PSA level (correlation = 0.09). CONCLUSIONS: Risk profiling can identify men at substantially increased or reduced risk of prostate cancer. The effect size, measured by OR per unit PRS, was higher in men at younger ages and in men with family history of prostate cancer. Incorporating additional newly identified loci into a PRS should improve the predictive value of risk profiles. IMPACT: We demonstrate that the risk profiling based on SNPs can identify men at substantially increased or reduced risk that could have useful implications for targeted prevention and screening programs..
Castro, E.
Goh, C.
Leongamornlert, D.
Saunders, E.
Tymrakiewicz, M.
Dadaev, T.
Govindasami, K.
Guy, M.
Ellis, S.
Frost, D.
Bancroft, E.
Cole, T.
Tischkowitz, M.
Kennedy, M.J.
Eason, J.
Brewer, C.
Evans, D.G.
Davidson, R.
Eccles, D.
Porteous, M.E.
Douglas, F.
Adlard, J.
Donaldson, A.
Antoniou, A.C.
Kote-Jarai, Z.
Easton, D.F.
Olmos, D.
Eeles, R.
(2015). Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. Eur urol,
Vol.68
(2),
pp. 186-193.
show abstract
BACKGROUND: Germline BRCA mutations are associated with worse prostate cancer (PCa) outcomes; however, the most appropriate management for mutation carriers has not yet been investigated. OBJECTIVE: To evaluate the response of BRCA carriers to conventional treatments for localised PCa by analysing metastasis-free survival (MFS) and cause-specific survival (CSS) following radical prostatectomy (RP) or external-beam radiation therapy (RT). DESIGN, SETTING, AND PARTICIPANTS: Tumour features and outcomes of 1302 patients with local/locally advanced PCa (including 67 BRCA mutation carriers) were analysed. RP was undergone by 535 patients (35 BRCA); 767 received RT (32 BRCA). Median follow-up was 64 mo. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Median survival and 3-, 5-, and 10-yr survival rates were estimated using the Kaplan-Meier method. Generated survival curves were compared using the log-rank test. Cox regression analyses were used to assess the prognostic value of BRCA mutations. RESULTS AND LIMITATIONS: A total of 67 BRCA carriers and 1235 noncarriers were included. At 3, 5, and 10 yr after treatment, 97%, 94%, and 84% of noncarriers and 90%, 72%, and 50% of carriers were free from metastasis (p<0.001). The 3-, 5- and 10-yr CSS rates were significantly better in the noncarrier cohort (99%, 97%, and 85%, respectively) than in carriers (96%, 76%, and 61%, respectively; p<0.001). Multivariate analysis confirmed BRCA mutations as an independent prognostic factor for MFS (hazard ratio [HR]: 2.36; 95% confidence interval [CI], 1.38-4.03; p=0.002) and CSS (HR: 2.17; 95% CI, 1.16-4.07; p=0.016). CONCLUSIONS: BRCA carriers had worse outcomes than noncarriers when conventionally treated for local/locally advanced PCa. PATIENT SUMMARY: Prostate cancer patients with germline BRCA mutations had worse outcomes than noncarriers when conventionally treated with surgery or radiation therapy..
Szulkin, R.
Whitington, T.
Eklund, M.
Aly, M.
Eeles, R.A.
Easton, D.
Kote-Jarai, Z.S.
Amin Al Olama, A.
Benlloch, S.
Muir, K.
Giles, G.G.
Southey, M.C.
Fitzgerald, L.M.
Henderson, B.E.
Schumacher, F.
Haiman, C.A.
Schleutker, J.
Wahlfors, T.
Tammela, T.L.
Nordestgaard, B.G.
Key, T.J.
Travis, R.C.
Neal, D.E.
Donovan, J.L.
Hamdy, F.C.
Pharoah, P.
Pashayan, N.
Khaw, K.-.
Stanford, J.L.
Thibodeau, S.N.
McDonnell, S.K.
Schaid, D.J.
Maier, C.
Vogel, W.
Luedeke, M.
Herkommer, K.
Kibel, A.S.
Cybulski, C.
Lubiński, J.
Kluźniak, W.
Cannon-Albright, L.
Brenner, H.
Butterbach, K.
Stegmaier, C.
Park, J.Y.
Sellers, T.
Lin, H.-.
Slavov, C.
Kaneva, R.
Mitev, V.
Batra, J.
Clements, J.A.
Australian Prostate Cancer BioResource,
Spurdle, A.
Teixeira, M.R.
Paulo, P.
Maia, S.
Pandha, H.
Michael, A.
Kierzek, A.
Practical Consortium,
Gronberg, H.
Wiklund, F.
(2015). Prediction of individual genetic risk to prostate cancer using a polygenic score. Prostate,
Vol.75
(13),
pp. 1467-1474.
show abstract
full text
BACKGROUND: Polygenic risk scores comprising established susceptibility variants have shown to be informative classifiers for several complex diseases including prostate cancer. For prostate cancer it is unknown if inclusion of genetic markers that have so far not been associated with prostate cancer risk at a genome-wide significant level will improve disease prediction. METHODS: We built polygenic risk scores in a large training set comprising over 25,000 individuals. Initially 65 established prostate cancer susceptibility variants were selected. After LD pruning additional variants were prioritized based on their association with prostate cancer. Six-fold cross validation was performed to assess genetic risk scores and optimize the number of additional variants to be included. The final model was evaluated in an independent study population including 1,370 cases and 1,239 controls. RESULTS: The polygenic risk score with 65 established susceptibility variants provided an area under the curve (AUC) of 0.67. Adding an additional 68 novel variants significantly increased the AUC to 0.68 (P = 0.0012) and the net reclassification index with 0.21 (P = 8.5E-08). All novel variants were located in genomic regions established as associated with prostate cancer risk. CONCLUSIONS: Inclusion of additional genetic variants from established prostate cancer susceptibility regions improves disease prediction..
Pashayan, N.
Duffy, S.W.
Neal, D.E.
Hamdy, F.C.
Donovan, J.L.
Martin, R.M.
Harrington, P.
Benlloch, S.
Amin Al Olama, A.
Shah, M.
Kote-Jarai, Z.
Easton, D.F.
Eeles, R.
Pharoah, P.D.
(2015). Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis. Genet med,
Vol.17
(10),
pp. 789-795.
show abstract
PURPOSE: This study aimed to quantify the probability of overdiagnosis of prostate cancer by polygenic risk. METHODS: We calculated the polygenic risk score based on 66 known prostate cancer susceptibility variants for 17,012 men aged 50-69 years (9,404 men identified with prostate cancer and 7,608 with no cancer) derived from three UK-based ongoing studies. We derived the probabilities of overdiagnosis by quartiles of polygenic risk considering that the observed prevalence of screen-detected prostate cancer is a combination of underlying incidence, mean sojourn time (MST), test sensitivity, and overdiagnosis. RESULTS: Polygenic risk quartiles 1 to 4 comprised 9, 18, 25, and 48% of the cases, respectively. For a prostate-specific antigen test sensitivity of 80% and MST of 9 years, 43, 30, 25, and 19% of the prevalent screen-detected cancers in quartiles 1 to 4, respectively, were likely to be overdiagnosed cancers. Overdiagnosis decreased with increasing polygenic risk, with 56% decrease between the lowest and the highest polygenic risk quartiles. CONCLUSION: Targeting screening to men at higher polygenic risk could reduce the problem of overdiagnosis and lead to a better benefit-to-harm balance in screening for prostate cancer..
Szulkin, R.
Karlsson, R.
Whitington, T.
Aly, M.
Gronberg, H.
Eeles, R.A.
Easton, D.F.
Kote-Jarai, Z.
Al Olama, A.A.
Benlloch, S.
Muir, K.
Giles, G.G.
Southey, M.C.
FitzGerald, L.M.
Henderson, B.E.
Schumacher, F.R.
Haiman, C.A.
Sipeky, C.
Tammela, T.L.
Nordestgaard, B.G.
Key, T.J.
Travis, R.C.
Neal, D.E.
Donovan, J.L.
Hamdy, F.C.
Pharoah, P.D.
Pashayan, N.
Khaw, K.-.
Stanford, J.L.
Thibodeau, S.N.
McDonnell, S.K.
Schaid, D.J.
Maier, C.
Vogel, W.
Luedeke, M.
Herkommer, K.
Kibel, A.S.
Cybulski, C.
Lubiński, J.
Kluźniak, W.
Cannon-Albright, L.
Brenner, H.
Herrmann, V.
Holleczek, B.
Park, J.Y.
Sellers, T.A.
Lim, H.-.
Slavov, C.
Kaneva, R.P.
Mitev, V.I.
Spurdle, A.
Teixeira, M.R.
Paulo, P.
Maia, S.
Pandha, H.
Michael, A.
Kierzek, A.
PRACTICAL consortium,
Batra, J.
Clements, J.A.
Australian Prostate Cancer BioResource,
Albanes, D.
Andriole, G.L.
Berndt, S.I.
Chanock, S.
Gapstur, S.M.
Giovannucci, E.L.
Hunter, D.J.
Kraft, P.
Le Marchand, L.
Ma, J.
Mondul, A.M.
Penney, K.L.
Stampfer, M.J.
Stevens, V.L.
Weinstein, S.J.
Trichopoulou, A.
Bueno-de-Mesquita, B.H.
Tjønneland, A.
Cox, D.G.
BPC3 consortium,
Maehle, L.
Schleutker, J.
Lindström, S.
Wiklund, F.
(2015). Genome-wide association study of prostate cancer-specific survival. Cancer epidemiol biomarkers prev,
Vol.24
(11),
pp. 1796-1800.
show abstract
BACKGROUND: Unnecessary intervention and overtreatment of indolent disease are common challenges in clinical management of prostate cancer. Improved tools to distinguish lethal from indolent disease are critical. METHODS: We performed a genome-wide survival analysis of cause-specific death in 24,023 prostate cancer patients (3,513 disease-specific deaths) from the PRACTICAL and BPC3 consortia. Top findings were assessed for replication in a Norwegian cohort (CONOR). RESULTS: We observed no significant association between genetic variants and prostate cancer survival. CONCLUSIONS: Common genetic variants with large impact on prostate cancer survival were not observed in this study. IMPACT: Future studies should be designed for identification of rare variants with large effect sizes or common variants with small effect sizes..
Castro, E.
Jugurnauth-Little, S.
Karlsson, Q.
Al-Shahrour, F.
Piñeiro-Yañez, E.
Van de Poll, F.
Leongamornlert, D.
Dadaev, T.
Govindasami, K.
Guy, M.
Eeles, R.
Kote-Jarai, Z.
UKGPCS, EMBRACE and IMPACT studies,
(2015). High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriers. Ann oncol,
Vol.26
(11),
pp. 2293-2300.
show abstract
BACKGROUND: Germline BRCA2 mutations are associated with poorer outcome prostate cancer (PCa) compared with sporadic tumours but this association remains to be characterised. In this study, we aim to assess if there is a signature set of copy number alterations (CNA) that could aid to the identification of BRCA2-mutated tumours and would assist us to understand their aggressive clinical behaviour. METHODS: High-resolution array comparative genomic hybridisation profiling of DNA from PCa and matched morphologically normal prostate samples from 9 BRCA2 germline mutation carriers and 16 non-carriers in combination with unsupervised analysis was used to define copy number features. RESULTS: PCa from BRCA2 germline mutation carriers (B2T) harbour significantly more CNA than non-carrier tumours (NCTs) (P = 14 × 10(-6)). A hundred and sixteen regions had a significantly different distribution with both false discovery rate (FDR) and P value <0.01, including CNA in the genomic region containing c-MYC that was present in 89% B2T versus 12.5% NCT (P = 3 × 10(-4)). Loss of heterozygosity (LOH) at the BRCA2 locus was observed in 67% of B2T. Elevated CNA are already present in 50% of the morphologically normal prostate tissue from BRCA2 carriers. CONCLUSION: The relative high amount of CNAs in morphologically normal prostate tissue of BRCA2 carriers implies a field effect and together with the observed LOH could be used as a marker of PCa risk in these men. Several features previously associated with poor PCa outcome have been found to be significantly more common in BRCA2-mutated PCa than in sporadic tumours and may help to explain their adverse prognosis and be of relevance for targeted therapies..
Davies, N.M.
Gaunt, T.R.
Lewis, S.J.
Holly, J.
Donovan, J.L.
Hamdy, F.C.
Kemp, J.P.
Eeles, R.
Easton, D.
Kote-Jarai, Z.
Al Olama, A.A.
Benlloch, S.
Muir, K.
Giles, G.G.
Wiklund, F.
Gronberg, H.
Haiman, C.A.
Schleutker, J.
Nordestgaard, B.G.
Travis, R.C.
Neal, D.
Pashayan, N.
Khaw, K.-.
Stanford, J.L.
Blot, W.J.
Thibodeau, S.
Maier, C.
Kibel, A.S.
Cybulski, C.
Cannon-Albright, L.
Brenner, H.
Park, J.
Kaneva, R.
Batra, J.
Teixeira, M.R.
Pandha, H.
PRACTICAL consortium,
Lathrop, M.
Smith, G.D.
Martin, R.M.
(2015). The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium. Cancer causes control,
Vol.26
(11),
pp. 1603-1616.
show abstract
BACKGROUND: Epidemiological studies suggest a potential role for obesity and determinants of adult stature in prostate cancer risk and mortality, but the relationships described in the literature are complex. To address uncertainty over the causal nature of previous observational findings, we investigated associations of height- and adiposity-related genetic variants with prostate cancer risk and mortality. METHODS: We conducted a case-control study based on 20,848 prostate cancers and 20,214 controls of European ancestry from 22 studies in the PRACTICAL consortium. We constructed genetic risk scores that summed each man's number of height and BMI increasing alleles across multiple single nucleotide polymorphisms robustly associated with each phenotype from published genome-wide association studies. RESULTS: The genetic risk scores explained 6.31 and 1.46% of the variability in height and BMI, respectively. There was only weak evidence that genetic variants previously associated with increased BMI were associated with a lower prostate cancer risk (odds ratio per standard deviation increase in BMI genetic score 0.98; 95% CI 0.96, 1.00; p = 0.07). Genetic variants associated with increased height were not associated with prostate cancer incidence (OR 0.99; 95% CI 0.97, 1.01; p = 0.23), but were associated with an increase (OR 1.13; 95 % CI 1.08, 1.20) in prostate cancer mortality among low-grade disease (p heterogeneity, low vs. high grade <0.001). Genetic variants associated with increased BMI were associated with an increase (OR 1.08; 95 % CI 1.03, 1.14) in all-cause mortality among men with low-grade disease (p heterogeneity = 0.03). CONCLUSIONS: We found little evidence of a substantial effect of genetically elevated height or BMI on prostate cancer risk, suggesting that previously reported observational associations may reflect common environmental determinants of height or BMI and prostate cancer risk. Genetically elevated height and BMI were associated with increased mortality (prostate cancer-specific and all-cause, respectively) in men with low-grade disease, a potentially informative but novel finding that requires replication..
Hung, R.J.
Ulrich, C.M.
Goode, E.L.
Brhane, Y.
Muir, K.
Chan, A.T.
Marchand, L.L.
Schildkraut, J.
Witte, J.S.
Eeles, R.
Boffetta, P.
Spitz, M.R.
Poirier, J.G.
Rider, D.N.
Fridley, B.L.
Chen, Z.
Haiman, C.
Schumacher, F.
Easton, D.F.
Landi, M.T.
Brennan, P.
Houlston, R.
Christiani, D.C.
Field, J.K.
Bickeböller, H.
Risch, A.
Kote-Jarai, Z.
Wiklund, F.
Grönberg, H.
Chanock, S.
Berndt, S.I.
Kraft, P.
Lindström, S.
Al Olama, A.A.
Song, H.
Phelan, C.
Wentzensen, N.
Peters, U.
Slattery, M.L.
GECCO,
Sellers, T.A.
FOCI,
Casey, G.
Gruber, S.B.
CORECT,
Hunter, D.J.
DRIVE,
Amos, C.I.
Henderson, B.
GAME-ON Network,
(2015). Cross Cancer Genomic Investigation of Inflammation Pathway for Five Common Cancers: Lung, Ovary, Prostate, Breast, and Colorectal Cancer. J natl cancer inst,
Vol.107
(11).
show abstract
BACKGROUND: Inflammation has been hypothesized to increase the risk of cancer development as an initiator or promoter, yet no large-scale study of inherited variation across cancer sites has been conducted. METHODS: We conducted a cross-cancer genomic analysis for the inflammation pathway based on 48 genome-wide association studies within the National Cancer Institute GAME-ON Network across five common cancer sites, with a total of 64 591 cancer patients and 74 467 control patients. Subset-based meta-analysis was used to account for possible disease heterogeneity, and hierarchical modeling was employed to estimate the effect of the subcomponents within the inflammation pathway. The network was visualized by enrichment map. All statistical tests were two-sided. RESULTS: We identified three pleiotropic loci within the inflammation pathway, including one novel locus in Ch12q24 encoding SH2B3 (rs3184504), which reached GWAS significance with a P value of 1.78 x 10(-8), and it showed an association with lung cancer (P = 2.01 x 10(-6)), colorectal cancer (GECCO P = 6.72x10(-6); CORECT P = 3.32x10(-5)), and breast cancer (P = .009). We also identified five key subpathway components with genetic variants that are relevant for the risk of these five cancer sites: inflammatory response for colorectal cancer (P = .006), inflammation related cell cycle gene for lung cancer (P = 1.35x10(-6)), and activation of immune response for ovarian cancer (P = .009). In addition, sequence variations in immune system development played a role in breast cancer etiology (P = .001) and innate immune response was involved in the risk of both colorectal (P = .022) and ovarian cancer (P = .003). CONCLUSIONS: Genetic variations in inflammation and its related subpathway components are keys to the development of lung, colorectal, ovary, and breast cancer, including SH2B3, which is associated with lung, colorectal, and breast cancer..
Litchfield, K.
Sultana, R.
Renwick, A.
Dudakia, D.
Seal, S.
Ramsay, E.
Powell, S.
Elliott, A.
Warren-Perry, M.
Eeles, R.
Peto, J.
Kote-Jarai, Z.
Muir, K.
Nsengimana, J.
UKTCC,
Stratton, M.R.
Easton, D.F.
Bishop, D.T.
Huddart, R.A.
Rahman, N.
Turnbull, C.
UKTCC,
(2015). Multi-stage genome-wide association study identifies new susceptibility locus for testicular germ cell tumour on chromosome 3q25. Hum mol genet,
Vol.24
(4),
pp. 1169-1176.
show abstract
Recent genome-wide association studies (GWAS) and subsequent meta-analyses have identified over 25 SNPs at 18 loci, together accounting for >15% of the genetic susceptibility to testicular germ cell tumour (TGCT). To identify further common SNPs associated with TGCT, here we report a three-stage experiment, involving 4098 cases and 18 972 controls. Stage 1 comprised previously published GWAS analysis of 307 291 SNPs in 986 cases and 4946 controls. In Stage 2, we used previously published customised Illumina iSelect genotyping array (iCOGs) data across 694 SNPs in 1064 cases and 10 082 controls. Here, we report new genotyping of eight SNPs showing some evidence of association in combined analysis of Stage 1 and Stage 2 in an additional 2048 cases of TGCT and 3944 controls (Stage 3). Through fixed-effects meta-analysis across three stages, we identified a novel locus at 3q25.31 (rs1510272) demonstrating association with TGCT [per-allele odds ratio (OR) = 1.16, 95% confidence interval (CI) = 1.06-1.27; P = 1.2 × 10(-9)]..
Zhang, C.
Doherty, J.A.
Burgess, S.
Hung, R.J.
Lindström, S.
Kraft, P.
Gong, J.
Amos, C.I.
Sellers, T.A.
Monteiro, A.N.
Chenevix-Trench, G.
Bickeböller, H.
Risch, A.
Brennan, P.
Mckay, J.D.
Houlston, R.S.
Landi, M.T.
Timofeeva, M.N.
Wang, Y.
Heinrich, J.
Kote-Jarai, Z.
Eeles, R.A.
Muir, K.
Wiklund, F.
Grönberg, H.
Berndt, S.I.
Chanock, S.J.
Schumacher, F.
Haiman, C.A.
Henderson, B.E.
Amin Al Olama, A.
Andrulis, I.L.
Hopper, J.L.
Chang-Claude, J.
John, E.M.
Malone, K.E.
Gammon, M.D.
Ursin, G.
Whittemore, A.S.
Hunter, D.J.
Gruber, S.B.
Knight, J.A.
Hou, L.
Le Marchand, L.
Newcomb, P.A.
Hudson, T.J.
Chan, A.T.
Li, L.
Woods, M.O.
Ahsan, H.
Pierce, B.L.
GECCO and GAME-ON Network: CORECT, DRIVE, ELLIPSE, FOCI, and TRICL,
(2015). Genetic determinants of telomere length and risk of common cancers: a Mendelian randomization study. Hum mol genet,
Vol.24
(18),
pp. 5356-5366.
show abstract
full text
Epidemiological studies have reported inconsistent associations between telomere length (TL) and risk for various cancers. These inconsistencies are likely attributable, in part, to biases that arise due to post-diagnostic and post-treatment TL measurement. To avoid such biases, we used a Mendelian randomization approach and estimated associations between nine TL-associated SNPs and risk for five common cancer types (breast, lung, colorectal, ovarian and prostate cancer, including subtypes) using data on 51 725 cases and 62 035 controls. We then used an inverse-variance weighted average of the SNP-specific associations to estimate the association between a genetic score representing long TL and cancer risk. The long TL genetic score was significantly associated with increased risk of lung adenocarcinoma (P = 6.3 × 10(-15)), even after exclusion of a SNP residing in a known lung cancer susceptibility region (TERT-CLPTM1L) P = 6.6 × 10(-6)). Under Mendelian randomization assumptions, the association estimate [odds ratio (OR) = 2.78] is interpreted as the OR for lung adenocarcinoma corresponding to a 1000 bp increase in TL. The weighted TL SNP score was not associated with other cancer types or subtypes. Our finding that genetic determinants of long TL increase lung adenocarcinoma risk avoids issues with reverse causality and residual confounding that arise in observational studies of TL and disease risk. Under Mendelian randomization assumptions, our finding suggests that longer TL increases lung adenocarcinoma risk. However, caution regarding this causal interpretation is warranted in light of the potential issue of pleiotropy, and a more general interpretation is that SNPs influencing telomere biology are also implicated in lung adenocarcinoma risk..
Gundem, G.
Van Loo, P.
Kremeyer, B.
Alexandrov, L.B.
Tubio, J.M.
Papaemmanuil, E.
Brewer, D.S.
Kallio, H.M.
Högnäs, G.
Annala, M.
Kivinummi, K.
Goody, V.
Latimer, C.
O'Meara, S.
Dawson, K.J.
Isaacs, W.
Emmert-Buck, M.R.
Nykter, M.
Foster, C.
Kote-Jarai, Z.
Easton, D.
Whitaker, H.C.
ICGC Prostate Group,
Neal, D.E.
Cooper, C.S.
Eeles, R.A.
Visakorpi, T.
Campbell, P.J.
McDermott, U.
Wedge, D.C.
Bova, G.S.
(2015). The evolutionary history of lethal metastatic prostate cancer. Nature,
Vol.520
(7547),
pp. 353-357.
show abstract
full text
Cancers emerge from an ongoing Darwinian evolutionary process, often leading to multiple competing subclones within a single primary tumour. This evolutionary process culminates in the formation of metastases, which is the cause of 90% of cancer-related deaths. However, despite its clinical importance, little is known about the principles governing the dissemination of cancer cells to distant organs. Although the hypothesis that each metastasis originates from a single tumour cell is generally supported, recent studies using mouse models of cancer demonstrated the existence of polyclonal seeding from and interclonal cooperation between multiple subclones. Here we sought definitive evidence for the existence of polyclonal seeding in human malignancy and to establish the clonal relationship among different metastases in the context of androgen-deprived metastatic prostate cancer. Using whole-genome sequencing, we characterized multiple metastases arising from prostate tumours in ten patients. Integrated analyses of subclonal architecture revealed the patterns of metastatic spread in unprecedented detail. Metastasis-to-metastasis spread was found to be common, either through de novo monoclonal seeding of daughter metastases or, in five cases, through the transfer of multiple tumour clones between metastatic sites. Lesions affecting tumour suppressor genes usually occur as single events, whereas mutations in genes involved in androgen receptor signalling commonly involve multiple, convergent events in different metastases. Our results elucidate in detail the complex patterns of metastatic spread and further our understanding of the development of resistance to androgen-deprivation therapy in prostate cancer..
Eeles, R.
Goh, C.
Castro, E.
Bancroft, E.
Guy, M.
Al Olama, A.A.
Easton, D.
Kote-Jarai, Z.
(2014). The genetic epidemiology of prostate cancer and its clinical implications. Nat rev urol,
Vol.11
(1),
pp. 18-31.
show abstract
Worldwide, familial and epidemiological studies have generated considerable evidence of an inherited component to prostate cancer. Indeed, rare highly penetrant genetic mutations have been implicated. Genome-wide association studies (GWAS) have also identified 76 susceptibility loci associated with prostate cancer risk, which occur commonly but are of low penetrance. However, these mutations interact multiplicatively, which can result in substantially increased risk. Currently, approximately 30% of the familial risk is due to such variants. Evaluating the functional aspects of these variants would contribute to our understanding of prostate cancer aetiology and would enable population risk stratification for screening. Furthermore, understanding the genetic risks of prostate cancer might inform predictions of treatment responses and toxicities, with the goal of personalized therapy. However, risk modelling and clinical translational research are needed before we can translate risk profiles generated from these variants into use in the clinical setting for targeted screening and treatment..
Hazelett, D.J.
Rhie, S.K.
Gaddis, M.
Yan, C.
Lakeland, D.L.
Coetzee, S.G.
Ellipse/GAME-ON consortium,
Practical consortium,
Henderson, B.E.
Noushmehr, H.
Cozen, W.
Kote-Jarai, Z.
Eeles, R.A.
Easton, D.F.
Haiman, C.A.
Lu, W.
Farnham, P.J.
Coetzee, G.A.
(2014). Comprehensive functional annotation of 77 prostate cancer risk loci. Plos genet,
Vol.10
(1),
p. e1004102.
show abstract
Genome-wide association studies (GWAS) have revolutionized the field of cancer genetics, but the causal links between increased genetic risk and onset/progression of disease processes remain to be identified. Here we report the first step in such an endeavor for prostate cancer. We provide a comprehensive annotation of the 77 known risk loci, based upon highly correlated variants in biologically relevant chromatin annotations--we identified 727 such potentially functional SNPs. We also provide a detailed account of possible protein disruption, microRNA target sequence disruption and regulatory response element disruption of all correlated SNPs at r(2) ≥ 0.88%. 88% of the 727 SNPs fall within putative enhancers, and many alter critical residues in the response elements of transcription factors known to be involved in prostate biology. We define as risk enhancers those regions with enhancer chromatin biofeatures in prostate-derived cell lines with prostate-cancer correlated SNPs. To aid the identification of these enhancers, we performed genomewide ChIP-seq for H3K27-acetylation, a mark of actively engaged enhancers, as well as the transcription factor TCF7L2. We analyzed in depth three variants in risk enhancers, two of which show significantly altered androgen sensitivity in LNCaP cells. This includes rs4907792, that is in linkage disequilibrium (r(2) = 0.91) with an eQTL for NUDT11 (on the X chromosome) in prostate tissue, and rs10486567, the index SNP in intron 3 of the JAZF1 gene on chromosome 7. Rs4907792 is within a critical residue of a strong consensus androgen response element that is interrupted in the protective allele, resulting in a 56% decrease in its androgen sensitivity, whereas rs10486567 affects both NKX3-1 and FOXA-AR motifs where the risk allele results in a 39% increase in basal activity and a 28% fold-increase in androgen stimulated enhancer activity. Identification of such enhancer variants and their potential target genes represents a preliminary step in connecting risk to disease process..
Mikropoulos, C.
Dadaev, T.
Tymrakiewicz, M.
Leongamornlert, D.
Saunders, E.
Little, S.J.
Govindasami, K.
Guy, M.
Wilkinson, R.
Morgan, A.
Donovan, J.
Neal, D.
Hamdy, F.
Antoniou, A.
Eeles, R.
Kote-Jarai, Z.
(2014). 751OPREVALENCE OF HOXB13G84E GERMLINE MUTATION IN UK PROSTATE CANCER CASES; CORRELATION WITH TUMOUR CHARACTERISTICS AND OUTCOMES. Ann oncol,
Vol.25
(suppl_4),
p. iv254.
Saunders, E.J.
Dadaev, T.
Leongamornlert, D.A.
Jugurnauth-Little, S.
Tymrakiewicz, M.
Wiklund, F.
Al Olama, A.A.
Benlloch, S.
Neal, D.E.
Hamdy, F.C.
Donovan, J.L.
Giles, G.G.
Severi, G.
Gronberg, H.
Aly, M.
Haiman, C.A.
Schumacher, F.
Henderson, B.E.
Lindstrom, S.
Kraft, P.
Hunter, D.J.
Gapstur, S.
Chanock, S.
Berndt, S.I.
Albanes, D.
Andriole, G.
Schleutker, J.
Weischer, M.
Nordestgaard, B.G.
Canzian, F.
Campa, D.
Riboli, E.
Key, T.J.
Travis, R.C.
Ingles, S.A.
John, E.M.
Hayes, R.B.
Pharoah, P.
Khaw, K.-.
Stanford, J.L.
Ostrander, E.A.
Signorello, L.B.
Thibodeau, S.N.
Schaid, D.
Maier, C.
Kibel, A.S.
Cybulski, C.
Cannon-Albright, L.
Brenner, H.
Park, J.Y.
Kaneva, R.
Batra, J.
Clements, J.A.
Teixeira, M.R.
Xu, J.
Mikropoulos, C.
Goh, C.
Govindasami, K.
Guy, M.
Wilkinson, R.A.
Sawyer, E.J.
Morgan, A.
COGS-CRUK GWAS-ELLIPSE (Part of GAME-ON) Initiative,
UK Genetic Prostate Cancer Study Collaborators,
UK ProtecT Study Collaborators,
PRACTICAL Consortium,
Easton, D.F.
Muir, K.
Eeles, R.A.
Kote-Jarai, Z.
(2014). Fine-mapping the HOXB region detects common variants tagging a rare coding allele: evidence for synthetic association in prostate cancer. Plos genet,
Vol.10
(2),
p. e1004129.
show abstract
The HOXB13 gene has been implicated in prostate cancer (PrCa) susceptibility. We performed a high resolution fine-mapping analysis to comprehensively evaluate the association between common genetic variation across the HOXB genetic locus at 17q21 and PrCa risk. This involved genotyping 700 SNPs using a custom Illumina iSelect array (iCOGS) followed by imputation of 3195 SNPs in 20,440 PrCa cases and 21,469 controls in The PRACTICAL consortium. We identified a cluster of highly correlated common variants situated within or closely upstream of HOXB13 that were significantly associated with PrCa risk, described by rs117576373 (OR 1.30, P = 2.62×10(-14)). Additional genotyping, conditional regression and haplotype analyses indicated that the newly identified common variants tag a rare, partially correlated coding variant in the HOXB13 gene (G84E, rs138213197), which has been identified recently as a moderate penetrance PrCa susceptibility allele. The potential for GWAS associations detected through common SNPs to be driven by rare causal variants with higher relative risks has long been proposed; however, to our knowledge this is the first experimental evidence for this phenomenon of synthetic association contributing to cancer susceptibility..
Teerlink, C.C.
Thibodeau, S.N.
McDonnell, S.K.
Schaid, D.J.
Rinckleb, A.
Maier, C.
Vogel, W.
Cancel-Tassin, G.
Egrot, C.
Cussenot, O.
Foulkes, W.D.
Giles, G.G.
Hopper, J.L.
Severi, G.
Eeles, R.
Easton, D.
Kote-Jarai, Z.
Guy, M.
Cooney, K.A.
Ray, A.M.
Zuhlke, K.A.
Lange, E.M.
FitzGerald, L.M.
Stanford, J.L.
Ostrander, E.A.
Wiley, K.E.
Isaacs, S.D.
Walsh, P.C.
Isaacs, W.B.
Wahlfors, T.
Tammela, T.
Schleutker, J.
Wiklund, F.
Gronberg, H.
Emanuelsson, M.
Carpten, J.
Bailey-Wilson, J.
Whittemore, A.S.
Oakley-Girvan, I.
Hsieh, C.-.
Catalona, W.J.
Zheng, S.L.
Jin, G.
Lu, L.
Xu, J.
Camp, N.J.
Cannon-Albright, L.A.
Genet, I.C.
(2014). Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease. Human genetics,
Vol.133
(3),
pp. 347-356.
full text
Knipe, D.W.
Evans, D.M.
Kemp, J.P.
Eeles, R.
Easton, D.F.
Kote-Jarai, Z.
Al Olama, A.A.
Benlloch, S.
Donovan, J.L.
Hamdy, F.C.
Neal, D.E.
Smith, G.D.
Lathrop, M.
Martin, R.M.
(2014). Genetic variation in prostate-specific antigen-detected prostate cancer and the effect of control selection on genetic association studies. Cancer epidemiol biomarkers prev,
Vol.23
(7),
pp. 1356-1365.
show abstract
BACKGROUND: Only a minority of the genetic components of prostate cancer risk have been explained. Some observed associations of SNPs with prostate cancer might arise from associations of these SNPs with circulating prostate-specific antigen (PSA) because PSA values are used to select controls. METHODS: We undertook a genome-wide association study (GWAS) of screen-detected prostate cancer (ProtecT: 1,146 cases and 1,804 controls); meta-analyzed the results with those from the previously published UK Genetic Prostate Cancer Study (1,854 cases and 1,437 controls); investigated associations of SNPs with prostate cancer using either "low" (PSA < 0.5 ng/mL) or "high" (PSA ≥ 3 ng/mL, biopsy negative) PSA controls; and investigated associations of SNPs with PSA. RESULTS: The ProtecT GWAS confirmed previously reported associations of prostate cancer at three loci: 10q11.23, 17q24.3, and 19q13.33. The meta-analysis confirmed associations of prostate cancer with SNPs near four previously identified loci (8q24.21,10q11.23, 17q24.3, and 19q13.33). When comparing prostate cancer cases with low PSA controls, alleles at genetic markers rs1512268, rs445114, rs10788160, rs11199874, rs17632542, rs266849, and rs2735839 were associated with an increased risk of prostate cancer, but the effect-estimates were attenuated to the null when using high PSA controls (Pheterogeneity in effect-estimates < 0.04). We found a novel inverse association of rs9311171-T with circulating PSA. CONCLUSIONS: Differences in effect-estimates for prostate cancer observed when comparing low versus high PSA controls may be explained by associations of these SNPs with PSA. IMPACT: These findings highlight the need for inferences from genetic studies of prostate cancer risk to carefully consider the influence of control selection criteria..
Bancroft, E.K.
Page, E.C.
Castro, E.
Lilja, H.
Vickers, A.
Sjoberg, D.
Assel, M.
Foster, C.S.
Mitchell, G.
Drew, K.
Mæhle, L.
Axcrona, K.
Evans, D.G.
Bulman, B.
Eccles, D.
McBride, D.
van Asperen, C.
Vasen, H.
Kiemeney, L.A.
Ringelberg, J.
Cybulski, C.
Wokolorczyk, D.
Selkirk, C.
Hulick, P.J.
Bojesen, A.
Skytte, A.-.
Lam, J.
Taylor, L.
Oldenburg, R.
Cremers, R.
Verhaegh, G.
van Zelst-Stams, W.A.
Oosterwijk, J.C.
Blanco, I.
Salinas, M.
Cook, J.
Rosario, D.J.
Buys, S.
Conner, T.
Ausems, M.G.
Ong, K.-.
Hoffman, J.
Domchek, S.
Powers, J.
Teixeira, M.R.
Maia, S.
Foulkes, W.D.
Taherian, N.
Ruijs, M.
Helderman-van den Enden, A.T.
Izatt, L.
Davidson, R.
Adank, M.A.
Walker, L.
Schmutzler, R.
Tucker, K.
Kirk, J.
Hodgson, S.
Harris, M.
Douglas, F.
Lindeman, G.J.
Zgajnar, J.
Tischkowitz, M.
Clowes, V.E.
Susman, R.
Ramón y Cajal, T.
Patcher, N.
Gadea, N.
Spigelman, A.
van Os, T.
Liljegren, A.
Side, L.
Brewer, C.
Brady, A.F.
Donaldson, A.
Stefansdottir, V.
Friedman, E.
Chen-Shtoyerman, R.
Amor, D.J.
Copakova, L.
Barwell, J.
Giri, V.N.
Murthy, V.
Nicolai, N.
Teo, S.-.
Greenhalgh, L.
Strom, S.
Henderson, A.
McGrath, J.
Gallagher, D.
Aaronson, N.
Ardern-Jones, A.
Bangma, C.
Dearnaley, D.
Costello, P.
Eyfjord, J.
Rothwell, J.
Falconer, A.
Gronberg, H.
Hamdy, F.C.
Johannsson, O.
Khoo, V.
Kote-Jarai, Z.
Lubinski, J.
Axcrona, U.
Melia, J.
McKinley, J.
Mitra, A.V.
Moynihan, C.
Rennert, G.
Suri, M.
Wilson, P.
Killick, E.
IMPACT Collaborators,
Moss, S.
Eeles, R.A.
(2014). Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. Eur urol,
Vol.66
(3),
pp. 489-499.
show abstract
full text
BACKGROUND: Men with germline breast cancer 1, early onset (BRCA1) or breast cancer 2, early onset (BRCA2) gene mutations have a higher risk of developing prostate cancer (PCa) than noncarriers. IMPACT (Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in BRCA1/2 mutation carriers and controls) is an international consortium of 62 centres in 20 countries evaluating the use of targeted PCa screening in men with BRCA1/2 mutations. OBJECTIVE: To report the first year's screening results for all men at enrollment in the study. DESIGN, SETTING AND PARTICIPANTS: We recruited men aged 40-69 yr with germline BRCA1/2 mutations and a control group of men who have tested negative for a pathogenic BRCA1 or BRCA2 mutation known to be present in their families. All men underwent prostate-specific antigen (PSA) testing at enrollment, and those men with PSA >3 ng/ml were offered prostate biopsy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: PSA levels, PCa incidence, and tumour characteristics were evaluated. The Fisher exact test was used to compare the number of PCa cases among groups and the differences among disease types. RESULTS AND LIMITATIONS: We recruited 2481 men (791 BRCA1 carriers, 531 BRCA1 controls; 731 BRCA2 carriers, 428 BRCA2 controls). A total of 199 men (8%) presented with PSA >3.0 ng/ml, 162 biopsies were performed, and 59 PCas were diagnosed (18 BRCA1 carriers, 10 BRCA1 controls; 24 BRCA2 carriers, 7 BRCA2 controls); 66% of the tumours were classified as intermediate- or high-risk disease. The positive predictive value (PPV) for biopsy using a PSA threshold of 3.0 ng/ml in BRCA2 mutation carriers was 48%-double the PPV reported in population screening studies. A significant difference in detecting intermediate- or high-risk disease was observed in BRCA2 carriers. Ninety-five percent of the men were white, thus the results cannot be generalised to all ethnic groups. CONCLUSIONS: The IMPACT screening network will be useful for targeted PCa screening studies in men with germline genetic risk variants as they are discovered. These preliminary results support the use of targeted PSA screening based on BRCA genotype and show that this screening yields a high proportion of aggressive disease. PATIENT SUMMARY: In this report, we demonstrate that germline genetic markers can be used to identify men at higher risk of prostate cancer. Targeting screening at these men resulted in the identification of tumours that were more likely to require treatment..
Al Olama, A.A.
Kote-Jarai, Z.
Berndt, S.I.
Conti, D.V.
Schumacher, F.
Han, Y.
Benlloch, S.
Hazelett, D.J.
Wang, Z.
Saunders, E.
Leongamornlert, D.
Lindstrom, S.
Jugurnauth-Little, S.
Dadaev, T.
Tymrakiewicz, M.
Stram, D.O.
Rand, K.
Wan, P.
Stram, A.
Sheng, X.
Pooler, L.C.
Park, K.
Xia, L.
Tyrer, J.
Kolonel, L.N.
Le Marchand, L.
Hoover, R.N.
Machiela, M.J.
Yeager, M.
Burdette, L.
Chung, C.C.
Hutchinson, A.
Yu, K.
Goh, C.
Ahmed, M.
Govindasami, K.
Guy, M.
Tammela, T.L.
Auvinen, A.
Wahlfors, T.
Schleutker, J.
Visakorpi, T.
Leinonen, K.A.
Xu, J.
Aly, M.
Donovan, J.
Travis, R.C.
Key, T.J.
Siddiq, A.
Canzian, F.
Khaw, K.-.
Takahashi, A.
Kubo, M.
Pharoah, P.
Pashayan, N.
Weischer, M.
Nordestgaard, B.G.
Nielsen, S.F.
Klarskov, P.
Røder, M.A.
Iversen, P.
Thibodeau, S.N.
McDonnell, S.K.
Schaid, D.J.
Stanford, J.L.
Kolb, S.
Holt, S.
Knudsen, B.
Coll, A.H.
Gapstur, S.M.
Diver, W.R.
Stevens, V.L.
Maier, C.
Luedeke, M.
Herkommer, K.
Rinckleb, A.E.
Strom, S.S.
Pettaway, C.
Yeboah, E.D.
Tettey, Y.
Biritwum, R.B.
Adjei, A.A.
Tay, E.
Truelove, A.
Niwa, S.
Chokkalingam, A.P.
Cannon-Albright, L.
Cybulski, C.
Wokołorczyk, D.
Kluźniak, W.
Park, J.
Sellers, T.
Lin, H.-.
Isaacs, W.B.
Partin, A.W.
Brenner, H.
Dieffenbach, A.K.
Stegmaier, C.
Chen, C.
Giovannucci, E.L.
Ma, J.
Stampfer, M.
Penney, K.L.
Mucci, L.
John, E.M.
Ingles, S.A.
Kittles, R.A.
Murphy, A.B.
Pandha, H.
Michael, A.
Kierzek, A.M.
Blot, W.
Signorello, L.B.
Zheng, W.
Albanes, D.
Virtamo, J.
Weinstein, S.
Nemesure, B.
Carpten, J.
Leske, C.
Wu, S.-.
Hennis, A.
Kibel, A.S.
Rybicki, B.A.
Neslund-Dudas, C.
Hsing, A.W.
Chu, L.
Goodman, P.J.
Klein, E.A.
Zheng, S.L.
Batra, J.
Clements, J.
Spurdle, A.
Teixeira, M.R.
Paulo, P.
Maia, S.
Slavov, C.
Kaneva, R.
Mitev, V.
Witte, J.S.
Casey, G.
Gillanders, E.M.
Seminara, D.
Riboli, E.
Hamdy, F.C.
Coetzee, G.A.
Li, Q.
Freedman, M.L.
Hunter, D.J.
Muir, K.
Gronberg, H.
Neal, D.E.
Southey, M.
Giles, G.G.
Severi, G.
Breast and Prostate Cancer Cohort Consortium (BPC3),
PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium,
COGS (Collaborative Oncological Gene-environment Study) Consortium,
GAME-ON/ELLIPSE Consortium,
Cook, M.B.
Nakagawa, H.
Wiklund, F.
Kraft, P.
Chanock, S.J.
Henderson, B.E.
Easton, D.F.
Eeles, R.A.
Haiman, C.A.
(2014). A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat genet,
Vol.46
(10),
pp. 1103-1109.
show abstract
Genome-wide association studies (GWAS) have identified 76 variants associated with prostate cancer risk predominantly in populations of European ancestry. To identify additional susceptibility loci for this common cancer, we conducted a meta-analysis of > 10 million SNPs in 43,303 prostate cancer cases and 43,737 controls from studies in populations of European, African, Japanese and Latino ancestry. Twenty-three new susceptibility loci were identified at association P < 5 × 10(-8); 15 variants were identified among men of European ancestry, 7 were identified in multi-ancestry analyses and 1 was associated with early-onset prostate cancer. These 23 variants, in combination with known prostate cancer risk variants, explain 33% of the familial risk for this disease in European-ancestry populations. These findings provide new regions for investigation into the pathogenesis of prostate cancer and demonstrate the usefulness of combining ancestrally diverse populations to discover risk loci for disease..
Leongamornlert, D.
Saunders, E.
Dadaev, T.
Tymrakiewicz, M.
Goh, C.
Jugurnauth-Little, S.
Kozarewa, I.
Fenwick, K.
Assiotis, I.
Barrowdale, D.
Govindasami, K.
Guy, M.
Sawyer, E.
Wilkinson, R.
UKGPCS Collaborators,
Antoniou, A.C.
Eeles, R.
Kote-Jarai, Z.
(2014). Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease. Br j cancer,
Vol.110
(6),
pp. 1663-1672.
show abstract
BACKGROUND: Prostate cancer (PrCa) is one of the most common diseases to affect men worldwide and among the leading causes of cancer-related death. The purpose of this study was to use second-generation sequencing technology to assess the frequency of deleterious mutations in 22 tumour suppressor genes in familial PrCa and estimate the relative risk of PrCa if these genes are mutated. METHODS: Germline DNA samples from 191 men with 3 or more cases of PrCa in their family were sequenced for 22 tumour suppressor genes using Agilent target enrichment and Illumina technology. Analysis for genetic variation was carried out by using a pipeline consisting of BWA, Genome Analysis Toolkit (GATK) and ANNOVAR. Clinical features were correlated with mutation status using standard statistical tests. Modified segregation analysis was used to determine the relative risk of PrCa conferred by the putative loss-of-function (LoF) mutations identified. RESULTS: We discovered 14 putative LoF mutations in 191 samples (7.3%) and these mutations were more frequently associated with nodal involvement, metastasis or T4 tumour stage (P=0.00164). Segregation analysis of probands with European ancestry estimated that LoF mutations in any of the studied genes confer a relative risk of PrCa of 1.94 (95% CI: 1.56-2.42). CONCLUSIONS: These findings show that LoF mutations in DNA repair pathway genes predispose to familial PrCa and advanced disease and therefore warrants further investigation. The clinical utility of these findings will become increasingly important as targeted screening and therapies become more widespread..
Killick, E.
Tymrakiewicz, M.
Cieza-Borrella, C.
Smith, P.
Thompson, D.J.
Pooley, K.A.
Easton, D.F.
Bancroft, E.
Page, E.
Leongamornlert, D.
IMPACT collaborators,
Kote-Jarai, Z.
Eeles, R.A.
(2014). Telomere length shows no association with BRCA1 and BRCA2 mutation status. Plos one,
Vol.9
(1),
p. e86659.
show abstract
This study aimed to determine whether telomere length (TL) is a marker of cancer risk or genetic status amongst two cohorts of BRCA1 and BRCA2 mutation carriers and controls. The first group was a prospective set of 665 male BRCA1/2 mutation carriers and controls (mean age 53 years), all healthy at time of enrollment and blood donation, 21 of whom have developed prostate cancer whilst on study. The second group consisted of 283 female BRCA1/2 mutation carriers and controls (mean age 48 years), half of whom had been diagnosed with breast cancer prior to enrollment. TL was quantified by qPCR from DNA extracted from peripheral blood lymphocytes. Weighted and unweighted Cox regressions and linear regression analyses were used to assess whether TL was associated with BRCA1/2 mutation status or cancer risk. We found no evidence for association between developing cancer or being a BRCA1 or BRCA2 mutation carrier and telomere length. It is the first study investigating TL in a cohort of genetically predisposed males and although TL and BRCA status was previously studied in females our results don't support the previous finding of association between hereditary breast cancer and shorter TL..
Mikropoulos, C.
Goh, C.
Leongamornlert, D.
Kote-Jarai, Z.
Eeles, R.
(2014). Translating genetic risk factors for prostate cancer to the clinic: 2013 and beyond. Future oncol,
Vol.10
(9),
pp. 1679-1694.
show abstract
Prostate cancer (PrCa) is the most commonly diagnosed cancer in the male UK population, with over 40,000 new cases per year. PrCa has a complex, polygenic predisposition, due to rare variants such as BRCA and common variants such as single nucleotide polymorphisms (SNPs). With the introduction of genome-wide association studies, 78 susceptibility loci (SNPs) associated with PrCa risk have been identified. Genetic profiling could risk-stratify a population, leading to the discovery of a higher proportion of clinically significant disease and a reduction in the morbidity related to age-based prostate-specific antigen screening. Based on the combined risk of the 78 SNPs identified so far, the top 1% of the risk distribution has a 4.7-times higher risk of developing PrCa compared with the average of the general population..
Mao, X.
Marzec, J.
Li, M.
Zhang, Z.
Feng, N.
Gou, X.
Sun, Z.
Xu, J.
Xue, Y.
Al Olama, A.A.
Xu, X.
Li, J.
He, W.
Benlloch, S.
Kote-Jarai, Z.
Wang, M.
Chelala, C.
Easton, D.F.
Eeles, R.A.
Lu, Y.-.
Zhang, H.
Consortium, P.R.
Grp, C.H.
(2014). Population differences in the genetic risk of prostate cancer and predisposition loci in the Chinese population. International journal of molecular medicine,
Vol.34,
pp. S89-S89.
deSouza, N.M.
Morgan, V.A.
Bancroft, E.
Sohaib, S.A.
Giles, S.L.
Kote-Jarai, Z.
Castro, E.
Hazell, S.
Jafar, M.
Eeles, R.
(2014). Diffusion-weighted MRI for detecting prostate tumour in men at increased genetic risk. Eur j radiol open,
Vol.1,
pp. 22-27.
show abstract
full text
BACKGROUND: Diffusion-weighted (DW)-MRI is invaluable in detecting prostate cancer. We determined its sensitivity and specificity and established interobserver agreement for detecting tumour in men with a family history of prostate cancer stratified by genetic risk. METHODS: 51 men with a family history of prostate cancer underwent T2-W + DW-endorectal MRI at 3.0 T. Presence of tumour was noted at right and left apex, mid and basal prostate sextants by 2 independent observers, 1 experienced and the other inexperienced in endorectal MRI. Sensitivity and specificity against a 10-core sampling technique (lateral and medial cores at each level considered together) in men with >2× population risk based on 71 SNP analysis versus those with lower genetic risk scores was established. Interobserver agreement was determined at a subject level. RESULTS: Biopsies indicated cancer in 28 sextants in 13/51 men; 32 of 51 men had twice the population risk (>0.25) based on 71 SNP profiling. Sensitivity/specificity per-subject for patients was 90.0%/86.4% (high-risk) vs. 66.7%/100% (low-risk, observer 1) and 60.0%/86.3% (high-risk) vs. 33.3%/93.8% (low-risk, observer 2) with moderate overall inter-observer agreement (kappa = 0.42). Regional sensitivities/specificities for high-risk vs. low-risk for observer 1 apex 72.2%/100% [33.3%/100%], mid 100%/93.1% [100%/97.3%], base 16.7%/98.3% [0%/100%] and for observer 2 apex 36.4%/98.1% [0%/100%], mid 28.6%/96.5% [100%/100%], base 20%/100% [0%/97.3%] were poorer as they failed to detect multiple lesions. CONCLUSION: Endorectal T2W + DW-MRI at 3.0 T yields high sensitivity and specificity for tumour detection by an experienced observer in screening men with a family history of prostate cancer and increased genetic risk..
Xu, J.
Lange, E.M.
Lu, L.
Zheng, S.L.
Wang, Z.
Thibodeau, S.N.
Cannon-Albright, L.A.
Teerlink, C.C.
Camp, N.J.
Johnson, A.M.
Zuhlke, K.A.
Stanford, J.L.
Ostrander, E.A.
Wiley, K.E.
Isaacs, S.D.
Walsh, P.C.
Maier, C.
Luedeke, M.
Vogel, W.
Schleutker, J.
Wahlfors, T.
Tammela, T.
Schaid, D.
McDonnell, S.K.
DeRycke, M.S.
Cancel-Tassin, G.
Cussenot, O.
Wiklund, F.
Gronberg, H.
Eeles, R.
Easton, D.
Kote-Jarai, Z.
Whittemore, A.S.
Hsieh, C.-.
Giles, G.G.
Hopper, J.L.
Severi, G.
Catalona, W.J.
Mandal, D.
Ledet, E.
Foulkes, W.D.
Hamel, N.
Mahle, L.
Moller, P.
Powell, I.
Bailey-Wilson, J.E.
Carpten, J.D.
Seminara, D.
Cooney, K.A.
Isaacs, W.B.
Genet, I.C.
(2013). HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Human genetics,
Vol.132
(1),
pp. 5-14.
Eeles, R.A.
Olama, A.A.
Benlloch, S.
Saunders, E.J.
Leongamornlert, D.A.
Tymrakiewicz, M.
Ghoussaini, M.
Luccarini, C.
Dennis, J.
Jugurnauth-Little, S.
Dadaev, T.
Neal, D.E.
Hamdy, F.C.
Donovan, J.L.
Muir, K.
Giles, G.G.
Severi, G.
Wiklund, F.
Gronberg, H.
Haiman, C.A.
Schumacher, F.
Henderson, B.E.
Le Marchand, L.
Lindstrom, S.
Kraft, P.
Hunter, D.J.
Gapstur, S.
Chanock, S.J.
Berndt, S.I.
Albanes, D.
Andriole, G.
Schleutker, J.
Weischer, M.
Canzian, F.
Riboli, E.
Key, T.J.
Travis, R.C.
Campa, D.
Ingles, S.A.
John, E.M.
Hayes, R.B.
Pharoah, P.D.
Pashayan, N.
Khaw, K.-.
Stanford, J.L.
Ostrander, E.A.
Signorello, L.B.
Thibodeau, S.N.
Schaid, D.
Maier, C.
Vogel, W.
Kibel, A.S.
Cybulski, C.
Lubinski, J.
Cannon-Albright, L.
Brenner, H.
Park, J.Y.
Kaneva, R.
Batra, J.
Spurdle, A.B.
Clements, J.A.
Teixeira, M.R.
Dicks, E.
Lee, A.
Dunning, A.M.
Baynes, C.
Conroy, D.
Maranian, M.J.
Ahmed, S.
Govindasami, K.
Guy, M.
Wilkinson, R.A.
Sawyer, E.J.
Morgan, A.
Dearnaley, D.P.
Horwich, A.
Huddart, R.A.
Khoo, V.S.
Parker, C.C.
Van As, N.J.
Woodhouse, C.J.
Thompson, A.
Dudderidge, T.
Ogden, C.
Cooper, C.S.
Lophatananon, A.
Cox, A.
Southey, M.C.
Hopper, J.L.
English, D.R.
Aly, M.
Adolfsson, J.
Xu, J.
Zheng, S.L.
Yeager, M.
Kaaks, R.
Diver, W.R.
Gaudet, M.M.
Stern, M.C.
Corral, R.
Joshi, A.D.
Shahabi, A.
Wahlfors, T.
Tammela, T.L.
Auvinen, A.
Virtamo, J.
Klarskov, P.
Nordestgaard, B.G.
Røder, M.A.
Nielsen, S.F.
Bojesen, S.E.
Siddiq, A.
Fitzgerald, L.M.
Kolb, S.
Kwon, E.M.
Karyadi, D.M.
Blot, W.J.
Zheng, W.
Cai, Q.
McDonnell, S.K.
Rinckleb, A.E.
Drake, B.
Colditz, G.
Wokolorczyk, D.
Stephenson, R.A.
Teerlink, C.
Muller, H.
Rothenbacher, D.
Sellers, T.A.
Lin, H.-.
Slavov, C.
Mitev, V.
Lose, F.
Srinivasan, S.
Maia, S.
Paulo, P.
Lange, E.
Cooney, K.A.
Antoniou, A.C.
Vincent, D.
Bacot, F.
Tessier, D.C.
COGS–Cancer Research UK GWAS–ELLIPSE (part of GAME-ON) Initiative,
Australian Prostate Cancer Bioresource,
UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology,
UK ProtecT (Prostate testing for cancer and Treatment) Study Collaborators,
PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium,
Kote-Jarai, Z.
Easton, D.F.
(2013). Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat genet,
Vol.45
(4),
pp. 385-391e2.
show abstract
Prostate cancer is the most frequently diagnosed cancer in males in developed countries. To identify common prostate cancer susceptibility alleles, we genotyped 211,155 SNPs on a custom Illumina array (iCOGS) in blood DNA from 25,074 prostate cancer cases and 24,272 controls from the international PRACTICAL Consortium. Twenty-three new prostate cancer susceptibility loci were identified at genome-wide significance (P < 5 × 10(-8)). More than 70 prostate cancer susceptibility loci, explaining ∼30% of the familial risk for this disease, have now been identified. On the basis of combined risks conferred by the new and previously known risk loci, the top 1% of the risk distribution has a 4.7-fold higher risk than the average of the population being profiled. These results will facilitate population risk stratification for clinical studies..
Orozco, G.
Goh, C.L.
Al Olama, A.A.
Benlloch-Garcia, S.
Govindasami, K.
Guy, M.
Muir, K.R.
Giles, G.G.
Severi, G.
Neal, D.E.
Hamdy, F.C.
Donovan, J.L.
Kote-Jarai, Z.
Easton, D.F.
Eyre, S.
Eeles, R.A.
(2013). Common genetic variants associated with disease from genome-wide association studies are mutually exclusive in prostate cancer and rheumatoid arthritis. Bju int,
Vol.111
(7),
pp. 1148-1155.
show abstract
full text
UNLABELLED: WHAT'S KNOWN ON THE SUBJECT? AND WHAT DOES THE STUDY ADD?: The link between inflammation and cancer has long been reported and inflammation is thought to play a role in the pathogenesis of many cancers, including prostate cancer (PrCa). Over the last 5 years, genome-wide association studies (GWAS) have reported numerous susceptibility loci that predispose individuals to many different traits. The present study aims to ascertain if there are common genetic risk profiles that might predispose individuals to both PrCa and the autoimmune inflammatory condition, rheumatoid arthritis. These results could have potential public heath impact in terms of screening and chemoprevention. OBJECTIVES: To investigate if potential common pathways exist for the pathogenesis of autoimmune disease and prostate cancer (PrCa). To ascertain if the single nucleotide polymorphisms (SNPs) reported by genome-wide association studies (GWAS) as being associated with susceptibility to PrCa are also associated with susceptibility to the autoimmune disease rheumatoid arthritis (RA). MATERIALS AND METHODS: The original Wellcome Trust Case Control Consortium (WTCCC) UK RA GWAS study was expanded to include a total of 3221 cases and 5272 controls. In all, 37 germline autosomal SNPs at genome-wide significance associated with PrCa risk were identified from a UK/Australian PrCa GWAS. Allele frequencies were compared for these 37 SNPs between RA cases and controls using a chi-squared trend test and corrected for multiple testing (Bonferroni). RESULTS: In all, 33 SNPs were able to be analysed in the RA dataset. Proxies could not be located for the SNPs in 3q26, 5p15 and for two SNPs in 17q12. After applying a Bonferroni correction for the number of SNPs tested, the SNP mapping to CCHCR1 (rs130067) retained statistically significant evidence for association (P = 6 × 10(-4) ; odds ratio [OR] = 1.15, 95% CI: 1.06-1.24); this has also been associated with psoriasis. However, further analyses showed that the association of this allele was due to confounding by RA-associated HLA-DRB1 alleles. CONCLUSIONS: There is currently no evidence that SNPs associated with PrCa at genome-wide significance are associated with the development of RA. Studies like this are important in determining if common genetic risk profiles might predispose individuals to many diseases, which could have implications for public health in terms of screening and chemoprevention..
Lose, F.
Batra, J.
O'Mara, T.
Fahey, P.
Marquart, L.
Eeles, R.A.
Easton, D.F.
Al Olama, A.A.
Kote-Jarai, Z.
Guy, M.
Muir, K.
Lophatananon, A.
Rahman, A.A.
Neal, D.E.
Hamdy, F.C.
Donovan, J.L.
Chambers, S.
Gardiner, R.A.
Aitken, J.F.
Yaxley, J.
Alexander, K.
Clements, J.A.
Spurdle, A.B.
Kedda, M.-.
Australian Prostate Cancer BioResource,
(2013). Common variation in Kallikrein genes KLK5, KLK6, KLK12, and KLK13 and risk of prostate cancer and tumor aggressiveness. Urol oncol,
Vol.31
(5),
pp. 635-643.
show abstract
The human tissue Kallikrein family consists of 15 genes with the majority shown to be differentially expressed in cancers and/or indicators of cancer prognosis. We sought to elucidate the role of common genetic variation in four of the Kallikrein genes, KLK5, KLK6, KLK12, and KLK13, in prostate cancer risk and tumor aggressiveness. Genotyping of all 22 tagging single nucleotide polymorphisms (tagSNPs) in the KLK5, KLK6, KLK12, and KLK13 genes was performed in approximately 1,000 prostate cancer cases and 1,300 male controls from Australia. Data from any positive results were also accessed for 1,844 cases and 1,886 controls from a previously published prostate cancer genome-wide association study set from the United Kingdom. For one SNP in KLK12, rs3865443, there was evidence for association with prostate cancer risk of similar direction and magnitude in the replication set to that seen in the Australian cohort. We conducted genotyping of a further 309 prostate cancer cases, and combined analyses revealed an increased risk of prostate cancer for carriers of the rare homozygous genotype for rs3865443 (OR 1.28, 95% CI 1.04-1.57; P = 0.018). No other tagSNPs in the KLK5, KLK6, and KLK13 genes were consistently associated with prostate cancer risk or tumor aggressiveness. Analysis of a combined sample of 3,153 cases and 3,199 controls revealed the KLK12 tagSNP rs3865443 to be marginally statistically significantly associated with risk of prostate cancer. Considering the total number of SNPs investigated in this study, this finding should be interpreted cautiously and requires additional validation from very large datasets such as those of the Prostate Cancer Association group to investigate cancer associated alterations (PRACTICAL) Consortium..
(2013). Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Human molecular genetics,
Vol.22
(20),
pp. 4239-4239.
Lai, J.
An, J.
Nelson, C.
Kote-Jarai, Z.
Easton, D.
Amin, A.
Eeles, R.
Clements, J.
Batra, J.
(2013). Genome-wide analyses reveal specific functional repetitive DNA that are proximal to prostate cancer risk alleles. Bju international,
Vol.112,
pp. 37-37.
Goh, C.L.
Saunders, E.J.
Leongamornlert, D.A.
Tymrakiewicz, M.
Thomas, K.
Selvadurai, E.D.
Woode-Amissah, R.
Dadaev, T.
Mahmud, N.
Castro, E.
Olmos, D.
Guy, M.
Govindasami, K.
O'Brien, L.T.
Hall, A.L.
Wilkinson, R.A.
Sawyer, E.J.
Al Olama, A.A.
Easton, D.F.
Kote-Jarai, Z.
Parker, C.C.
Eeles, R.A.
(2013). Clinical implications of family history of prostate cancer and genetic risk single nucleotide polymorphism (SNP) profiles in an active surveillance cohort. Bju international,
Vol.112
(5),
pp. 666-673.
Castro, E.
Goh, C.
Olmos, D.
Saunders, E.
Leongamornlert, D.
Tymrakiewicz, M.
Mahmud, N.
Dadaev, T.
Govindasami, K.
Guy, M.
Sawyer, E.
Wilkinson, R.
Ardern-Jones, A.
Ellis, S.
Frost, D.
Peock, S.
Evans, D.G.
Tischkowitz, M.
Cole, T.
Davidson, R.
Eccles, D.
Brewer, C.
Douglas, F.
Porteous, M.E.
Donaldson, A.
Dorkins, H.
Izatt, L.
Cook, J.
Hodgson, S.
Kennedy, M.J.
Side, L.E.
Eason, J.
Murray, A.
Antoniou, A.C.
Easton, D.F.
Kote-Jarai, Z.
Eeles, R.
(2013). Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J clin oncol,
Vol.31
(14),
pp. 1748-1757.
show abstract
PURPOSE: To analyze the baseline clinicopathologic characteristics of prostate tumors with germline BRCA1 and BRCA2 (BRCA1/2) mutations and the prognostic value of those mutations on prostate cancer (PCa) outcomes. PATIENTS AND METHODS: This study analyzed the tumor features and outcomes of 2,019 patients with PCa (18 BRCA1 carriers, 61 BRCA2 carriers, and 1,940 noncarriers). The Kaplan-Meier method and Cox regression analysis were used to evaluate the associations between BRCA1/2 status and other PCa prognostic factors with overall survival (OS), cause-specific OS (CSS), CSS in localized PCa (CSS_M0), metastasis-free survival (MFS), and CSS from metastasis (CSS_M1). RESULTS: PCa with germline BRCA1/2 mutations were more frequently associated with Gleason ≥ 8 (P = .00003), T3/T4 stage (P = .003), nodal involvement (P = .00005), and metastases at diagnosis (P = .005) than PCa in noncarriers. CSS was significantly longer in noncarriers than in carriers (15.7 v 8.6 years, multivariable analyses [MVA] P = .015; hazard ratio [HR] = 1.8). For localized PCa, 5-year CSS and MFS were significantly higher in noncarriers (96% v 82%; MVA P = .01; HR = 2.6%; and 93% v 77%; MVA P = .009; HR = 2.7, respectively). Subgroup analyses confirmed the poor outcomes in BRCA2 patients, whereas the role of BRCA1 was not well defined due to the limited size and follow-up in this subgroup. CONCLUSION: Our results confirm that BRCA1/2 mutations confer a more aggressive PCa phenotype with a higher probability of nodal involvement and distant metastasis. BRCA mutations are associated with poor survival outcomes and this should be considered for tailoring clinical management of these patients..
Amin Al Olama, A.
Kote-Jarai, Z.
Schumacher, F.R.
Wiklund, F.
Berndt, S.I.
Benlloch, S.
Giles, G.G.
Severi, G.
Neal, D.E.
Hamdy, F.C.
Donovan, J.L.
Hunter, D.J.
Henderson, B.E.
Thun, M.J.
Gaziano, M.
Giovannucci, E.L.
Siddiq, A.
Travis, R.C.
Cox, D.G.
Canzian, F.
Riboli, E.
Key, T.J.
Andriole, G.
Albanes, D.
Hayes, R.B.
Schleutker, J.
Auvinen, A.
Tammela, T.L.
Weischer, M.
Stanford, J.L.
Ostrander, E.A.
Cybulski, C.
Lubinski, J.
Thibodeau, S.N.
Schaid, D.J.
Sorensen, K.D.
Batra, J.
Clements, J.A.
Chambers, S.
Aitken, J.
Gardiner, R.A.
Maier, C.
Vogel, W.
Dörk, T.
Brenner, H.
Habuchi, T.
Ingles, S.
John, E.M.
Dickinson, J.L.
Cannon-Albright, L.
Teixeira, M.R.
Kaneva, R.
Zhang, H.-.
Lu, Y.-.
Park, J.Y.
Cooney, K.A.
Muir, K.R.
Leongamornlert, D.A.
Saunders, E.
Tymrakiewicz, M.
Mahmud, N.
Guy, M.
Govindasami, K.
O'Brien, L.T.
Wilkinson, R.A.
Hall, A.L.
Sawyer, E.J.
Dadaev, T.
Morrison, J.
Dearnaley, D.P.
Horwich, A.
Huddart, R.A.
Khoo, V.S.
Parker, C.C.
Van As, N.
Woodhouse, C.J.
Thompson, A.
Dudderidge, T.
Ogden, C.
Cooper, C.S.
Lophatonanon, A.
Southey, M.C.
Hopper, J.L.
English, D.
Virtamo, J.
Le Marchand, L.
Campa, D.
Kaaks, R.
Lindstrom, S.
Diver, W.R.
Gapstur, S.
Yeager, M.
Cox, A.
Stern, M.C.
Corral, R.
Aly, M.
Isaacs, W.
Adolfsson, J.
Xu, J.
Zheng, S.L.
Wahlfors, T.
Taari, K.
Kujala, P.
Klarskov, P.
Nordestgaard, B.G.
Røder, M.A.
Frikke-Schmidt, R.
Bojesen, S.E.
FitzGerald, L.M.
Kolb, S.
Kwon, E.M.
Karyadi, D.M.
Orntoft, T.F.
Borre, M.
Rinckleb, A.
Luedeke, M.
Herkommer, K.
Meyer, A.
Serth, J.
Marthick, J.R.
Patterson, B.
Wokolorczyk, D.
Spurdle, A.
Lose, F.
McDonnell, S.K.
Joshi, A.D.
Shahabi, A.
Pinto, P.
Santos, J.
Ray, A.
Sellers, T.A.
Lin, H.-.
Stephenson, R.A.
Teerlink, C.
Muller, H.
Rothenbacher, D.
Tsuchiya, N.
Narita, S.
Cao, G.-.
Slavov, C.
Mitev, V.
UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology,
UK ProtecT Study Collaborators,
Australian Prostate Cancer Bioresource,
PRACTICAL Consortium,
Chanock, S.
Gronberg, H.
Haiman, C.A.
Kraft, P.
Easton, D.F.
Eeles, R.A.
(2013). A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Hum mol genet,
Vol.22
(2),
pp. 408-415.
show abstract
Genome-wide association studies (GWAS) have identified multiple common genetic variants associated with an increased risk of prostate cancer (PrCa), but these explain less than one-third of the heritability. To identify further susceptibility alleles, we conducted a meta-analysis of four GWAS including 5953 cases of aggressive PrCa and 11 463 controls (men without PrCa). We computed association tests for approximately 2.6 million SNPs and followed up the most significant SNPs by genotyping 49 121 samples in 29 studies through the international PRACTICAL and BPC3 consortia. We not only confirmed the association of a PrCa susceptibility locus, rs11672691 on chromosome 19, but also showed an association with aggressive PrCa [odds ratio = 1.12 (95% confidence interval 1.03-1.21), P = 1.4 × 10(-8)]. This report describes a genetic variant which is associated with aggressive PrCa, which is a type of PrCa associated with a poorer prognosis..
Kote-Jarai, Z.
Saunders, E.J.
Leongamornlert, D.A.
Tymrakiewicz, M.
Dadaev, T.
Jugurnauth-Little, S.
Ross-Adams, H.
Al Olama, A.A.
Benlloch, S.
Halim, S.
Russell, R.
Dunning, A.M.
Luccarini, C.
Dennis, J.
Neal, D.E.
Hamdy, F.C.
Donovan, J.L.
Muir, K.
Giles, G.G.
Severi, G.
Wiklund, F.
Gronberg, H.
Haiman, C.A.
Schumacher, F.
Henderson, B.E.
Le Marchand, L.
Lindstrom, S.
Kraft, P.
Hunter, D.J.
Gapstur, S.
Chanock, S.
Berndt, S.I.
Albanes, D.
Andriole, G.
Schleutker, J.
Weischer, M.
Canzian, F.
Riboli, E.
Key, T.J.
Travis, R.C.
Campa, D.
Ingles, S.A.
John, E.M.
Hayes, R.B.
Pharoah, P.
Khaw, K.-.
Stanford, J.L.
Ostrander, E.A.
Signorello, L.B.
Thibodeau, S.N.
Schaid, D.
Maier, C.
Vogel, W.
Kibel, A.S.
Cybulski, C.
Lubinski, J.
Cannon-Albright, L.
Brenner, H.
Park, J.Y.
Kaneva, R.
Batra, J.
Spurdle, A.
Clements, J.A.
Teixeira, M.R.
Govindasami, K.
Guy, M.
Wilkinson, R.A.
Sawyer, E.J.
Morgan, A.
Dicks, E.
Baynes, C.
Conroy, D.
Bojesen, S.E.
Kaaks, R.
Vincent, D.
Bacot, F.
Tessier, D.C.
COGS-CRUK GWAS-ELLIPSE (Part of GAME-ON) Initiative,
UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology,
UK ProtecT Study Collaborators,
PRACTICAL Consortium,
Easton, D.F.
Eeles, R.A.
(2013). Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Hum mol genet,
Vol.22
(12),
pp. 2520-2528.
show abstract
Associations between single nucleotide polymorphisms (SNPs) at 5p15 and multiple cancer types have been reported. We have previously shown evidence for a strong association between prostate cancer (PrCa) risk and rs2242652 at 5p15, intronic in the telomerase reverse transcriptase (TERT) gene that encodes TERT. To comprehensively evaluate the association between genetic variation across this region and PrCa, we performed a fine-mapping analysis by genotyping 134 SNPs using a custom Illumina iSelect array or Sequenom MassArray iPlex, followed by imputation of 1094 SNPs in 22 301 PrCa cases and 22 320 controls in The PRACTICAL consortium. Multiple stepwise logistic regression analysis identified four signals in the promoter or intronic regions of TERT that independently associated with PrCa risk. Gene expression analysis of normal prostate tissue showed evidence that SNPs within one of these regions also associated with TERT expression, providing a potential mechanism for predisposition to disease..
Pooley, K.A.
Bojesen, S.E.
Weischer, M.
Nielsen, S.F.
Thompson, D.
Al Olama, A.A.
Michailidou, K.
Tyrer, J.P.
Benlloch, S.
Brown, J.
Audley, T.
Luben, R.
Khaw, K.-.
Neal, D.E.
Hamdy, F.C.
Donovan, J.L.
Kote-Jarai, Z.
Baynes, C.
Shah, M.
Bolla, M.K.
Wang, Q.
Dennis, J.
Dicks, E.
Yang, R.
Rudolph, A.
Schildkraut, J.
Chang-Claude, J.
Burwinkel, B.
Chenevix-Trench, G.
Pharoah, P.D.
Berchuck, A.
Eeles, R.A.
Easton, D.F.
Dunning, A.M.
Nordestgaard, B.G.
(2013). A genome-wide association scan (GWAS) for mean telomere length within the COGS project: identified loci show little association with hormone-related cancer risk. Human molecular genetics,
Vol.22
(24),
pp. 5056-5064.
Killick, E.
Morgan, R.
Launchbury, F.
Bancroft, E.
Page, E.
Castro, E.
Kote-Jarai, Z.
Aprikian, A.
Blanco, I.
Clowes, V.
Domchek, S.
Douglas, F.
Eccles, D.
Evans, D.G.
Harris, M.
Kirk, J.
Lam, J.
Lindeman, G.
Mitchell, G.
Pachter, N.
Selkirk, C.
Tucker, K.
Zgajnar, J.
Eeles, R.
Pandha, H.
(2013). Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men. Sci rep,
Vol.3,
p. 2059.
show abstract
Controversy surrounds the use of PSA as a biomarker for prostate cancer detection, leaving an unmet need for a novel biomarker in this setting; urinary EN2 may identify individuals with clinically relevant prostate cancer. Male BRCA1 and BRCA2 mutation carriers are at increased risk of clinically significant prostate cancer and may benefit from screening. Urine samples from 413 BRCA1 and BRCA2 mutation carriers and controls were evaluated. Subjects underwent annual PSA screening with diagnostic biopsy triggered by PSA > 3.0 ng/ml; 21 men were diagnosed with prostate cancer. Urinary EN2 levels were measured by ELISA and had a sensitivity of 66.7% and specificity of 89.3% for cancer detection. There was no statistically significant difference in EN2 levels according to genetic status or Gleason score. Urinary EN2 may be useful as a non-invasive early biomarker for prostate cancer detection in genetically high-risk individuals..
Goh, C.L.
Schumacher, F.R.
Easton, D.
Muir, K.
Henderson, B.
Kote-Jarai, Z.
Eeles, R.A.
(2012). Genetic variants associated with predisposition to prostate cancer and potential clinical implications. J intern med,
Vol.271
(4),
pp. 353-365.
show abstract
Prostate cancer is the commonest cancer in the developed world. There is an inherited component to this disease as shown in familial and twin studies. However, the discovery of these variants has been difficult. The emergence of genome-wide association studies has led to the identification of over 46 susceptibility loci. Their clinical utility to predict risk, response to treatment, or treatment toxicity, remains undefined. Large consortia are needed to achieve adequate statistical power to answer these genetic-clinical and genetic-epidemiological questions. International collaborations are currently underway to link genetic with clinical/epidemiological data to develop risk prediction models, which could direct screening and treatment programs..
Jin, G.
Lu, L.
Cooney, K.A.
Ray, A.M.
Zuhlke, K.A.
Lange, E.M.
Cannon-Albright, L.A.
Camp, N.J.
Teerlink, C.C.
FitzGerald, L.M.
Stanford, J.L.
Wiley, K.E.
Isaacs, S.D.
Walsh, P.C.
Foulkes, W.D.
Giles, G.G.
Hopper, J.L.
Severi, G.
Eeles, R.
Easton, D.
Kote-Jarai, Z.
Guy, M.
Rinckleb, A.
Maier, C.
Vogel, W.
Cancel-Tassin, G.
Egrot, C.
Cussenot, O.
Thibodeau, S.N.
McDonnell, S.K.
Schaid, D.J.
Wiklund, F.
Gronberg, H.
Emanuelsson, M.
Whittemore, A.S.
Oakley-Girvan, I.
Hsieh, C.-.
Wahlfors, T.
Tammela, T.
Schleutker, J.
Catalona, W.J.
Zheng, S.L.
Ostrander, E.A.
Isaacs, W.B.
Xu, J.
(2012). Validation of prostate cancer risk-related loci identified from genome-wide association studies using family-based association analysis: evidence from the International Consortium for Prostate Cancer Genetics (ICPCG). Human genetics,
Vol.131
(7),
pp. 1095-1103.
Leongamornlert, D.
Mahmud, N.
Tymrakiewicz, M.
Saunders, E.
Dadaev, T.
Castro, E.
Goh, C.
Govindasami, K.
Guy, M.
O'Brien, L.
Sawyer, E.
Hall, A.
Wilkinson, R.
Easton, D.
UKGPCS Collaborators,
Goldgar, D.
Eeles, R.
Kote-Jarai, Z.
(2012). Germline BRCA1 mutations increase prostate cancer risk. Br j cancer,
Vol.106
(10),
pp. 1697-1701.
show abstract
BACKGROUND: Prostate cancer (PrCa) is one of the most common cancers affecting men but its aetiology is poorly understood. Family history of PrCa, particularly at a young age, is a strong risk factor. There have been previous reports of increased PrCa risk in male BRCA1 mutation carriers in female breast cancer families, but there is a controversy as to whether this risk is substantiated. We sought to evaluate the role of germline BRCA1 mutations in PrCa predisposition by performing a candidate gene study in a large UK population sample set. METHODS: We screened 913 cases aged 36–86 years for germline BRCA1 mutation, with the study enriched for cases with an early age of onset. We analysed the entire coding region of the BRCA1 gene using Sanger sequencing. Multiplex ligation-dependent probe amplification was also used to assess the frequency of large rearrangements in 460 cases. RESULTS: We identified 4 deleterious mutations and 45 unclassified variants (UV). The frequency of deleterious BRCA1 mutation in this study is 0.45%; three of the mutation carriers were affected at age 65 years and one developed PrCa at 69 years. Using previously estimated population carrier frequencies, deleterious BRCA1 mutations confer a relative risk of PrCa of ~3.75-fold, (95% confidence interval 1.02–9.6) translating to a 8.6% cumulative risk by age 65. CONCLUSION: This study shows evidence for an increased risk of PrCa in men who harbour germline mutations in BRCA1. This could have a significant impact on possible screening strategies and targeted treatments..
Killick, E.
Bancroft, E.
Kote-Jarai, Z.
Eeles, R.
(2012). Beyond prostate-specific antigen - future biomarkers for the early detection and management of prostate cancer. Clin oncol (r coll radiol),
Vol.24
(8),
pp. 545-555.
show abstract
Prostate-specific antigen is currently commonly used as a screening biomarker for prostate cancer, but it has limitations in both sensitivity and specificity. The development of novel biomarkers for early cancer detection has the potential to improve survival, reduce unnecessary investigations and benefit the health economy. Here we review the use and limitations of prostate-specific antigen and its subtypes, urinary biomarkers including PCA3, alpha-methylacyl-CoA racemase, the TMPRSS2-ERG fusion gene and microseminoprotein-beta, and other novel markers in both serum and urine. Many of these biomarkers are at early stages of development and require evaluation in prospective trials to determine their potential usefulness in clinical practice. Genetic profiling may allow for the targeting of high-risk populations for screening and may offer the opportunity to combine biomarker results with genotype to aid risk assessment..
Cheng, I.
Chen, G.K.
Nakagawa, H.
He, J.
Wan, P.
Laurie, C.C.
Shen, J.
Sheng, X.
Pooler, L.C.
Crenshaw, A.T.
Mirel, D.B.
Takahashi, A.
Kubo, M.
Nakamura, Y.
Al Olama, A.A.
Benlloch, S.
Donovan, J.L.
Guy, M.
Hamdy, F.C.
Kote-Jarai, Z.
Neal, D.E.
Wilkens, L.R.
Monroe, K.R.
Stram, D.O.
Muir, K.
Eeles, R.A.
Easton, D.F.
Kolonel, L.N.
Henderson, B.E.
Le Marchand, L.
Haiman, C.A.
(2012). Evaluating genetic risk for prostate cancer among Japanese and Latinos. Cancer epidemiol biomarkers prev,
Vol.21
(11),
pp. 2048-2058.
show abstract
BACKGROUND: There have been few genome-wide association studies (GWAS) of prostate cancer among diverse populations. To search for novel prostate cancer risk variants, we conducted GWAS of prostate cancer in Japanese and Latinos. In addition, we tested prostate cancer risk variants and developed genetic risk models of prostate cancer for Japanese and Latinos. METHODS: Our first-stage GWAS of prostate cancer included Japanese (cases/controls = 1,033/1,042) and Latino (cases/controls = 1,043/1,057) from the Multiethnic Cohort (MEC). Significant associations from stage I (P < 1.0 × 10(-4)) were examined in silico in GWAS of prostate cancer (stage II) in Japanese (cases/controls = 1,583/3,386) and Europeans (cases/controls = 1,854/1,894). RESULTS: No novel stage I single-nucleotide polymorphism (SNP) outside of known risk regions reached genome-wide significance. For Japanese, in stage I, the most notable putative novel association was seen with 10 SNPs (P ≤ 8.0 × 10(-6)) at chromosome 2q33; however, this was not replicated in stage II. For Latinos, the most significant association was observed with rs17023900 at the known 3p12 risk locus (stage I: OR = 1.45; P = 7.01 × 10(-5) and stage II: OR = 1.58; P = 3.05 × 10(-7)). The majority of the established risk variants for prostate cancer, 79% and 88%, were positively associated with prostate cancer in Japanese and Latinos (stage I), respectively. The cumulative effects of these variants significantly influence prostate cancer risk (OR per allele = 1.10; P = 2.71 × 10(-25) and OR = 1.07; P = 1.02 × 10(-16) for Japanese and Latinos, respectively). CONCLUSION AND IMPACT: Our GWAS of prostate cancer did not identify novel genome-wide significant variants. However, our findings show that established risk variants for prostate cancer significantly contribute to risk among Japanese and Latinos..
Killick, E.
Morgan, R.
Launchbury, F.
Annels, N.
Bancroft, E.
Page, E.
Castro, E.
Kote-Jarai, Z.
Eeles, R.
Pandha, H.
Comm, I.M.
Collaborators, I.M.
(2012). Detecting prostate cancer in BRCA1 and BRCA2 mutation carriers: A role for EN2. Cancer research,
Vol.72.
Goh, C.L.
Schumacher, F.
Kote-Jarai, Z.
Kraft, P.
Easton, D.
Henderson, B.
Eeles, R.
(2012). Overview of the clinical ELLIPSE (ELucidating Loci Involved in Prostate cancer SuscEptibility) Consortium (CEC). Cancer research,
Vol.72.
Bancroft, E.K.
Castro, E.
Page, E.
Saunders, E.
Dadaev, T.
Keating, D.
Amin, A.
Neai, D.
Hamdy, F.
Easton, D.
Kote-Jarai, Z.
Antoniou, A.
Eeles, R.
(2012). The PROFILE study; Germline genetic profiling: Correlation with targeted prostate cancer screening and treatment. Cancer research,
Vol.72.
Goh, C.L.
Saunders, E.
Leongamornlert, D.
Tymrakiewicz, M.
Thomas, K.
Selvadurai, E.
Woode-Amissah, R.
Dadaev, T.
Mahmud, N.
Castro, E.
Olmos, D.
Guy, M.
Govindasami, K.
O'Brien, L.
Hall, A.
Wilkinson, R.
Sawyer, E.
Al Olama, A.A.
Easton, D.
Kote-Jarai, Z.
Parker, C.
Eeles, R.
(2012). Clinical implications of family history of prostate cancer in an active surveillance cohort. Cancer research,
Vol.72.
Mitra, A.V.
Bancroft, E.K.
Barbachano, Y.
Page, E.C.
Foster, C.S.
Jameson, C.
Mitchell, G.
Lindeman, G.J.
Stapleton, A.
Suthers, G.
Evans, D.G.
Cruger, D.
Blanco, I.
Mercer, C.
Kirk, J.
Maehle, L.
Hodgson, S.
Walker, L.
Izatt, L.
Douglas, F.
Tucker, K.
Dorkins, H.
Clowes, V.
Male, A.
Donaldson, A.
Brewer, C.
Doherty, R.
Bulman, B.
Osther, P.J.
Salinas, M.
Eccles, D.
Axcrona, K.
Jobson, I.
Newcombe, B.
Cybulski, C.
Rubinstein, W.S.
Buys, S.
Townshend, S.
Friedman, E.
Domchek, S.
Ramon Y Cajal, T.
Spigelman, A.
Teo, S.H.
Nicolai, N.
Aaronson, N.
Ardern-Jones, A.
Bangma, C.
Dearnaley, D.
Eyfjord, J.
Falconer, A.
Grönberg, H.
Hamdy, F.
Johannsson, O.
Khoo, V.
Kote-Jarai, Z.
Lilja, H.
Lubinski, J.
Melia, J.
Moynihan, C.
Peock, S.
Rennert, G.
Schröder, F.
Sibley, P.
Suri, M.
Wilson, P.
Bignon, Y.J.
Strom, S.
Tischkowitz, M.
Liljegren, A.
Ilencikova, D.
Abele, A.
Kyriacou, K.
van Asperen, C.
Kiemeney, L.
IMPACT Study Collaborators,
Easton, D.F.
Eeles, R.A.
(2011). Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. Bju int,
Vol.107
(1),
pp. 28-39.
show abstract
full text
OBJECTIVE: To evaluate the role of targeted prostate cancer screening in men with BRCA1 or BRCA2 mutations, an international study, IMPACT (Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in BRCA1/2 mutation carriers and controls), was established. This is the first multicentre screening study targeted at men with a known genetic predisposition to prostate cancer. A preliminary analysis of the data is reported. PATIENTS AND METHODS: Men aged 40-69 years from families with BRCA1 or BRCA2 mutations were offered annual prostate specific antigen (PSA) testing, and those with PSA > 3 ng/mL, were offered a prostate biopsy. Controls were men age-matched (± 5 years) who were negative for the familial mutation. RESULTS: In total, 300 men were recruited (205 mutation carriers; 89 BRCA1, 116 BRCA2 and 95 controls) over 33 months. At the baseline screen (year 1), 7.0% (21/300) underwent a prostate biopsy. Prostate cancer was diagnosed in ten individuals, a prevalence of 3.3%. The positive predictive value of PSA screening in this cohort was 47·6% (10/21). One prostate cancer was diagnosed at year 2. Of the 11 prostate cancers diagnosed, nine were in mutation carriers, two in controls, and eight were clinically significant. CONCLUSIONS: The present study shows that the positive predictive value of PSA screening in BRCA mutation carriers is high and that screening detects clinically significant prostate cancer. These results support the rationale for continued screening in such men..
Schumacher, F.R.
Berndt, S.I.
Siddiq, A.
Jacobs, K.B.
Wang, Z.
Lindstrom, S.
Stevens, V.L.
Chen, C.
Mondul, A.M.
Travis, R.C.
Stram, D.O.
Eeles, R.A.
Easton, D.F.
Giles, G.
Hopper, J.L.
Neal, D.E.
Hamdy, F.C.
Donovan, J.L.
Muir, K.
Al Olama, A.A.
Kote-Jarai, Z.
Guy, M.
Severi, G.
Grönberg, H.
Isaacs, W.B.
Karlsson, R.
Wiklund, F.
Xu, J.
Allen, N.E.
Andriole, G.L.
Barricarte, A.
Boeing, H.
Bueno-de-Mesquita, H.B.
Crawford, E.D.
Diver, W.R.
Gonzalez, C.A.
Gaziano, J.M.
Giovannucci, E.L.
Johansson, M.
Le Marchand, L.
Ma, J.
Sieri, S.
Stattin, P.
Stampfer, M.J.
Tjonneland, A.
Vineis, P.
Virtamo, J.
Vogel, U.
Weinstein, S.J.
Yeager, M.
Thun, M.J.
Kolonel, L.N.
Henderson, B.E.
Albanes, D.
Hayes, R.B.
Feigelson, H.S.
Riboli, E.
Hunter, D.J.
Chanock, S.J.
Haiman, C.A.
Kraft, P.
(2011). Genome-wide association study identifies new prostate cancer susceptibility loci. Hum mol genet,
Vol.20
(19),
pp. 3867-3875.
show abstract
Prostate cancer (PrCa) is the most common non-skin cancer diagnosed among males in developed countries and the second leading cause of cancer mortality, yet little is known regarding its etiology and factors that influence clinical outcome. Genome-wide association studies (GWAS) of PrCa have identified at least 30 distinct loci associated with small differences in risk. We conducted a GWAS in 2782 advanced PrCa cases (Gleason grade ≥ 8 or tumor stage C/D) and 4458 controls with 571 243 single nucleotide polymorphisms (SNPs). Based on in silico replication of 4679 SNPs (Stage 1, P < 0.02) in two published GWAS with 7358 PrCa cases and 6732 controls, we identified a new susceptibility locus associated with overall PrCa risk at 2q37.3 (rs2292884, P= 4.3 × 10(-8)). We also confirmed a locus suggested by an earlier GWAS at 12q13 (rs902774, P= 8.6 × 10(-9)). The estimated per-allele odds ratios for these loci (1.14 for rs2292884 and 1.17 for rs902774) did not differ between advanced and non-advanced PrCa (case-only test for heterogeneity P= 0.72 and P= 0.61, respectively). Further studies will be needed to assess whether these or other loci are differentially associated with PrCa subtypes..
Rahman, A.A.
Lophatananon, A.
Lobaz, J.
Robinson, F.
Brown, S.S.
Parker, T.
Easton, D.
Kote-Jarai, Z.
Pocock, R.
Dearnaley, D.
Guy, M.
Wilkinson, R.A.
Hall, A.L.
Sawyer, E.
Page, E.
Liu, J.-.
Eeles, R.A.
Muir, K.R.
(2011). OMEGA 3 POLYUNSATURATED FATTY ACIDS (PUFAS) AND RISK OF EARLY ONSET PROSTATE CANCER. Journal of epidemiology and community health,
Vol.65,
pp. A290-2.
Rahman, A.A.
Lophatananon, A.
Stewart-Brown, S.
Harriss, D.
Anderson, J.
Parker, T.
Easton, D.
Kote-Jarai, Z.
Pocock, R.
Dearnaley, D.
Guy, M.
O'Brien, L.
Wilkinson, R.A.
Hall, A.L.
Sawyer, E.
Page, E.
Liu, J.-.
UK Genetic Prostate Cancer Study Collaborators,
British Association of Urological Surgeons' Section of Oncology,
Eeles, R.A.
Muir, K.
(2011). Hand pattern indicates prostate cancer risk. Br j cancer,
Vol.104
(1),
pp. 175-177.
show abstract
BACKGROUND: The ratio of digit lengths is fixed in utero, and may be a proxy indicator for prenatal testosterone levels. METHODS: We analysed the right-hand pattern and prostate cancer risk in 1524 prostate cancer cases and 3044 population-based controls. RESULTS: Compared with index finger shorter than ring finger (low 2D : 4D), men with index finger longer than ring finger (high 2D : 4D) showed a negative association, suggesting a protective effect with a 33% risk reduction (odds ratio (OR) 0.67, 95% confidence interval (CI) 0.57-0.80). Risk reduction was even greater (87%) in age group <60 (OR 0.13, 95% CI 0.09-0.21). CONCLUSION: Pattern of finger lengths may be a simple marker of prostate cancer risk, with length of 2D greater than 4D suggestive of lower risk..
Kote-Jarai, Z.
Amin Al Olama, A.
Leongamornlert, D.
Tymrakiewicz, M.
Saunders, E.
Guy, M.
Giles, G.G.
Severi, G.
Southey, M.
Hopper, J.L.
Sit, K.C.
Harris, J.M.
Batra, J.
Spurdle, A.B.
Clements, J.A.
Hamdy, F.
Neal, D.
Donovan, J.
Muir, K.
Pharoah, P.D.
Chanock, S.J.
Brown, N.
Benlloch, S.
Castro, E.
Mahmud, N.
O'Brien, L.
Hall, A.
Sawyer, E.
Wilkinson, R.
Easton, D.F.
Eeles, R.A.
(2011). Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript. Hum genet,
Vol.129
(6),
pp. 687-694.
show abstract
Genome-wide association studies (GWAS) have identified more than 30 prostate cancer (PrCa) susceptibility loci. One of these (rs2735839) is located close to a plausible candidate susceptibility gene, KLK3, which encodes prostate-specific antigen (PSA). PSA is widely used as a biomarker for PrCa detection and disease monitoring. To refine the association between PrCa and variants in this region, we used genotyping data from a two-stage GWAS using samples from the UK and Australia, and the Cancer Genetic Markers of Susceptibility (CGEMS) study. Genotypes were imputed for 197 and 312 single nucleotide polymorphisms (SNPs) from HapMap2 and the 1000 Genome Project, respectively. The most significant association with PrCa was with a previously unidentified SNP, rs17632542 (combined P = 3.9 × 10(-22)). This association was confirmed by direct genotyping in three stages of the UK/Australian GWAS, involving 10,405 cases and 10,681 controls (combined P = 1.9 × 10(-34)). rs17632542 is also shown to be associated with PSA levels and it is a non-synonymous coding SNP (Ile179Thr) in KLK3. Using molecular dynamic simulation, we showed evidence that this variant has the potential to introduce alterations in the protein or affect RNA splicing. We propose that rs17632542 may directly influence PrCa risk..
Macinnis, R.J.
Antoniou, A.C.
Eeles, R.A.
Severi, G.
Al Olama, A.A.
McGuffog, L.
Kote-Jarai, Z.
Guy, M.
O'Brien, L.T.
Hall, A.L.
Wilkinson, R.A.
Sawyer, E.
Ardern-Jones, A.T.
Dearnaley, D.P.
Horwich, A.
Khoo, V.S.
Parker, C.C.
Huddart, R.A.
Van As, N.
McCredie, M.R.
English, D.R.
Giles, G.G.
Hopper, J.L.
Easton, D.F.
(2011). A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact. Genet epidemiol,
Vol.35
(6),
pp. 549-556.
show abstract
full text
Genome wide association studies have identified several single nucleotide polymorphisms (SNPs) that are independently associated with small increments in risk of prostate cancer, opening up the possibility for using such variants in risk prediction. Using segregation analysis of population-based samples of 4,390 families of prostate cancer patients from the UK and Australia, and assuming all familial aggregation has genetic causes, we previously found that the best model for the genetic susceptibility to prostate cancer was a mixed model of inheritance that included both a recessive major gene component and a polygenic component (P) that represents the effect of a large number of genetic variants each of small effect, where . Based on published studies of 26 SNPs that are currently known to be associated with prostate cancer, we have extended our model to incorporate these SNPs by decomposing the polygenic component into two parts: a polygenic component due to the known susceptibility SNPs, , and the residual polygenic component due to the postulated but as yet unknown genetic variants, . The resulting algorithm can be used for predicting the probability of developing prostate cancer in the future based on both SNP profiles and explicit family history information. This approach can be applied to other diseases for which population-based family data and established risk variants exist..
Huddart, R.
Horwich, A.
Khoo, V.
Parker, C.
Dearnaley, D.
Eeles, R.
Kote-Jarai, Z.
(2011). A Risk Prediction Algorithm Based on Family History and Common Genetic Variants: Application to Prostate Cancer with Potential Clinical Impact. Genetic epidemiology,
Vol.35
(6),
pp. 549-556.
show abstract
Genome wide association studies have identified several single nucleotide polymorphisms ( SNPs) that are independently associated with small increments in risk of prostate cancer, opening up the possibility for using such variants in risk prediction. Using segregation analysis of population-based samples of 4,390 families of prostate cancer patients from the UK and Australia, and assuming all familial aggregation has genetic causes, we previously found that the best model for the genetic susceptibility to prostate cancer was a mixed model of inheritance that included both a recessive major gene component and a polygenic component (P) that represents the effect of a large number of genetic variants each of small effect, where P similar to N(0, sigma(2)(P)). Based on published studies of 26 SNPs that are currently known to be associated with prostate cancer, we have extended our model to incorporate these SNPs by decomposing the polygenic component into two parts: a polygenic component due to the known susceptibility SNPs, P(K) similar to N(0, sigma(2)(K)), and the residual polygenic component due to the postulated but as yet unknown genetic variants, P(U) similar to N(0, sigma(2)(U)). The resulting algorithm can be used for predicting the probability of developing prostate cancer in the future based on both SNP profiles and explicit family history information. This approach can be applied to other diseases for which population-based family data and established risk variants exist. Genet. Epidemiol. 35: 549-556, 2011. (C) 2011Wiley-Liss, Inc..
Kote-Jarai, Z.
Olama, A.A.
Giles, G.G.
Severi, G.
Schleutker, J.
Weischer, M.
Campa, D.
Riboli, E.
Key, T.
Gronberg, H.
Hunter, D.J.
Kraft, P.
Thun, M.J.
Ingles, S.
Chanock, S.
Albanes, D.
Hayes, R.B.
Neal, D.E.
Hamdy, F.C.
Donovan, J.L.
Pharoah, P.
Schumacher, F.
Henderson, B.E.
Stanford, J.L.
Ostrander, E.A.
Sorensen, K.D.
Dörk, T.
Andriole, G.
Dickinson, J.L.
Cybulski, C.
Lubinski, J.
Spurdle, A.
Clements, J.A.
Chambers, S.
Aitken, J.
Gardiner, R.A.
Thibodeau, S.N.
Schaid, D.
John, E.M.
Maier, C.
Vogel, W.
Cooney, K.A.
Park, J.Y.
Cannon-Albright, L.
Brenner, H.
Habuchi, T.
Zhang, H.-.
Lu, Y.-.
Kaneva, R.
Muir, K.
Benlloch, S.
Leongamornlert, D.A.
Saunders, E.J.
Tymrakiewicz, M.
Mahmud, N.
Guy, M.
O'Brien, L.T.
Wilkinson, R.A.
Hall, A.L.
Sawyer, E.J.
Dadaev, T.
Morrison, J.
Dearnaley, D.P.
Horwich, A.
Huddart, R.A.
Khoo, V.S.
Parker, C.C.
Van As, N.
Woodhouse, C.J.
Thompson, A.
Christmas, T.
Ogden, C.
Cooper, C.S.
Lophatonanon, A.
Southey, M.C.
Hopper, J.L.
English, D.R.
Wahlfors, T.
Tammela, T.L.
Klarskov, P.
Nordestgaard, B.G.
Røder, M.A.
Tybjærg-Hansen, A.
Bojesen, S.E.
Travis, R.
Canzian, F.
Kaaks, R.
Wiklund, F.
Aly, M.
Lindstrom, S.
Diver, W.R.
Gapstur, S.
Stern, M.C.
Corral, R.
Virtamo, J.
Cox, A.
Haiman, C.A.
Le Marchand, L.
Fitzgerald, L.
Kolb, S.
Kwon, E.M.
Karyadi, D.M.
Orntoft, T.F.
Borre, M.
Meyer, A.
Serth, J.
Yeager, M.
Berndt, S.I.
Marthick, J.R.
Patterson, B.
Wokolorczyk, D.
Batra, J.
Lose, F.
McDonnell, S.K.
Joshi, A.D.
Shahabi, A.
Rinckleb, A.E.
Ray, A.
Sellers, T.A.
Lin, H.-.
Stephenson, R.A.
Farnham, J.
Muller, H.
Rothenbacher, D.
Tsuchiya, N.
Narita, S.
Cao, G.-.
Slavov, C.
Mitev, V.
Easton, D.F.
Eeles, R.A.
UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology,
UK ProtecT Study Collaborators, The Australian Prostate Cancer BioResource,
PRACTICAL Consortium,
(2011). Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat genet,
Vol.43
(8),
pp. 785-791.
show abstract
Prostate cancer (PrCa) is the most frequently diagnosed male cancer in developed countries. We conducted a multi-stage genome-wide association study for PrCa and previously reported the results of the first two stages, which identified 16 PrCa susceptibility loci. We report here the results of stage 3, in which we evaluated 1,536 SNPs in 4,574 individuals with prostate cancer (cases) and 4,164 controls. We followed up ten new association signals through genotyping in 51,311 samples in 30 studies from the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) consortium. In addition to replicating previously reported loci, we identified seven new prostate cancer susceptibility loci on chromosomes 2p11, 3q23, 3q26, 5p12, 6p21, 12q13 and Xq12 (P = 4.0 × 10(-8) to P = 2.7 × 10(-24)). We also identified a SNP in TERT more strongly associated with PrCa than that previously reported. More than 40 PrCa susceptibility loci, explaining ∼25% of the familial risk in this disease, have now been identified..
Kote-Jarai, Z.
Leongamornlert, D.
Saunders, E.
Tymrakiewicz, M.
Castro, E.
Mahmud, N.
Guy, M.
Edwards, S.
O'Brien, L.
Sawyer, E.
Hall, A.
Wilkinson, R.
Dadaev, T.
Goh, C.
Easton, D.
Goldgar, D.
Eeles, R.
(2011). BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. British journal of cancer,
Vol.105
(8),
pp. 1230-5.
Kote-Jarai, Z.
Leongamornlert, D.
Saunders, E.
Tymrakiewicz, M.
Castro, E.
Mahmud, N.
Guy, M.
Edwards, S.
O'Brien, L.
Hall, A.
Wilkinson, R.
Goh, C.
Goldgar, D.
Easton, D.
Eeles, R.
Collaborators, U.K.
(2011). BRCA2 is a moderate penetrance gene contributing to young onset prostate cancer, but not disease over 65 years. Cancer research,
Vol.71.
Castro, E.
Goh, C.L.
Olmos, D.
Leongamornlert, D.
Saunders, E.
Tymrakiewicz, M.
Mahmud, N.
Dadaev, T.
Govindasami, K.
Guy, M.
OBrien, L.
Sawyer, E.
Hall, A.
Wilkinson, R.
Kote-Jarai, Z.
Eeles, R.A.
Collaborators, U.K.
(2011). Correlation of germ-line BRCA2 mutations with aggressive prostate cancer and outcome. Journal of clinical oncology,
Vol.29
(15).
Castro, E.
Goh, C.L.
Olmos, D.
Leongamornlert, D.
Saunders, E.
Tymrakiewicz, M.
Mahmud, N.
Dadaev, T.
Govindasami, K.
Guy, M.
OBrien, L.
Sawyer, E.
Hall, A.
Wilkinson, R.
Kote-Jarai, Z.
Eeles, R.A.
UKGPCS collaborators,
(2011). Correlation of germ-line BRCA2 mutations with aggressive prostate cancer and outcome. J clin oncol,
Vol.29
(15_suppl),
p. 1517.
show abstract
1517 Background: Previous studies have linked some BRCA1/2 mutations with increased incidence and poor overall survival (OS) in prostate cancer (PCa). In this study both BRCA genes were screened for germline mutations in a larger cohort of PCa and mutation status was correlated with PCa prognostic factors (PFs). METHODS: 3818 patients (pts) were enrolled in the UK Genetic Prostate Cancer Study (UKGPCS) between1990-2005. Inclusion criteria for our analysis were available genomic DNA and clinical and survival data in our prospectively maintained UKGPCS database. Genomic DNA was screened for BRCA1/2 mutations. The Kaplan-Meier method and Cox Regression models were used to study the association between BRCA mutation carrier status and other PCa PFs with OS, cause specific OS (CSS), and metastasis free survival (MFS). RESULTS: 2181 pts were eligible for analysis. Median age was 57yrs (range 32-89). BRCA1and BRCA2mutations were detected in 5 and 34 patients respectively. BRCA2 tumors were associated with higher histologic grade (Gleason≥8: BRCA2 50%, BRCA120%, Non carriers [NC] 21%; p=0.017), nodal disease (N1: BRCA2 35%, BRCA1 50%, NC 11%; p<0.001), metastasis (M1: BRCA221%, BRCA1 20%, NC9%, p=0.034) and advanced stage (BRCA2 62%, BRCA1 50% NC18%, p<0.001). Median OS for BRCA2 was significantly inferior to NC (10.8 vs 13.3 yrs, respectively, HR 2.5, p<0.001). The later difference was greater when analyzing CSS (8.6 vs 16.3 yrs, HR 2.8, p<0.001). PFs for CSS in the multivariate analysis (MVA) included stage and PSA doubling time but not BRCA2 per se (HR 1.9, CI95% 0.7-6.7). BRCA2 pts had a worse 10 yrs MFS rate than NC (63% vs 86%, HR 3.6, p=0.001). Median OS from M1 was not significantly different between BRCA2 and NC (2.8 vs 3.4 yrs, p=0.7). BRCA1 pts had a shorter median OS and CSS (10.6 yrs) than NC (p=0.14 and p=0.09), but this trend was lost in the MVA. CONCLUSIONS: Our results confirm that PCa pts with BRCA mutations have a poor outcome. Both BRCA1 and BRCA2mutation carriers with PCa are more likely to have nodal involvement and metastasis at diagnosis and earlier disease progression. OS and CSS are significantly lower in men with BRCA2 mutations.These data should be taken into account in the screening and management of BRCA mutation carriers..
Batra, J.
Lose, F.
O'Mara, T.
Marquart, L.
Stephens, C.
Alexander, K.
Srinivasan, S.
Eeles, R.A.
Easton, D.F.
Al Olama, A.A.
Kote-Jarai, Z.
Guy, M.
Muir, K.
Lophatananon, A.
Rahman, A.A.
Neal, D.E.
Hamdy, F.C.
Donovan, J.L.
Chambers, S.
Gardiner, R.A.
Aitken, J.
Yaxley, J.
Kedda, M.-.
Clements, J.A.
Spurdle, A.B.
(2011). Association between Prostinogen (KLK15) Genetic Variants and Prostate Cancer Risk and Aggressiveness in Australia and a Meta-Analysis of GWAS Data. Plos one,
Vol.6
(11).
Rahman, A.A.
Lophatananon, A.
Stewart-Brown, S.
Harriss, D.
Anderson, J.
Parker, T.
Easton, D.
Kote-Jarai, Z.
Pocock, R.
Dearnaley, D.
Guy, M.
O'Brien, L.
Wilkinson, R.A.
Hall, A.L.
Sawyer, E.
Page, E.
Liu, J.F.
Eeles, R.A.
Muir, K.R.
(2011). Reply: 'Hand pattern indicates risk of prostate cancer'. Br j cancer,
Vol.105
(3),
p. 467.
Rahman, A.A.
Lophatananon, A.
Brown, S.S.
Harriss, D.
Anderson, J.
Parker, T.
Easton, D.
Kote-Jarai, Z.
Pocock, R.
Dearnaley, D.
Guy, M.
O'Brien, L.
Wilkinson, R.A.
Hall, A.L.
Sawyer, E.
Page, E.
Liu, J.-.
Eeles, R.A.
Muir, K.
(2010). HAND PATTERN AND EARLY-ONSET PROSTATE CANCER RISK. Epidemiologia & prevenzione,
Vol.34
(5-6),
pp. 104-1.
Kirby, R.S.
Eeles, R.A.
Kote-Jarai, Z.
Guy, M.
Easton, D.
Fitzpatrick, J.M.
(2010). Screening for prostate cancer: the way ahead. Bju int,
Vol.105
(3),
pp. 295-297.
Mitra, A.V.
Jameson, C.
Barbachano, Y.
Sodha, N.
Kote-Jarai, Z.
Javed, A.
Bancroft, E.
Fletcher, A.
Cooper, C.
Peock, S.
IMPACT and EMBRACE Collaborators,
Easton, D.
Eeles, R.
Foster, C.S.
(2010). Elevated expression of Ki-67 identifies aggressive prostate cancers but does not distinguish BRCA1 or BRCA2 mutation carriers. Oncol rep,
Vol.23
(2),
pp. 299-305.
show abstract
Prostate cancers in men with germline BRCA1 and BRCA2 mutations are more aggressive than morphologically similar cancers in men without these mutations. This study was performed to test the hypothesis that enhanced expression of Ki-67, as a surrogate of cell proliferation, is a characteristic feature of prostate cancers occurring in BRCA1 or BRCA2 mutation carriers. The study cohort comprised 20 cases of prostate cancer in mutation carriers and 126 control sporadic prostate cancers. Of the combined sample cohort, 65.7% stained only within malignant tissues while 0.7% stained in both malignant and benign tissues (p<0.001). Significantly increased expression of Ki-67 occurred in prostate cancers with higher Gleason score (p<0.001). Elevated Ki-67 expression was identified in 71% of prostate cancers in BRCA1 or BRCA2 mutation carriers and in 67% of the sporadic controls (p>0.5). Similar results were obtained when the data were analysed using a threshold set at 3.5 and 7.1%. This study shows that elevated expression of Ki-67 is associated both with aggressive prostate cancers and with high Gleason score irrespective of whether their occurrence is against a background of BRCA1 or BRCA2 mutations or as sporadic disease. The data suggest that, since elevated Ki-67 does not distinguish prostate cancers occurring in BRCA1 or BRCA2 mutation carriers from sporadic prostatic malignancies, the effects of these genetic mutations are probably independent. While all prostate cancers occurring in the presence of BRCA germline mutations are clinically aggressive, their potentially different phenotypes consistently involve maximal rates of cell proliferation..
Lophatananon, A.
Archer, J.
Easton, D.
Pocock, R.
Dearnaley, D.
Guy, M.
Kote-Jarai, Z.
O'Brien, L.
Wilkinson, R.A.
Hall, A.L.
Sawyer, E.
Page, E.
Liu, J.-.
Barratt, S.
Rahman, A.A.
UK Genetic Prostate Cancer Study Collaborators,
British Association of Urological Surgeons' Section of Oncology,
Eeles, R.
Muir, K.
(2010). Dietary fat and early-onset prostate cancer risk. Br j nutr,
Vol.103
(9),
pp. 1375-1380.
show abstract
The UK incidence of prostate cancer has been increasing in men aged < 60 years. Migrant studies and global and secular variation in incidence suggest that modifiable factors, including a high-fat diet, may contribute to prostate cancer risk. The aim of the present study was to investigate the role of dietary fat intake and its derivatives on early-onset prostate cancer risk. During 1999-2004, a population-based case-control study with 512 cases and 838 controls was conducted. Cases were diagnosed with prostate cancer when < or = 60 years. Controls were sourced from UK GP practice registers. A self-administered FFQ collected data on typical past diet. A nutritional database was used to calculate daily fat intake. A positive, statistically significant risk estimate for the highest v. lowest quintile of intake of total fat, SFA, MUFA and PUFA was observed when adjusted for confounding variables: OR 2.53 (95 % CI 1.72, 3.74), OR 2.49 (95 % CI 1.69, 3.66), OR 2.69 (95 % CI 1.82, 3.96) and OR 2.34 (95 % CI 1.59, 3.46), respectively, with all P for trend < 0.001. In conclusion, there was a positive statistically significant association between prostate cancer risk and energy-adjusted intake of total fat and fat subtypes. These results potentially identify a modifiable risk factor for early-onset prostate cancer..
Bancroft, E.K.
Locke, I.
Ardern-Jones, A.
D'Mello, L.
McReynolds, K.
Lennard, F.
Barbachano, Y.
Barwell, J.
Walker, L.
Mitchell, G.
Dorkins, H.
Cummings, C.
Paterson, J.
Kote-Jarai, Z.
Mitra, A.
Jhavar, S.
Thomas, S.
Houlston, R.
Shanley, S.
Eeles, R.A.
(2010). The carrier clinic: an evaluation of a novel clinic dedicated to the follow-up of BRCA1 and BRCA2 carriers--implications for oncogenetics practice. J med genet,
Vol.47
(7),
pp. 486-491.
show abstract
BACKGROUND: A novel oncogenetic clinic was established in 2002 at the Royal Marsden NHS Foundation Trust offering advice and specialist follow-up for families with a germline mutation in BRCA1 or BRCA2. The remit of this multidisciplinary clinic, staffed by individuals in both oncology and genetics, is to provide individualised screening recommendations, support in decision making, risk reducing strategies, cascade testing, and an extensive research portfolio. METHODS: A retrospective analysis was performed to evaluate uptake of genetic testing, risk reducing surgery and cancer prevalence in 346 BRCA1/BRCA2 families seen between January 1996 and December 2006. RESULTS: 661 individuals attended the clinic and 406 mutation carriers were identified; 85.8% mutation carriers have chosen to attend for annual follow-up. 70% of mutation carriers elected for risk reducing bilateral salpingo-oophorectomy (RRBSO). 32% of unaffected women chose risk reducing bilateral mastectomy. 32% of women with breast cancer chose contralateral risk reducing mastectomy at time of diagnosis. Some women took over 8 years to decide to have surgery. 91% of individuals approached agreed to participate in research programmes. INTERPRETATION: A novel specialist clinic for BRCA1/2 mutation carriers has been successfully established. The number of mutation positive families is increasing. This, and the high demand for RRBSO in women over 40, is inevitably going to place an increasing demand on existing health resources. Our clinic model has subsequently been adopted in other centres and this will greatly facilitate translational studies and provide a healthcare structure for management and follow-up of such people who are at a high cancer risk..
Edwards, S.M.
Evans, D.G.
Hope, Q.
Norman, A.R.
Barbachano, Y.
Bullock, S.
Kote-Jarai, Z.
Meitz, J.
Falconer, A.
Osin, P.
Fisher, C.
Guy, M.
Jhavar, S.G.
Hall, A.L.
O'Brien, L.T.
Gehr-Swain, B.N.
Wilkinson, R.A.
Forrest, M.S.
Dearnaley, D.P.
Ardern-Jones, A.T.
Page, E.C.
Easton, D.F.
Eeles, R.A.
UK Genetic Prostate Cancer Study Collaborators and BAUS Section of Oncology,
(2010). Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. Br j cancer,
Vol.103
(6),
pp. 918-924.
show abstract
BACKGROUND: The germline BRCA2 mutation is associated with increased prostate cancer (PrCa) risk. We have assessed survival in young PrCa cases with a germline mutation in BRCA2 and investigated loss of heterozygosity at BRCA2 in their tumours. METHODS: Two cohorts were compared: one was a group with young-onset PrCa, tested for germline BRCA2 mutations (6 of 263 cases had a germline BRAC2 mutation), and the second was a validation set consisting of a clinical set from Manchester of known BRCA2 mutuation carriers (15 cases) with PrCa. Survival data were compared with a control series of patients in a single clinic as determined by Kaplan-Meier estimates. Loss of heterozygosity was tested for in the DNA of tumour tissue of the young-onset group by typing four microsatellite markers that flanked the BRCA2 gene, followed by sequencing. RESULTS: Median survival of all PrCa cases with a germline BRCA2 mutation was shorter at 4.8 years than was survival in controls at 8.5 years (P=0.002). Loss of heterozygosity was found in the majority of tumours of BRCA2 mutation carriers. Multivariate analysis confirmed that the poorer survival of PrCa in BRCA2 mutation carriers is associated with the germline BRCA2 mutation per se. CONCLUSION: BRCA2 germline mutation is an independent prognostic factor for survival in PrCa. Such patients should not be managed with active surveillance as they have more aggressive disease..
Whitaker, H.C.
Kote-Jarai, Z.
Ross-Adams, H.
Warren, A.Y.
Burge, J.
George, A.
Bancroft, E.
Jhavar, S.
Leongamornlert, D.
Tymrakiewicz, M.
Saunders, E.
Page, E.
Mitra, A.
Mitchell, G.
Lindeman, G.J.
Evans, D.G.
Blanco, I.
Mercer, C.
Rubinstein, W.S.
Clowes, V.
Douglas, F.
Hodgson, S.
Walker, L.
Donaldson, A.
Izatt, L.
Dorkins, H.
Male, A.
Tucker, K.
Stapleton, A.
Lam, J.
Kirk, J.
Lilja, H.
Easton, D.
Cooper, C.
Eeles, R.
Neal, D.E.
(2010). The rs10993994 Risk Allele for Prostate Cancer Results in Clinically Relevant Changes in Microseminoprotein-Beta Expression in Tissue and Urine. Plos one,
Vol.5
(10),
p. 8.
Whitaker, H.C.
Warren, A.Y.
Eeles, R.
Kote-Jarai, Z.
Neal, D.E.
(2010). The Potential Value of Microseminoprotein-beta as a Prostate Cancer Biomarker and Therapeutic Target. Prostate,
Vol.70
(3),
pp. 333-8.
Kote-Jarai, Z.
Leongamornlert, D.
Tymrakiewicz, M.
Field, H.
Guy, M.
Al Olama, A.A.
Morrison, J.
O'Brien, L.
Wilkinson, R.
Hall, A.
Sawyer, E.
Muir, K.
Hamdy, F.
Donovan, J.
Neal, D.
Easton, D.
Eeles, R.
(2010). Mutation analysis of the MSMB gene in familial prostate cancer. Br j cancer,
Vol.102
(2),
pp. 414-418.
show abstract
BACKGROUND: MSMB, a gene coding for beta-microseminoprotein, has been identified as a candidate susceptibility gene for prostate cancer (PrCa) in two genome-wide association studies (GWAS). SNP rs10993994 is 2 bp upstream of the transcription initiation site of MSMB and was identified as an associated PrCa risk variant. The MSMB protein is underexpressed in PrCa and it was previously proposed to be an independent marker for the recurrence of cancer after radical prostatectomy. METHODS: In this study, the coding region of this gene and 1500 bp upstream of the 5'UTR has been sequenced in germline DNA in 192 PrCa patients with family history. To evaluate the possible effects of these variants we used in silico analysis. RESULTS: No deleterious mutations were identified, however, nine new sequence variants were found, most of these in the promoter and 5'UTR region. In silico analysis suggests that four of these SNPs are likely to have some effect on gene expression either by affecting ubiquitous or prostate-specific transcription factor (TF)-binding sites or modifying splicing efficiency. INTERPRETATION: We conclude that MSMB is unlikely to be a familial PrCa gene and propose that the high-risk alleles of the SNPs in the 5'UTR effect PrCa risk by modifying MSMB gene expression in response to hormones in a tissue-specific manner..
Guy, M.
Kote-Jarai, Z.
Giles, G.G.
Al Olama, A.A.
Jugurnauth, S.K.
Mulholland, S.
Leongamornlert, D.A.
Edwards, S.M.
Morrison, J.
Field, H.I.
Southey, M.C.
Severi, G.
Donovan, J.L.
Hamdy, F.C.
Dearnaley, D.P.
Muir, K.R.
Smith, C.
Bagnato, M.
Ardern-Jones, A.T.
Hall, A.L.
O'Brien, L.T.
Gehr-Swain, B.N.
Wilkinson, R.A.
Cox, A.
Lewis, S.
Brown, P.M.
Jhavar, S.G.
Tymrakiewicz, M.
Lophatananon, A.
Bryant, S.L.
UK Genetic Prostate Cancer Study Collaborators,
British Association of Urological Surgeons' Section of Oncology,
UK ProtecT Study Collaborators,
Horwich, A.
Huddart, R.A.
Khoo, V.S.
Parker, C.C.
Woodhouse, C.J.
Thompson, A.
Christmas, T.
Ogden, C.
Fisher, C.
Jameson, C.
Cooper, C.S.
English, D.R.
Hopper, J.L.
Neal, D.E.
Easton, D.F.
Eeles, R.A.
(2009). Identification of new genetic risk factors for prostate cancer. Asian j androl,
Vol.11
(1),
pp. 49-55.
show abstract
There is evidence that a substantial part of genetic predisposition to prostate cancer (PCa) may be due to lower penetrance genes which are found by genome-wide association studies. We have recently conducted such a study and seven new regions of the genome linked to PCa risk have been identified. Three of these loci contain candidate susceptibility genes: MSMB, LMTK2 and KLK2/3. The MSMB and KLK2/3 genes may be useful for PCa screening, and the LMTK2 gene might provide a potential therapeutic target. Together with results from other groups, there are now 23 germline genetic variants which have been reported. These results have the potential to be developed into a genetic test. However, we consider that marketing of tests to the public is premature, as PCa risk can not be evaluated fully at this stage and the appropriate screening protocols need to be developed. Follow-up validation studies, as well as studies to explore the psychological implications of genetic profile testing, will be vital prior to roll out into healthcare..
Kote-Jarai, Z.
Leongamornlert, D.
Tymrakiewitc, M.
Field, H.
Guy, M.
O'Brien, L.
Wilkinson, R.
Hall, A.
Muir, K.
Lophatananon, A.
Hamdy, F.
Donovan, J.
Neal, D.
Easton, D.
Eeles, R.
Collaborators, U.K.
(2009). Mutation analysis of the MSMB gene and its 5' UTR region in familial prostate cancer. Cancer research,
Vol.69.
Eeles, R.
Kote-Jarai, Z.
Easton, D.
Guy, M.
Al Olama, A.
Morrison, J.
Giles, G.
Hopper, J.
Severi, G.
Hamdy, F.
Donovan, J.
Neal, D.
Muir, K.
Lophatananon, A.
Consoritum, U.K.
(2009). Identification of a further novel profile of SPNs associated with prostate cancer. Cancer research,
Vol.69.
Jhavar, S.
Brewer, D.
Edwards, S.
Kote-Jarai, Z.
Attard, G.
Clark, J.
Flohr, P.
Christmas, T.
Thompson, A.
Parker, M.
Shepherd, C.
Stenman, U.-.
Marchbank, T.
Playford, R.J.
Woodhouse, C.
Ogden, C.
Fisher, C.
Kovacs, G.
Corbishley, C.
Jameson, C.
Norman, A.
De-Bono, J.
Bjartell, A.
Eeles, R.
Cooper, C.S.
(2009). Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer. Bju int,
Vol.103
(9),
pp. 1256-1269.
show abstract
OBJECTIVE: To integrate the mapping of ERG alterations with the collection of expression microarray (EMA) data, as previous EMA analyses have failed to consider the genetic heterogeneity and complex patterns of ERG alteration frequently found in cancerous prostates. MATERIALS AND METHODS: We determined genome-wide expression levels with GeneChip Human Exon 1.0 ST arrays (Affymetrix, Santa Clara, CA, USA) using RNA prepared from 35 specimens of prostate cancer from 28 prostates. RESULTS: The expression profiles showed clustering, in unsupervised hierarchical analyses, into two distinct prostate cancer categories, with one group strongly associated with indicators of poor clinical outcome. The two categories are not tightly linked to ERG status. By analysis of the data we identified a subgroup of cancers lacking ERG rearrangements that showed an outlier pattern of SPINK1 mRNA expression. There was a major distinction between ERG rearranged and non-rearranged cancers that involves the levels of expression of genes linked to exposure to beta-oestradiol, and to retinoic acid. CONCLUSIONS: Expression profiling of prostate cancer samples containing single patterns of ERG alterations can provide novel insights into the mechanism of prostate cancer development, and support the view that factors other than ERG status are the major determinants of poor clinical outcome..
Collin, S.M.
Metcalfe, C.
Zuccolo, L.
Lewis, S.J.
Chen, L.
Cox, A.
Davis, M.
Lane, J.A.
Donovan, J.
Smith, G.D.
Neal, D.E.
Hamdy, F.C.
Gudmundsson, J.
Sulem, P.
Rafnar, T.
Benediktsdottir, K.R.
Eeles, R.A.
Guy, M.
Kote-Jarai, Z.
UK Genetic Prostate Cancer Study Group,
Morrison, J.
Al Olama, A.A.
Stefansson, K.
Easton, D.F.
Martin, R.M.
(2009). Association of folate-pathway gene polymorphisms with the risk of prostate cancer: a population-based nested case-control study, systematic review, and meta-analysis. Cancer epidemiol biomarkers prev,
Vol.18
(9),
pp. 2528-2539.
show abstract
Folate-pathway gene polymorphisms have been implicated in several cancers and investigated inconclusively in relation to prostate cancer. We conducted a systematic review, which identified nine case-control studies (eight included, one excluded). We also included data from four genome-wide association studies and from a case-control study nested within the UK population-based Prostate Testing for Cancer and Treatment study. We investigated by meta-analysis the effects of eight polymorphisms: MTHFR C677T (rs1801133; 12 studies; 10,745 cases; 40,158 controls), MTHFR A1298C (rs1801131; 5 studies; 3,176 cases; 4,829 controls), MTR A2756G (rs1805087; 8 studies; 7,810 cases; 37,543 controls), MTRR A66G (rs1801394; 4 studies; 3,032 cases; 4,515 controls), MTHFD1 G1958A (rs2236225; 6 studies; 7,493 cases; 36,941 controls), SLC19A1/RFC1 G80A (rs1051266; 4 studies; 6,222 cases; 35,821 controls), SHMT1 C1420T (rs1979277; 2 studies; 2,689 cases; 4,110 controls), and FOLH1 T1561C (rs202676; 5 studies; 6,314 cases; 35,190 controls). The majority (10 of 13) of eligible studies had 100% Caucasian subjects; only one study had <90% Caucasian subjects. We found weak evidence of dominant effects of two alleles: MTR 2756A>G [random effects pooled odds ratio, 1.06 (1.00-1.12); P = 0.06 (P = 0.59 for heterogeneity across studies)] and SHMT1 1420C>T [random effects pooled odds ratio, 1.11 (1.00-1.22); P = 0.05 (P = 0.38 for heterogeneity across studies)]. We found no effect of MTHFR 677C>T or any of the other alleles in dominant, recessive or additive models, or in comparing a/a versus A/A homozygous. Neither did we find any difference in effects on advanced or localized cancers. Our meta-analysis suggests that known common folate-pathway single nucleotide polymorphisms do not have significant effects on susceptibility to prostate cancer..
Al Olama, A.A.
Kote-Jarai, Z.
Giles, G.G.
Guy, M.
Morrison, J.
Severi, G.
Leongamornlert, D.A.
Tymrakiewicz, M.
Jhavar, S.
Saunders, E.
Hopper, J.L.
Southey, M.C.
Muir, K.R.
English, D.R.
Dearnaley, D.P.
Ardern-Jones, A.T.
Hall, A.L.
O'Brien, L.T.
Wilkinson, R.A.
Sawyer, E.
Lophatananon, A.
UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology,
UK Prostate testing for cancer and Treatment study (ProtecT Study) Collaborators,
Horwich, A.
Huddart, R.A.
Khoo, V.S.
Parker, C.C.
Woodhouse, C.J.
Thompson, A.
Christmas, T.
Ogden, C.
Cooper, C.
Donovan, J.L.
Hamdy, F.C.
Neal, D.E.
Eeles, R.A.
Easton, D.F.
(2009). Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat genet,
Vol.41
(10),
pp. 1058-1060.
show abstract
Previous studies have identified multiple loci on 8q24 associated with prostate cancer risk. We performed a comprehensive analysis of SNP associations across 8q24 by genotyping tag SNPs in 5,504 prostate cancer cases and 5,834 controls. We confirmed associations at three previously reported loci and identified additional loci in two other linkage disequilibrium blocks (rs1006908: per-allele OR = 0.87, P = 7.9 x 10(-8); rs620861: OR = 0.90, P = 4.8 x 10(-8)). Eight SNPs in five linkage disequilibrium blocks were independently associated with prostate cancer susceptibility..
Eeles, R.A.
Kote-Jarai, Z.
Al Olama, A.A.
Giles, G.G.
Guy, M.
Severi, G.
Muir, K.
Hopper, J.L.
Henderson, B.E.
Haiman, C.A.
Schleutker, J.
Hamdy, F.C.
Neal, D.E.
Donovan, J.L.
Stanford, J.L.
Ostrander, E.A.
Ingles, S.A.
John, E.M.
Thibodeau, S.N.
Schaid, D.
Park, J.Y.
Spurdle, A.
Clements, J.
Dickinson, J.L.
Maier, C.
Vogel, W.
Dörk, T.
Rebbeck, T.R.
Cooney, K.A.
Cannon-Albright, L.
Chappuis, P.O.
Hutter, P.
Zeegers, M.
Kaneva, R.
Zhang, H.-.
Lu, Y.-.
Foulkes, W.D.
English, D.R.
Leongamornlert, D.A.
Tymrakiewicz, M.
Morrison, J.
Ardern-Jones, A.T.
Hall, A.L.
O'Brien, L.T.
Wilkinson, R.A.
Saunders, E.J.
Page, E.C.
Sawyer, E.J.
Edwards, S.M.
Dearnaley, D.P.
Horwich, A.
Huddart, R.A.
Khoo, V.S.
Parker, C.C.
Van As, N.
Woodhouse, C.J.
Thompson, A.
Christmas, T.
Ogden, C.
Cooper, C.S.
Southey, M.C.
Lophatananon, A.
Liu, J.-.
Kolonel, L.N.
Le Marchand, L.
Wahlfors, T.
Tammela, T.L.
Auvinen, A.
Lewis, S.J.
Cox, A.
FitzGerald, L.M.
Koopmeiners, J.S.
Karyadi, D.M.
Kwon, E.M.
Stern, M.C.
Corral, R.
Joshi, A.D.
Shahabi, A.
McDonnell, S.K.
Sellers, T.A.
Pow-Sang, J.
Chambers, S.
Aitken, J.
Gardiner, R.A.
Batra, J.
Kedda, M.A.
Lose, F.
Polanowski, A.
Patterson, B.
Serth, J.
Meyer, A.
Luedeke, M.
Stefflova, K.
Ray, A.M.
Lange, E.M.
Farnham, J.
Khan, H.
Slavov, C.
Mitkova, A.
Cao, G.
UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology,
UK ProtecT Study Collaborators,
PRACTICAL Consortium,
Easton, D.F.
(2009). Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat genet,
Vol.41
(10),
pp. 1116-1121.
show abstract
Prostate cancer (PrCa) is the most frequently diagnosed cancer in males in developed countries. To identify common PrCa susceptibility alleles, we previously conducted a genome-wide association study in which 541,129 SNPs were genotyped in 1,854 PrCa cases with clinically detected disease and in 1,894 controls. We have now extended the study to evaluate promising associations in a second stage in which we genotyped 43,671 SNPs in 3,650 PrCa cases and 3,940 controls and in a third stage involving an additional 16,229 cases and 14,821 controls from 21 studies. In addition to replicating previous associations, we identified seven new prostate cancer susceptibility loci on chromosomes 2, 4, 8, 11 and 22 (with P = 1.6 x 10(-8) to P = 2.7 x 10(-33))..
Mitra, A.
Jameson, C.
Barbachano, Y.
Sanchez, L.
Kote-Jarai, Z.
Peock, S.
Sodha, N.
Bancroft, E.
Fletcher, A.
Cooper, C.
Easton, D.
IMPACT Steering Committee and IMPACT and EMBRACE Collaborators,
Eeles, R.
Foster, C.S.
(2009). Overexpression of RAD51 occurs in aggressive prostatic cancer. Histopathology,
Vol.55
(6),
pp. 696-704.
show abstract
AIMS: To test the hypothesis that, in a matched series of prostatic cancers, either with or without BRCA1 or BRCA2 mutations, RAD51 protein expression is enhanced in association with BRCA mutation genotypes. METHODS AND RESULTS: RAD51 expression identified immunohistochemically was compared between prostatic cancers occurring in BRCA1 or BRCA2 mutation carriers and controls. RAD51 protein expression in the cytoplasm and nuclei of the benign tissues was significantly less than in the malignant tissues (P < 0.001). In all cancers, cytoplasmic expression of RAD51 was more prevalent and associated with higher Gleason score (P < 0.05) irrespective of BRCA mutational status, than its expression in benign tissues (P < 0.001). Although nuclear immunoreactivity was not observed in BRCA-associated cancers with Gleason score < or =7, it was significantly increased in all other groups of prostatic cancers when compared with benign tissues (P < 0.001). CONCLUSIONS: RAD51 protein is strongly expressed in high-grade prostatic cancers, whether sporadic or associated with BRCA germ-line mutations. Distinct localization of RAD51 between cytoplasm and nucleus, particularly in cancers of Gleason score < or =7, reflects distinct levels of RAD51 regulatory activity, from transcription to DNA repair. This biomarker may be of value in identifying patients requiring urgent treatment at diagnosis as well as in analysing biological mechanisms underlying aggressive phenotype of human prostatic cancer..
Kote-Jarai, Z.
Jugurnauth, S.
Mulholland, S.
Leongamornlert, D.A.
Guy, M.
Edwards, S.
Tymrakiewitcz, M.
O'Brien, L.
Hall, A.
Wilkinson, R.
Al Olama, A.A.
Morrison, J.
Muir, K.
Neal, D.
Donovan, J.
Hamdy, F.
Easton, D.F.
Eeles, R.
UKGPCS Collaborators,
British Association of Urological Surgeons' Section of Oncology,
(2009). A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancer. Br j cancer,
Vol.100
(2),
pp. 426-430.
show abstract
Although prostate cancer (PrCa) is one of the most common cancers in men in Western countries, little is known about the inherited factors that influence PrCa risk. On the basis of the fact that BRIP1/FANCJ interacts with BRCA1 and functions as a regulator of DNA double-strand break repair pathways, and that germline mutations within the BRIP1/FANCJ gene predispose to breast cancer, we chose this gene as a candidate for mutation screening in familial and young-onset PrCa cases. We identified a truncating mutation, R798X, in the BRIP1/FANCJ gene in 4 out of 2714 UK PrCa cases enriched for familial (2 out of 641; 0.3%) and young-onset cases (2 out of 2073; 0.1%). On screening 2045 controls from the UK population, we found one R798X sequence alteration (0.05%; odds ratio 2.4 (95% CI 0.25-23.4)). In addition, using our data from a genome-wide association study, we analysed 25 SNPs in the genomic region of the BRIP1/FANCJ gene. Two SNPs showed evidence of association with familial and young-onset PrCa (rs6504074; P(trend)=0.04 and rs8076727; P(trend)=0.01). These results suggest that truncating mutations in BRIP1/FANCJ might confer an increased risk of PrCa and common SNPs might also contribute to the alteration of risk, but larger case-control series will be required to confirm or refute this association..
Jhavar, S.
Reid, A.
Clark, J.
Kote-Jarai, Z.
Christmas, T.
Thompson, A.
Woodhouse, C.
Ogden, C.
Fisher, C.
Corbishley, C.
De-Bono, J.
Eeles, R.
Brewer, D.
Cooper, C.
(2008). Detection of TMPRSS2-ERG translocations in human prostate cancer by expression profiling using GeneChip Human Exon 1 0 ST arrays. J mol diagn,
Vol.10
(1),
pp. 50-57.
show abstract
full text
Translocation of TMPRSS2 to the ERG gene, found in a high proportion of human prostate cancer, results in overexpression of the 3'-ERG sequences joined to the 5'-TMPRSS2 promoter. The studies presented here were designed to test the ability of expression analysis on GeneChip Human Exon 1.0 ST arrays to detect 5'-TMPRSS2-ERG-3' hybrid transcripts encoded by this translocation. Monitoring the relative expression of each ERG exon revealed altered transcription of the ERG gene in 15 of a series of 27 prostate cancer samples. In all cases, exons 4 to 11 exhibited enhanced expression compared with exons 2 and 3. This pattern of expression indicated that the most abundant hybrid transcripts involve fusions to ERG exon 4, and RT-PCR analyses confirmed the joining of TMPRSS2 exon 1 to ERG exon 4 in all 15 cases. The exon expression patterns also indicated that TMPRSS2-ERG fusion transcripts commonly contain deletion of ERG exon 8. Analysis of gene-level data from the arrays allowed the identification of genes whose expression levels significantly correlated with the presence of the translocation. These studies demonstrate that expression analyses using exon arrays represent a valuable approach for detecting ETS gene translocation in prostate cancer, in parallel with analyses of gene expression profiles..
Ghoussaini, M.
Song, H.
Koessler, T.
Al Olama, A.A.
Kote-Jarai, Z.
Driver, K.E.
Pooley, K.A.
Ramus, S.J.
Kjaer, S.K.
Hogdall, E.
DiCioccio, R.A.
Whittemore, A.S.
Gayther, S.A.
Giles, G.G.
Guy, M.
Edwards, S.M.
Morrison, J.
Donovan, J.L.
Hamdy, F.C.
Dearnaley, D.P.
Ardern-Jones, A.T.
Hall, A.L.
O'Brien, L.T.
Gehr-Swain, B.N.
Wilkinson, R.A.
Brown, P.M.
Hopper, J.L.
Neal, D.E.
Pharoah, P.D.
Ponder, B.A.
Eeles, R.A.
Easton, D.F.
Dunning, A.M.
UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology,
UK ProtecT Study Collaborators,
(2008). Multiple loci with different cancer specificities within the 8q24 gene desert. J natl cancer inst,
Vol.100
(13),
pp. 962-966.
show abstract
Recent studies based on genome-wide association, linkage, and admixture scan analysis have reported associations of various genetic variants in 8q24 with susceptibility to breast, prostate, and colorectal cancer. This locus lies within a 1.18-Mb region that contains no known genes but is bounded at its centromeric end by FAM84B and at its telomeric end by c-MYC, two candidate cancer susceptibility genes. To investigate the associations of specific loci within 8q24 with specific cancers, we genotyped the nine previously reported cancer-associated single-nucleotide polymorphisms across the region in four case-control sets of prostate (1854 case subjects and 1894 control subjects), breast (2270 case subjects and 2280 control subjects), colorectal (2299 case subjects and 2284 control subjects), and ovarian (1975 case subjects and 3411 control subjects) cancer. Five different haplotype blocks within this gene desert were specifically associated with risks of different cancers. One block was solely associated with risk of breast cancer, three others were associated solely with the risk of prostate cancer, and a fifth was associated with the risk of prostate, colorectal, and ovarian cancer, but not breast cancer. We conclude that there are at least five separate functional variants in this region..
Eeles, R.A.
Kote-Jarai, Z.
Giles, G.G.
Olama, A.A.
Guy, M.
Jugurnauth, S.K.
Mulholland, S.
Leongamornlert, D.A.
Edwards, S.M.
Morrison, J.
Field, H.I.
Southey, M.C.
Severi, G.
Donovan, J.L.
Hamdy, F.C.
Dearnaley, D.P.
Muir, K.R.
Smith, C.
Bagnato, M.
Ardern-Jones, A.T.
Hall, A.L.
O'Brien, L.T.
Gehr-Swain, B.N.
Wilkinson, R.A.
Cox, A.
Lewis, S.
Brown, P.M.
Jhavar, S.G.
Tymrakiewicz, M.
Lophatananon, A.
Bryant, S.L.
UK Genetic Prostate Cancer Study Collaborators,
British Association of Urological Surgeons' Section of Oncology,
UK ProtecT Study Collaborators,
Horwich, A.
Huddart, R.A.
Khoo, V.S.
Parker, C.C.
Woodhouse, C.J.
Thompson, A.
Christmas, T.
Ogden, C.
Fisher, C.
Jamieson, C.
Cooper, C.S.
English, D.R.
Hopper, J.L.
Neal, D.E.
Easton, D.F.
(2008). Multiple newly identified loci associated with prostate cancer susceptibility. Nat genet,
Vol.40
(3),
pp. 316-321.
show abstract
Prostate cancer is the most common cancer affecting males in developed countries. It shows consistent evidence of familial aggregation, but the causes of this aggregation are mostly unknown. To identify common alleles associated with prostate cancer risk, we conducted a genome-wide association study (GWAS) using blood DNA samples from 1,854 individuals with clinically detected prostate cancer diagnosed at
Kote-Jarai, Z.
Easton, D.F.
Stanford, J.L.
Ostrander, E.A.
Schleutker, J.
Ingles, S.A.
Schaid, D.
Thibodeau, S.
Dörk, T.
Neal, D.
Donovan, J.
Hamdy, F.
Cox, A.
Maier, C.
Vogel, W.
Guy, M.
Muir, K.
Lophatananon, A.
Kedda, M.-.
Spurdle, A.
Steginga, S.
John, E.M.
Giles, G.
Hopper, J.
Chappuis, P.O.
Hutter, P.
Foulkes, W.D.
Hamel, N.
Salinas, C.A.
Koopmeiners, J.S.
Karyadi, D.M.
Johanneson, B.
Wahlfors, T.
Tammela, T.L.
Stern, M.C.
Corral, R.
McDonnell, S.K.
Schürmann, P.
Meyer, A.
Kuefer, R.
Leongamornlert, D.A.
Tymrakiewicz, M.
Liu, J.-.
O'Mara, T.
Gardiner, R.A.
Aitken, J.
Joshi, A.D.
Severi, G.
English, D.R.
Southey, M.
Edwards, S.M.
Al Olama, A.A.
PRACTICAL Consortium,
Eeles, R.A.
(2008). Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. Cancer epidemiol biomarkers prev,
Vol.17
(8),
pp. 2052-2061.
show abstract
A recent genome-wide association study found that genetic variants on chromosomes 3, 6, 7, 10, 11, 19 and X were associated with prostate cancer risk. We evaluated the most significant single-nucleotide polymorphisms (SNP) in these loci using a worldwide consortium of 13 groups (PRACTICAL). Blood DNA from 7,370 prostate cancer cases and 5,742 male controls was analyzed by genotyping assays. Odds ratios (OR) associated with each genotype were estimated using unconditional logistic regression. Six of the seven SNPs showed clear evidence of association with prostate cancer (P = 0.0007-P = 10(-17)). For each of these six SNPs, the estimated per-allele OR was similar to those previously reported and ranged from 1.12 to 1.29. One SNP on 3p12 (rs2660753) showed a weaker association than previously reported [per-allele OR, 1.08 (95% confidence interval, 1.00-1.16; P = 0.06) versus 1.18 (95% confidence interval, 1.06-1.31)]. The combined risks associated with each pair of SNPs were consistent with a multiplicative risk model. Under this model, and in combination with previously reported SNPs on 8q and 17q, these loci explain 16% of the familial risk of the disease, and men in the top 10% of the risk distribution have a 2.1-fold increased risk relative to general population rates. This study provides strong confirmation of these susceptibility loci in multiple populations and shows that they make an important contribution to prostate cancer risk prediction..
Kadouri, L.
Kote-Jarai, Z.
Hubert, A.
Baras, M.
Abeliovich, D.
Hamburger, T.
Peretz, T.
Eeles, R.A.
(2008). Glutathione-S-transferase M1, T1 and P1 polymorphisms, and breast cancer risk, in BRCA1/2 mutation carriers. Br j cancer,
Vol.98
(12),
pp. 2006-2010.
show abstract
Variation in penetrance estimates for BRCA1/2 carriers suggests that other environmental and genetic factors may modify cancer risk in carriers. The GSTM1, T1 and P1 isoenzymes are involved in metabolism of environmental carcinogens. The GSTM1 and GSTT1 gene is absent in a substantial proportion of the population. In GSTP1, a single-nucleotide polymorphism that translates to Ile112Val was associated with lower activity. We studied the effect of these polymorphisms on breast cancer (BC) risk in BRCA1/2 carriers. A population of 320 BRCA1/2 carriers were genotyped; of them 262 were carriers of one of the three Ashkenazi founder mutations. Two hundred and eleven were affected with BC (20 also with ovarian cancer (OC)) and 109 were unaffected with BC (39 of them had OC). Risk analyses were conducted using Cox proportional hazard models adjusted for origin (Ashkenazi vs non-Ashkenazi). We found an estimated BC HR of 0.89 (95% CI 0.65-1.12, P=0.25) and 1.11 (95% CI 0.81-1.52, P=0.53) for the null alleles of GSTM1 and GSTT1, respectively. For GSTP1, HR for BC was 1.36 (95% CI 1.02-1.81, P=0.04) for individuals with Ile/Val, and 2.00 (95% CI 1.18-3.38) for carriers of the Val/Val genotype (P=0.01). An HR of 3.20 (95% CI 1.26-8.09, P=0.01), and younger age at BC onset (P=0.2), were found among Val/Val, BRCA2 carriers, but not among BRCA1 carriers. In conclusion, our results indicate significantly elevated risk for BC in carriers of BRCA2 mutations with GSTP1-Val allele with dosage effect, as implicated by higher risk in homozygous Val carriers. The GSTM1- and GSTT1-null allele did not seem to have a major effect..
Mitra, A.
Fisher, C.
Foster, C.S.
Jameson, C.
Barbachanno, Y.
Bartlett, J.
Bancroft, E.
Doherty, R.
Kote-Jarai, Z.
Peock, S.
Easton, D.
IMPACT and EMBRACE Collaborators,
Eeles, R.
(2008). Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br j cancer,
Vol.98
(2),
pp. 502-507.
show abstract
There is a high and rising prevalence of prostate cancer (PRCA) within the male population of the United Kingdom. Although the relative risk of PRCA is higher in male BRCA2 and BRCA1 mutation carriers, the histological characteristics of this malignancy in these groups have not been clearly defined. We present the histopathological findings in the first UK series of BRCA1 and BRCA2 mutation carriers with PRCA. The archived histopathological tissue sections of 20 BRCA1/2 mutation carriers with PRCA were collected from histopathology laboratories in England, Ireland and Scotland. The cases were matched to a control group by age, stage and serum PSA level of PRCA cases diagnosed in the general population. Following histopathological evaluation and re-grading according to current conventional criteria, Gleason scores of PRCA developed by BRCA1/2 mutation carriers were identified to be significantly higher (Gleason scores 8, 9 or 10, P=0.012) than those in the control group. Since BRCA1/2 mutation carrier status is associated with more aggressive disease, it is a prognostic factor for PRCA outcome. Targeting screening to this population may detect disease at an earlier clinical stage which may therefore be beneficial..
Barwell, J.
Pangon, L.
Georgiou, A.
Kesterton, I.
Langman, C.
Arden-Jones, A.
Bancroft, E.
Salmon, A.
Locke, I.
Kote-Jarai, Z.
MorriS, J.R.
Solomon, E.
Berg, J.
DochertY, Z.
Camplejohn, R.
Eeles, R.
Hodgson, S.V.
(2007). Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibility. International journal of cancer,
Vol.121
(7),
pp. 1631-6.
Kote-Jarai, Z.
Powles, T.J.
Mitchell, G.
Tidy, A.
Ashley, S.
Easton, D.
Assersohn, L.
Sodha, N.
Salter, J.
Gusterson, B.
Dowsett, M.
Eeles, R.
(2007). BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial. Cancer lett,
Vol.247
(2),
pp. 259-265.
show abstract
We have analysed the pedigrees of all 70 women who developed cancer in the Royal Marsden Hospital (RMH) tamoxifen chemoprevention trial, using the Claus model, to assess breast cancer susceptibility heterozygote risk (HR) and screened the entire coding regions of BRCA1 and 2 genes in 62 of these cases. We found a reduced incidence of breast cancers developing on tamoxifen in women who have a lower HR, but not in women with higher HR. There were too few BRCA1/2 mutations (4 cases) to be able to determine the efficacy of tamoxifen by BRCA status. Immunohistochemical analysis showed a significantly lower frequency of median ER (p=0.03) in the cancers developing in tamoxifen-treated patients. These results suggest that tamoxifen is less likely to be effective at reducing breast cancers which are ER negative and also in some individuals at higher HR..
Locke, I.
Kote-Jarai, Z.
Fackler, M.J.
Bancroft, E.
Osin, P.
Nerurkar, A.
Izatt, L.
Pichert, G.
Gui, G.P.
Eeles, R.A.
(2007). Gene promoter hypermethylation in ductal lavage fluid from healthy BRCA gene mutation carriers and mutation-negative controls. Breast cancer res,
Vol.9
(1),
p. R20.
show abstract
INTRODUCTION: Female germline BRCA gene mutation carriers are at increased risk for developing breast cancer. The purpose of our study was to establish whether healthy BRCA mutation carriers demonstrate an increased frequency of aberrant gene promoter hypermethylation in ductal lavage (DL) fluid, compared with predictive genetic test negative controls, that might serve as a surrogate marker of BRCA1/2 mutation status and/or breast cancer risk. METHODS: The pattern of CpG island hypermethylation within the promoter region of a panel of four genes (RAR-beta, HIN-1, Twist and Cyclin D2) was assessed by methylation-specific polymerase chain reaction using free DNA extracted from DL fluid. RESULTS: Fifty-one DL samples from 24 healthy women of known BRCA mutation status (7 BRCA1 mutation carriers, 12 BRCA2 mutation carriers and 5 controls) were available for methylation analysis. Eight of 19 (42.1%) BRCA mutation carriers were found to have at least one hypermethylated gene in the four-gene panel. Two BRCA mutation carriers, in whom aberrant methylation was found, also had duct epithelial cell atypia identified. No hypermethylation was found in DL samples from 5 negative controls (p = 0.13). CONCLUSION: We found substantial levels of aberrant methylation, with the use of a four-gene panel, in the fluid from the breasts of healthy BRCA mutation carriers compared with controls. Methylation analysis of free DNA in DL fluid may offer a useful surrogate marker for BRCA1/2 mutation status and/or breast cancer risk. Further studies are required for the evaluation of the specificity and predictive value of aberrant methylation in DL fluid for future breast cancer development in BRCA1/2 mutation carriers..
Kote-Jarai, Z.
Matthews, L.
Osorio, A.
Shanley, S.
Giddings, I.
Moreews, F.
Locke, I.
Evans, D.G.
Eccles, D.
Carrier Clinic Collaborators,
Williams, R.D.
Girolami, M.
Campbell, C.
Eeles, R.
(2006). Accurate prediction of BRCA1 and BRCA2 heterozygous genotype using expression profiling after induced DNA damage. Clin cancer res,
Vol.12
(13),
pp. 3896-3901.
show abstract
PURPOSE: In this study, the differential gene expression changes following radiation-induced DNA damage in healthy cells from BRCA1/BRCA1 mutation carriers have been compared with controls using high-density microarray technology. We aimed to establish if BRCA1/BRCA2 mutation carriers could be distinguished from noncarriers based on expression profiling of normal cells. EXPERIMENTAL DESIGN: Short-term primary fibroblast cultures were established from skin biopsies from 10 BRCA1 and 10 BRCA2 mutation carriers and 10 controls, all of whom had previously had breast cancer. The cells were subjected to 15 Gy ionizing irradiation to induce DNA damage. RNA was extracted from all cell cultures, preirradiation and at 1 hour postirradiation. For expression profiling, 15 K spotted cDNA microarrays manufactured by the Cancer Research UK DNA Microarray Facility were used. Statistical feature selection was used with a support vector machine (SVM) classifier to determine the best feature set for predicting BRCA1 or BRCA2 heterozygous genotype. To investigate prediction accuracy, a nonprobabilistic classifier (SVM) and a probabilistic Gaussian process classifier were used. RESULTS: In the task of distinguishing BRCA1 and BRCA2 mutation carriers from noncarriers and from each other following radiation-induced DNA damage, the SVM achieved 90%, and the Gaussian process classifier achieved 100% accuracy. This effect could not be achieved without irradiation. In addition, the SVM identified a set of BRCA genotype predictor genes. CONCLUSIONS: We conclude that after irradiation-induced DNA damage, BRCA1 and BRCA2 mutation carrier cells have a distinctive expression phenotype, and this may have a future role in predicting genotypes, with application to clinical detection and classification of mutations..
Locke, I.
Kote-Jarai, Z.
Bancroft, E.
Bullock, S.
Jugurnauth, S.
Osin, P.
Nerurkar, A.
Izatt, L.
Pichert, G.
Gui, G.P.
Eeles, R.A.
(2006). Loss of heterozygosity at the BRCA1 and BRCA2 loci detected in ductal lavage fluid from BRCA gene mutation carriers and controls. Cancer epidemiol biomarkers prev,
Vol.15
(7),
pp. 1399-1402.
show abstract
Female BRCA gene mutation carriers are at increased risk for developing breast cancer. Ductal lavage is a novel method for sampling breast ductal fluid, providing epithelial cells for cytologic assessment and a source of free DNA for molecular analyses. Loss of heterozygosity (LOH) at the BRCA loci in ductal lavage fluid is a potential biomarker of breast cancer risk. The LOH rate was measured at the BRCA1/2 loci and compared with that at a control locus (APC) using free DNA from the ductal lavage fluid of BRCA carriers and predictive test negative controls. We evaluated the reproducibility of these analyses. Free DNA sufficient for PCR amplification was obtained from 33 ductal lavage samples of 17 healthy women of known BRCA status (14 BRCA carriers and 3 controls). LOH rates of 36.4% to 56.3% at the BRCA1 locus and 45% to 61.5% at the BRCA2 locus were found among BRCA carriers. The LOH rate at the APC locus was lower (18.5%). The interaliquot reproducibility for the D17S855 marker of the BRCA1 locus was 66.7%. Intraaliquot reproducibility was 90%. Although we successfully isolated sufficient free DNA from ductal lavage fluid for PCR amplification, the degree of reproducibility of these LOH studies raises questions about the robustness of this technique as a risk assessment tool in the evaluation of high-risk women. Further studies are required to evaluate the specificity and predictive value of LOH in ductal lavage fluid for breast cancer development..
Kote-Jarai, Z.
Salmon, A.
Mengitsu, T.
Copeland, M.
Ardern-Jones, A.
Locke, I.
Shanley, S.
Summersgill, B.
Lu, Y.-.
Shipley, J.
Eeles, R.
(2006). Increased level of chromosomal damage after irradiation of lymphocytes from BRCA1 mutation carriers. Br j cancer,
Vol.94
(2),
pp. 308-310.
show abstract
Deleterious mutations in the BRCA1 gene predispose women to an increased risk of breast and ovarian cancer. Many functional studies have suggested that BRCA1 has a role in DNA damage repair and failure in the DNA damage response pathway often leads to the accumulation of chromosomal aberrations. Here, we have compared normal lymphocytes with those heterozygous for a BRCA1 mutation. Short-term cultures were irradiated (8Gy) using a high dose rate and subsequently metaphases were analysed by 24-colour chromosome painting (M-FISH). We scored the chromosomal rearrangements in the metaphases from five BRCA1 mutation carriers and from five noncarrier control samples 6 days after irradiation. A significantly higher level of chromosomal damage was detected in the lymphocytes heterozygous for BRCA1 mutations compared with normal controls; the average number of aberrations per mitosis was 3.48 compared with 1.62 in controls (P=0.0001). This provides new evidence that heterozygous mutation carriers have a different response to DNA damage compared with noncarriers and that BRCA1 has a role in DNA damage surveillance. Our finding has implications for treatment and screening of BRCA1 mutation carriers using modalities that involve irradiation..
Jefferies, S.
Kote-Jarai, Z.
Goldgar, D.
Houlston, R.
Frazer-Williams, M.-.
A'Hern, R.
Eeles, R.
Henk, J.
Gore, M.
Rhys-Evans, P.
Archer, D.
Bishop, K.
Solomon, E.
Hodgson, S.
McGurk, M.
Hibbert, J.
O'Connell, M.
Partridge, M.
Chevretton, E.
Calman, F.
Saunders, M.
Shotton, K.
Brown, A.
Whittaker, S.
Foulkes, W.
MPT Collaborators,
MPT Collaborators:,
(2005). Association between polymorphisms of the GPX1 gene and second primary tumours after index squamous cell cancer of the head and neck. Oral oncol,
Vol.41
(5),
pp. 455-461.
show abstract
We investigated the association between genetic polymorphisms in GPX1 gene amongst patients who had index squamous cell carcinoma (SCCHN) and a second primary tumour (SPT) after a primary SCCHN in a case-control study. GPX1 genotypes were determined for 61 patients with SPT and for 259 control subjects by a PCR technique using a fluorescent-labelled primer. Analysis was by an ABI automated fluorescent sequencer. The associations between specific genotypes and the development of SPT were examined by logistic regression. A significant difference was found between the control group and the SPT cases in allele frequencies of GPX1 ALA( *)6 and ALA( *)7 (p(trend)=0.04). These results suggest that polymorphisms in the GPX1 gene may be a marker for SPT development and further studies are indicated..
Forrest, M.S.
Edwards, S.M.
Houlston, R.
Kote-Jarai, Z.
Key, T.
Allen, N.
Knowles, M.A.
Turner, F.
Ardern-Jones, A.
Murkin, A.
Williams, S.
Oram, R.
Bishop, D.T.
Eeles, R.A.
CR-UK/BPG UK prostate cancer study collaborators,
(2005). Association between hormonal genetic polymorphisms and early-onset prostate cancer. Prostate cancer prostatic dis,
Vol.8
(1),
pp. 95-102.
show abstract
We investigated the association between seven polymorphisms in four candidate genes involved in vitamin D and androgen metabolism with early-onset prostate cancer (CaP) risk. The polymorphisms were genotyped in 288 UK males who were diagnosed with CaP at the age of 55 y or younger and up to 700 population-based controls. An additional 50 cases (not selected for age) and 76 controls were also genotyped. Short (< or =22 repeats) AR (CAG)(n) repeats were associated with a significantly reduced risk of early onset CaP (OR 0.68, 95% CI 0.50-0.91) compared with men with long (> 22) repeats. Men homozygous for the leucine variant of SRD5A2 p.89V > L were also found to be at a significantly increased risk of CaP compared with men who were homozygous for the valine allele (OR 1.84, 95% CI 1.15-2.98). No associations were found with the AR (GGC)(n), CYP17 Msp A1 I, VDR Taq I, SRD5A2 (TA)(n) and p.49A >T polymorphisms and CaP risk. These findings suggest that common polymorphisms in the AR and SRD5A2 genes may be associated with early-onset CaP in British men..
Kote-Jarai, Z.
Williams, R.D.
Cattini, N.
Copeland, M.
Giddings, I.
Wooster, R.
tePoele, R.H.
Workman, P.
Gusterson, B.
Peacock, J.
Gui, G.
Campbell, C.
Eeles, R.
(2004). Gene expression profiling after radiation-induced DNA damage is strongly predictive of BRCA1 mutation carrier status. Clin cancer res,
Vol.10
(3),
pp. 958-963.
show abstract
PURPOSE: The impact of the presence of a germ-line BRCA1 mutation on gene expression in normal breast fibroblasts after radiation-induced DNA damage has been investigated. EXPERIMENTAL DESIGN: High-density cDNA microarray technology was used to identify differential responses to DNA damage in fibroblasts from nine heterozygous BRCA1 mutation carriers compared with five control samples without personal or family history of any cancer. Fibroblast cultures were irradiated, and their expression profile was compared using intensity ratios of the cDNA microarrays representing 5603 IMAGE clones. RESULTS: Class comparison and class prediction analysis has shown that BRCA1 mutation carriers can be distinguished from controls with high probability (approximately 85%). Significance analysis of microarrays and the support vector machine classifier identified gene sets that discriminate the samples according to their mutation status. These include genes already known to interact with BRCA1 such as CDKN1B, ATR, and RAD51. CONCLUSIONS: The results of this initial study suggest that normal cells from heterozygous BRCA1 mutation carriers display a different gene expression profile from controls in response to DNA damage. Adaptations of this pilot result to other cell types could result in the development of a functional assay for BRCA1 mutation status..
Kadouri, L.
Kote-Jarai, Z.
Hubert, A.
Durocher, F.
Abeliovich, D.
Glaser, B.
Hamburger, T.
Eeles, R.A.
Peretz, T.
(2004). A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers. Br j cancer,
Vol.90
(10),
pp. 2002-2005.
show abstract
Variation in the penetrance estimates for BRCA1 and BRCA2 mutation carriers suggests that other genetic polymorphisms may modify the cancer risk in carriers. The RAD51 gene, which participates in homologous recombination double-strand breaks (DSB) repair in the same pathway as the BRCA1 and BRCA2 gene products, is a candidate for such an effect. A single-nucleotide polymorphism (SNP), RAD51-135g-->c, in the 5' untranslated region of the gene has been found to elevate breast cancer (BC) risk among BRCA2 carriers. We genotyped 309 BRCA1/2 mutation carriers, of which 280 were of Ashkenazi origin, 166 noncarrier BC patients and 152 women unaffected with BC (a control group), for the RAD51-135g-->c SNP. Risk analyses were conducted using COX proportional hazard models for the BRCA1/2 carriers and simple logistic regression analysis for the noncarrier case-control population. BRCA2 carriers were also studied using logistic regression and Kaplan-Meier survival analyses. The estimated BC hazard ratio (HR) for RAD51-135c carriers adjusted for origin (Ashkenazi vs non-Ashkenazi) was 1.28 (95% CI 0.85-1.90, P=0.23) for BRCA1/2 carriers, and 2.09 (95% CI 1.04-4.18, P=0.04) when the analysis was restricted to BRCA2 carriers. The median BC age was younger in BCRA2-RAD51-135c carriers (45 (95% CI 36-54) vs 52 years (95% CI 48-56), P=0.05). In a logistic regression analysis, the odds ratio (OR) was 5.49 (95% CI 0.5-58.8, P=0.163). In noncarrier BC cases, carrying RAD51-135c was not associated with BC risk (0.97; 95% CI 0.47-2.00). These results indicate significantly elevated risk for BC in carriers of BRCA2 mutations who also carry a RAD51-135c allele. In BRCA1 carriers and noncarriers, no effect for this SNP was found..
Kadouri, L.
Kote-Jarai, Z.
Easton, D.F.
Hubert, A.
Hamoudi, R.
Glaser, B.
Abeliovich, D.
Peretz, T.
Eeles, R.A.
(2004). Polyglutamine repeat length in the AIB1 gene modifies breast cancer susceptibility in BRCA1 carriers. Int j cancer,
Vol.108
(3),
pp. 399-403.
show abstract
Variation in the penetrance estimates for BRCA1 and BRCA2 mutation carriers suggests that other factors may modify cancer risk from specific mutations. One possible mechanism is an epigenetic effect of polymorphisms in other genes. Genes involved in hormonal signal transduction are possible candidates. The AIB1 gene, an estrogen receptor (ER) coactivator, is frequently amplified in breast and ovarian tumors. Variation of a CAG repeat length has been reported within this gene that encodes a polyglutamine repeat in the C-terminus of the protein. Three hundred eleven BRCA1/2 mutation carriers (257 were of Ashkenazi origin) were genotyped for the AIB1 polyglutamine repeat. Relative risks (RR) were estimated using a maximum likelihood approach. The estimated breast cancer (BC) RR per average repeat length adjusted for population type (Ashkenazi vs. non-Ashkenazi) was 1.15 (95% CI = 1.02-1.30; p = 0.01) for BRCA1/2 carriers, and 1.25 (95% CI = 1.09-1.42; p = 0.001) when analysis was restricted to BRCA1 carriers. RR of BC was 1.17 (95% CI = 0.91-1.74), for individuals with 2 alleles >/=29 polyglutamine repeats and 0.78 (95% CI = 0.50-1.16) for those with at least 1 allele of /=29 repeats respectively (p = 0.025). These results indicate significant association of the risk for BC in carriers of BRCA1 mutations with the polyglutamine chain of the AIB1 gene. Longer repeat length correlates with elevated risk, whereas in carriers of a shorter AIB1 allele BC risk was reduced. The AIB1 polyglutamine length did not affect BC risk among BRCA2 mutation carriers..
Edwards, S.M.
Kote-Jarai, Z.
Meitz, J.
Hamoudi, R.
Hope, Q.
Osin, P.
Jackson, R.
Southgate, C.
Singh, R.
Falconer, A.
Dearnaley, D.P.
Ardern-Jones, A.
Murkin, A.
Dowe, A.
Kelly, J.
Williams, S.
Oram, R.
Stevens, M.
Teare, D.M.
Ponder, B.A.
Gayther, S.A.
Easton, D.F.
Eeles, R.A.
Cancer Research UK/Bristish Prostate Group UK Familial Prostate Cancer Study Collaborators,
British Association of Urological Surgeons Section of Oncology,
(2003). Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am j hum genet,
Vol.72
(1),
pp. 1-12.
show abstract
Studies of families with breast cancer have indicated that male carriers of BRCA2 mutations are at increased risk of prostate cancer, particularly at an early age. To evaluate the contribution of BRCA2 mutations to early-onset prostate cancer, we screened the complete coding sequence of BRCA2 for germline mutations, in 263 men with diagnoses of prostate cancer who were
Kote-Jarai, Z.
Singh, R.
Durocher, F.
Easton, D.
Edwards, S.M.
Ardern-Jones, A.
Dearnaley, D.P.
Houlston, R.
Kirby, R.
Eeles, R.
(2003). Association between leptin receptor gene polymorphisms and early-onset prostate cancer. Bju int,
Vol.92
(1),
pp. 109-112.
show abstract
OBJECTIVE: To report a case-control study examining the relationship between polymorphisms in the leptin receptor (OBR) gene and the development of young-onset prostate cancer, because epidemiological studies report that prostate cancer risk is associated with animal fat intake, and thus we investigated if this association occurs via this genetic mechanism. PATIENTS, SUBJECTS AND METHODS: The Lys109Arg (OBR1) and Gln223Arg (OBR2) polymorphisms in the coding region of OBR were studied in blood DNA from 271 patients with prostate cancer aged < 56 years at diagnosis and 277 geographically matched control subjects. Cases were collected through the Cancer Research UK/British Prostate Group Familial Prostate Cancer Study. Blood DNA was genotyped using the polymerase chain reaction and a restriction enzyme digest. RESULTS: There was no statistically significant association between the OBR genotype and prostate cancer risk; men homozygous for 109Arg genotype had a slightly increased risk for prostate cancer, with a relative risk (95% confidence interval) of 1.36 (0.65-2.85), and those homozygous for the 223Arg allele had some reduction in prostate cancer risk, at 0.82 (0.58-1.26), but neither was statistically significant. CONCLUSION: This case-control study showed no significant association between leptin receptor gene polymorphisms and the risk of young-onset prostate cancer, suggesting that genetic variations in OBR are unlikely to have a major role in the development of early-onset prostate cancer in the UK..
Yuille, M.
Condie, A.
Hudson, C.
Kote-Jarai, Z.
Stone, E.
Eeles, R.
Matutes, E.
Catovsky, D.
Houlston, R.
(2002). Relationship between glutathione S-transferase M1, T1, and P1 polymorphisms and chronic lymphocytic leukemia. Blood,
Vol.99
(11),
pp. 4216-4218.
show abstract
Interindividual differences in susceptibility to hematologic malignancies may be mediated in part through polymorphic variability in the bioactivation and detoxification of carcinogens. The glutathione S-transferases (GSTs) have been implicated as susceptibility genes in this context for a number of cancers. The aim of this study was to examine whether polymorphic variation in GSTs confers susceptibility to chronic lymphocytic leukemia (CLL). GSTM1, GSTT1, and GSTP1 genotypes were determined in 138 patients and 280 healthy individuals. The frequency of both GSTM1 and GSTT1 null genotypes and the GSTP1-Ile allele was higher in cases than in controls. There was evidence of a trend in increasing risk with the number of putative "high-risk" alleles of the GST family carried (P =.04). The risk of CLL associated with possession of all 3 "high-risk" genotypes was increased 2.8-fold (OR = 2.8, 95% confidence interval: 1.1-6.9). Our findings suggest that heritable GST status may influence the risk of developing CLL..
Kote-Jarai, Z.
Durocher, F.
Edwards, S.M.
Hamoudi, R.
Jackson, R.A.
Ardern-Jones, A.
Murkin, A.
Dearnaley, D.P.
Kirby, R.
Houlston, R.
Easton, D.F.
Eeles, R.
CRC/BPG UK Familial Prostrate Cancer Collaborators,
(2002). Association between the GCG polymorphism of the selenium dependent GPX1 gene and the risk of young onset prostate cancer. Prostate cancer prostatic dis,
Vol.5
(3),
pp. 189-192.
show abstract
Epidemiological studies have suggested an association between low selenium levels and the development of prostate cancer. Human cellular glutathione peroxidase I (hGPX1) is a selenium-dependent enzyme that protects against oxidative damage and its peroxidase activity is a plausible mechanism for cancer prevention by selenium. The GPX1 gene has a GCG repeat polymorphism in exon 1, coding for a polyalanine tract of five to seven alanine residues. To test if the GPX1 GCG repeat polymorphism associates with the risk of young-onset prostate cancer we conducted a case-control study. The GPX1Ala genotypes were determined for 267 prostate cancer cases and 260 control individuals using polymerase chain reaction (PCR) amplification with fluorescently labelled primers and an ABI 377 automated genotyper. Associations between specific genotypes and the risk of prostate cancer were examined by logistic regression. We found no significant association between the GPX1 genotypes and prostate cancer. There was however an increased frequency of the GPX1Ala6/Ala6 genotype in the prostate cancer cases compared to controls (OR: 1.67; 95% CI: 0.97-2.87). The result of this study suggests that the GPX1 genotype is unlikely to be associated with the risk of developing prostate cancer..
Eeles, R.
Edwards, S.
Kote-Jarai, Z.
Hamoudi, R.
Deamaley, D.
Ardem-Jones, A.
Murkin, A.
(2001). 2% of men with early onset prostate cancer harbour deleterious germline mutations in the BRCA2 gene. American journal of human genetics,
Vol.69
(4),
pp. 191-1.
Kote-Jarai, Z.
Kadouri, L.
Durocher, F.
Easton, D.F.
Huber, A.
Abeliovich, D.
Glaser, B.
Peretz, T.
Eeles, R.
(2001). CAG repeat length in the gene AIB1 gene modifies breast cancer risk in BRCA1/2 mutation carriers. American journal of human genetics,
Vol.69
(4),
pp. 274-1.
Edwards, S.M.
Kote-Jarai, Z.
Hamoudi, R.
Eeles, R.A.
(2001). An improved high throughput heteroduplex mutation detection system for screening BRCA2 mutations-fluorescent mutation detection (F-MD). Hum mutat,
Vol.17
(3),
pp. 220-232.
show abstract
We describe an improved, fast, automated method for screening large genes such as BRCA2 for germline genomic mutations. The method is based on heteroduplex analysis, and has been adapted for a high throughput application by combining the fluorescent technology of automated sequencers and robotic sample handling. This novel approach allows the entire BRCA2 gene to be screened with appropriate overlaps in four lanes of an ABI 377 gel. The method will detect all types of mutations, especially point mutations, more reliably and robustly than other commonly used conformational sensitive methods (e.g. CSGE). In addition we show that this approach, which relies on band shift detection, is able to detect single base substitutions that have hitherto only been detectable by direct sequencing methods..
Kote-Jarai, Z.
Easton, D.
Edwards, S.M.
Jefferies, S.
Durocher, F.
Jackson, R.A.
Singh, R.
Ardern-Jones, A.
Murkin, A.
Dearnaley, D.P.
Shearer, R.
Kirby, R.
Houlston, R.
Eeles, R.
CRC/BPG UK Familial Prostate Cancer Study Collaborators,
(2001). Relationship between glutathione S-transferase M1, P1 and T1 polymorphisms and early onset prostate cancer. Pharmacogenetics,
Vol.11
(4),
pp. 325-330.
show abstract
There is evidence suggesting that polymorphic variations in the glutathione S-transferases (GSTs) are associated with cancer susceptibility. Inter-individual differences in cancer susceptibility may be mediated in part through polymorphic variability in the bioactivation and detoxification of carcinogens. The GSTs have been consistently implicated as cancer susceptibility genes in this context. The GST supergene family includes several loci with well characterized polymorphisms. Approximately 50% of the Caucasian population are homozygous for deletions in GSTM1 and approximately 20% are homozygous for deletions in GSTT1, resulting in conjugation deficiency of mutagenic electrophiles to glutathione. The GSTP1 gene has a polymorphism at codon 105 resulting in an Ile to Val substitution which consequently alters the enzymatic activity of the protein and this has been suggested as a putative high-risk genotype in various cancers. We investigated the relationship between GST polymorphisms and young onset prostate cancer in a case-control study. GSTM1, GSTT1 and GSTP1 genotypes were determined for 275 prostate cancer patients and for 280 geographically matched control subjects. We found no significant difference in the frequency of GSTM1 or GSTT1 null genotypes between cases and controls. GSTP1 genotype was, however, significantly associated with prostate cancer risk: the Ile/Ile homozygotes had the lowest risk and there was a trend in increasing the risk with the number of 105 Val alleles: Ile/Val odds ratio (OR)= 1.30 (95% FCI 0.99-1.69), Val/Val OR = 1.80 (95% FCI 1.11-2.91); Ptrend = 0.026. These results suggest that the GSTP1 polymorphism may be a risk factor for developing young onset prostate cancer. We also found that carrying more than one putative high-risk allele in the carcinogen metabolizing GST family was associated with an elevated risk for early onset prostate cancer (OR 2.48, 95% FCI 1.22-5.04, Ptrend = 0.017)..
Kadouri, L.
Easton, D.F.
Edwards, S.
Hubert, A.
Kote-Jarai, Z.
Glaser, B.
Durocher, F.
Abeliovich, D.
Peretz, T.
Eeles, R.A.
(2001). CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers. Br j cancer,
Vol.85
(1),
pp. 36-40.
show abstract
Variation in the penetrance estimates for BRCA1 and BRCA2 mutations carriers suggests that other genetic polymorphisms may modify the cancer risk in carriers. A previous study has suggested that BRCA1 carriers with longer lengths of the CAG repeat in the androgen receptor (AR) gene are at increased risk of breast cancer (BC). We genotyped 188 BRCA1/2 carriers (122 affected and 66 unaffected with breast cancer), 158 of them of Ashkenazi origin, 166 BC cases without BRCA1/2 mutations and 156 Ashkenazi control individuals aged over 56 for the AR CAG and GGC repeats. In carriers, risk analyses were conducted using a variant of the log-rank test, assuming two sets of risk estimates in carriers: penetrance estimates based on the Breast Cancer Linkage Consortium (BCLC) studies of multiple case families, and lower estimates as suggested by population-based studies. We found no association of the CAG and GGC repeats with BC risk in either BRCA1/2 carriers or in the general population. Assuming BRCA1/2 penetrance estimates appropriate to the Ashkenazi population, the estimated RR per repeat adjusted for ethnic group (Ashkenazi and non-Ashkenazi) was 1.05 (95%CI 0.97-1.17) for BC and 1.00 (95%CI 0.83-1.20) for ovarian cancer (OC) for CAG repeats and 0.96 (95%CI 0.80-1.15) and 0.90 (95%CI 0.60-1.22) respectively for GGC repeats. The corresponding RR estimates for the unselected case-control series were 1.00 (95%CI 0.91-1.10) for the CAG and 1.05 (95%CI 0.90-1.22) for the GGC repeats. The estimated relative risk of BC in carriers associated with > or =28 CAG repeats was 1.08 (95%CI 0.45-2.61). Furthermore, no significant association was found if attention was restricted to the Ashkenazi carriers, or only to BRCA1 or BRCA2 carriers. We conclude that, in contrast to previous observations, if there is any effect of the AR repeat length on BRCA1 penetrance, it is likely to be weak..
Jefferies, S.
Kote-Jarai, Z.
Houlston, R.
Fraser-Williams, M.J.
A'Hern, R.
Foulkes, W.D.
Goldgar, D.
Eeles, R.A.
(2000). Association between polymorphisms of the GPX1 gene and multiple primary tumours (MPT). American journal of human genetics,
Vol.67
(4),
pp. 104-1.
Eeles, R.A.
Powles, T.P.
Ashley, S.
Easton, D.F.
Assersohn, L.
Sodha, N.
Dowsett, M.
Gusterson, B.
Tidy, A.
Mitchell, G.
Kote-Jarai, Z.
(2000). BRCA1, BRCA2 mutation and pedigree genetic analysis to determine genetic risk in the UK Royal Marsden Hospital tamoxifen prevention trial. British journal of cancer,
Vol.83,
pp. 25-1.
Singh, R.
Eeles, R.A.
Durocher, F.
Simard, J.
Edwards, S.
Badzioch, M.
Kote-Jarai, Z.
Teare, D.
Ford, D.
Dearnaley, D.
Ardern-Jones, A.
Murkin, A.
Dowe, A.
Shearer, R.
Kelly, J.
Labrie, F.
Easton, D.
Narod, S.A.
Tonin, P.N.
Foulkes, W.D.
(2000). High risk genes predisposing to prostate cancer development-do they exist?. Prostate cancer prostatic dis,
Vol.3
(4),
pp. 241-247.
show abstract
There is evidence for genetic predisposition to prostate cancer. However, prostate cancer genes have been more difficult to find than genes for some of the other common cancers, such as breast and colon cancer. The reasons for this are discussed in this article and it is now becoming clear that prostate cancer is probably due to multiple genes, many of which are moderate or low penetrance. The advances in the Human Genome Project and technology, especially that of robotics, will help to overcome these problems. Prostate Cancer and Prostatic Diseases (2000) 3, 241-247.
Eeles, R.A.
Powles, T.P.
Ashley, S.
Easton, D.F.
Assersohn, L.
Sodha, N.
Dowsett, M.
Gusterson, B.
Tidy, A.
Mitchell, G.
Kote-Jarai, Z.
(1999). BRCA1, BRCA2 and pedigree genetic analysis to determine genetic risk in the UK Royal Marsden Hospital tamoxifen prevention trial. American journal of human genetics,
Vol.65
(4),
pp. A124-1.
Kote-Jarai, Z.
Edwards, S.
Easton, D.
Jackson, R.
Ardern-Jones, A.
Murkin, A.
Dearnaley, D.
(1999). Association between the GSTM1, GSTP1 and GSTT1 gene polymorphisms and young onset prostate cancer in the UK. American journal of human genetics,
Vol.65
(4),
pp. A133-1.
Kote-Jarai, Z.
Eeles, R.A.
(1999). BRCA1, BRCA2 and their possible function in DNA damage response. Br j cancer,
Vol.81
(7),
pp. 1099-1102.
Ramus, S.J.
Kote-Jarai, Z.
Friedman, L.S.
van der Looij, M.
Gayther, S.A.
Csokay, B.
Ponder, B.A.
Olah, E.
(1997). Analysis of BRCA1 and BRCA2 mutations in Hungarian families with breast or breast-ovarian cancer. Am j hum genet,
Vol.60
(5),
pp. 1242-1246.
Turnbull, C.A.
Ruark, E.
Seal, S.
McDonald, H.
Zhang, F.
Elliot, A.
Lau, K.
Perdeaux, E.
Rapley, E.
Eeles, R.
Peto, J.
Kote-Jarai, Z.
Muir, K.
Nsengimana, J.
Shipley, J.
UKTCC,
Bishop, D.T.
Stratton, M.
Easton, D.F.
Huddart, R.
Rahman, N.
Identification of nine new loci for testicular cancer, including variants located near DAZL and PRDM14, genes involved in germ cell development. Nature genetics,
.
show abstract
full text
Testicular germ cell tumor (TGCT) is the most common cancer in young men and is notable for its high familial risks. To date, six loci associated with TGCT have been reported. From GWAS analysis of 307,291 SNPs in 986 cases and 4,946 controls, we selected for follow-up 694 SNPs, which we genotyped in a further 1,064 TGCT cases and 10,082 controls from the UK. We identified SNPs at nine new loci showing association with TGCT (P<5x10-8), at 1q22, 1q24.1, 3p24.3, 4q24, 5q31.1, 8q13.3, 16q12.1, 17q22 and 21q22.3, which together account for an additional 4-6% of the familial risk of TGCT. The loci include genes plausibly related to TGCT development. PRDM14, at 8q13.3, is essential for early germ cell specification whilst DAZL, at 3p24.3, is required for regulation of germ cell developmen. Furthermore, PITX1, at 5q31.1 regulates TERT expression, and is the third TGCT locus implicated in telomerase regulation..